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Cerebrovascular disease is a major cause of mortality and disability worldwide. 
Treatment options for stroke, the acute clinical manifestation of cerebrovascular disease, 
remain restricted and the development of new therapeutic strategies is hampered by the 
difficulties in identifying neuroprotective approaches. Thus, current efforts are focused 
on prevention. The development of effective preventive strategies requires enriching our 
knowledge regarding stroke etiology. Stroke is a highly heterogeneous disease. While 
multiple risk factors have been found for stroke as a whole, there is only limited evidence 
about specific risk factors for etiologically-defined stroke subtypes. Evidence regarding 
risk factors for stroke subtypes is mainly derived from observational studies, which could 
be biased because of confounding and reverse causation.  
In this thesis, I aimed to explore potential risk factors and drug targets for stroke, stroke 
subtypes, and manifestations of cerebral small vessel disease (SVD) by using Mendelian 
randomization (MR). MR is a novel approach for exploring associations based on the use 
of data from genome-wide association studies (GWAS). By using genetic variants as 
proxies for a trait of interest, MR overcomes key limitations of observational studies and 
allows for investigation of causal effects on outcomes. By restricting the selection of 
variants to the vicinity of genes encoding candidate drug targets, MR further enables the 
prediction of the effects and side-effects of pharmacological interventions. 
On the basis of experimental and clinical evidence suggesting a key role of inflammation 
in atherosclerosis, my collaborators and I explored the associations of inflammatory 
mediators with the risk of stroke and stroke subtypes. First, using GWAS data on the 
circulating levels of 41 cytokines and growth factors (n=8,293), we explored the 
association of their genetic determinants with stroke and stroke subtypes (n=521,612). 
We found genetic predisposition to higher levels of monocyte-chemoattractant protein-1 
(MCP-1), a chemokine attracting monocytes to the sites of inflammation, to be associated 
with a higher risk of ischemic stroke, and particularly large artery and cardioembolic 
stroke. We further found similar associations for the atherosclerotic phenotypes of 
coronary artery disease and myocardial infarction. Second, to validate these findings, we 
explored the association between MCP-1 levels and risk of incident stroke in a meta-
analysis of 6 population-based cohort studies (n=17,180, mean age 57 years, 51% 
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women). Over a follow-up of 16 years, we found higher MCP-1 levels to be associated with 
a higher risk of any stroke and ischemic stroke, but not hemorrhagic stroke. Third, we 
constructed a genetic score reflecting the activity of interleukin-6 (IL-6) signaling and 
explored associations with ischemic stroke. We found genetically downregulated IL-6 
signaling to be associated with lower risk of ischemic stroke, particularly large artery and 
small vessel stroke. Interestingly, in observational data, IL-6 and MCP-1 levels were both 
associated with ischemic stroke risk, independently of each other, thus indicating that 
targeting the two pathways might offer complementary benefits in reducing stroke risk. 
We further explored the effects of genetic predisposition to traditional vascular risk 
factors on different stroke subtypes and SVD. Using GWAS data (n=757,601), We 
identified genetic proxies for the effects of common first-line antihypertensive 
medications that showed associations with stroke and coronary artery disease that were 
comparable to those derived from clinical trials. In a phenome-wide association study, 
using these genetic proxies, we were able to detect and validate with observational data 
a previously unreported adverse effect of calcium channel blockers on risk of 
diverticulosis. We then used these genetic proxies to explore associations with stroke 
subtypes and cerebral SVD. Aside from the expected associations between genetically 
predicted blood pressure and all major stroke subtypes, we found the proxies for calcium-
channel blockers to show particularly strong associations with small vessel stroke and the 
related radiological SVD phenotype of white matter hyperintensities (WMH). When 
exploring blood lipids, genetic predisposition to higher levels of high-density lipoprotein 
cholesterol (HDL-C) was associated with lower risk of small vessel stroke risk and WMH. 
This effect was primarily driven by cholesterol concentration in medium-sized HDL 
particles. Genetic proxies for CETP inhibitors, an HDL-C-raising drug class, showed 
associations with lower risk of ischemic SVD manifestations (small vessel stroke, WMH), 
but also with higher risk of intracerebral hemorrhage, a hemorrhagic SVD manifestation. 
In conclusion, using genetic data from humans, this thesis identified novel risk factors and 
drug targets for stroke subtypes and cerebral SVD. Specifically, I provide evidence 
supporting MCP-1 and IL-6 signaling as promising novel strategies for lowering the risk 
of ischemic stroke. Already approved strategies like lowering blood pressure with calcium 
channel blockade and increasing HDL-C by CETP inhibition might offer benefits for 
preventing the ischemic manifestations of cerebral SVD.  
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LIST OF ABBREVIATIONS 
 
AF atrial fibrillation 
CCL2 CC chemokine ligand-2 
CCR2 CC chemokine receptor-2 
CETP cholesteryl-ester transfer protein 
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HDL-C high-density lipoprotein cholesterol 
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MR Mendelian randomization 
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MRI magnetic resonance imaging 
RCT randomized controlled trial 
PheWAS phenome-wide association study 
SBP systolic blood pressure 
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TOAST trial of ORG 10172 in acute stroke treatment 









Cerebrovascular disease refers to a variety of disorders that affect the brain vessels or 
blood supply to the brain. Stroke, the most extreme clinical manifestation of 
cerebrovascular disease, is a focal neurological injury due to a vascular cause, which 
includes infarction of the central nervous system (CNS), defined as cell death in the brain, 
the spinal cord or the retina based on either pathological and imaging evidence of 
ischemic injury in a defined vascular distribution or clinical evidence of symptoms of 
acute neurological dysfunction persisting for ≥24 hours or until death (Sacco et al., 2013). 
Stroke may occur as a result of either CNS ischemia (ischemic stroke) or CNS hemorrhage 
(hemorrhagic stroke) (Hankey, 2017). Despite the undisputable progresses in our 
understanding of the etiology, the pathophysiology, and the consequences of stroke, it 
remains a devastating disease with a huge burden for the patients, their caregivers, the 
public health systems (Feigin et al., 2016b). Given the limited options and difficulties 
associated with stroke treatment and rehabilitation, the attention has shifted towards 
stroke prevention (Feigin et al., 2016a). Current evidence suggests that stroke is a disease 
with a very high potential for prevention (Tikk et al., 2014). Although the major risk 
factors for stroke, like hypertension, diabetes mellitus, hypercholesterolemia, and 
smoking are in common with those for other vascular disorders, little is known about the 
associations of these risk factors with the highly heterogeneous etiological subtypes of 
stroke. Taking into account the heterogeneity of the underlying etiology might further be 
important in identifying novel risk factors and drug targets for specific stroke subtypes, 





Epidemiology of stroke 
Stroke is a major public health issue. It is estimated that more than 80 million people live 
with stroke worldwide, 15 million people suffer a stroke, and 6 million people die because 
of stroke every year (Feigin et al., 2017; Thrift et al., 2017; G. B. D. Stroke Collaborators, 
2019). Stroke accounts for more than 5% of disability-adjusted life-years worldwide, 
comprising along with ischemic heart disease, the most common cause of disability 
worldwide (G. B. D. DALYs Hale Collaborators, 2017). Furthermore, stroke accounts for 
more than 10% of all deaths worldwide being the second most common cause of death 
after ischemic heart disease (G. B. D. Causes of Death Collaborators, 2017). Besides, 
functional disability and death, stroke has also been recognized as a major contributor to 
cognitive decline and dementia (Pendlebury et al., 2019), as well as to depression 
(Towfighi et al., 2017). 
The lifetime risk of stroke from the age of 25 onwards is around 25% and is similar 
between men and women. Yet, there is significant regional and between-country 
heterogeneity, with the highest lifetime risk being noted in East Asia (mainly due to a very 
high rate in China), Central Europe, and Eastern Europe (G. B. D. Lifetime Risk of Stroke 
Collaborators et al., 2018). Stroke is a disease of the elderly with a steep increase in 
incidence rates with increasing ages (Benjamin et al., 2017). Men have a higher incidence 
of stroke at ages lower than 75 years, but this trend is reversed at around 75 years of age, 
with women having a higher incidence thereafter (Leening et al., 2014; Benjamin et al., 
2017). In a background of increasing life expectancy worldwide (G. B. D. Mortality 
Collaborators, 2017), the lifetime risk of stroke has increased over the last decades (G. B. 
D. Lifetime Risk of Stroke Collaborators et al., 2018).  
The incidence of stroke is decreasing in high-income countries (Koton et al., 2014; 
Vangen-Lonne et al., 2017), but is increasing in low-income countries (Feigin et al., 2014). 
Although stroke mortality and disability rates have decreased worldwide since 1990, its 
global burden in terms of absolute numbers of people who died from stroke, survived a 
stroke, remained disabled from stroke, and affected by stroke remains very high and has 
increased dramatically (1.4- to 1.8-fold increases) (Feigin et al., 2017). These numbers 
call for preventive actions, especially given the strong evidence suggesting that 
substantial prevention of stroke is feasible (Tikk et al., 2014). There are well-known 
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modifiable risk factors for stroke, which account for more than 90% of the attributable 
risk of stroke across both sexes,  all age groups, and ethnicities (O'Donnell et al., 2016).  
 
Stroke subtypes and underlying etiology 
Stroke is a heterogeneous disease. At a primary level, stroke may be classified as ischemic 
or hemorrhagic, depending on whether the underlying cause is an occlusion or a rupture 
of a blood vessel, respectively (Hankey, 2017). Yet, even the two major subtypes have 
different underlying etiologies.  
According to the Trial of Organization 10172 in Acute Stroke Treatment (TOAST) 
classification system, which is the most commonly used tool for stroke classification in 
clinical practice, ischemic stroke may be classified to five major etiological subtypes: large 
artery atherosclerosis, cardioembolism, small vessel disease (SVD), stroke of other 
determined etiology (e.g. arterial dissection), and stroke of undetermined etiology 
(Adams et al., 1993). Determination of stroke etiology is important in clinical practice as 
it then guides secondary prevention of recurrent stroke (Kernan et al., 2014). Based on 
the TOAST criteria, epidemiological studies suggest that approximately 15% of ischemic 
strokes may be defined as large artery atherosclerotic strokes, 30% as cardioembolic 
strokes, 25% as small vessel strokes, and <5% as strokes of other determined etiologies 
(Petty et al., 1999; Kolominsky-Rabas et al., 2001; Schneider et al., 2004). In around 25-
30% of patients with stroke, the etiology cannot be sufficiently determined (Petty et al., 
1999; Kolominsky-Rabas et al., 2001; Schneider et al., 2004). 
Large artery atherosclerotic stroke is caused by atherosclerotic lesions in the large 
extracranial (common and internal carotids, vertebral arteries) or intracranial arteries 
(circle of Willis and proximal branches). Atherosclerotic plaques in extracranial and 
intracranial arteries may cause a stroke by either reducing blood flow beyond obstructive 
lesions or by serving as sources of intra-arterial emboli. Thrombi are often superimposed 
upon the atherosclerotic plaques. Clinically, the determination of large artery 
atherosclerotic stroke requires a stenosis of >50% or occlusion of the relevant artery, as 
determined by vascular imaging (Adams et al., 1993; Adams and Biller, 2015). Vascular 
imaging initially included arteriography and carotid duplex or transcranial Doppler 
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ultrasonography, and has now further expanded to magnetic resonance arteriography or 
computed tomography (CT) angiography. The patients usually manifest neurological 
findings consistent with infarction of the cerebral cortex or both deep and cortical 
structures, the brain stem, or cerebellum, accompanied by imaging findings of infarction 
of the respective areas. In the majority of cases, there is also evidence for risk factors for 
accelerated atherosclerosis or symptomatic atherosclerotic disease in other vascular beds 
(e.g. coronary and peripheral arterial disease) (Adams et al., 1993; Adams and Biller, 
2015).  
Cardioembolic stroke is caused by emboli arising from the heart, which are transmitted 
with blood flow to the brain, thus leading to occlusion of cerebral arteries and infarction 
of the supplied territories (Adams et al., 1993; Adams and Biller, 2015; Kamel and Healey, 
2017). Cardioembolic strokes may arise from a known cardiac source or may be of a 
possible cardiac or ascending aortic source based on transthoracic or transesophageal 
echocardiographic findings (Adams et al., 1993; Adams and Biller, 2015). Cardioembolism 
leads to strokes of higher severity, as compared to other stroke etiologies (Lin et al., 
1996). The main cardiac source of emboli to the brain is atrial fibrillation (AF) (Kamel and 
Healey, 2017), which may be diagnosed by electrographic investigation and cardiac 
rhythm monitoring. Other causes of cardioembolism might include valvular disease, 
patent foramen ovale, recent myocardial infarction, forms of cardiomyopathy, infective 
endocarditis, atrial septal aneurysm, and atheroma of the ascending aorta or the proximal 
aortic arch (Adams et al., 1993; Adams and Biller, 2015). 
Small vessel stroke refers to small (0.2 to 15 mm in diameter) noncortical infarcts caused 
by occlusion of a penetrating branch of a large cerebral artery (Adams et al., 1993; Adams 
and Biller, 2015). These branches arise from the large arteries of the circle of Willis, stem 
of the middle cerebral artery, and the basilar artery. Most lacunes occur in the basal 
ganglia, subcortical white matter, and pons (Pantoni, 2010). These arteries are usually 
affected by either lipohyalinosis and fibrinoid degeneration (usually secondary to 
hypertension) or microatheroma at their origin or in the parent large artery (Fisher, 1968, 
1978, 1979; Pantoni, 2010). Clinically, these patients usually have evidence of arterial 
hypertension or diabetes mellitus, which are recognized risk factors for SVD (Jackson and 
Sudlow, 2005). Imaging requirements further include demonstration of a small (<1.5 cm) 
deep infarction restricted to the basal ganglia, internal capsule, thalamus, or brain stem 
(Adams et al., 1993; Adams and Biller, 2015). In addition, vascular imaging should not 
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demonstrate findings consistent with large artery atherosclerosis in the clinically relevant 
vessel (Adams et al., 1993; Adams and Biller, 2015). 
Hemorrhagic stroke may be subdivided into intracerebral (ICH) and subarachnoid 
hemorrhages, which relate to bleeding directly into the brain parenchyma or the 
surrounding subarachnoid space, respectively (Cordonnier et al., 2018). The primary 
causes of ICH include pathologies of the small arteries, which might include lipohyalinosis 
or cerebral amyloid angiopathy (Cordonnier et al., 2018). Interestingly, there is an 
anatomical distinction between ICHs caused by lipohyalinosis versus those causes by 
cerebral amyloid angiopathy. Most commonly, isolated lobar hemorrhages are caused by 
cerebral amyloid angiopathy (Rodrigues et al., 2018), whereas hemorrhages in deeper 
brain structures are primarily caused by lipohyalinosis, usually as a consequence of 
hypertension (Jackson and Sudlow, 2006; Martini et al., 2012). Clinically, the neurologic 
symptoms related to ICH may not begin abruptly and are not at maximal intensity at onset, 
but they usually increase gradually over minutes or a few hours. Headache, vomiting, and 
a decreased level of consciousness develop if the hematoma becomes large enough to 
increase intracranial pressure or cause shifts in intracranial contents (Cordonnier et al., 
2018). ICH causes damage to the brain parenchyma as it enlarges. The pressure created 
by blood and surrounding edema is life-threatening; ICHs have very high mortality and 
morbidity (van Asch et al., 2010; Cordonnier et al., 2018). 
The two major causes of subarachnoid hemorrhage are rupture of arterial aneurysms that 
are situated at the base of the brain and bleeding from vascular malformations that lie 
near the pial surface (Lawton and Vates, 2017; Muehlschlegel, 2018). Symptoms of 
subarachnoid hemorrhage begin abruptly in contrast to the more gradual onset of ICH 
(Edlow et al., 2008; Lawton and Vates, 2017) with instantly severe and widespread 
headache comprising the most common presenting symptom (Linn et al., 1994). Vomiting 
occurs soon after onset (Edlow et al., 2008). The prognosis of the disease is poor with the 
pre-hospital and 30-day fatality rates being at 15% and 35%, respectively (Nieuwkamp 




Cerebral small vessel disease 
The term cerebral SVD describes the pathological processes affecting the perforating 
arterioles, capillaries, and venules of the brain (Pantoni, 2010; Wardlaw et al., 2013a). 
Cerebral SVD is strongly associated with aging and its manifestations are at least to some 
extent present in almost all elderly individuals (de Leeuw et al., 2001). SVD is the major 
vascular contributor to dementia (Debette et al., 2018), accounts for about 25% of 
ischemic strokes (Sudlow and Warlow, 1997) and for almost all cases of intracerebral 
hemorrhage (Qureshi et al., 2001; Qureshi et al., 2009), and is an independent predictor 
of mortality (Debette et al., 2018). SVD has further been associated with physical and 
psychological sequalae in the elderly, including gait (de Laat et al., 2010), functional 
(Inzitari et al., 2009), mood (van Agtmaal et al., 2017), and urinary disturbances (Poggesi 
et al., 2008). 
As conventional imaging techniques do not allow direct assessment of cerebral small 
vessels in vivo, SVD is mainly defined by its neuroimaging manifestations, according to 
standard criteria (Wardlaw et al., 2013b). The typical lesions that are associated with SVD 
include lacunes and recent small subcortical infarcts, alterations in white matter, which 
are observed as hyperintensities in T2 sequences in magnetic resonance imaging (MRI), 
cerebral microbleeds and intracerebral hemorrhages, and enlarged perivascular spaces 
(Wardlaw et al., 2013b). More sensitive imaging methods further show pathological 
changes in the otherwise normal-appearing parenchyma, especially in the white matter, 
which are believed to arise as a result of demyelination or increased interstitial fluid 
(Baykara et al., 2016; Munoz Maniega et al., 2017). 
The most common pathological alterations associated with cerebral SVD include 
arteriolosclerosis and cerebral amyloid angiopathy (Pantoni, 2010). Arteriolosclerosis, 
otherwise commonly called “hypertensive arteriopathy”, describes a pathological process 
related to degenerative alterations of the vessel walls, which is common in small 
perforating end arterioles of the deep grey nuclei and deep white matter of the brain, but 
is also a systemic disorder (Pantoni, 2010). Arteriolosclerotic microvascular lesions 
outside the brain are characteristically found in the microcirculation of the kidneys and 
the retina. They are strongly associated with aging and with vascular risk factors, 
particularly hypertension and diabetes. This type of SVD is characterized by loss of 
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smooth muscle cells from the tunica media, deposits of fibro-hyaline material 
(lipohyalinosis), narrowing of the lumen, and thickening of the vessel wall (Fisher, 1968, 
1978, 1979; Lammie, 2002; Pantoni, 2010). Microaneurysms and microatheromas in the 
parent vessels often co-exist with arteriolosclerosis (Fisher, 1968, 1978, 1979; Pantoni, 
2010). 
Cerebral amyloid angiopathy is the second most common type of SVD and is characterized 
by the accumulation of the amyloid β (Αβ) protein in the media and adventitia of small-
to-medium-sized arteries and arterioles predominantly located in the leptomeningeal 
space and the cortex (Vinters and Gilbert, 1983; Banerjee et al., 2017). The accumulation 
of Αβ makes the vessel fragile and vulnerable to rupture and is thus associated with 
microbleeds and intracerebral hemorrhages (Vinters and Gilbert, 1983; Banerjee et al., 
2017). Although the extent to which it might contribute to ischemic manifestations of SVD 
remains uncertain, the presence of microbleeds due to CAA might influence treatment 
decisions in patients with ischemic stroke, such as the use of antithrombotic and 
anticoagulant agents (Wang et al., 2014; Wilson et al., 2018). A definite diagnosis of CAA 
requires neuropathological evidence of presence of Aβ in the vessel wall. Yet, the 
development of standard clinical and diagnostic criteria with high specificity for the 
diagnosis of CAA, have enabled the investigation of the disease with neuroimaging studies 
(Knudsen et al., 2001; Linn et al., 2010). 
Despite its major impact on public health, the etiology of SVD remains largely unknown, 
thus hampering the development of treatments that could reduce the burden of the 
disease (Bath and Wardlaw, 2015; Wardlaw et al., 2019). Several mechanisms have been 
proposed as playing a key role in the pathogenesis of the disease. These include 
endothelial dysfunction leading to blood-brain barrier dysfunction and impaired 
vasodilation (Wardlaw et al.; Rajani et al., 2018; Nation et al., 2019), vessel stiffening 
causing dysfunctional blood flow and interstitial fluid drainage (Shi et al., 2016; Mestre et 





Genetic risk factors for stroke and cerebral small vessel disease 
Genetic risk factors contribute to cerebrovascular disease. Having a first-degree relative 
with stroke increases the risk of stroke by 30% (Flossmann et al., 2004), whereas 
monozygotic twin are twice more likely to be concordant for stroke as compared to 
dizygotic twins (de Faire et al., 1975; Flossmann et al., 2004). The overall heritability of 
ischemic stroke is estimated to 38%, but varies across subtypes (from 16% for small 
vessel stroke to >40% for large artery stroke) (Bevan et al., 2012) and heritability for ICH 
is estimated to 29% (Devan et al., 2013), based on genome-wide associations study 
(GWAS) data. The heritability of subclinical radiological markers of cerebral SVD (WMH, 
enlarged perivascular spaces), is estimated to be even >50% (Duperron et al., 2018). 
Hereditary factors that increase the risk of cerebrovascular disease could either comprise 
rare single mutations with high penetration that lead to mendelian forms of disease or 
common genetic variants that increase the risk modestly.   
Rare single mutations may cause familial disorders with stroke as the primary 
manifestation. Advances in sequencing technology have facilitated the discovery of such 
single-gene disorders associated with stroke, and especially SVD, which can manifest with 
either stroke or cognitive decline and other manifestations (Haffner et al., 2016). Typical 
examples in this category involve cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive 
arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL), or pontine 
autosomal dominant microangiopathy with leukoencephalopathy (PADMAL) (Dichgans 
et al., 2019). CADASIL is the most common hereditary cause of stroke and cognitive 
decline, and has gained great interest as the model disease to study the more common 
sporadic form of SVD (Chabriat et al., 2009; Dichgans et al., 2019). It is caused by 
mutations in NOTCH3 and leads to thickening of the arteriolar walls, accumulation of an 
amyloid granular osmiophilic material in the arterial walls, and prominent degeneration 
of vascular smooth muscle cells (Joutel et al., 1996; Chabriat et al., 2009; Dichgans et al., 
2019). CADASIL is considered a disease model for arteriolosclerosis. Similarly, hereditary 
forms of cerebral amyloid angiopathy have been described, but they are very rare in the 
general population (Biffi and Greenberg, 2011). Single mutations could also lead to 
familial disorders with more complex phenotypes with cerebrovascular disease being one 
of several manifestations. Typical examples in this category include Marfan’s syndrome 
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and the vascular Ehler’s Danlos syndrome, which are both characteristically associated 
with arterial dissection (Dichgans et al., 2019).  
Common genetic variants (typically single nucleotide polymorphisms with allele 
frequencies >0.5-1%) might be associated with small increases in the risk of stroke. These 
genetic variants are identified through GWASs, which compare the frequency of all 
common variants in the genome between individuals having suffered a stroke and stroke-
free controls. The largest to-date GWAS for stroke using data from the MEGASTROKE 
Consortium, was a meta-analysis of 67,162 cases and 454,450 controls and identified 32 
loci associated with either any stroke, ischemic stroke, or one of the major ischemic stroke 
subtypes (Malik et al., 2018a). A subsequent meta-analysis of the MEGASTROKE data with 
the UK Biobank (72,147 stroke patients and 823,869 controls) further increased the 
number of significant loci to 35 (Malik et al., 2018b). Some of the identified variants were 
specific for etiological stroke subtype: 6 loci were specific for large artery stroke, 4 for 
cardioembolic stroke, and 2 for small vessel stroke (Malik et al., 2018a). The majority of 
the identified variants were common (minor allele frequency >5%), showed modest 
increases in risk of stroke (OR<1.30) and were located in non-coding regions (Malik et al., 
2018a; Dichgans et al., 2019). Some genetic variants can confer risk of stroke by 
influencing the risk of causal stroke risk factors. Indeed, almost half of the identified loci 
in the abovementioned GWAS meta-analyses have been associated in previous studies 
with high blood pressure, blood lipid levels, carotid plaque, and atrial fibrillation (AF) 
(Malik et al., 2018a). Similarly, trans-ethnic and European-based GWAS meta-analyses for 
white matter hyperintensities (WMH) have identified 9 loci associated at a genome-wide 
significance threshold (Verhaaren et al., 2015; Traylor et al., 2019). Interestingly, a genetic 
risk score for WMH volume constructed based on these studies has been found to be also 
associated with the risk of small vessel stroke, thus indicating common genetic 





Risk factors for stroke and cerebral small vessel disease 
Although the high heterogeneity in the etiology of cerebrovascular disease complicates 
the exploration of risk factors, multiple modifiable and non-modifiable risk factors have 
been identified. For stroke, an international case-control study (INTERSTROKE) recently 
showed that a set of 10 risk factors including hypertension, smoking, waist-to-hip ratio, 
diet, physical activity, alcohol intake, psychosocial stress, cardiac disease (e.g. atrial 
fibrillation), and the ratio of apolipoprotein B to A1 could explain up to 90% of stroke 
population-attributable risk (O'Donnell et al., 2010). All of these risk factors were 
associated with risk of ischemic stroke, whereas hypertension, smoking, waist-to-hip 
ratio, diet, and alcohol intake were also significantly associated with the risk of 
hemorrhagic stroke (O'Donnell et al., 2010). 
Hypertension is the leading risk factor for both ischemic and hemorrhagic stroke 
estimated to account for ~50% of the population attributed risk of stroke worldwide 
(Feigin et al., 2016b; O'Donnell et al., 2016; Forouzanfar et al., 2017). Both systolic (SBP) 
and diastolic blood pressure (DBP) are linearly associated with stroke incidence and 
mortality in both sexes and across all age groups (Lewington et al., 2002; Lacey et al., 
2018). Furthermore, hypertension is considered the primary risk factors for cerebral SVD 
and particularly arteriolosclerosis (Wardlaw et al., 2019). Antihypertensive treatment 
remains one of the primary targets for lowering the global burden of cerebrovascular 
disease (Blood Pressure Lowering Treatment Trialists, 2014; Meschia et al., 2014; Ettehad 
et al., 2016; Xie et al., 2016; Brunstrom and Carlberg, 2018). Interestingly, clinical trials 
show that BP lowering with different antihypertensive drug classes might differentially 
influence the risk of stroke. Specifically, calcium channel blockers were shown to be 
superior for primary prevention of stroke, as compared to beta blockers (Rothwell et al., 
2010; Webb et al., 2010; Ettehad et al., 2016). While hypertension is an established risk 
factor for both ischemic and hemorrhagic stroke (O'Donnell et al., 2016; Lacey et al., 
2018), the effects of BP and different antihypertensive drug classes on etiologically 
defined stroke subtypes (Adams et al., 1993), in particular, large artery stroke, 
cardioembolic stroke, small vessel stroke, deep and lobar intracerebral hemorrhage 
(ICH), remain largely unknown. Only a few observational studies have examined whether 
BP is differentially associated with stroke subtypes (Schulz and Rothwell, 2003; Ohira et 
19 |  
 
al., 2006; Zia et al., 2007; Li et al., 2015), but data from BP lowering trials on stroke 
subtypes are missing (Ettehad et al., 2016).  
Blood lipids are a well-established risk factor for large artery atherosclerosis (Collins et 
al., 2016). Lipid-modifying therapies have shown benefits in reducing risk of both 
coronary artery disease and large artery stroke (Cholesterol Treatment Trialists 
Collaboration et al., 2010; Chou et al., 2016). Current guidelines for secondary stroke 
prevention recommend treatment with statins after ischemic stroke or transient ischemic 
attack (European Stroke Organisation Executive Committee and E. S. O. Writing 
Committee, 2008; Kernan et al., 2014; Intercollegiate Stroke Working Party, 2016; Stroke 
Foundation, 2017) referring to large-scale clinical trials data and meta-analyses 
(Amarenco et al., 2006; Amarenco and Labreuche, 2009; Manktelow and Potter, 2009). 
However, most trials provided no sub-analyses for ischemic stroke subtypes. Thus, the 
role of blood lipids in forms of cerebrovascular disease other than large artery stroke 
remains largely elusive. The J-STARS trial, the only study providing sub-analyses, found 
statins to reduce recurrence of large artery stroke but not small vessel stroke (Hosomi et 
al., 2015). Results from the SPARCL trial suggest that statins may increase the risk of ICH 
in patients with stroke or transient ischemic attack (Amarenco et al., 2006), especially in 
patients with SVS as an entry event (Goldstein et al., 2008). 
AF is an arrhythmia with very high prevalence among the elderly population (>10% 
among those aged >80 years) (Chugh et al., 2014). AF is associated with a predisposition 
towards atrial thrombi formation and is considered a major source of cardioembolism, 
thus increasing the risk for cardioembolic stroke. Observational cohort studies have 
found AF to increase the risk of stroke by 3- to 5-fold (Wolf et al., 1991). The number of 
patients with AF may double and the number of AF-related strokes may triple in the next 
few decades based on projections from high-income countries, such as the United States 
(Go et al., 2001). Current guidelines for stroke classification and prevention of recurrent 
stroke clearly highlight the need to identify AF among patients with stroke, and treating 
them with anticoagulation depending on the cumulative risk of stroke among every 
individual patient (Kernan et al., 2014). 
Diabetes mellitus is another major risk factor for cerebrovascular disease. Prospective 
cohort studies have consistently shown presence of diabetes mellitus to be associated 
with 1.5- to 2-fold increases in risk of ischemic and hemorrhagic stroke (Emerging Risk 
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Factors et al., 2010). Fasting glucose levels in non-diabetic individuals, pre-diabetes, and 
duration of the period living with diabetes are also strong independent risk factors for 
stroke and cerebral SVD (Abbott et al., 1987; Sui et al., 2011; Banerjee et al., 2012; Lee et 
al., 2012). Furthermore, intensive glycemic control in patients with type II diabetes 
mellitus has been shown to decrease stroke risk and stroke mortality (Gaede et al., 2008).  
A number of other behavioral risk factors have further been associated with the risk of 
stroke in a similar way that they have been associated with other forms of vascular 
disease. These include overweight and obesity (Strazzullo et al., 2010), alcohol intake 
(Millwood et al., 2019b), smoking (Larsson et al., 2019; Pan et al., 2019), physical 
inactivity and sedentary behavior (Kivimaki et al., 2019), and specific nutritional choices 
(Psaltopoulou et al., 2013; Iacoviello et al., 2018). Although the associations of all these 
factors with risk of stroke are considered well-established, again there is only limited 
evidence regarding associations with specific stroke etiologies. 
 
Inflammation as a novel risk factor for cerebrovascular disease 
Extensive experimental evidence suggests atherosclerosis, one of the major underlying 
etiologies of ischemic stroke, to be a primarily chronic inflammatory disorder (Hansson, 
2005; Libby et al., 2011). Both innate and adaptive immune mechanisms have been found 
to participate in the initiation and propagation of atherosclerosis (Hansson, 2005; Libby 
et al., 2011). Furthermore, inflammation has pro-thrombotic effects and is even involved 
in the pathogenesis of major risk factors for stroke such as atrial fibrillation (Kamel and 
Iadecola, 2012). Epidemiological studies consistently show biomarkers of inflammation 
to be associated with the risk of atherosclerotic events independently of traditional 
vascular risk factors (Kaptoge et al., 2010; Kaptoge et al., 2014). Despite the aggressive 
control of blood pressure, lipids, and glucose levels, there is still a high prevalence of both 
coronary artery disease events and stroke. As in these individuals, inflammatory 
biomarkers, and particularly circulating levels of high-sensitivity C-reactive protein 
(hsCRP), have been associated with the risk of vascular events, a new concept of residual 
inflammatory risk has been developed (Ridker, 2017; Bohula et al., 2018). This concept is 
further supported by clinical data. Statin treatment has been shown in several trials to 
reduce markers of inflammation in a dose-response manner and these decreases are 
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proportional to the final vascular benefit, especially among patients with high hsCRP 
levels at the time of treatment initiation (Ridker et al., 2008; Bohula et al., 2018).  
In the last years, two large randomized clinical trials specifically targeted vascular 
inflammation in patients with established cardiovascular disease and provided novel 
insights into the role of inflammatory mechanisms as potential drug targets for reducing 
vascular risk. In the CANTOS trial, treatment with an anti-IL-1β (interleukin-1β) 
monoclonal antibody reduced the levels of IL-6 (interleukin-6) and hsCRP leading to a 
reduction in the combined primary endpoint of nonfatal myocardial infarction, nonfatal 
stroke or cardiovascular death independent of low-density lipoprotein cholesterol (LDL-
C) levels in patients with a history of myocardial infarction and hsCRP levels ≥2 mg/l 
(Ridker et al., 2017). On the contrary, treatment with low-dose methotrexate in the CIRT 
trial neither reduced cardiovascular event rates nor the levels of IL-1β, IL-6, and hsCRP in 
patients with stable coronary artery disease (Ridker et al., 2019a). 
These discordant results from the CANTOS (Ridker et al., 2017; Aday and Ridker, 2019; 
Ridker, 2019; Ridker et al., 2019a) and CIRT (Ridker et al., 2019a) randomized controlled 
trials emphasize the importance of targeting specific mediators and pathways for 
lowering vascular risk (Ridker et al., 2017; Aday and Ridker, 2019; Ridker, 2019; Ridker 
et al., 2019a). IL-6, a key regulator of the inflammatory cascade, acts by binding to either 
its membrane-bound or soluble receptor (IL-6R, IL-6 receptor) and induces 
proinflammatory downstream effects including increases in the circulating levels of CRP 
(Scheller et al., 2011; Ridker, 2016). IL-6 has been implicated in the pathogenesis of 
several inflammatory diseases (Scott, 2017; Stone et al., 2017; Danese et al., 2019) and 
downregulation of its signaling cascade has been proposed as a potential strategy for 
lowering cardiovascular risk (Ridker, 2016, 2019). IL-6 levels have consistently been 
associated with risk of coronary artery disease in cohort studies (Ridker et al., 2000; 
Kaptoge et al., 2014). Mendelian randomization (MR) studies further showed that a 
variant in the gene encoding IL-6R with effects resembling pharmacological IL-6R 
inhibition is associated with a lower risk of coronary artery disease (Il R. Genetics 
Consortium Emerging Risk Factors Collaboration et al., 2012; Interleukin-6 Receptor 
Mendelian Randomisation Analysis Consortium et al., 2012). Finally, secondary analyses 
from CANTOS demonstrated that the magnitude of the therapeutic benefit of IL-1β 
targeting was associated with the reduction of circulating IL-6 levels (Ridker et al., 2018a; 
Ridker, 2019) and that even after IL-1β inhibition, the residual cardiovascular risk was 
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proportional to the post-treatment IL-6 levels (Ridker et al., 2019b). These results from 
CANTOS provide indirect clinical evidence that interfering with IL-6 signaling might lower 
cardiovascular risk and suggest that an approach directly targeting IL-6 signaling could 
offer additional benefit for cardiovascular prevention beyond IL-1β inhibition. 
However, the IL-1β/IL-6/CRP axis is only one of the inflammatory pathways that are 
involved in the pathogenesis of atherosclerosis. Identification and exploration of different 
pathways, which might include other inflammatory mediators with more specific roles in 
the initiation and progression of atherosclerosis are considered crucial for the 
development of successful anti-inflammatory strategies. The complex system of 
chemokines is one such pathway (Noels et al., 2019). Chemokines are part of the innate 
immunity and act in an orchestrated and complex way by attracting specific inflammatory 
cells in the sites of inflammation. They contribute to accumulation of inflammatory cells 
in the atherosclerotic plaque, expansion of the plaque, plaque destabilization, and 
thrombosis (Noels et al., 2019). Although animal studies in experimental models of 
atherosclerosis have long suggested the chemokine system as a potential target for 
lowering vascular risk, there is only scarce evidence from humans regarding the potential 
efficacy of such an approach (Noels et al., 2019). Monocyte-chemoattractant protein-1 
(MCP-1) or CC chemokine ligand-2 (CCL2), the prototypical CC chemokine has attracted 
major attention, due to its key role in recruiting monocytes to the atherosclerotic plaque 
(Nelken et al., 1991; Lutgens et al., 2005; Lin et al., 2014). Evidence from animal models 
of atherosclerosis suggests that knocking out either MCP-1 or its receptor CCR2 (CC 
chemokine receptor-2) could lead to attenuation of the atherosclerotic phenotype (Boring 
et al., 1998; Gu et al., 1998; Combadiere et al., 2008; Liehn et al., 2010; Bot et al., 2017). 
Yet, data from humans regarding the role of MCP-1 in atherosclerosis remain scarce. 
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Mendelian Randomization 
The gold-standard approach for inferring causality in medical research is a randomized 
controlled trial (RCT). However, the majority of the known risk factors for 
cerebrovascular disease have been identified through epidemiological observational 
studies, typically population-based longitudinal cohort studies that might be biased 
because of confounding and reverse causation (Fewell et al., 2007). Yet, conducting RCTs 
is very expensive and time-consuming and RCTs have further been found to have very low 
success rates.  The main reason for RCT failures is lack of efficacy of the respective drug 
target (Harrison, 2016). This is assumed to be partly the result of a low-quality evidence 
basis that supports conducting an RCT (Khakoo et al., 2019). Particularly, consistently 
biased results from large-scale observational studies and the inability to translate 
findings from animal models to humans are believed to be the main reasons for these high 
failure rates (Smith et al., 2007). Hence, it is of crucial importance to prioritize 
interventions to be tested in RCTs based on unbiased evidence in order to maximize the 
probability of success.  
MR is a methodology developed over the last three decades that overcomes the inherent 
limitations of observational studies (confounding and reverse causation) while using 
observational data and thus enables exploration of causal associations without the need 
of conducting an RCT (Zheng et al., 2017; Bandres-Ciga et al., 2019). It is a type of 
instrumental variable analysis that instead of measuring a risk factor directly, uses 
information from genetics to create an instrument of genetic predisposition to the risk 
factor under study (Zheng et al., 2017). Then, using this genetic instrument, MR explores 
its effect on outcomes of interest (Zheng et al., 2017). By grouping individuals in the 
population according to the presence or not of specific genetic variants that modify a risk 
factor allows researchers exploring if a biomarker is causally related to a disease (Holmes 
et al., 2017). This inference is based on the fundamental characteristics of the genome: 
first, because of the random allocation of alleles during meiotic segregation, genetic 
variants used as instrument variables should be free from confounding effects; second, 
owing to the non-modifiable nature of the germline genome, bias due to reverse causation 




Figure 1. Exploration of associations of (A) potential risk factors and (B) drug target effects 
with risk of stroke using Mendelian randomization (MR). Schematic representations of the 
principles and assumptions of MR analyses. (A) By using genetic variants throughout the genome 
that associate with a risk factor we can generate causal association estimates with a disease 
outcome (e.g. stroke). (B) When restricting the selection of variants to those located in the vicinity 
of the gene encoding a protein drug target and associated with a downstream drug target effect, 
we can estimate the effects that a drug intervention could have on the studied disease outcome. 
In both occasions the assumptions are the same: the genetic variants (instruments) must be 
associated with the exposure (assumption 1); the variants must not be associated with 
confounders (assumption 2); the variants must influence the outcome only through the risk factor 
under study (assumption 3). 
 
In the last decade, the expansion of GWASs to a broad range of phenotypes, the wide 
availability of summary data from these studies, and the development of statistical 
methods to utilize these data to perform MR analyses, have led to an explosion in the MR 
field (Bandres-Ciga et al., 2019). MR may be used to explore the global effects of a risk 
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In the first case, MR uses genetic variants throughout the genome, which have been found 
in a GWAS to independently influence a risk factor, as instruments to proxy the effects of 
the risk factor (Burgess and Davey Smith, 2019). In the second approach, the selection of 
instruments may be restricted to the locus of a known or promising novel drug target 
(Mokry et al., 2015). By then using genetic variants in this locus associated with the risk 
factor under study, MR may be used to study the effects of a specific target-exerted 
modification in the risk factor (Ference, 2018; Gill et al., 2019). This approach has 
consistently been found to compute association estimates with disease endpoints that are 
comparable to those derived from RCTs (Ference, 2018; Roberts, 2018). 
MR has been proven especially effective in establishing causal relationships and 
prioritizing drug targets for clinical study in the field of cardiovascular medicine. For 
example, in the absence of data from clinical trials, MR analyses using genetic variants 
that influence CRP circulating levels in the gene encoding CRP, showed that there is no 
evidence for a causal effect of CRP on risk of stroke, coronary artery disease, or other 
atherosclerotic phenotypes (Zacho et al., 2008; Elliott et al., 2009; Prins et al., 2016; 
Ligthart et al., 2018). Furthermore, MR provided evidence for a lack of a protective effect 
of low alcohol consumption on risk of stroke and coronary artery disease (Holmes et al., 
2014; Millwood et al., 2019a). Regarding drug targets, in a series of studies using MR 
analyses, it was shown that lipid-lowering drug targets primarily exert their efficacy 
against coronary artery disease by influencing the levels of apolipoprotein B and LDL-C 
(Ference et al., 2015; Ference et al., 2017a; Ference et al., 2017b; Ference et al., 2018; 
Ference et al., 2019). 
However, as every methodological design, MR is based on specific assumptions and could 
be prone to bias, if these assumptions are violated. The primary assumptions are the 
following: (1) the genetic variants used as instruments must be associated with the risk 
factor under study; (2) these variants should affect the risk of the disease under study 
only through the explored risk factor and not through other independent mechanisms; 
(3) these variants should not be associated with known or unknown confounders that are 
associated both with the risk factor and the disease under study (Holmes et al., 2017; 
Zheng et al., 2017; Burgess and Davey Smith, 2019). While the first assumption relates to 
the quality and strength of the genetic instruments and might be relatively easy to assess 
with GWAS data, the second and third assumption might be violated if the variants used 
as instruments affect other phenotypes beyond the risk factor under study. Specifically, 
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pleiotropic genetic variants, i.e. variants influencing several phenotypes, might violate the 
latest two assumptions and if used as genetic instruments in an MR study might bias the 
results. The use of multiple genetic variants as instruments and the development of more 
advanced statistical approaches allow for the assessment of the probability of horizontal 
pleiotropy and the adjustment of the results (Holmes et al., 2017; Zheng et al., 2017; 
Burgess and Davey Smith, 2019). Furthermore, the use of alternative MR approaches with 
different underlying assumptions enables the exploration of the robustness of the 
findings (Burgess and Davey Smith, 2019). Studies using MR should therefore explore 
potential violations of the assumptions of the method and these requirements should be 
kept in mind when interpreting any MR results. 
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AIMS OF THE THESIS 
 
While multiple risk factors have long been identified for stroke, the highly heterogeneous 
nature of the disease makes it extremely challenging to identify specific risk factors for 
the major etiological stroke subtypes. In light of largely variable mechanisms between 
stroke subtypes, there might further exist differences in the effects of approved drugs or 
treatments under development, which could have relevance for therapeutic decisions in 
specific patient subgroups.  
The large number of events and the depth of phenotypic information available through 
GWASs permits exploration of outcomes for which there are no adequate data from 
observational studies or RCTs, such as stroke subtypes. Therefore, the overarching goal 
of the current PhD thesis was to leverage large-scale genetic data and apply MR analyses 
to (i) detect novel risk factors and promising drug targets for cerebrovascular disease and 
(ii) investigate the effects of known risk factors and drug targets for stroke as a whole on 
etiological stroke subtypes and cerebral SVD, 
The following specific aims were addressed by the six individual studies included in the 
current PhD thesis: 
(1) First, we used data from a large-scale GWAS investigating genetic determinants for 
the circulating levels of 41 cytokines and growth factors and implemented two-sample 
MR analyses to: (i) explore associations between genetic predisposition to higher or lower 
circulating cytokine levels with risk of any stroke; (ii) evaluate specific associations with 
ischemic stroke and its major etiologic subtypes (large artery stroke, cardioembolic 
stroke, and small vessel stroke), as well as with intracerebral hemorrhage; (iii) examine 
associations with etiologically related cardiovascular outcomes including coronary artery 
disease (CAD), myocardial infarction (MI), and atrial fibrillation (AF). 
 
(2) Second, motivated by the results from this study, we performed a meta-analysis of 
6 population-based cohorts encompassing 17,180 stroke-free individuals with long-term 
follow-up and aimed to: (i) determine the association between circulating MCP-1 levels 
and risk of incident stroke, (ii) explore associations of MCP-1 levels with risk of major 
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stroke subtypes (incident ischemic and hemorrhagic stroke); (iii) assess whether any 
association with stroke risk is independent of the IL-6 and CRP  levels. 
 
(3) Third, we identified and validated genetic proxies for downregulated IL-6 signaling 
on the basis of effects on upstream regulators and downstream effectors of the pathway 
aiming to: (i) explore associations of genetic predisposition to downregulated IL-6 
signaling with risk of ischemic stroke and coronary artery disease; (ii) examine 
associations with major etiological subtypes of ischemic stroke (large artery, 
cardioembolic, and small vessel stroke); (iii) examine associations with a broad range of 
other cardiovascular phenotypes. 
 
(4) Fourth, we set out to: (i) identify genetic variants within genes corresponding to 
the targets of common antihypertensive agents for hypertension that proxy the effects of 
these treatments; (ii) validate these variants by exploring their effects on coronary artery 
disease and stroke risk in MR and comparing them with those derived from RCTs; (iii) 
offer insights towards their adverse effect profiles and repurposing potential by 
undertaking a phenome-wide association study (PheWAS). 
 
(5) Fifth, we used large-scale genetic data for blood pressure and the abovementioned 
genetic proxies for antihypertensive treatments with the aims to: (i) examine the effects 
of genetically determined SBP and DBP on the risk of etiological stroke subtypes; (ii) 
explore the effects of genetic proxies for different antihypertensive drug classes on 
etiological stroke subtypes; (iii) examine associations of these genetic proxies with the 
radiological phenotype of WMH, a manifestation of cerebral SVD etiologically related to 
small vessel stroke and ICH. 
 
(6) Finally, we leveraged data from large GWASs on blood lipid levels, as well as on 
ischemic (small vessel stroke, WMH volume) and hemorrhagic (ICH) manifestations of 
cerebral SVD aiming to: (i) examine the effects of genetic determinants of levels of HDL-
C, LDL-C, and triglycerides (TG) on SVD manifestations; (ii) explore associations between 
genetic determinants of lipoprotein particle fractions with these phenotypes; (iii) 
determine the effects of genetic predisposition to HDL-C-raising, LDL-C-lowering, and TG-
lowering  through variants in genes encoding lipid-modifying drug targets on SVD.  
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BACKGROUND: Cytokines and growth factors have been implicated in 
the initiation and propagation of vascular disease. Observational studies 
have shown associations of their circulating levels with stroke. Our 
objective was to explore whether genetically determined circulating levels 
of cytokines and growth factors are associated with stroke and its etiologic 
subtypes by conducting a 2-sample Mendelian randomization (MR) study.
METHODS: Genetic instruments for 41 cytokines and growth factors 
were obtained from a genome-wide association study of 8293 healthy 
adults. Their associations with stroke and stroke subtypes were evaluated 
in the MEGASTROKE genome-wide association study data set (67 162 
cases; 454 450 controls) applying inverse variance–weighted meta-analysis, 
weighted-median analysis, Mendelian randomization–Egger regression, 
and multivariable Mendelian randomization. The UK Biobank cohort was 
used as an independent validation sample (4985 cases; 364 434 controls). 
Genetic instruments for monocyte chemoattractant protein-1 (MCP-1/
CCL2) were further tested for association with etiologically related vascular 
traits by using publicly available genome-wide association study data.
RESULTS: Genetic predisposition to higher MCP-1 levels was associated with 
higher risk of any stroke (odds ratio [OR] per 1 SD increase, 1.06; 95% CI, 
1.02–1.09; P=0.0009), any ischemic stroke (OR, 1.06; 95% CI, 1.02–1.10; 
P=0.002), large-artery stroke (OR, 1.19; 95% CI, 1.09–1.30; P=0.0002), 
and cardioembolic stroke (OR, 1.14; 95% CI, 1.06–1.23; P=0.0004), but 
not with small-vessel stroke or intracerebral hemorrhage. The results were 
stable in sensitivity analyses and remained significant after adjustment 
for cardiovascular risk factors. Analyses in the UK Biobank showed similar 
associations for available phenotypes (any stroke: OR, 1.08; 95% CI, 
0.99–1.17; P=0.09; any ischemic stroke: OR, 1.07; 95% CI, 0.97–1.18; 
P=0.17). Genetically determined higher MCP-1 levels were further associated 
with coronary artery disease (OR, 1.04; 95% CI, 1.00–1.08; P=0.04) and 
myocardial infarction (OR, 1.05; 95% CI, 1.01–1.09; P=0.02), but not with 
atrial fibrillation. A meta-analysis of observational studies showed higher 
circulating MCP-1 levels in patients with stroke in comparison with controls.
CONCLUSIONS: Genetic predisposition to elevated circulating levels of 
MCP-1 is associated with higher risk of stroke, in particular with large-
artery stroke and cardioembolic stroke. Whether targeting MCP-1 or its 
receptors can lower stroke incidence requires further study.
© 2018 American Heart Association, Inc.
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ORIGINAL RESEARCH 
ARTICLE
Stroke is the leading cause of long-term disability and the second most common cause of death worldwide,1,2 with a growing burden on global 
health.3 Inflammatory mechanisms have been implicat-
ed in stroke and etiologic stroke subtypes,4–6 and spe-
cifically demonstrated for large-artery atherosclerotic 
stroke.4,5 Cytokines and growth factors regulate the in-
flammatory response4 and thus may serve as targets for 
cardiovascular disease prevention.7 Indeed, the CAN-
TOS trial (Canakinumab Anti-Inflammatory Thrombosis 
Outcome Study) recently demonstrated the potential of 
targeting specific inflammatory cytokines in reducing 
vascular end points.8
Few studies have investigated associations between 
the circulating levels of inflammatory cytokines and risk 
of stroke. Levels of interleukin (IL)–1β and IL-6 were 
found to be associated with incident and recurrent is-
chemic stroke.4 However, these associations derived 
from observational studies preclude conclusions about 
causal relationships because of possible confounding 
and reverse causation.9 Also, associations with etiologic 
stroke subtypes were not investigated in depth.4 Hence, 
the potential causative role of individual cytokines in 
determining stroke risk remains elusive. Developing 
meaningful strategies for stroke prevention will require 
defining these relationships.10
Mendelian randomization (MR) aims to overcome 
the limitations of conventional epidemiological studies 
with respect to confounding and reverse causation. By 
using genetic variants as instrumental variables for a 
trait, MR enables an investigation of associations inde-
pendent of the conventional biases accompanying ob-
servational studies.11 A recent genome-wide association 
study (GWAS) in 8293 healthy subjects of Finnish an-
cestry identified multiple common genetic variants that 
influence circulating levels of 41 cytokines and growth 
factors (referred to hereafter as cytokines for simplic-
ity),12 thus providing comprehensive data on genetic 
determinants of circulating inflammatory biomarkers.12
Here, by leveraging data from this recent GWAS on 
cytokines12 and the largest GWAS meta-analysis on 
stroke and stroke subtypes to date,13 we implemented 
a 2-sample MR study to (1) explore the associations be-
tween genetic predisposition to higher or lower circu-
lating cytokine levels with risk of any stroke; (2) evaluate 
specific associations with ischemic stroke and its major 
etiologic subtypes (large-artery stroke, cardioembolic 
stroke, and small-vessel stroke), and with intracerebral 
hemorrhage, as well; (3) validate these findings in UK 
Biobank as an independent cohort; (4) compare the MR 
associations with estimates of association derived from 
meta-analyses of observational studies; and (5) examine 
the association with etiologically related cardiovascular 
outcomes including coronary artery disease (CAD), my-
ocardial infarction (MI), and atrial fibrillation (AF).
METHODS
Access to Publicly Available Data
The analyses for this study were based on publicly available 
summary statistics from GWAS consortia. The web links for 
downloading the data are provided in Table I in the online-
only Data Supplement along with descriptive characteristics 
of the consortia. The retrieved summary data for the current 
analysis and the code script are available on reasonable re-
quest to the corresponding author. Because all analyses have 
been based on publicly available summary statistics and not 
individual-level data, no ethical approval from an institutional 
review board was required.
Study Design and Data Sources
The overall design of this study is displayed in Figure 1. Table 
I in the online-only Data Supplement summarizes our data 
sources for this MR study. The genetic instruments were 
taken from publicly available summary statistics.12 For each 
of the 41 cytokines (full list provided in Table II in the online-
only Data Supplement) we selected single-nucleotide poly-
morphisms (SNPs) associated with their circulating levels at 
a significance threshold of a false discovery rate <5%.14 To 
avoid bias by selection of false-positive instruments, we per-
formed additional analyses using a genome-wide threshold 
of significance (P<5×10–8). After extracting the summary sta-
tistics for significant SNPs, we pruned all SNPs in linkage dis-
equilibrium (r2<0.1 in the European 1000 Genomes Project 
reference panel), retaining SNPs with the lowest P value as 
an independent instrument. We identified 698 SNPs not in 
linkage disequilibrium to be significantly associated with cir-
culating cytokine levels; 615 of them were also available in 
the MEGASTROKE data set. To avoid the use of pleiotropic 
instruments, we excluded 126 SNPs that were associated with 
levels of >1 cytokine,15 leaving 489 SNPs as the final instru-
ments. These instruments related to the circulating levels of 
Clinical Perspective
What Is New?
• Genetic predisposition to higher circulating levels 
of monocyte chemoattractant protein-1 was asso-
ciated with higher risk of stroke.
• Associations were also found for etiologic stroke 
subtypes, specifically large-artery stroke and car-
dioembolic stroke.
• Genetically determined levels monocyte chemoat-
tractant protein-1 also associated with higher risk 
of the related phenotypes of coronary artery di-
sease and myocardial infarction.
What Are the Clinical Implications?
• Additional work is needed to determine whether 
targeting monocyte chemoattractant protein-1 or 
its downstream effectors is a meaningful strategy 
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23 cytokines, whereas for 18 cytokines, no SNPs associated 
with their circulating levels at a significance level of false dis-
covery rate <5% could be identified.
The primary outcomes for this study were any stroke, 
any ischemic stroke, etiologic ischemic stroke subtypes de-
fined by TOAST criteria (Trial of Org 10172 in Acute Stroke 
Treatment) (large-artery stroke, cardioembolic stroke, and 
small-vessel stroke),16 and intracerebral hemorrhage. We 
extracted estimates for the associations of the selected 
instruments with any stroke, any ischemic stroke and its 
subtypes from the MEGASTROKE multiancestry GWAS data 
set (67 162 cases; 454 450 controls).13 Sensitivity analyses re-
stricted to individuals of European ancestry (40 528 cases; 
445 396 controls) were conducted, to minimize ancestral 
mismatch with the Finnish population used for the discovery 
GWAS on cytokines.12 For intracerebral hemorrhage, we 
extracted data from publicly available summary statistics of 
a GWAS meta-analysis on 1545 cases and 1481 controls of 
European ancestry.17
We computed F statistics to quantify the strength of the 
selected instruments18 and performed power calculations.19 
The F statistic for the 489 instrument SNPs ranged from 17 
to 789 (Table III in the online-only Data Supplement), well 
above the threshold of F>10 typically recommended for MR 
analyses.20 Based on the sample size of MEGASTROKE, there 
was >80% power to detect significant associations with any 
stroke and any ischemic stroke for 18 of 23 cytokines at an 
effect size (odds ratio [OR]) of 1.10. Power was lower for the 
remaining 5 cytokines and for subanalyses for ischemic stroke 
subtypes and intracerebral hemorrhage (Table III in the online-
only Data Supplement).
For validation of significant associations in MEGASTROKE, 
we used the UK Biobank data set as detailed in the Methods 
in the online-only Data Supplement. We included cases of 
prevalent and incident stroke. Cases with an unconfirmed 
self-reported diagnosis of stroke were excluded from the anal-
ysis. The final sample size consisted of 369 419 individuals, 
including 4985 patients with any stroke and 3628 patients 
with any ischemic stroke. No data were available on ischemic 
stroke subtypes.
Cytokines that were significantly associated with stroke 
were subsequently explored for an association with etiolog-
ically related vascular outcomes. Publicly available summary 
statistics were extracted from the CARDIoGRAMplusC4D 
(Coronary Artery Disease Genome wide Replication and 
Meta-analysis [CARDIoGRAM] plus The Coronary Artery 
Disease [C4D] Genetics) consortium for CAD and MI (60 801 
CAD and 43 676 MI cases; 123 504 controls),21 and the AFGen 
(Atrial Fibrillation Genetics) consortium for AF (17 931 cases; 
115 142 controls).22
Statistical Analysis
After extraction of data and harmonization of the effect 
alleles across GWASs, we computed individual MR estimates 
and standard errors from the SNP-cytokine and SNP-outcome 
associations using the Wald estimator and the Delta method 
that weight all estimates based on the magnitude of the SNP-
cytokine association.23 The MR association between each cy-
tokine and stroke was estimated after pooling individual SNP 
MR estimates using fixed-effects inverse variance–weighted 
(IVW) meta-analysis.23 Statistical significance for the MR asso-
ciations with stroke was set at a P value corrected for multiple 
comparisons (based on the number of cytokines) using the 
Bonferroni method. We further report on results corrected for 
both the number of cytokines and the number of examined 
phenotypes. A P<0.05, but above the Bonferroni-corrected 
threshold, was considered as suggestive for association. The 
IVW MR approach assumes that instruments affect the out-
come only through the exposure under consideration, and not 
by some alternative pathway.23 Any violation of this assump-
tion would represent horizontal pleiotropy of the instrument 
and could introduce bias to the MR estimate. In the absence 
of any such horizontal pleiotropy, there would not be any ex-
pected heterogeneity in the MR estimates obtained from dif-
ferent instruments. As such, heterogeneity markers (I2>25% 
or Cochran Q-derived P<0.05) from the IVW MR were used as 
indicators of possible horizontal pleiotropy.24
For cytokines showing either significant or suggestive asso-
ciations or significant heterogeneity in the primary IVW MR 
analysis, we conducted additional sensitivity analyses that vary 
Figure 1. Schematic representation of the study design.  
Methods used to test for associations and for violations of the Mendelian randomization assumptions (dashed lines). AF indicates atrial fibrillation; CAD, coronary 
artery disease; DBP, diastolic blood pressure; HDL, high-density lipoprotein; HTN, hypertension; IVW, inverse variance–weighted; LDL, low-density lipoprotein; MI, 
myocardial infarction; MR, Mendelian randomization; MR-PRESSO, Mendelian Randomization Pleiotropy Residual Sum and Outlier; SBP, systolic blood pressure; 
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in their underlying assumptions regarding the presence of pleio-
tropic genetic variants that may be associated with the outcome 
independently of the exposure. In particular, we used MR-Egger 
regression, which requires that the strengths of the instru-
ments are independent of their direct associations with the 
outcome,25 and the weighted median method, which requires 
that at least half of the information for the MR analysis comes 
from valid instruments.26 We used the intercept obtained from 
the MR-Egger regression as a measure of directional pleiotropy 
(P<0.05 was considered significant),25 and also tested for outlier 
SNPs using MR-Pleiotropy Residual Sum and Outlier.27
To generate MR estimates unaffected by the presence of 
pleiotropic pathways acting through cardiovascular risk fac-
tors, we performed regression-based multivariable MR with 
summary genetic association estimates28 that adjusted for the 
genetic association of instruments with circulating lipid levels 
(low-density lipoprotein cholesterol, high-density lipoprotein 
cholesterol, triglycerides), type 2 diabetes mellitus, and blood 
pressure measurements (systolic and diastolic blood pressure, 
hypertension). Genetic association estimates for these pheno-
types were extracted from the GLGC (Global Lipids Genetic 
Consortium),29 the DIAGRAM consortium (Diabetes Genetics 
Replication and Meta-Analysis),30 and the UK Biobank,31 pub-
lished by the Neale laboratory, respectively.
Instrument SNPs for cytokines showing significant associa-
tions with stroke were mapped to the nearest gene by using 
the GRCh37/hg19 reference genome. We used the STRING 
database (Search Tool for the Retrieval of Interacting Genes)32 
to look for protein-protein interactions between gene prod-
ucts and the cytokines and identified interacting subnet-
works. As a sensitivity analysis, and to gain further insight 
into the biological processes involved in the examined asso-
ciations, we performed IVW MR analyses with SNPs restricted 
to the specific subnetworks.
The GWAS used to select cytokine instruments included 
no replication, and its estimates of association were further 
adjusted for body mass index, besides age and sex.12 As a sen-
sitivity analysis for bias that may be introduced by this body 
mass index adjustment,33 we also calculated an unweighted 
allele score for any cytokines demonstrating a significant as-
sociation in our main IVW MR analysis.34 Such an unweighted 
allele score may offer evidence of a causal effect of the ex-
posure on the outcome without suffering from bias in the 
genetic association estimates for the exposure, although this 
is at the cost of not being able to estimate the magnitude of 
any such effect.34 Statistical analyses were conducted in Stata 
13.1 (StataCorp).
Meta-Analysis of Observational Studies
For the cytokines that showed significant associations with 
stroke in MR, we performed a meta-analysis of observa-
tional studies. We searched Medline until December 10, 2017 
(search strategy is available in the Methods in the online-
only Data Supplement), for case-control studies comparing 
the circulating cytokine levels between patients with stroke 
and controls, and cohort studies exploring the association of 
baseline levels with incident or recurrent stroke. We extracted 
relevant data and applied random-effects meta-analyses for 
hazard ratios (cohort studies) or standardized mean differ-
ences (case-control studies). We evaluated heterogeneity with 
the I2 and the Cochran Q.
RESULTS
Genetically Determined Circulating 
Levels of Cytokines and Risk of Stroke
The primary results of the MR analyses for the 23 cy-
tokines are presented in Figure  2. Following Bon-
ferroni correction for testing multiple cytokines 
(P<0.05/23=2.2×10–3), the only cytokine showing sta-
Figure 2. Mendelian randomization associations of circulating cytokine and growth factor levels with stroke and stroke subtypes.  
Shown are the results derived from the fixed-effects inverse variance weighted meta-analysis. BNGF indicates beta nerve growth factor; CTACK, cutaneous T-cell-
attracting chemokine; GRO-α, growth-regulated oncogene alpha; HGF, hepatocyte growth factor; IL, interleukin; IP-10, interferon gamma-induced protein 10 MCP-1, 
monocyte chemoattractant protein-1; MIF, macrophage migration inhibitory factor; MIG, monokine induced by gamma interferon; MIP-1b, macrophage inflammatory 
protein 1 beta; PDGF-bb, platelet-derived growth factor-bb; SCF, stem cell factor; SCGF-b, stem cell growth factor beta; SNP, single-nucleotide polymorphism; TNF, tumor 
necrosis factor; TRAIL, TNF-related apoptosis-inducing ligand; and VEGF, vascular endothelial growth factor. *Significant heterogeneity (I2>25% or Cochran Q-derived 
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tistically significant associations with stroke was the CC 
chemokine monocyte chemoattractant protein-1 (MCP-
1/CCL2). As depicted in Figure 3A and Figure I in the 
online-only Data Supplement, genetically determined 
higher circulating MCP-1 levels (1 SD increase) were as-
sociated with 6% higher odds for both any stroke (OR, 
1.06; 95% CI, 1.02–1.09; P=9×10–4; 523 047 individu-
als; 66 856 cases) and any ischemic stroke (OR, 1.06; 
95% CI, 1.02–1.10; P=1.8×10–3; 511 551 individuals; 
60 341 cases) in MR analyses. Corresponding analyses 
for ischemic stroke subtypes revealed significant associ-
ations for large-artery stroke (OR, 1.19; 95% CI, 1.09–
1.30; P=1.7×10–4; 245 201 individuals; 6688 cases) and 
cardioembolic stroke (OR, 1.14; 95% CI, 1.06–1.23; 
P=3.5×10–4; 361 858 individuals; 9006 cases), but not 
for small-vessel stroke (OR, 1.03; 95% CI, 0.95–1.11; 
P=0.50; 298 777 individuals; 11 710 cases). In addition, 
we found no significant association of genetically de-
termined MCP-1 levels with intracerebral hemorrhage 
(OR, 1.24; 95% CI, 0.94–1.64; P=0.13), although this 
might be related to the lower sample size (3026 indi-
viduals; 1545 cases). It is important to note that the 
results for large-artery stroke and cardioembolic stroke 
remained significant when further correcting for both 
the number of examined cytokines and the number 
of examined phenotypes (P<0.05/138=3.6×10–4; Fig-
ure 2). Subanalyses restricted to lobar (OR, 1.25; 95% 
CI, 0.88–1.79; P=0.22; 2145 individuals; 664 cases) and 
nonlobar intracerebral hemorrhage (OR, 1.03; 95% CI, 
0.72–1.49; P=0.16; 2362 individuals; 881 cases) also 
showed no significant associations with genetically de-
termined MCP-1 levels. The individual SNPs associated 
with MCP-1 levels explained 14.7% of the variance of 
MCP-1 levels (Table III in the online-only Data Supple-
ment) and are presented in Table IV in the online-only 
Data Supplement.
Figure 3. Mendelian randomization analysis for circulating MCP-1 levels and risk of stroke.  
A, MR-derived associations between genetically determined circulating MCP-1 levels (1 SD increase) and risk of any stroke and stroke subtypes. B, Associations 
between genetically determined circulating MCP-1 levels and risk of large-artery (left) and cardioembolic (right) stroke based on different MR methods. I2 refers to 
heterogeneity in the Mendelian randomization analysis (inverse variance–weighted method). IVW indicates inverse variance–weighted; MCP-1, monocyte chemoat-
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There was no evidence for heterogeneity in any of the 
MCP-1 associations as measured by I2 and Cochran Q 
(Figure 3A), and no outlier SNPs were detected with the 
MR-Pleiotropy Residual Sum and Outlier method. Also, 
there was no indication for directional pleiotropy ef-
fects as assessed by the MR-Egger intercept (any stroke, 
P=0.41; any ischemic stroke, P=0.39; large-artery stroke, 
P=0.98; cardioembolic stroke, P=0.67; small-vessel 
stroke, P=0.70; intracerebral hemorrhage, P=0.94). The 
weighted median estimator and the MR-Egger regres-
sion analysis provided estimates of the same magnitude 
as the fixed-effects IVW meta-analysis for large-artery 
stroke (OR, 1.22; 95% CI, 1.07–1.40; P=2×10–3 and OR, 
1.19; 95% CI, 0.93–1.53; P=0.13, respectively) and car-
dioembolic stroke (OR, 1.13; 95% CI, 1.01–1.27; P=0.04 
and OR, 1.21; 95% CI, 0.96–1.53; P=0.09, respectively, 
Figure 3B), although with wider confidence intervals as 
would be expected given the lower statistical power 
of these approaches.25,26 Use of an unweighted allele 
score for the MCP-1 instrument SNPs also showed sta-
tistically significant associations with risk of large-artery 
(P=1.5×10–4) and cardioembolic stroke (P=2.8×10–4). The 
significant association between MCP-1 and outcomes 
was retained both when restricting the analysis to indi-
viduals of European ancestry (Figure II in the online-only 
Data Supplement), and when applying the more con-
servative threshold of P<5×10–8 for instrument selection 
(Figure III in the online-only Data Supplement).
To explore whether the MR association between 
genetically determined MCP-1 levels and stroke was 
attributable through pleiotropic pathways relating to 
cardiovascular risk factors, we conducted multivariable 
MR analysis adjusting for circulating lipid levels, type 2 
diabetes mellitus, and blood pressure. The results re-
mained stable regardless of the model (unadjusted, sin-
gle, or fully adjusted model), thus supporting an inde-
pendent association between MCP-1 levels and stroke 
and stroke subtypes (Table).
None of the genetic instruments for MCP-1 was 
within or close to the MCP1 gene. Assessing genes clos-
est to the instruments for MCP-1, we noted that several 
of them encoded proteins that show a biological rela-
tionship with MCP-1, eg, CCR2, the main receptor for 
MCP-1 (Table IV in the online-only Data Supplement). To 
minimize the risk of using nonspecific instruments that 
might exert pleiotropic effects, we performed an addi-
tional sensitivity analysis focusing on instruments in the 
vicinity of these genes. Using the STRING database, we 
found the chemokine receptors CCR2, CCR1, CCR3, and 
CCR9, the chemokine-binding protein CCBP2, and the 
receptor of the complement C5a (C5aR1) to integrate 
into a subnetwork of established interactions with MCP-
1 (Figure IVA in the online-only Data Supplement). Re-
stricting the MR analysis to the respective SNPs resulted 
in significant estimates of association for large-artery (OR 
per 1 SD increase in MCP-1 levels, 1.25; 95% CI, 1.08–
1.45; P=2×10–3) and cardioembolic stroke (OR, 1.21; 
95% CI, 1.07–1.37; P=3×10–3), and intracerebral hemor-
rhage, as well (OR, 2.19; 95% CI, 1.30–3.69; P=3×10–3) 
(Figure IVB in the online-only Data Supplement).
Several other cytokines not reaching the Bonferroni-
corrected threshold showed suggestive (P<0.05) as-
sociations with risk of stroke in MR analyses: genetic 
predisposition to higher levels of eotaxin, interferon gam-
ma-induced protein 10, monokine induced by gamma 
interferon, platelet-derived growth factor-bb, and vas-













No. in sample 523 047 511 551 245 201 361 858 298 777 3026
N. of cases 66 856 60 341 6688 9006 11 710 1545
Unadjusted model 1.06 (1.02–1.09) 1.06 (1.02–1.10) 1.19 (1.09–1.30) 1.14 (1.06–1.23) 1.03 (0.95–1.11) 1.24 (0.94–1.64)
Adjusted for T2D 1.07 (1.03–1.11) 1.07 (1.03–1.11) 1.22 (1.12–1.33) 1.17 (1.08–1.27) 1.03 (0.97–1.10) 1.06 (0.94–1.20)
Adjusted for LDL-C 1.06 (1.02–1.10) 1.06 (1.02–1.11) 1.20 (1.10–1.31) 1.16 (1.06–1.24) 1.03 (0.98–1.09) 1.26 (0.93–1.71)
Adjusted for HDL-C 1.07 (1.03–1.11) 1.07 (1.02–1.11) 1.21 (1.11–1.33) 1.15 (1.06–1.25) 1.04 (0.97–1.10) 1.27 (0.94–1.72)
Adjusted for TG 1.06 (1.02–1.10) 1.06 (1.02–1.10) 1.19 (1.09–1.30) 1.16 (1.06–1.26) 1.03 (0.97–1.10) 1.28 (0.94–1.73)
Adjusted for SBP 1.08 (1.04–1.12) 1.09 (1.05–1.14) 1.23 (1.12–1.35) 1.20 (1.10–1.32) 1.03 (0.96–1.11) 1.81 (1.13–1.90)
Adjusted for DBP 1.08 (1.04–1.13) 1.09 (1.05–1.14) 1.22 (1.11–1.34) 1.20 (1.10–1.32) 1.04 (0.96–1.11) 1.53 (0.89–2.65)
Adjusted for HTN 1.07 (1.03–1.11) 1.07 (1.03–1.11) 1.19 (1.09–1.29) 1.18 (1.08–1.29) 1.03 (0.95–1.11) 1.03 (0.93–1.14)
Fully adjusted model (T2D, 
LDL-C*, SBP†)
1.08 (1.03–1.12) 1.09 (1.04–1.13) 1.23 (1.11–1.35) 1.20 (1.10–1.32) 1.04 (0.97–1.12) 1.06 (0.92–1.21)
The results are presented as odds ratios (95% CIs) for the effect of 1 SD increase in MCP-1 levels. DBP indicates diastolic blood pressure; HDL-C, high-density 
lipoprotein cholesterol; HTN, hypertension; LDL-C, low-density lipoprotein cholesterol; MCP-1, monocyte chemoattractant protein-1; SBP, systolic blood pressure; 
T2D, type 2 diabetes mellitus; and TG, triglyceride.
*Restricted to LDL-C to avoid collinearity with HDL-C and TG levels. 
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cular endothelial growth factor were associated with an 
higher risk of stroke, whereas predisposition to higher 
levels of stem cell factor and stem cell growth factor beta 
were associated with lower risk of stroke (Figure 2).
Genetically Determined Circulating 
Levels of MCP-1 and Risk of Stroke in UK 
Biobank
We next explored the MR association between genet-
ically determined MCP-1 levels and risk of any stroke 
and risk of any ischemic stroke in the independent UK 
Biobank sample and meta-analyzed the MEGASTROKE 
and UK Biobank data (Figure 4A and Figure V in the 
online-only Data Supplement). Estimates of association 
in UK Biobank were similar to MEGASTROKE for any 
stroke (OR per 1 SD increase, 1.08; 95% CI, 0.99–1.17; 
P=0.09; 369 419 individuals, 4985 cases) and any is-
chemic stroke (OR, 1.07; 95% CI, 0.97–1.18; P=0.17; 
369 419, 3628 cases), but did not reach statistical sig-
nificance. Genetically elevated circulating MCP-1 levels 
were significantly associated with both any stroke (OR, 
Figure 4. Associations between circulating MCP-1 levels and risk of stroke in Mendelian randomization and in observational studies.  
A, MR-derived associations between genetically determined circulating MCP-1 levels (1 SD increase) and risk of any stroke and any ischemic stroke in MEGAS-
TROKE, in UK Biobank, and a meta-analysis of both samples. B, Meta-analysis–derived associations between circulating MCP-1 levels (1 SD increase) and risk of is-
chemic stroke in case-control and cohort studies. k refers to number of included studies. I2 in Figure 4A refers to heterogeneity in the MR analysis (inverse variance 
weighted method), and, in Figure 4B, to heterogeneity in the random-effects meta-analyses of observational studies. HR indicates hazard ratio; MCP-1, monocyte 
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1.06; 95% CI, 1.03–1.09; P=2×10–4) and any ischemic 
stroke (OR, 1.06; 95% CI, 1.03–1.10; P=7×10–4) in the 
meta-analysis of MEGASTROKE and UK Biobank.
Circulating Levels of MCP-1 and Risk of 
Stroke: Meta-Analysis of Observational 
Studies
Next, we compared the MR estimates with those de-
rived from a meta-analysis of observational studies. Our 
search yielded 17 case-control studies of patients with 
ischemic stroke and controls, 2 cohort studies on pa-
tients with a history of stroke or cardiovascular disease 
exploring the risk of recurrent ischemic stroke, and 1 
case-cohort study of incident ischemic stroke in a com-
munity population (Tables V and VI in the online-only 
Data Supplement and Figure VI in the online-only Data 
Supplement). Patients with any ischemic stroke were 
found to have significantly higher MCP-1 levels than 
controls in the case-control studies (Hedges’ g: 0.66; 
95% CI, 0.18–1.15 [corresponding to a medium to 
strong effect size35]; 1137 cases, 717 controls; heter-
ogeneity: I2=89%, P<0.001; Figure 4B and Figure VIIA 
in the online-only Data Supplement). Studies on re-
current stroke (2642 individuals, 605 events) yielded a 
hazard ratio of 1.11 (95% CI, 0.92–1.33) for 1 SD in-
crease in MCP-1 levels (heterogeneity: I2=32%, P=0.28; 
Figure 4B and Figure VIIB in the online-only Data Sup-
plement), whereas the single study examining incident 
ischemic stroke (95 cases, 190 controls) reported a haz-
ard ratio of 0.99 (95% CI, 0.68–1.45).
Genetically Determined Circulating 
Levels of MCP-1 and Etiologically Related 
Vascular Outcomes
Figure 5 depicts the MR association between genetically 
determined MCP-1 levels and risk of CAD, MI, and AF. 
Genetic predisposition to higher MCP-1 levels was asso-
ciated with CAD (OR per 1 SD increase, 1.04; 95% CI, 
1.00–1.08; P=0.04; 184 305 individuals, 60 801 cases) 
and MI (OR, 1.05; 95% CI, 1.01–1.09; P=0.02; 167 180 
individuals, 43 676 cases). Given the association of 
MCP-1 with cardioembolic stroke, we further explored 
the relationship between genetically determined MCP-1 
levels and risk of AF in MR analysis, but found no associ-
ation (OR, 0.96; 95% CI, 0.91–1.01; P=0.09).
DISCUSSION
Exploring 41 cytokines in a 2-sample MR approach in-
volving the largest GWAS data sets available, we found 
that genetic predisposition to higher levels of MCP-1/
CCL2 is associated with higher risk of any stroke, any 
ischemic stroke, large-artery stroke, and cardioembolic 
stroke. The results were stable in alternative MR meth-
ods and sensitivity analyses and remained significant af-
ter adjustment for cardiovascular risk factors. Moreover, 
effect sizes for any stroke and any ischemic stroke were 
similar in the UK Biobank. We further found associa-
tions between genetic predisposition to higher MCP-1 
levels and higher risk of CAD and MI as etiologically re-
lated outcomes. Collectively, our findings suggest that 
lifelong elevated circulating MCP-1 levels increase the 
risk of stroke.
The directionality of the MR association between ge-
netically determined levels of MCP-1 and risk of large-
artery stroke is consistent with experimental data show-
ing a key role for this chemokine in atherogenesis and 
atheroprogression. Acting mainly through its receptor 
CCR2, MCP-1 is the prototypical CC family chemokine 
that is upregulated by chronic inflammatory conditions 
and attracts monocytes to the subendothelial space of 
the atherogenic arterial wall.36 Mice lacking MCP-137 or 
CCR238 are less susceptible to atherosclerosis, and anti–
MCP-1 gene therapy,39 MCP-1 competitors,40 and CCR2 
Figure 5. Mendelian randomization (MR) analysis for genetically determined circulating MCP-1 levels and etiologically related vascular outcomes.  
MR-derived associations between genetically determined circulating MCP-1 levels (1 SD increase) and risk of coronary artery disease, myocardial infarction, and 
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antagonists41 reduce plaque size and inhibit plaque pro-
gression and destabilization in experimental atheroscle-
rosis. Conversely, overexpression of MCP-1 leads to in-
flammation, accumulation of lipids, and smooth muscle 
cell proliferation in atherosclerotic plaques.42
We further found an MR association between ge-
netic predisposition to higher MCP-1 levels and risk of 
cardioembolic stroke. Genetic predisposition to higher 
MCP-1 levels is associated with higher risk of CAD and 
MI, which could promote the formation of left ventric-
ular thrombus from myocardial damage, thus resulting 
in cardioembolic stroke. Furthermore, MCP-1 has been 
reported to promote myocardial fibrosis,43 an estab-
lished risk factor for AF.44 However, we found no associ-
ation between the genetic instruments for MCP-1 and 
AF risk. Other investigators have found an association 
between circulating MCP-1 levels and the presence of 
atrial thrombi in patients with AF.45 Hence, it might be 
that MCP-1 increases the risk of cardioembolic stroke by 
promoting thrombus formation in patients with estab-
lished AF. Alternative explanations for the association 
between circulating MCP-1 levels and cardioembolic 
stroke might include less frequent causes of cardioem-
bolism, such as valvular disease and the misclassifica-
tion of patients with multiple competing stroke etiolo-
gies including atherosclerosis.
In contrast, our analysis provides no evidence for an 
association of genetically determined MCP-1 levels with 
small-vessel stroke even though the sample size was 
larger than for other stroke subtypes. In fact, we found 
none of the cytokines to be associated with small-vessel 
stroke (all P>0.05, Figure 2). Overall, these observations 
agree with the notion that inflammatory processes are 
less important in small-vessel disease than in large-ar-
tery atherosclerosis, although this has so far not been 
systematically examined.
The lack of a signal with intracerebral hemorrhage, 
and, in particular, deep intracerebral hemorrhage, 
which, like small-vessel stroke, is attributed to small-
vessel disease,17 is in line with this result. However, this 
analysis was based on a rather small sample size. Also, 
following restriction of the analysis to SNPs in the vi-
cinity of genes interacting with MCP-1, we identified a 
significant association between genetically determined 
MCP-1 levels and intracerebral hemorrhage. This differ-
ence in results might relate to the exclusion of nonspe-
cific instruments in the sensitivity analyses and should 
be explored further in larger samples.
Our meta-analysis of case-control studies revealed 
higher circulating MCP-1 levels in patients with ische-
mic stroke than in healthy controls. Our systematic 
search identified only 3 prospective cohort studies, one 
on incident46 and 2 on recurrent stroke events,47,48 none 
of which showed significant results. However, these 
studies had small sample sizes and a low number of 
events. Also, ischemic stroke subtypes were not consid-
ered, thus precluding meaningful comparisons with our 
MR results. It is interesting to note that observational 
cohort studies on CAD found higher MCP-1 levels to 
be associated with a higher risk of incident49 and re-
current50 events, consistent with the observed associa-
tion with atherosclerotic stroke. Serial measurements of 
MCP-1 in large population-based cohorts with data on 
ischemic stroke subtypes would offer further insights 
into the relationship between MCP-1 and the risk of 
stroke.
Targeting specific inflammatory cytokines might re-
duce vascular risk. The recent multicenter CANTOS trial 
showed that canakinumab, a monoclonal antibody a-
gainst IL-1β, decreases the rate of recurrent cardiovas-
cular events, including nonfatal MI, nonfatal stroke, 
and cardiovascular mortality, among patients with 
MI and elevated circulating C-reactive protein levels.8 
Unfortunately, the original cytokine GWAS did not i-
dentify any genetic instruments for IL-1β circulating 
levels,12 thus precluding a comparison of the MR re-
sults with the results of the CANTOS trial.8 The MCP-1/
CCR2 pathway was targeted in a small phase II clini-
cal trial in patients with risk factors for atherosclero-
sis and elevated circulating C-reactive protein levels. 
MLN1202, a humanized monoclonal antibody against 
CCR2, reduced C-reactive protein levels after 4 and 12 
weeks.51 However, the effects on clinical end points 
were not assessed51 and would need to be determined 
in a larger trial.
This study has several methodological strengths. We 
used the most recent and comprehensive data set for 
cytokine levels and the largest available GWAS data set 
for stroke and stroke subtypes. Results were confirmed 
through sensitivity analyses for pleiotropy, including al-
ternative MR methods, in subanalyses on a biologically 
plausible protein-protein interaction network, and in 
analyses on etiologically related outcomes (CAD and 
MI).
Our study also has limitations. First, none of the 
SNPs used as instruments for MCP-1 were located in 
the vicinity of the MCP1 gene, thus precluding analyses 
restricted to SNPs within this locus. Consequently, al-
though we found no statistical evidence for pleiotropy, 
we cannot preclude nonspecific effects of the MCP-1 
trans-acting instruments. Second, our instrument se-
lection was based on a single-discovery GWAS that 
adjusted for body mass index. Although the associa-
tion remained consistent when using an unweighted 
allele score, we cannot exclude that the body mass in-
dex adjustment led to collider bias during instrument 
selection. Third, we could not obtain reliable genetic 
instruments for 18 cytokines, and several analyses for 
ischemic stroke subtypes were underpowered. Thus, 
we might have missed associations for several cyto-
kines that have previously been implicated in vascular 
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6. Targeted studies incorporating further GWAS data 
on individual cytokines might reveal additional as-
sociations not captured by our approach. Fourth, ge-
netic instruments were selected using a false discovery 
rate–based approach, which might have weakened the 
instruments. However, the F statistics were high, and 
the results were in line with those derived when select-
ing instruments based on the genome-wide threshold 
(P<5×10–8). Finally, the UK Biobank analysis was rather 
underpowered and did not include stroke subtypes. Yet 
the consistency of both the direction and magnitude of 
the associations between genetically determined MCP-
1 and risk of any stroke and any ischemic stroke sup-
ports our results.
In conclusion, this study demonstrates that lifelong 
elevated circulating MCP-1 levels are associated with 
higher risk of stroke and, in particular, with the large-
artery and the cardioembolic subtypes. Future studies 
should explore in more depth whether targeting MCP-
1 or its downstream effectors could be a meaningful 
strategy to reduce stroke risk.
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Circulating Monocyte Chemoattractant Protein-1 
and Risk of Stroke
Meta-Analysis of Population-Based Studies Involving 17 180 Individuals
Marios K. Georgakis, Rainer Malik, Harry Björkbacka, Tiberiu Alexandru Pana, Serkalem Demissie, Colby Ayers,  
Mohamed A. Elhadad, Myriam Fornage, Alexa S. Beiser, Emelia J. Benjamin, Matthijs S. Boekholdt, Gunnar Engström,  
Christian Herder, Ron C. Hoogeveen, Wolfgang Koenig, Olle Melander, Marju Orho-Melander, Alexandru Schiopu,  
Martin Söderholm, Nick Wareham, Christie M. Ballantyne, Annette Peters, Sudha Seshadri, Phyo K. Myint, Jan Nilsson,  
James A. de Lemos, Martin Dichgans
RATIONALE: Proinflammatory cytokines have been identified as potential targets for lowering vascular risk. Experimental 
evidence and Mendelian randomization suggest a role of MCP-1 (monocyte chemoattractant protein-1) in atherosclerosis 
and stroke. However, data from large-scale observational studies are lacking.
OBJECTIVE: To determine whether circulating levels of MCP-1 are associated with risk of incident stroke in the general population.
METHODS AND RESULTS: We used previously unpublished data on 17 180 stroke-free individuals (mean age, 56.7±8.1 years; 
48.8% men) from 6 population-based prospective cohort studies and explored associations between baseline circulating MCP-
1 levels and risk of any stroke, ischemic stroke, and hemorrhagic stroke during a mean follow-up interval of 16.3 years (280 522 
person-years at risk; 1435 incident stroke events). We applied Cox proportional-hazards models and pooled hazard ratios (HRs) 
using random-effects meta-analyses. After adjustments for age, sex, race, and vascular risk factors, higher MCP-1 levels were 
associated with increased risk of any stroke (HR per 1-SD increment in ln-transformed MCP-1, 1.07; 95% CI, 1.01–1.14). 
Focusing on stroke subtypes, we found a significant association between baseline MCP-1 levels and higher risk of ischemic 
stroke (HR, 1.11 [1.02–1.21]) but not hemorrhagic stroke (HR, 1.02 [0.82–1.29]). The results followed a dose-response 
pattern with a higher risk of ischemic stroke among individuals in the upper quartiles of MCP-1 levels as compared with the 
first quartile (HRs, second quartile: 1.19 [1.00–1.42]; third quartile: 1.35 [1.14–1.59]; fourth quartile: 1.38 [1.07–1.77]). There 
was no indication for heterogeneity across studies, and in a subsample of 4 studies (12 516 individuals), the risk estimates 
were stable after additional adjustments for circulating levels of IL (interleukin)-6 and high-sensitivity CRP (C-reactive protein).
CONCLUSIONS: Higher circulating levels of MCP-1 are associated with increased long-term risk of stroke. Our findings along with 
genetic and experimental evidence suggest that MCP-1 signaling might represent a therapeutic target to lower stroke risk.
VISUAL OVERVIEW: An online visual overview is available for this article. 
Key Words: atherosclerosis ◼ cerebrovascular disorders ◼ chemokine CCL2 ◼ inflammation ◼ stroke
Stroke is the leading cause of adult disability and the second most common cause of death worldwide.1,2 Inflammatory mechanisms contribute to the pathogen-
esis of stroke, most notably to large artery atherosclerotic 
stroke,3,4 but the specific proinflammatory factors mediat-
ing stroke risk are largely elusive. Discordant results from 
the CANTOS (Canakinumab Anti-Inflammatory Throm-
bosis Outcomes Study)5–8 and CIRT (Cardiovascular 
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Inflammation Reduction Trial)6 randomized controlled trials 
emphasize the importance of targeting specific mediators 
and pathways for lowering vascular risk.5–8 Treatment with 
an anti–IL (interleukin)-1β monoclonal antibody reduced 
the levels of IL-6 and high-sensitivity CRP [C-reactive pro-
tein] (hsCRP) leading to a reduction in the combined pri-
mary end point of nonfatal myocardial infarction, nonfatal 
stroke, or cardiovascular death independent of LDL (low-
density lipoprotein) cholesterol levels,5 whereas treatment 
with low-dose methotrexate neither reduced cardiovascu-
lar event rates nor the levels of IL-1β, IL-6, and hsCRP.6
In a Mendelian randomization study on circulating 
levels of 41 cytokines and growth factors, we recently 
found genetic predisposition to higher levels of the CC-
chemokine MCP-1 (monocyte chemoattractant protein-1; 
also known as CCL2 [CC-chemokine ligand 2]) to be 
associated with increased risk of stroke, ischemic stroke, 
coronary artery disease (CAD), and myocardial infarction.9 
MCP-1 recruits monocytes to the subendothelial space 
of the atherogenic arterial wall,10–12 and studies in experi-
mental models of atherosclerosis suggest that targeting 
MCP-1 or its receptor CCR2 (C-C chemokine receptor 
type 2) limits plaque size, plaque progression, and plaque 
destabilization.13–17 These findings define the MCP-1/
CCR2 axis as a potential additional target for reducing 
residual inflammatory risk in vascular disease. However, 
data on MCP-1 and vascular risk in humans remain scarce.
Nonstandard Abbreviations and Acronyms
ARIC  Atherosclerosis Risk in Communities
CAD  coronary artery disease
CANTOS   Canakinumab Anti-Inflammatory 
Thrombosis Outcomes Study
CCL2  CC-chemokine ligand 2
CRP  C-reactive protein
DHS  Dallas Heart Study
eGFR  estimated glomerular filtration rate
EPIC-Norfolk  Norfolk Arm of the European Pro-
spective Investigation of Cancer
FHS  Framingham Heart Study
HbA1c  glycosylated hemoglobin type A1C
HDL  high-density lipoprotein
HR  hazard ratio
hsCRP  high-sensitivity C-reactive protein
IL  interleukin
KORA   Kooperative Gesundheitsforschung 
in der Region Augsburg
LDL  low-density lipoprotein
MCP-1  monocyte chemoattractant protein-1
MDCS  Malmö Diet and Cancer Study
MONICA   Monitoring of Trends and Determinants 
in Cardiovascular Disease Communities
Novelty and Significance
What Is Known?
• Inflammatory mechanisms contribute to the pathogen-
esis of vascular disease, and inflammatory cytokines 
have been identified as potential therapeutic targets 
for lowering vascular risk.
• Using genetic data, we recently showed in Mendelian 
randomization that lifetime higher MCP-1 (monocyte 
chemoattractant protein-1) levels are associated with 
a higher risk of ischemic stroke.
• Preclinical studies in animal models of experimental 
atherosclerosis further suggest a critical role of MCP-1 
in the initiation and propagation of atherosclerosis.
What New Information Does This Article  
Contribute?
• We performed a meta-analysis of 6 population-based 
cohort studies involving 17 000 stroke-free individuals 
who were followed up for 16 years.
• After adjustment for traditional vascular risk factors, 
higher baseline MCP-1 levels were associated with a 
higher risk of any stroke and ischemic stroke but not 
hemorrhagic stroke over follow-up.
• On top of experimental and genetic data, our findings 
provide additional evidence supporting MCP-1 signal-
ing as a promising target for lowering stroke risk.
In view of recent findings suggesting the efficacy of anti-
inflammatory approaches in lowering vascular risk, there is 
a need for identification of specific inflammatory media-
tors that show promise as potential therapeutic targets. 
Experimental and genetic evidence suggests MCP-1—a 
chemokine involved in monocyte recruitment—to play a 
critical role in atherosclerosis and stroke. Here, we aimed 
to amplify this concept by exploring in a meta-analysis of 
6 previously unpublished cohort studies whether MCP-1 
levels are associated with risk of stroke. Following up 
17 000 stroke-free individuals for a mean of 16 years, 
we found baseline MCP-1 levels to be associated with 
a higher risk of any stroke, independently of traditional 
vascular risk factors. Across stroke subtypes, there was 
a significant association of MCP-1 levels with the risk of 
ischemic stroke but not hemorrhagic stroke. Adjustments 
for IL-6 (interleukin-6) and CRP (C-reactive protein) levels 
did not attenuate these associations, thus indicating that 
MCP-1 signaling might contribute to stroke risk indepen-
dently of the well-established IL-6–CRP axis. Along with 
genetic and experimental data, our findings provide trian-
gulation of evidence suggesting MCP-1 as a causal risk 
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Among patients with acute coronary syndromes in 
the OPUS-TIMI 16 (Orbofiban in Patients With Unstable 
Coronary Syndromes by the Thrombolysis in Myocardial 
Infarction Study Group)18 and A-to-Z trial,19 high circu-
lating MCP-1 levels were associated with a significantly 
increased risk of death or myocardial infarction during 
follow-up, independently of baseline variables including 
hsCRP levels. In population-based studies, higher MCP-1 
levels were associated with subclinical atherosclerosis and 
incident CAD during follow-up.20,21 In contrast, the relation-
ship between circulating MCP-1 levels and incident stroke 
remains unknown as does the relationship between MCP-
1, IL-6, and CRP in mediating vascular risk.
Here, leveraging data from 6 population-based prospec-
tive cohort studies encompassing 17 180 stroke-free indi-
viduals with long-term follow-up, we set out to (1) determine 
the association between circulating MCP-1 levels at baseline 
and risk of incident stroke, (2) explore associations of MCP-1 
levels with risk of major stroke subtypes (incident ischemic 
and hemorrhagic stroke), and (3) assess whether any asso-
ciation with stroke risk is independent of the IL-6/CRP axis 
by adjusting for the circulating levels of IL-6 and hsCRP.
METHODS
This study is based on summary statistics produced by the 
studies included in the systematic review. The main individual-
study results are provided in the Online Data Supplement. All 
summary data that support the findings of this study are further 
available from the corresponding author on reasonable request. 
For accessing individual-level data of the included studies the 
readers should contact the authors representing the respective 
studies and follow the required processes.
Systematic Review
We systematically searched PubMed from inception through 
March 15, 2019, for population-based prospective cohort stud-
ies exploring associations between circulating MCP-1 levels 
and the risk of incident vascular outcomes including CAD, myo-
cardial infarction, fatal or nonfatal stroke, and peripheral artery 
disease. The reference lists of the identified studies were further 
hand searched. The detailed search strategy is available in the 
Online Appendix. We subsequently contacted the correspond-
ing authors of the selected studies inquiring about their interest 
to contribute data for the current meta-analysis examining the 
association between circulating MCP-1 levels and risk of inci-
dent stroke. Investigators of the following 6 studies agreed to 
participate, and the following studies were thus included in the 
current meta-analysis: the ARIC study (Atherosclerosis Risk in 
Communities),20 DHS (Dallas Heart Study),21 the EPIC-Norfolk 
study (Norfolk Arm of the European Prospective Investigation 
of Cancer),22 the Offspring Cohort of FHS (Framingham Heart 
Study),23 the MONICA (Monitoring of Trends and Determinants 
in Cardiovascular Disease) subcohort of the KORA study 
(Kooperative Gesundheitsforschung in der Region Augsburg),24 
and the cardiovascular subcohort of MDCS (Malmö Diet and 
Cancer Study).25 With the exception of the FHS Offspring study, 
which had previously published part of the data included in this 
analysis (96 versus 172 incident events),23 none of the stud-
ies previously published data on the association between circu-
lating MCP-1 levels and risk of incident stroke. The flowchart 
describing the study selection is depicted in Online Figure I.
Study Populations, MCP-1 Level Measurements, 
and Assessment of Stroke Outcomes
The study design, population characteristics, methods used for 
quantifying circulating MCP-1 levels, stroke outcome definitions, 
and assessments in individual cohorts are detailed in Online Table I. 
In brief, all studies were population-based prospective cohorts, and 
participants included in the current analyses were selected from 
these cohorts based on the availability of MCP-1 measurements 
at baseline. Circulating MCP-1 levels were measured in serum or 
plasma samples drawn during the baseline assessments. Because 
incident stroke was the primary outcome of the current study, 
all participants with a history of stroke at baseline assessments 
(prevalent cases) were excluded from subsequent analyses. Stroke 
occurrence was assessed at follow-up visits during mean intervals 
of 11 to 23 years based on self-reported information and validation 
from medical records of the participants. In addition to information 
on any stroke, all studies further provided information on the major 
stroke subtypes (ischemic versus hemorrhagic stroke).
Quality Assessment
Study quality was assessed using the cohort subscale of the 
Newcastle-Ottawa scale.26 The criteria for awarding quality points 
were the following: a general population sample (representative-
ness of exposed cohort), selection of patients for inclusion inde-
pendently of MCP-1 levels (selection of the nonexposed cohort), 
measurement of MCP-1 levels in the serum or plasma based 
on a validated assay (ascertainment of exposure), exclusion of 
patients with prevalent stroke at baseline (outcome not present 
at the start of study), adjustments for age and sex, as well as for 
conventional vascular risk factors (comparability items), assess-
ment of stroke outcomes blindly to MCP-1 levels with validation 
based on medical records (assessment of outcome), a follow-
up interval >5 years (follow-up duration), and a completion of 
follow-up rate of >90% (adequacy of follow-up cohorts).
Statistical Analysis
A predefined analysis protocol was circulated to investigators 
of each of the cohort studies requesting summary results for 
meta-analysis. MCP-1 levels were ln-transformed in all studies 
for normalization. We did not consider absolute MCP-1 values 
because of marked differences in mean MCP-1 level values 
between studies, probably related to different assays used for 
MCP-1 quantification (Table). We first examined descriptive 
associations between MCP-1 levels and conventional vascular 
risk factors. We pooled study-specific Z scores reflecting dif-
ferences of MCP-1 levels from the overall mean of each study 
with random-effects models across the risk factor categories 
and statistically examined associations using meta-regression.
To examine associations between baseline MCP-1 levels 
and incident stroke, Cox proportional-hazards models were 
fit in each study. MCP-1 levels were included in the models 
as either a continuous variable (1-SD increment in ln-trans-
formed MCP-1 levels) or categorized in 4 quartiles (first 
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nonlinear associations. We applied 3 models with different lev-
els of adjustment: model 1 was adjusted for age, sex, and race; 
model 2 was additionally adjusted for conventional vascular 
risk factors (hypertension, diabetes mellitus, hypercholester-
olemia, body mass index, smoking [current versus noncurrent], 
estimated glomerular filtration rate [eGFR], CAD, atrial fibrilla-
tion, and heart failure); and model 3 was further adjusted for 
circulating hsCRP levels on top of these variables. Model 2 was 
predefined as our main model for analyses. In these models, 
we defined hypertension as a history of physician-diagnosed 
hypertension, systolic blood pressure ≥140 mm Hg, diastolic 
blood pressure ≥90 mm Hg, or use of ≥1 antihypertensive 
medications.27 We defined diabetes mellitus as a history of 
physician-diagnosed diabetes mellitus, HbA1c (glycosylated 
hemoglobin type A1C) ≥6.5%, fasting glucose ≥126 mg/
dL, random glucose levels ≥200 mg/dL, or use of glucose-
lowering medications.28 Hypercholesterolemia was defined as 
LDL cholesterol levels ≥130 mg/dL, total cholesterol levels 
≥200 mg/dL (if LDL cholesterol was not available) or use of 
lipid-lowering drugs,29 and chronic kidney disease as eGFR 
<60 mL/min per 1.73 m2.30 In an alternative model (alter-
native model 2), we directly adjusted for the components of 
these definitions instead of the binary variables: thus, instead 
of hypertension, diabetes mellitus, hypercholesterolemia, and 
chronic kidney disease, we included systolic blood pressure 
(as a continuous variable), use of antihypertensive medica-
tions, fasting glucose levels (as continuous), use of glucose-
lowering medications, LDL cholesterol levels (as continuous), 
administration of lipid-lowering medications, and eGFR (as 
continuous).
Table. Descriptive Baseline Characteristics of the 6 Included Population-Based Prospective Cohort Studies
Cohort ARIC DHS EPIC-Norfolk FHS Offspring MONICA/KORA MDCS-CV
Geographic setting (baseline  
assessment)
The United States 
(1986–1989)










Individuals included in the analysis, n 1234 2931 3182 3069 2055 4709
Follow-up, y 23.0 [13.2–27.8] 11.0 (1.7) 16.8 (6.4) 13.8 (3.7) 15.7 (6.4) 19.5 (4.9)
Incident stroke events, n 153 64 503 172 116 427
Incident ischemic stroke events, n 141 42 458 141 99 352
Incident hemorrhagic stroke events, n 12 9 76 22 17 69
Fatal stroke events, n 10 6 132 26 22 30
Age, y 56.9 (5.3) 44.0 (10.0) 65.3 (7.8) 61.6 (9.4) 52.4 (10.3) 57.5 (4.9)
Male sex, n (%) 738 (59.8) 1254 (42.8) 2009 (63.1) 1421 (46.3) 1093 (53.2) 1873 (39.8)
Hypertension, n (%) 417 (33.9) 944 (32.7) 2029 (63.8) 1378 (44.9) 877 (42.7) 2958 (62.8)
SBP, mm Hg 125 (20) 124 (19) 141 (18) 127 (19) 133 (19) 141 (19)
DBP, mm Hg 74 (12) 78 (10) 85 (11) 74 (10) 82 (11) 87 (9)
Diabetes mellitus, n (%) 156 (12.6) 296 (10.1) 623 (19.6) 379 (12.3) 103 (5.0) 183 (3.9)
Hypercholesterolemia, n (%) 760 (61.6) 377 (12.9) 414 (13.0) 1615 (52.6) 1251 (57.4) 2918 (62.8)
LDL cholesterol levels, mg/dL 142.8 (39.9) 107.4 (35.3) 160.1 (39.4) 119.9 (32.7) 148.5 (2.4) 161.3 (37.9)
HDL cholesterol levels, mg/dL 49.6 (16.5) 50.0 (14.6) 51.8 (15.1) 53.9 (16.7) 56.0 (17.0) 53.8 (14.3)
BMI, kg/m2 27.4 (5.1) 29.7 (7.0) 26.6 (3.6) 28.1 (5.3) 27.2 (4.1) 25.6 (3.9)
Smoking status, n (%)       
 Never smokers 461 (37.3) 1639 (55.9) 1201 (10.3) 1077 (35.1) 947 (46.1) 1916 (40.1)
 Ex-smokers 397 (32.2) 496 (16.9) 1652 (51.9) 1604 (52.3) 591 (28.8) 1777 (37.8)
 Current smokers 376 (30.5) 796 (27.2) 329 (37.7) 388 (12.6) 517 (25.1) 1010 (21.5)
eGFR, mL/min per 1.73 m2 100.0 (16.6) 99.5 (23.7) 74.5 (24.9) 83.3 (16.5) 87.9 (17.4) 76.9 (15.3)
Coronary artery disease, n (%) 68 (5.5) 79 (2.7) 0 (0) 265 (8.6) 46 (2.2) 78 (1.7)
Atrial fibrillation, n (%) 1 (0.1) 35 (1.2) NA 119 (3.9) NA 34 (0.7)
Heart failure, n (%) 53 (4.3) 83 (2.8) 0 (0) 31 (1.0) 119 (5.7) 2 (0.04)
hsCRP levels, mg/L 2.4 [1.3–5.3] 2.8 [1.2–6.8] 2.0 [1.0–3.8] 2.2 [1.0–5.1] 1.4 [0.7–3.3] 1.3 [0.7-2.7]
Sample used for MCP-1 assessment Plasma Plasma Serum Serum Serum Plasma












The numbers correspond to n (%) for categorical variables and to mean (SD) or median [25th–75th percentile] for continuous variables. ARIC indicates Atherosclerosis 
Risk in Communities Study; BMI, body mass index; DBP, diastolic blood pressure; DHS, Dallas Heart Study; eGFR, estimated glomerular filtration rate; EPIC-Norfolk, 
European Prospective Investigation of Cancer, Norfolk; FHS Offspring, Framingham Heart Study–Offspring Cohort; HDL, high-density lipoprotein; hsCRP, high-sensitivity 
C-reactive protein; KORA, Kooperative Gesundheitsforschung in der Region Augsburg; LDL, low-density lipoprotein; MCP-1, monocyte chemoattractant protein-1; 
MDCS-CV, Malmö Diet and Cancer Study–Cardiovascular Subcohort; MONICA, Monitoring of Trends and Determinants in Cardiovascular Disease; NA, not available; 
PEA, proximity extension assay; and SBP, systolic blood pressure.
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The purpose of the main models was to explore MCP-1 as 
a potentially causal risk factor for stroke and not to evaluate 
the predictive values of its levels. In subsequent models, we 
aimed to explore whether the association between MCP-1 lev-
els and risk of stroke is independent of the IL-6/CRP pathway 
that was recently shown to provide an efficient drug target for 
reducing vascular risk.31 To indirectly examine this, we applied 
additional adjustments for circulating IL-6 and hsCRP levels. 
In one model, we included IL-6 on top of age, sex, race, and 
vascular risk factors, and in a subsequent model, we included 
both IL-6 and hsCRP levels. We did this because CRP is a 
downstream effector of IL-6 but also comprises a more general 
marker of inflammation, and thus the alternative adjustments 
provide different levels of information regarding the involved 
inflammatory pathways. Data for IL-6 circulating levels were not 
available in ARIC and the EPIC-Norfolk. Thus, these cohorts 
were not included in these analyses.
Analyses were conducted separately for any stroke, isch-
emic stroke, and hemorrhagic stroke. DHS was excluded 
from the analysis for hemorrhagic stroke, where MCP-1 was 
examined in quartiles, because of the low numbers of incident 
events across the quartile categories of MCP-1 levels. The 
hazard ratios (HRs) and the 95% CIs derived from each study 
were pooled with random-effects (DerSimonian-Laird) meta-
analyses to allow for heterogeneity across studies related to 
the different baseline characteristics and the different meth-
ods of MCP-1 assessment. Heterogeneity across studies was 
assessed with the I2 and the Cochran Q statistic (I2 >50% and 
P<0.10 were considered statistically significant).
To examine whether the pooled risk estimates were driven by 
any individual study, we also applied sensitivity analyses by pool-
ing the risk estimates across studies after excluding one study 
at a time. To explore potential interactions between MCP-1 
levels and known cardiovascular risk factors, we performed 
meta-regression analyses examining how the prevalence of 
cardiovascular risk factors or the mean or median values of bio-
markers were associated with the risk estimates for stroke in 
each study. We further performed subgroup analyses by sex, 
presence of hypertension, presence of diabetes mellitus, and 
body mass index levels (<30 versus ≥30 kg/m2). Differences in 
the effect sizes across the subgroup categories were examined 
by assessing heterogeneity (I2 >50% and P<0.10 were con-
sidered statistically significant). Finally, we performed separate 
analyses for fatal and nonfatal stroke (fatal stroke defined as 
death occurring within 30 days after the stroke event).
Statistical significance was set at a 2-sided P<0.05 for the 
main analysis for any stroke. For the subsequent analysis for 
stroke subtypes, we corrected for multiple comparisons based 
on the Bonferroni method (P<0.05/2 stroke subtypes, 0.025). 
Finally, we corrected for multiple comparisons in the descrip-
tive analyses exploring the correlations between MCP-1 levels 
and baseline variables (threshold for statistical significance at 
P<0.05/12 variables, 0.004). All analyses were conducted with 
SAS (v9.4) and Stata (v13.0).
RESULTS
Following a systematic review and contact with the lead 
investigators, 6 population-based prospective cohort 
studies contributed previously unpublished data for this 
meta-analysis. All studies scored high in quality as they 
fulfilled the full set of Newcastle-Ottawa scale criteria 
(Online Table II). The baseline characteristics of each 
study are presented in the Table. In total, 17 180 indi-
viduals (mean age, 56.7±8.1 years; 48.8% men), who 
were stroke-free at baseline, were followed for a mean 
interval of 16.3 years (range of mean follow-up, 11–23 
years) with 280 522 person-years at risk. A total of 1435 
incident stroke cases were diagnosed during follow-up, 
which were classified as ischemic in 1233 cases and 
as hemorrhagic in 205 cases. Two hundred twenty-
six (15.7%) incident stroke events were fatal. Median 
MCP-1 levels differed between studies possibly reflect-
ing differences in the methods used for MCP-1 quanti-
fication (Online Table I). Figure 1 displays associations 
of standardized MCP-1 levels with conventional vascular 
risk factors in the pooled sample. We found the following 
baseline factors to be associated with higher circulating 
MCP-1 levels: older age, male sex, higher systolic blood 
pressure, presence of diabetes mellitus, higher LDL 
cholesterol levels, higher HDL (high-density lipoprotein) 
cholesterol levels, higher body mass index, current smok-
ing, lower eGFR, history of CAD, higher hsCRP levels, 
and higher IL-6 levels.
In the pooled analysis, we found higher MCP-1 levels 
at baseline to be associated with an increased risk of 
any stroke both in a model adjusted for age, sex, and 
race (model 1: HR per 1-SD increment in ln-transformed 
MCP-1, 1.10; 95% CI, 1.01–1.19; P=0.02) and in the 
main model further adjusted for vascular risk factors 
(model 2: HR, 1.07; 95% CI, 1.01–1.14; P=0.03; Fig-
ure 2; Online Table III). In analyses comparing MCP-1 
quartiles, we found the association between MCP-1 lev-
els and risk of stroke to follow a dose-response pattern 
with a higher risk among individuals in the upper quar-
tiles of circulating MCP-1 levels as compared with the 
first quartile (HRs from model 2: second quartile, 1.16 
[95% CI, 0.99–1.36; P=0.07]; third quartile, 1.31 [95% 
CI, 1.12–1.53; P=0.001]; fourth quartile, 1.33 [95% CI, 
1.05–1.68; P=0.008]). The results were further stable 
in a model additionally adjusting for circulating hsCRP 
levels (model 3 in Figure 2 and Online Table III).
We next examined the associations of circulating 
MCP-1 levels at baseline with stroke subtypes (Figure 3; 
Online Tables IV and V) and found significant associations 
of higher MCP-1 levels at baseline with the risk of isch-
emic stroke (HR per 1-SD increment in ln-MCP-1 from 
model 2, 1.11; 95% CI, 1.02–1.21; P=0.009) but not with 
hemorrhagic stroke (model: HR, 1.02; 95% CI, 0.82–
1.29; P=0.83). MCP-1 levels in the second, third, and 
fourth quartiles, as compared to the first, were associated 
with a higher risk for ischemic stroke after adjusting for 
age, sex, race, and vascular risk factors (HRs from model 
2: second quartile, 1.19 [95% CI, 1.00–1.42; P=0.05]; 
third quartile, 1.35 [95% CI, 1.14–1.59; P<0.001]; fourth 
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were highly consistent in the model additionally adjusting 
for circulating hsCRP levels on top of the vascular risk 
factors (model 3 in Figure 3 and Online Table IV).
Study-specific risk estimates are depicted in Online 
Figures II through IV. There was no evidence of hetero-
geneity in any of the analyses (I2 <50% and Cochran 
Q-derived P>0.10), except for moderate heterogene-
ity in the analysis of the upper fourth MCP-1 quartile 
for any stroke and ischemic stroke (I2=49.8%, P=0.08 
and I2=46.1%, P=0.10, respectively). The results were 
similar for both fatal and nonfatal stroke (I2=0% for 
between-subgroup comparisons), although the CIs 
Figure 2. Associations between baseline circulating MCP-1 (monocyte chemoattractant protein-1) levels and risk of any stroke.  
Shown are the results from random-effects meta-analyses of the pooled sample consisting of 6 population-based studies. Model 1 is adjusted for 
age, sex, and race. Model 2 is adjusted for age, sex, race, and vascular risk factors including body mass index (1 kg/m2 increment [incr.]), smoking 
(current vs noncurrent), estimated glomerular filtration rate (1 mL/min per 1.73 m2 incr.), history of coronary artery disease, diabetes mellitus, 
hypercholesterolemia, hypertension, atrial fibrillation, and heart failure at baseline. Model 3 is additionally adjusted for circulating high-sensitivity 
CRP (C-reactive protein) levels. Analyses for 1-SD incr. correspond to ln-transformed MCP-1 levels. HR indicates hazard ratio.
Figure 1. Cross-sectional associations between baseline circulating MCP-1 (monocyte chemoattractant protein-1) levels, 
demographic factors, conventional vascular risk factors, and inflammatory biomarkers.  
Shown are the results from the pooled sample consisting of 6 population-based studies. Z score for circulating MCP-1 levels correspond to 
differences from the mean value of each study. P values are derived from meta-regression. BMI indicates body mass index; eGFR, estimated 
glomerular filtration rate; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; IL, interleukin; LDL, low-density lipoprotein; 
and SBP, systolic blood pressure. *Statistically significant results (after correction for multiple comparisons, statistical significance was set at 
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for fatal stroke were wider probably because of lower 
statistical power (Online Figure V). The association 
estimates remained consistent in alternative models 
directly adjusting for the crude components of vascu-
lar risk factors (systolic blood pressure, fasting glucose 
levels, LDL cholesterol, and eGFR) and use of antihy-
pertensive, glucose-lowering, or lipid-lowering medica-
tions (alternative model 2; Online Tables III through V). 
Furthermore, the results remained stable in sensitivity 
analyses omitting one study per time (leave-one-out 
analysis) showing that the results were not driven by 
any individual study (Online Figures VI through VIII). 
Meta-regression analyses showed that none of the 
examined study population characteristics nor the sam-
ple source (serum versus plasma) modified the asso-
ciations of MCP-1 with the risk of any stroke, ischemic 
stroke, or hemorrhagic stroke (Online Table VI). Finally, 
in subgroup analyses stratifying for sex, hypertension, 
diabetes mellitus, and body mass index (≥30 versus 
<30 kg/m2), there was no indication for heterogeneity 
in the risk estimates for any stroke, ischemic stroke, and 
hemorrhagic stroke between subgroups (I2=0%; Online 
Figure IX).
As a last step, we performed analyses with addi-
tional adjustments for IL-6 and hsCRP levels in 4 stud-
ies (12 516 individuals; 758 incident stroke events) with 
available data. Adjustment for IL-6 levels showed that the 
risk estimates between MCP-1 levels and risk of stroke 
and stroke subtypes remained stable, although with 
wider CIs than the main analysis, as would be expected 
given the smaller sample sizes (Online Table VII). Simi-
larly, simultaneous adjustments for both IL-6 and hsCRP 
did not alter the risk estimates between MCP-1 and risk 
of stroke or stroke subtypes, even though both variables 
Figure 3. Associations between baseline circulating MCP-1 levels and risk of ischemic and hemorrhagic stroke.  
Shown are the results from random-effects meta-analyses of the pooled sample consisting of 6 population-based studies for (A) ischemic and 
(B) hemorrhagic stroke. Model 1 is adjusted for age, sex, and race. Model 2 is adjusted for age, sex, race, and vascular risk factors including body 
mass index (1 kg/m2 increment [incr.]), smoking (current vs noncurrent), estimated glomerular filtration rate (1 mL/min per 1.73 m2 incr.), history of 
coronary artery disease, diabetes mellitus, hypercholesterolemia, hypertension, atrial fibrillation, and heart failure at baseline. Model 3 is additionally 
adjusted for circulating high-sensitivity CRP (C-reactive protein) levels. Analyses for 1-SD incr. correspond to ln-transformed MCP-1 levels. HR 
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were associated with the risk of any stroke and ischemic 
stroke (Online Table VII).
DISCUSSION
Pooling data from 6 population-based cohort studies 
involving 17 180 stroke-free individuals, we found higher 
circulating levels of MCP-1 at baseline to be associated 
with a higher long-term risk of stroke after accounting 
for age, sex, race, and vascular risk factors. In analy-
ses for stroke subtypes, MCP-1 levels were specifically 
associated with the risk of ischemic stroke but not with 
hemorrhagic stroke. These associations followed a dose-
response pattern, and risk estimates were stable after 
additional adjustments for serum levels of IL-6 or hsCRP.
Our results, which were obtained in studies with long-
term follow-up, confirm and extend our recent Mende-
lian randomization finding of a higher stroke risk among 
individuals with genetic predisposition to higher lifetime 
MCP-1 levels.9 The results were remarkably consistent 
between the 2 approaches: with Mendelian randomiza-
tion, the odds ratio for stroke was 1.06 per SD incre-
ment in genetically determined MCP-1 levels, which is 
almost identical to the HR for incident stroke observed 
in the current meta-analysis of observational studies. In 
accord with the Mendelian randomization results, higher 
MCP-1 levels were further associated with a higher risk 
of incident ischemic stroke, but not hemorrhagic stroke, 
which is consistent with the established role of MCP-1 in 
experimental atherosclerosis. The magnitude of associa-
tion of MCP-1 with incident ischemic stroke was mod-
est suggesting that MCP-1 measurement is not likely 
to be of value as a risk marker for stroke although this 
would need to be formally examined. Of note, however, 
risk estimates compare well with those for lipoprotein 
(a),32,33 which is established as a causal risk factor for 
atherosclerosis currently under investigation in clinical 
trials.34,35 When viewed together with the genetic9 and 
experimental data,13–17 our findings provide triangulation 
of evidence regarding a role of MCP-1 as a causal risk 
factor for stroke.
Only limited human data exist supporting vascular 
benefits by reducing inflammation. Secondary analyses 
from the CANTOS trial showed that the reductions in vas-
cular event rates after IL-1β inhibition were restricted to 
individuals with a substantial decrease in IL-6 or hsCRP 
levels.31,36 Importantly, the risk estimates for stroke by 
MCP-1 levels in our study remained stable after addi-
tional adjustments for the baseline levels of IL-6, hsCRP, 
and both IL-6 and hsCRP. This observation provides 
indirect evidence suggesting that elevated levels of 
MCP-1 might influence risk of stroke independently of 
the IL-1β/IL-6/CRP axis. Thus, targeting the MCP-1/
CCR2 pathway might serve as an alternative anti-inflam-
matory strategy with independent and complementary 
effects in reducing vascular event rates on top of current 
approaches.
Deficiency of either MCP-115, 17 or its receptor CCR216 
decreases plaque burden and limits lipid deposition and 
macrophage infiltration in experimental models of ath-
erosclerosis. Similar effects are observed with pharma-
cological treatment using MCP-1 competitors13 or CCR2 
antagonists.14,37–39 In contrast, overexpression of MCP-1 
promotes oxidized lipid accumulation, macrophage infil-
tration, and smooth muscle cell proliferation, thus accel-
erating atherosclerosis.40 To our knowledge, there has 
been only one small phase II randomized controlled trial 
in the context of atherosclerosis in humans that targeted 
the MCP-1/CCR2 axis. Among 108 patients with cardio-
vascular risk factors and hsCRP levels >3 mg/L, those 
treated with a single intravenous infusion of MLN1202—
a humanized monoclonal antibody against CCR2—exhib-
ited significant reductions in hsCRP levels after 4 weeks 
and continuing through 12 weeks after dosing.41 How-
ever, this study did not assess clinical outcomes, which 
would need to be examined in a larger trial.41
Our study has several strengths. The pooled analy-
sis was based on a large sample size of >17 000 indi-
viduals from 6 previously unpublished population-based 
prospective studies with long follow-up intervals and 
a large number of incident events, thus providing suf-
ficient statistical power to identify robust associations. 
The included studies fulfilled all of the criteria of quality 
assessment, which minimized the risk of several sources 
of bias. We further applied extensive adjustments for 
demographic and vascular risk factors thus accounting 
for confounding and enabling the identification of inde-
pendent associations between MCP-1 levels and risk of 
stroke. Finally, in 4 of the cohorts, we had available data 
on IL-6 and hsCRP measurements, which allowed exam-
ining the associations between MCP-1 and stroke after 
adjusting for these biomarkers.
Our study also has limitations. First, the different assays 
used by individual studies to quantify circulating MCP-1 lev-
els and the different sample sources (plasma versus serum) 
resulted in substantial variations in MCP-1 levels between 
studies. Although our analyses standardized MCP-1 lev-
els across studies, it was not possible to explore associa-
tions between absolute MCP-1 values and risk of stroke. 
Second, studies differed in terms of demographic charac-
teristics and prevalence of vascular risk factors. While we 
found no evidence of substantial heterogeneity between 
studies, there was moderate heterogeneity in the analy-
ses for the highest quartiles of MCP-1, which could pos-
sibly be explained by the differences in baseline MCP-1 
levels and in vascular risk profiles between studies. Third, 
we could not explore associations between MCP-1 levels 
and risk of ischemic stroke subtypes (large artery, cardio-
embolic, and small vessel stroke) because information on 
deeper phenotyping was not available for the majority of 
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European ancestry individuals and do thus not necessar-
ily apply to other ethnic groups. Fifth, we cannot exclude 
residual confounding. Finally, based on our a priori deter-
mined approach and power calculations, we corrected for 
multiple comparisons within each level of analysis but not 
across all analyses. Although this would not be expected to 
have any impact on the findings, future studies with even 
larger sample sizes would be useful in replicating our results
In conclusion, this meta-analysis demonstrates that 
higher circulating levels of MCP-1 among stroke-free 
individuals are associated with increased long-term risk 
of ischemic stroke. The results extend and corroborate 
experimental and genetic evidence suggesting a key role 
of MCP-1 in atherosclerosis and stroke. Additional work 
is needed to examine whether interventions aimed at 
interfering with MCP-1 signaling would lower stroke risk.
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Background: Studies in humans and experimental models highlight a role of interleukin-6 (IL-
6) in cardiovascular disease. Indirect evidence suggests that inhibition of IL-6 signaling could 
lower risk of coronary artery disease. However, whether such an approach would be effective for 
ischemic stroke and other cardiovascular outcomes remains unknown. 
Methods: In a genome-wide association study (GWAS) of 204,402 European individuals, we 
identified genetic proxies for downregulated IL-6 signaling as genetic variants in the IL-6 
receptor (IL6R) locus that were associated with lower C-reactive protein (CRP) levels, a 
downstream effector of IL-6 signaling. We then applied two-sample Mendelian randomization 
(MR) to explore associations with ischemic stroke and its major subtypes (large artery stroke, 
cardioembolic stroke, small vessel stroke) in the MEGASTROKE dataset (34,217 cases and 
404,630 controls), with coronary artery disease in the CARDIoGRAMplusC4D dataset (60,801 
cases and 123,504 control), and with other cardiovascular outcomes in the UK Biobank (up to 
321,406 individuals) and in phenotype-specific GWAS datasets. All effect estimates were scaled 
to the CRP-decreasing effects of tocilizumab, a monoclonal antibody targeting IL-6R.  
Results: We identified 7 genetic variants as proxies for downregulated IL-6 signaling, which 
showed effects on upstream regulators (IL-6 and soluble IL-6R levels) and downstream effectors 
(CRP and fibrinogen levels) of the pathway that were consistent with pharmacological blockade 
of IL-6R. In MR, proxies for downregulated IL-6 signaling were associated with lower risk of 
ischemic stroke (Odds Ratio [OR]: 0.89, 95%CI: 0.82-0.97) and coronary artery disease (OR: 
0.84, 95%CI: 0.77-0.90). Focusing on ischemic stroke subtypes, we found significant 
associations with risk of large artery (OR: 0.76, 95%CI: 0.62-0.93) and small vessel stroke (OR: 
0.71, 95%CI: 0.59-0.86), but not cardioembolic stroke (OR: 0.95, 95%CI: 0.74-1.22). Proxies for 
IL-6 signaling inhibition were further associated with a lower risk of myocardial infarction, 
aortic aneurysm, atrial fibrillation and carotid plaque. 
3 
 
Conclusions: We provide evidence for a causal effect of IL-6 signaling on ischemic stroke, 
particularly large artery and small vessel stroke, and a range of other cardiovascular outcomes. 
IL-6R blockade might represent a valid therapeutic target for lowering cardiovascular risk and 
should thus be investigated in clinical trials. 
 
Key Words: Interleukin-6; inflammation; cytokines; Mendelian randomization; genetics, 







What is new? 
• We identified genetic proxies for downregulated IL-6 signaling that had effects on 
upstream and downstream regulators of the IL-6 signaling pathway consistent with those 
of pharmacological IL-6R blockade  
• Genetically downregulated IL-6 signaling was associated with a lower risk of ischemic 
stroke, and in particular large artery and small vessel stroke 
• Similar associations were obtained for a broad range of other cardiovascular outcomes 
 
What are the clinical implications? 
• Inhibition of IL-6 signaling is a promising therapeutic target for lowering risk of stroke 





Stroke is the leading cause of adult disability and the second most common cause of mortality 
worldwide1, 2 with an increasing burden on global health.3, 4 Inflammation is involved in the 
pathogenesis of ischemic stroke, as has specifically been demonstrated for large artery 
atherosclerotic stroke.5, 6 Cytokines regulate inflammatory responses5 and could thus serve as 
targets for cardiovascular disease prevention.7 In the recent Canakinumab Anti-Inflammatory 
Thrombosis Outcomes Study (CANTOS), treatment with an interleukin-1β (IL-1β) antagonist 
reduced cardiovascular event rates in patients with a history of myocardial infarction.8 However, 
whether interfering with other cytokines would likewise offer benefit remains largely unknown. 
Also, there are few data on stroke and other cardiovascular outcomes beyond coronary artery 
disease.9-11 
Interleukin-6 (IL-6), a key regulator of the inflammatory cascade, acts by binding to either its 
membrane-bound or soluble receptor (IL-6R) and induces proinflammatory downstream effects 
including increases in the levels of C-reactive protein (CRP).12, 13 IL-6 has been implicated in the 
pathogenesis of multiple inflammatory diseases and inhibitors of IL-6R are used for the 
treatment of rheumatoid arthritis,14 inflammatory bowel disease,15 and other autoimmune 
disorders.16 Downregulation of IL-6 signaling has further been proposed as a potential strategy 
for lowering cardiovascular risk.11, 13 IL-6 levels have consistently been associated with risk of 
coronary artery disease in cohort studies.17, 18 Mendelian randomization (MR) studies further 
showed that a variant in the gene encoding IL-6R with effects resembling pharmacological IL-
6R inhibition is associated with a lower risk of coronary artery disease.19, 20 Finally, secondary 
analyses from CANTOS demonstrated that the magnitude of the therapeutic benefit of IL-1β 
targeting was associated with the reduction of circulating IL-6 levels11, 21 and that even after IL-
1β inhibition, the residual cardiovascular risk was proportional to the post-treatment IL-6 
levels.22 These results provide indirect clinical evidence that interfering with IL-6 signaling 
6 
 
might lower cardiovascular risk and suggest that an approach directly targeting IL-6 signaling 
could offer additional benefit for cardiovascular prevention beyond IL-1β inhibition. 
The effects of IL-6 signaling on risk of ischemic stroke remain largely unknown. While 
population-based cohort studies have found that circulating IL-6 levels are associated with a 
higher risk of ischemic stroke,23, 24 these associations preclude conclusions about causal 
relationships because of possible confounding and reverse causation bias.25 Also, there are no 
data on etiological stroke subtypes and other cardiovascular outcomes beyond coronary artery 
disease. Developing meaningful strategies for the prevention of ischemic stroke and 
cardiovascular disease in general would require defining these relationships.26  
By using genetic variants as proxies for a trait of interest, MR overcomes key limitations of 
observational studies such as confounding and reverse causation and allows for investigation of 
causal effects on outcomes.27, 28 MR further allows for prediction of the effects of 
pharmacological interventions by using variants located close to genes encoding candidate drug 
targets.29, 30 Hence, MR has become a powerful strategy to prioritize interventions for 
exploration in clinical trials.28 
Here, leveraging data from large genome-wide association studies (GWASs)31-33 and applying 
MR analyses, we aimed to: (i) identify genetic proxies for downregulated IL-6 signaling on the 
basis of their effects on CRP levels, a well-established IL-6 signaling downstream effector,13, 20, 
34 (ii) validate their utility by comparing the consistency of their effects on upstream regulators 
and downstream effectors of the IL-6 signaling pathway with the effects of pharmacological IL-
6R inhibition, as derived from clinical trials, (iii) explore associations of genetic predisposition 
to downregulated IL-6 signaling with the risk of ischemic stroke and coronary artery disease, (iv) 
examine associations with major etiological subtypes of ischemic stroke (large artery, 
cardioembolic, and small vessel stroke), and (v) examine associations with a broad range of 
other cardiovascular phenotypes. To derive clinically meaningful effect sizes that would be 
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comparable to those derived from potential future clinical trials, we weighted our instruments 
based on the CRP-decreasing effects of tocilizumab, a monoclonal antibody targeting IL-6R. 
 
METHODS 
Selection of genetic proxies for IL-6 signaling and validation of the instruments 
The data sources for this study are described in Table 1. To identify instruments for genetic 
predisposition to downregulated IL-6 signaling, we selected variants within or near the IL6R 
gene, which encodes the receptor of IL-6. Specifically, we selected single-nucleotide 
polymorphisms (SNPs) in the IL6R gene or a region of 300 kB upstream or downstream from the 
IL6R gene (GRCh37/hg19 coordinates: chr1:154,077,669-154,741,926; Supplementary Figure 
1) that were associated with circulating CRP levels. We selected and weighted genetic 
instruments for genetic predisposition to IL-6 signaling on the basis of their associations with 
CRP levels, because elevated CRP levels are a well-described downstream effect of IL-6 
signaling (Figure 1).13, 20, 34 Genetic association estimates with circulating CRP levels were 
obtained from a GWAS of 204,402 individuals of European ancestry drawn from the Cohorts for 
Heart and Aging Research in Genomic Epidemiology (CHARGE) Inflammation Working 
Group.31 We selected variants that were associated with circulating CRP levels at genome-wide 
significance (p<5x10-8) and clumped these variants to a linkage disequilibrium (LD) threshold of 
r2 < 0.1 according to the European reference panel of the 1000 Genomes project.35 We estimated 
the variance in CRP levels explained by each of the SNPs by calculating the R2,36 and the 
strength of the instruments by calculating the F-statistic.37  
In sensitivity analyses, we restricted our selection of instruments to SNPs within the IL6R gene 
(GRCh37/hg19 coordinates: chr1:154,377,669-154,441,926), to avoid potential pleiotropic 
effects through genes neighboring IL6R and increase confidence in the effects of the instruments 
through IL-6 signaling. As the instruments used in the current setting were not identified based 
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on established biological effects, but solely on the basis of their statistical associations with CRP 
levels, in an additional sensitivity analysis, we restricted our genetic instrument to a single SNP 
(rs2228145) within the IL6R gene with well-established biological effects leading to a 
downregulation of the IL-6 signaling.20, 34, 38, 39  
To disentangle the effects of IL-6 signaling from the respective effects of CRP, we selected 
SNPs associated with CRP levels at genome-wide significance (p<5x10-8) throughout the 
genome and clumped them to r2 < 0.1. We then performed MR analyses using all these SNPs as 
instruments, and performed 10,000 permutations for each outcome using 7 randomly selected 
SNPs (the same number as those used as instruments for IL-6 signaling). We further performed 
MR analyses using SNPs at the CRP locus as instruments (within a region of 300 kB upstream or 
downstream to the CRP gene; GRCh37/hg19 coordinates: chr1: 159,382,079- 159,984,379).  
To validate the instruments, we explored their associations with circulating levels of IL-6 and 
soluble IL-6R, which have previously been reported to increase as a result of both 
pharmacological inhibition and genetic downregulation of IL-6 signaling.20 We further explored 
association with fibrinogen levels, which is a downstream effector of IL-6 signaling and 
decreases after its blockade.20 The effects of genetic variants on IL-6 levels were obtained from a 
GWAS of 8,293 healthy individuals of Finnish ancestry.40 For soluble IL-6R levels, we used the 
summary statistics from the INTERVAL study exploring the human plasma proteome,41 as made 
publicly available through the PhenoScanner database.42 For fibrinogen levels, we used GWAS 
data from the CHARGE Inflammation Working Group on 120,246 European individuals.43 
 
Outcomes 
The primary outcomes for this study were ischemic stroke and coronary artery disease. Genetic 
association estimates for ischemic stroke and coronary artery disease were derived from the 
MEGASTROKE32 and CARDIoGRAMplusC4D44 consortia, respectively. Specifically, for 
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ischemic stroke we used the European sub-dataset of MEGASTROKE (34,217 cases and 
404,630 controls) to avoid population stratification with the CRP GWAS dataset, which also 
included solely individuals of European ancestry.32 The CARDIoGRAMplusC4D refers to a 
GWAS of 60,801 cases with coronary artery disease and 123,504 controls, primarily (77%) of 
European ancestry.44 Definitions for major ischemic stroke subtypes in MEGASTROKE 
followed the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria with the following 
samples for analysis: large artery stroke (4,373 cases), cardioembolic stroke (7,193 cases), and 
small vessel stroke (5,386 cases; 404,630 controls for all subtypes).45 We further extended our 
analyses to other cardiovascular outcomes including myocardial infarction, aortic aneurysm, 
carotid artery plaque, peripheral artery disease, heart failure, atrial fibrillation, venous 
thromboembolism, deep vein thrombosis, and pulmonary embolism. The data sources and the 
sample sizes for these studies are presented in Table 1. For aortic aneurysm, heart failure, 
peripheral artery disease, deep vein thrombosis, and pulmonary embolism we used data from the 
UK Biobank, as described in Supplementary Methods.  
 
Mendelian Randomization analyses 
After extracting the association estimates between the variants and the outcomes and harmonizing 
the direction of estimates by effect alleles, we computed MR estimates for each instrument with 
the Wald estimator and standard errors with the Delta method.46 We then pooled individual MR 
estimates using fixed-effects inverse-variance weighted (IVW) meta-analyses.47 To provide 
clinically relevant results, all effect estimates were scaled to the CRP-decreasing effect of 
tocilizumab (8 mg/kg), between 4 and 24 weeks after administration (a decrease of CRP levels by 
67%), as determined by a meta-analysis of 4 clinical trials.20 For the main IVW analyses, we 
performed power calculations and estimated the minimum and maximum effects that we had 80% 
statistical power to detect.48 
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The IVW method was our primary MR analysis approach. Although the selection of instruments 
on a specific gene reduces the possibility of invalid variants,49 the derived estimates might still be 
biased in case of directional pleiotropy. Hence, we further applied sensitivity MR analyses that are 
more robust to the inclusion of pleiotropic variants: the weighted median estimator, the 
contamination mixture method, and the MR Pleiotropy Residual Sum and Outlier (MR-PRESSO). 
The weighted median estimator provides consistent estimates as long as at least half of the variants 
used in the MR analysis are valid.50 The contamination mixture method constructs a likelihood 
function of the individual estimates and under the assumption that the estimates of the valid 
instruments would follow a distribution centered around the causal effect and any invalid 
instruments would follow a distribution around zero, it calculates MR estimates that would 
maximize this likelihood.51 The contamination method assumes that only some of the genetic 
variants used are valid instruments and it has been found to perform better than other methods 
under the presence of invalid instruments.52 Finally, we applied MR-PRESSO, which regresses 
the SNP-outcome estimates against the SNP-exposure estimates to test, using residual errors, 
whether there are outlier SNPs. Outliers are detected by sequentially removing all genetic variants 
from the analyses and comparing the residual sum of squares as a global heterogeneity measure 
(p-value for detecting outliers <0.05).53 MR-PRESSO then removes the identified outliers and 
provides outlier-corrected MR estimates.53 MR-PRESSO, is outlier-robust, but still relies on the 
assumption that at least half of the variants are valid instruments.53 
For the primary analyses (associations between downregulated IL-6 signaling and risk of ischemic 
stroke or coronary artery disease), we set a statistical significance threshold at a two-sided p-value 
of < 0.05. For ischemic stroke subtypes and for other cardiovascular outcomes, we corrected for 
multiple comparisons with the Bonferroni method. Thus, the statistical significance thresholds 
were set at p<0.05/3=0.017 for the 3 ischemic stroke subtypes, and at p<0.05/9=0.0055 for the 9 
cardiovascular outcomes. Associations not reaching these thresholds, but showing p-values <0.05 
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Identification and validation of genetic variants as proxies of downregulated IL-6 signaling  
Using our pre-defined selection criteria, we identified 7 SNPs to serve as instruments for 
downregulated IL-6 signaling (Table 2). Three of these instruments were situated within the 
IL6R gene (Supplementary Figure 1). The F-statistics of the 7 SNPs ranged from 81 to 764 
indicating a low probability of weak instrument bias.37 Power calculations indicated that these 
instruments provide adequate statistical power (>80%) to detect ORs at the magnitude of 0.90 or 
lower for ischemic stroke and coronary artery disease regarding the effect of genetically 
downregulated IL-6 signaling (scaled to the CRP-decreasing effect of tocilizumab) (Table S1). 
We were further sufficiently powered (>80%) to detect ORs at the magnitude of 0.80 or lower 
for ischemic stroke subtypes.  
To validate the 7 instruments, we explored associations of genetically downregulated IL-6 
signaling with circulating IL-6, soluble IL-6R, and fibrinogen levels. In accordance with 
randomized clinical trials testing the effects of tocilizumab versus placebo (8 mg/kg),20 
genetically downregulated IL-6 signaling was associated with higher circulating IL-6 and soluble 
IL-6R levels and with lower circulating concentration of fibrinogen with the strongest effects 






Genetically downregulated IL-6 signaling, ischemic stroke and coronary artery disease 
We next explored associations between genetically downregulated IL-6 signaling (scaled to the 
CRP-decreasing effect of tocilizumab) with the risk of ischemic stroke and coronary artery 
disease (Figure 3). In the primary IVW analysis, downregulated IL-6 signaling was associated 
with a lower risk of both ischemic stroke (OR: 0.89, 95%CI: 0.82-0.97, p=3x10-3) and coronary 
artery disease (OR: 0.84, 95%CI: 0.77-0.90, p=7x10-6). The alternative MR approaches 
(weighted median, contamination mixture, MR-PRESSO) all showed consistent association 
estimates (Figure S2).  
In sensitivity analyses restricted to the 3 instruments within the IL6R gene, we likewise found 
genetically downregulated IL-6 signaling to be associated with a lower risk of ischemic stroke 
and coronary artery disease (Figure 3 and Figure S2). Further restricting the analysis to a single 
SNP (rs2228145) with a well-described effect proxying the effects of pharmacological IL-6 
signaling inhibition,20 we found presence of the allele linked to downregulated IL-6 signaling to 
be associated with lower risk of both ischemic stroke (OR: 0.88, 95%CI: 0.79-0.99, p=0.033) 
and coronary artery disease (OR: 0.75, 95%CI: 0.67-0.85, p=2x10-7).  
To disentangle the effect of downregulated IL-6 signaling from the effect of CRP, we next 
performed MR analyses to explore associations between SNPs associated with CRP, and risk of 
ischemic stroke and coronary artery disease. These analyses showed no associations between 
genetically determined CRP levels and risk of either ischemic stroke or coronary artery disease 
independent of whether we used all variants reaching genome-wide significance (p<5x10-8) for 
association with CRP (187 SNPs), or whether we restricted the analyses to significant SNPs at 
the CRP locus (24 SNPs) (Figure S3). We further performed 10,000 permutations of MR 
analyses randomly selecting 7 out of the 187 SNPs associated with CRP. The effects of the 7 
SNPs selected as instruments for downregulated IL-6 signaling on ischemic stroke and coronary 
artery disease were located at the 4th and 1st lowest percentiles of the respective distributions, 
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corresponding to p-values of 0.04 and 0.01, respectively (Figure 3C and Figure S4), thus 
indicating that the effects of IL-6 signaling are independent of the effects of CRP itself.   
 
Genetically downregulated IL-6 signaling and ischemic stroke subtypes 
Focusing on etiological stroke subtypes (Figure 4), we found genetic downregulation of IL-6 
signaling to be associated with a lower risk of large artery stroke (OR: 0.76, 95%CI: 0.62-0.93, 
p=8x10-3) and small vessel stroke (OR: 0.71, 95%CI: 0.59-0.86, p=3x10-4), but not 
cardioembolic stroke (OR: 0.95, 95%CI: 0.74-1.22, p=0.667). The results were stable in all MR 
sensitivity analyses, including when restricting the analyses to the instruments within the IL6R 
gene (Figure S5). We further found no associations between genetically determined CRP levels, 
as determined by SNPs throughout the genome or SNPs at the CRP locus, and any of the 
ischemic stroke subtypes (Figure S6). Similarly, in permutations of analyses including 7 
randomly allocated SNPs throughout the genome, the effects of the SNPs proxying the 
downregulated IL-6 signaling on large artery and small vessel stroke, were at the 3rd and 0.1th 
percentiles (corresponding to p-values of 0.03 and 0.001), respectively, thus supporting that the 
observed effects were again independent of CRP (Figure S7).  
 
Genetically downregulated IL-6 signaling and other cardiovascular outcomes 
In a last step, we expanded the analyses to other cardiovascular outcomes (Figure 5). Genetic 
predisposition to downregulated IL-6 signaling was associated with lower risks of myocardial 
infarction (OR: 0.88, 95%CI: 0.81-0.96, p=3x10-3) and aortic aneurysm (OR: 0.51, 95%CI: 0.37-
0.68, p=1x10-5). We further found suggestive associations (p<0.05) with atrial fibrillation (OR: 
0.83, 95%CI: 0.71-0.96, p=0.013) and carotid plaque (OR: 0.87, 95%CI: 0.77-0.99, p=0.041). In 
contrast, we found no significant associations with peripheral artery disease (OR: 0.91, 95%CI: 
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0.74-1.11, p=0.349), heart failure (OR: 0.90, 95%CI: 0.79-1.04, p=0.156), venous 
thromboembolism (OR: 0.98, 95%CI: 0.81-1.15, p=0.809), deep vein thrombosis (OR: 1.15, 
95%CI: 0.94-1.40, p=0.183), and pulmonary embolism (OR: 0.92, 95%CI: 0.78-1.10, p=0.373). 
 
DISCUSSION 
Leveraging large-scale genetic data from multiple sources we identified variants serving as 
proxies for a genetic predisposition to downregulated IL-6 signaling and validated them using 
clinical trial data on pharmacological IL-6R inhibition. The identified proxies showed significant 
associations with a lower risk of both ischemic stroke and coronary artery disease. Among 
ischemic stroke subtypes, genetic predisposition to downregulated IL-6 signaling was associated 
with lower risks of large artery and small vessel stroke, but not cardioembolic stroke. Proxies for 
IL-6 signaling inhibition further showed significant associations with myocardial infarction and 
aortic aneurysm, and suggestive associations with atrial fibrillation and carotid plaque.    
The MR association between genetically downregulated IL-6 signaling and lower risk of large 
artery stroke extends previous clinical,17, 18, 21 genetic,19, 20 and experimental54, 55 data 
demonstrating a key role of IL-6 signaling in atherosclerosis. By binding to IL-6R, IL-6 
promotes downstream effects that include induction of macrophage recruitment56 and arterial 
smooth muscle cell proliferation,55, 57 and have been linked with plaque initiation,58 plaque 
destabilization,54 microvascular flow dysfunction,59 and adverse outcomes in the setting of acute 
ischemia.60 Moreover, pharmacological inhibition of IL-6R has been shown to attenuate 
atherosclerotic lesions in an experimental model of atherosclerosis.61 Our finding of an effect of 
genetic predisposition to downregulated IL-6 signaling on multiple atherosclerotic phenotypes 
(large artery stroke, coronary artery disease, myocardial infarction, aortic aneurysm, atrial 
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fibrillation, carotid plaque) provides further support that IL-6 signaling is critically implicated in 
atherogenesis and atheroprogression and might represent a valid therapeutic target. 
Notably, we found genetically downregulated IL-6 signaling to be further associated with small 
vessel stroke. There is only limited evidence regarding a role of inflammation in general and of 
IL-6 signaling in particular in cerebral small vessel disease.62 In a small prospective study of 123 
patients with manifestations of cerebral small vessel disease, IL-6 circulating levels were 
associated with a higher risk of incident lacunes, a marker of small vessel disease on brain 
magnetic resonance imaging.63 However, cross-sectional analyses from larger population-based 
studies showed inconsistent findings for lacunes, silent brain infarcts and other manifestations of 
small vessel disease.64-69 While the specific mechanisms underlying our MR results remain 
unknown, our findings suggest that inhibition of IL-6 signaling aside from being a candidate 
treatment for atherosclerosis might also lower the risk of small vessel stroke. 
Our results strongly support the candidacy of IL-6 signaling as a target for vascular prevention 
over and beyond previous data. The CANTOS trial targeted IL-1β rather than IL-6R and thus 
provided only indirect evidence for a benefit of interfering with IL-6 signaling.11, 21 Interestingly, 
the study further showed that part of the residual vascular risk after IL-1β inhibition could be 
explained by IL-6 levels, thus providing evidence that direct IL-6 signaling inhibition might 
represent a more effective strategy.22 Also, CANTOS was based on a population of individuals 
with coronary artery disease and explored a combined vascular endpoint rather than offering 
information on individual cardiovascular outcomes. With respect to stroke, there was a 7% 
reduction in incident stroke events in the IL-1β arm, which however did not reach statistical 
significance, possibly because of insufficient power.8 Our MR results provide evidence for 
directionally consistent effects of IL-6 signaling in multiple cardiovascular outcomes. Thus, our 
findings offer a solid basis for future clinical trials exploring the benefit of pharmacological IL-
6R inhibition for the range of phenotypes examined here. 
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Interestingly, we found a particularly strong effect of genetically downregulated IL-6 signaling 
on aortic aneurysm. A role of IL-6 signaling in the pathogenesis of aortic aneurysm has been 
previously demonstrated by genetic studies.38, 70, 71 IL-6 signaling might contribute to the 
formation of aortic aneurysms through mechanisms aside from atherosclerosis, thus explaining 
the large effect. For instance, IL-6 signaling is a key pathway in the pathogenesis of large vessel 
vasculitides,72 which are strongly associated with the formation of aortic aneurysms.16, 73, 74 
Our analysis provides no evidence for an association of genetically downregulated IL-6 signaling 
with cardioembolic stroke. In conjunction with the lack of significant MR associations with 
thrombotic phenotypes (venous thromboembolism, deep vein thrombosis, pulmonary embolism), 
our results do not support a role of IL-6 signaling in promoting coagulation and thrombosis. Yet, 
in accord with previous observational studies,75-77 we found IL-6 signaling to show a suggestive 
association with atrial fibrillation, the primary cause of cardioembolism and a common 
complication of coronary artery disease.78, 79 Given the relatively small magnitude of this 
association, any effect of IL-6 signaling on risk of cardioembolic stroke through atrial fibrillation 
would be expected to be small. 
Our study has several strengths. Utilizing the most recent genetic data on CRP levels, ischemic 
stroke, and other cardiovascular phenotypes, we were sufficiently powered to show significant 
associations between genetically downregulated IL-6 signaling and multiple outcomes of 
interest. Using CRP levels, as a proxy for downstream IL-6 signaling enabled us to scale the 
derived association estimates to the respective effects of tocilizumab, as recorded in previous 
clinical trials, thus providing clinically meaningful estimates that might be comparable to those 
obtained from future trials. We further validated the effects of the selected proxies on upstream 
regulators (IL-6 and soluble IL-6R) and downstream effectors (fibrinogen) of IL-6 signaling, 
which were consistent with the effects observed with pharmacological inhibition of IL-6R. 
Finally, we could disentangle the effect of IL-6 signaling from the direct effect of CRP by 
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determining the effects of CRP levels on risk of the examined outcomes and performing 
permutations for the effects of randomly selected CRP-decreasing variants. 
Our study also has limitations. First, to proxy IL-6 signaling we used CRP levels, which are a 
downstream effect of the classical membrane-bound IL-6R-mediated signaling in hepatocytes.80 
However, IL-6 also acts on other tissues not expressing the membrane-bound IL-6R, by binding 
to its soluble form, which is known as trans-signaling.80 Thus, our results may be interpreted as 
an effect of downstream regulation of classical IL-6 signaling but not IL-6 trans-signaling. 
Second, by design, our MR study assessed the effects of lifetime downregulated IL-6 signaling, 
which might differ from a shorter pharmacological inhibition. Third, there might be unknown 
pleiotropic effects of the genetic proxies used as instruments in the current study that might bias 
the associations. Of note, however, the results were remarkably consistent in sensitivity MR 
methods that are more robust to the inclusion of pleiotropic variants. Finally, our results were 
mainly based on individuals of European origin, and might thus not apply to other ethnic groups. 
In conclusion, this study provides evidence for a causal effect of IL-6 signaling on ischemic 
stroke, particularly large artery and small vessel stroke, as well as a range of cardiovascular 
phenotypes. IL-6R blockade might represent a valid therapeutic target for lowering 





Acknowledgements: We thank the following consortia for making data publicly available: 
MEGASTROKE Consortium, CARDIoGRAMplusC4D Consortium, AFGen Consortium, the 
YFS/FINRISK studies, and the INTERVAL study. This research has been conducted using the 
UK Biobank Resource (UK Biobank application 2532, “UK Biobank stroke study: developing an 
in-depth understanding of the determinants of stroke and its subtypes”).  
Funding: M. Georgakis was funded by scholarships from the Onassis Foundation and the 
German Academic Exchange Service (DAAD). D. Gill is funded by the Wellcome Trust. This 
project has received funding from the European Union’s Horizon 2020 research and innovation 
programme (No 666881), SVDs@target (to M. Dichgans) and No 667375, CoSTREAM (to M. 
Dichgans); the DFG as part of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy – 
ID 390857198) and the CRC 1123 (B3) (to M. Dichgans); the Corona Foundation (to M. 
Dichgans); the Fondation Leducq (Transatlantic Network of Excellence on Pathogenesis of 
Small Vessel Disease of the Brain, to M. Dichgans); the e:Med program (e:AtheroSysMed, to M. 
Dichgans) and the FP7/2007-2103 European Union project CVgenes@target (grant agreement 
number Health-F2-2013-601456, to M. Dichgans).  
Disclosures: No conflicts of interest to disclose.  
Affiliations: From Institute for Stroke and Dementia Research (ISD), University Hospital of 
Ludwig-Maximilians-University (LMU), Munich, Germany (M.G., R.M., M.D.); Graduate 
School for Systemic Neurosciences (GSN), Ludwig-Maximilians-University LMU, Munich, 
Germany (M.G.); Department of Biostatistics and Epidemiology, School of Public Health, 
Imperial College London, London, UK (D.G., C.S.); Department of Epidemiology, UNC 
Gillings Global School of Public Health, Chapel Hill, NC, USA (N.F.); Institute for Genetics and 
Molecular Medicine, University of Edinburgh, UK (C.S.); Munich Cluster for Systems 
Neurology (SyNergy), Munich, Germany (M.D.); German Centre for Neurodegenerative 




1. DALYs GBD and Collaborators H. Global, regional, and national disability-adjusted life-years (DALYs) 
for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global 
Burden of Disease Study 2015. Lancet. 2016;388:1603-1658. 
2. Mortality GBD and Causes of Death C. Global, regional, and national life expectancy, all-cause mortality, 
and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of 
Disease Study 2015. Lancet. 2016;388:1459-1544. 
3. Collaborators GBDLRoS, Feigin VL, Nguyen G, Cercy K, Johnson CO, Alam T, Parmar PG, Abajobir 
AA, Abate KH, Abd-Allah F, Abejie AN, Abyu GY, Ademi Z, Agarwal G, Ahmed MB, Akinyemi RO, Al-Raddadi 
R, Aminde LN, Amlie-Lefond C, Ansari H, Asayesh H, Asgedom SW, Atey TM, Ayele HT, Banach M, Banerjee A, 
Barac A, Barker-Collo SL, Barnighausen T, Barregard L, Basu S, Bedi N, Behzadifar M, Bejot Y, Bennett DA, 
Bensenor IM, Berhe DF, Boneya DJ, Brainin M, Campos-Nonato IR, Caso V, Castaneda-Orjuela CA, Rivas JC, 
Catala-Lopez F, Christensen H, Criqui MH, Damasceno A, Dandona L, Dandona R, Davletov K, de Courten B, 
deVeber G, Dokova K, Edessa D, Endres M, Faraon EJA, Farvid MS, Fischer F, Foreman K, Forouzanfar MH, Gall 
SL, Gebrehiwot TT, Geleijnse JM, Gillum RF, Giroud M, Goulart AC, Gupta R, Gupta R, Hachinski V, Hamadeh 
RR, Hankey GJ, Hareri HA, Havmoeller R, Hay SI, Hegazy MI, Hibstu DT, James SL, Jeemon P, John D, Jonas JB, 
Jozwiak J, Kalani R, Kandel A, Kasaeian A, Kengne AP, Khader YS, Khan AR, Khang YH, Khubchandani J, Kim 
D, Kim YJ, Kivimaki M, Kokubo Y, Kolte D, Kopec JA, Kosen S, Kravchenko M, Krishnamurthi R, Kumar GA, 
Lafranconi A, Lavados PM, Legesse Y, Li Y, Liang X, Lo WD, Lorkowski S, Lotufo PA, Loy CT, Mackay MT, 
Abd El Razek HM, Mahdavi M, Majeed A, Malekzadeh R, Malta DC, Mamun AA, Mantovani LG, Martins SCO, 
Mate KK, Mazidi M, Mehata S, Meier T, Melaku YA, Mendoza W, Mensah GA, Meretoja A, Mezgebe HB, 
Miazgowski T, Miller TR, Ibrahim NM, Mohammed S, Mokdad AH, Moosazadeh M, Moran AE, Musa KI, Negoi 
RI, Nguyen M, Nguyen QL, Nguyen TH, Tran TT, Nguyen TT, Anggraini Ningrum DN, Norrving B, Noubiap JJ, 
O'Donnell MJ, Olagunju AT, Onuma OK, Owolabi MO, Parsaeian M, Patton GC, Piradov M, Pletcher MA, 
Pourmalek F, Prakash V, Qorbani M, Rahman M, Rahman MA, Rai RK, Ranta A, Rawaf D, Rawaf S, Renzaho 
AM, Robinson SR, Sahathevan R, Sahebkar A, Salomon JA, Santalucia P, Santos IS, Sartorius B, Schutte AE, 
Sepanlou SG, Shafieesabet A, Shaikh MA, Shamsizadeh M, Sheth KN, Sisay M, Shin MJ, Shiue I, Silva DAS, 
Sobngwi E, Soljak M, Sorensen RJD, Sposato LA, Stranges S, Suliankatchi RA, Tabares-Seisdedos R, Tanne D, 
Nguyen CT, Thakur JS, Thrift AG, Tirschwell DL, Topor-Madry R, Tran BX, Nguyen LT, Truelsen T, Tsilimparis 
N, Tyrovolas S, Ukwaja KN, Uthman OA, Varakin Y, Vasankari T, Venketasubramanian N, Vlassov VV, Wang W, 
Werdecker A, Wolfe CDA, Xu G, Yano Y, Yonemoto N, Yu C, Zaidi Z, El Sayed Zaki M, Zhou M, Ziaeian B, 
Zipkin B, Vos T, Naghavi M, Murray CJL and Roth GA. Global, Regional, and Country-Specific Lifetime Risks of 
Stroke, 1990 and 2016. N Engl J Med. 2018;379:2429-2437. 
4. Feigin VL, Norrving B and Mensah GA. Global Burden of Stroke. Circ Res. 2017;120:439-448. 
5. Esenwa CC and Elkind MS. Inflammatory risk factors, biomarkers and associated therapy in ischaemic 
stroke. Nat Rev Neurol. 2016;12:594-604. 
6. Libby P, Ridker PM, Hansson GK and Leducq Transatlantic Network on Atherothrombosis. Inflammation 
in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-38. 
7. Ridker PM. Targeting inflammatory pathways for the treatment of cardiovascular disease. Eur Heart J. 
2014;35:540-3. 
8. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, 
Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, 
Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, 
Glynn RJ and Group CT. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 
2017;377:1119-1131. 
9. Georgakis MK, Gill D, Rannikmae K, Traylor M, Anderson CD, Lee JM, Kamatani Y, Hopewell JC, 
Worrall BB, Bernhagen J, Sudlow CLM, Malik R and Dichgans M. Genetically Determined Levels of Circulating 
Cytokines and Risk of Stroke. Circulation. 2019;139:256-268. 
10. Georgakis MK, Malik R, Bjorkbacka H, Pana TA, Demissie S, Ayers C, Elhadad MA, Fornage M, Beiser 
AS, Benjamin EJ, Boekholdt MS, Engstrom G, Herder C, Hoogeveen RC, Koenig W, Melander O, Orho-Melander 
M, Schiopu A, Soderholm M, Wareham N, Ballantyne CM, Peters A, Seshadri S, Myint PK, Nilsson J, de Lemos JA 
and Dichgans M. Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke: A Meta-Analysis of 
Population-Based Studies Involving 17,180 Individuals. Circ Res. 2019. 
11. Ridker PM. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of 
Atherothrombosis. Circ Res. 2019;124:437-450. 
12. Scheller J, Chalaris A, Schmidt-Arras D and Rose-John S. The pro- and anti-inflammatory properties of the 
cytokine interleukin-6. Biochim Biophys Acta. 2011;1813:878-88. 
13. Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify 
Novel Targets for Atheroprotection. Circ Res. 2016;118:145-56. 
20 
 
14. Scott LJ. Tocilizumab: A Review in Rheumatoid Arthritis. Drugs. 2017;77:1865-1879. 
15. Danese S, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G, Kohn A, Desreumaux P, Leong RW, 
Comer GM, Cataldi F, Banerjee A, Maguire MK, Li C, Rath N, Beebe J and Schreiber S. Randomised trial and 
open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). Gut. 
2019;68:40-48. 
16. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, 
Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH and Collinson N. Trial of 
Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377:317-328. 
17. Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A, Di Angelantonio E, Gudnason 
V, Rumley A, Lowe GD, Jorgensen T and Danesh J. Inflammatory cytokines and risk of coronary heart disease: new 
prospective study and updated meta-analysis. Eur Heart J. 2014;35:578-89. 
18. Ridker PM, Rifai N, Stampfer MJ and Hennekens CH. Plasma concentration of interleukin-6 and the risk 
of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-72. 
19. Collaboration IRGCERF, Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, Gao 
P, Saleheen D, Rendon A, Nelson CP, Braund PS, Hall AS, Chasman DI, Tybjaerg-Hansen A, Chambers JC, 
Benjamin EJ, Franks PW, Clarke R, Wilde AA, Trip MD, Steri M, Witteman JC, Qi L, van der Schoot CE, de Faire 
U, Erdmann J, Stringham HM, Koenig W, Rader DJ, Melzer D, Reich D, Psaty BM, Kleber ME, Panagiotakos DB, 
Willeit J, Wennberg P, Woodward M, Adamovic S, Rimm EB, Meade TW, Gillum RF, Shaffer JA, Hofman A, 
Onat A, Sundstrom J, Wassertheil-Smoller S, Mellstrom D, Gallacher J, Cushman M, Tracy RP, Kauhanen J, 
Karlsson M, Salonen JT, Wilhelmsen L, Amouyel P, Cantin B, Best LG, Ben-Shlomo Y, Manson JE, Davey-Smith 
G, de Bakker PI, O'Donnell CJ, Wilson JF, Wilson AG, Assimes TL, Jansson JO, Ohlsson C, Tivesten A, Ljunggren 
O, Reilly MP, Hamsten A, Ingelsson E, Cambien F, Hung J, Thomas GN, Boehnke M, Schunkert H, Asselbergs 
FW, Kastelein JJ, Gudnason V, Salomaa V, Harris TB, Kooner JS, Allin KH, Nordestgaard BG, Hopewell JC, 
Goodall AH, Ridker PM, Holm H, Watkins H, Ouwehand WH, Samani NJ, Kaptoge S, Di Angelantonio E, Harari O 
and Danesh J. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. 
Lancet. 2012;379:1205-13. 
20. Interleukin-6 Receptor Mendelian Randomisation Analysis C, Swerdlow DI, Holmes MV, Kuchenbaecker 
KB, Engmann JE, Shah T, Sofat R, Guo Y, Chung C, Peasey A, Pfister R, Mooijaart SP, Ireland HA, Leusink M, 
Langenberg C, Li KW, Palmen J, Howard P, Cooper JA, Drenos F, Hardy J, Nalls MA, Li YR, Lowe G, Stewart M, 
Bielinski SJ, Peto J, Timpson NJ, Gallacher J, Dunlop M, Houlston R, Tomlinson I, Tzoulaki I, Luan J, Boer JM, 
Forouhi NG, Onland-Moret NC, van der Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Baceviciene M, 
Tamosiunas A, Pajak A, Topor-Madry R, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, de Faire U, Ferrucci 
L, Bandenelli S, Tanaka T, Meschia JF, Singleton A, Navis G, Mateo Leach I, Bakker SJ, Gansevoort RT, Ford I, 
Epstein SE, Burnett MS, Devaney JM, Jukema JW, Westendorp RG, Jan de Borst G, van der Graaf Y, de Jong PA, 
Mailand-van der Zee AH, Klungel OH, de Boer A, Doevendans PA, Stephens JW, Eaton CB, Robinson JG, Manson 
JE, Fowkes FG, Frayling TM, Price JF, Whincup PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Redline 
S, Lange LA, Kumari M, Wareham NJ, Verschuren WM, Benjamin EJ, Whittaker JC, Hamsten A, Dudbridge F, 
Delaney JA, Wong A, Kuh D, Hardy R, Castillo BA, Connolly JJ, van der Harst P, Brunner EJ, Marmot MG, 
Wassel CL, Humphries SE, Talmud PJ, Kivimaki M, Asselbergs FW, Voevoda M, Bobak M, Pikhart H, Wilson JG, 
Hakonarson H, Reiner AP, Keating BJ, Sattar N, Hingorani AD and Casas JP. The interleukin-6 receptor as a target 
for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379:1214-24. 
21. Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, Koenig W, Shimokawa H, 
Everett BM and Glynn RJ. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic 
events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study 
(CANTOS). Eur Heart J. 2018;39:3499-3507. 
22. Ridker PM, MacFadyen JG, Thuren T and Libby P. Residual inflammatory risk associated with interleukin-
18 and interleukin-6 after successful interleukin-1beta inhibition with canakinumab: further rationale for the 
development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Eur Heart J. 2019. 
23. Cainzos-Achirica M, Enjuanes C, Greenland P, McEvoy JW, Cushman M, Dardari Z, Nasir K, Budoff MJ, 
Al-Mallah MH, Yeboah J, Miedema MD, Blumenthal RS, Comin-Colet J and Blaha MJ. The prognostic value of 
interleukin 6 in multiple chronic diseases and all-cause death: The Multi-Ethnic Study of Atherosclerosis (MESA). 
Atherosclerosis. 2018;278:217-225. 
24. Jenny NS, Callas PW, Judd SE, McClure LA, Kissela B, Zakai NA and Cushman M. Inflammatory 
cytokines and ischemic stroke risk: The REGARDS cohort. Neurology. 2019;92:e2375-e2384. 
25. Smith GD and Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to 
understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1-22. 
26. Kelly PJ, Murphy S, Coveney S, Purroy F, Lemmens R, Tsivgoulis G and Price C. Anti-inflammatory 
approaches to ischaemic stroke prevention. J Neurol Neurosurg Psychiatry. 2018;89:211-218. 
27. Holmes MV, Ala-Korpela M and Smith GD. Mendelian randomization in cardiometabolic disease: 
challenges in evaluating causality. Nat Rev Cardiol. 2017;14:577-590. 
28. Roberts R. Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval. JACC 
Basic Transl Sci. 2018;3:690-703. 
21 
 
29. Walker VM, Davey Smith G, Davies NM and Martin RM. Mendelian randomization: a novel approach for 
the prediction of adverse drug events and drug repurposing opportunities. Int J Epidemiol. 2017;46:2078-2089. 
30. Gill D, Georgakis MK, Koskeridis F, Jiang L, Feng Q, Wei WQ, Theodoratou E, Elliott P, Denny JC, 
Malik R, Evangelou E, Dehghan A, Dichgans M and Tzoulaki I. Use of Genetic Variants Related to 
Antihypertensive Drugs to Inform on Efficacy and Side Effects. Circulation. 2019;140:270-279. 
31. Ligthart S, Vaez A, Vosa U, Stathopoulou MG, de Vries PS, Prins BP, Van der Most PJ, Tanaka T, Naderi 
E, Rose LM, Wu Y, Karlsson R, Barbalic M, Lin H, Pool R, Zhu G, Mace A, Sidore C, Trompet S, Mangino M, 
Sabater-Lleal M, Kemp JP, Abbasi A, Kacprowski T, Verweij N, Smith AV, Huang T, Marzi C, Feitosa MF, 
Lohman KK, Kleber ME, Milaneschi Y, Mueller C, Huq M, Vlachopoulou E, Lyytikainen LP, Oldmeadow C, 
Deelen J, Perola M, Zhao JH, Feenstra B, LifeLines Cohort S, Amini M, Group CIW, Lahti J, Schraut KE, Fornage 
M, Suktitipat B, Chen WM, Li X, Nutile T, Malerba G, Luan J, Bak T, Schork N, Del Greco MF, Thiering E, 
Mahajan A, Marioni RE, Mihailov E, Eriksson J, Ozel AB, Zhang W, Nethander M, Cheng YC, Aslibekyan S, Ang 
W, Gandin I, Yengo L, Portas L, Kooperberg C, Hofer E, Rajan KB, Schurmann C, den Hollander W, Ahluwalia 
TS, Zhao J, Draisma HHM, Ford I, Timpson N, Teumer A, Huang H, Wahl S, Liu Y, Huang J, Uh HW, Geller F, 
Joshi PK, Yanek LR, Trabetti E, Lehne B, Vozzi D, Verbanck M, Biino G, Saba Y, Meulenbelt I, O'Connell JR, 
Laakso M, Giulianini F, Magnusson PKE, Ballantyne CM, Hottenga JJ, Montgomery GW, Rivadineira F, Rueedi R, 
Steri M, Herzig KH, Stott DJ, Menni C, Franberg M, St Pourcain B, Felix SB, Pers TH, Bakker SJL, Kraft P, Peters 
A, Vaidya D, Delgado G, Smit JH, Grossmann V, Sinisalo J, Seppala I, Williams SR, Holliday EG, Moed M, 
Langenberg C, Raikkonen K, Ding J, Campbell H, Sale MM, Chen YI, James AL, Ruggiero D, Soranzo N, Hartman 
CA, Smith EN, Berenson GS, Fuchsberger C, Hernandez D, Tiesler CMT, Giedraitis V, Liewald D, Fischer K, 
Mellstrom D, Larsson A, Wang Y, Scott WR, Lorentzon M, Beilby J, Ryan KA, Pennell CE, Vuckovic D, Balkau 
B, Concas MP, Schmidt R, Mendes de Leon CF, Bottinger EP, Kloppenburg M, Paternoster L, Boehnke M, Musk 
AW, Willemsen G, Evans DM, Madden PAF, Kahonen M, Kutalik Z, Zoledziewska M, Karhunen V, Kritchevsky 
SB, Sattar N, Lachance G, Clarke R, Harris TB, Raitakari OT, Attia JR, van Heemst D, Kajantie E, Sorice R, 
Gambaro G, Scott RA, Hicks AA, Ferrucci L, Standl M, Lindgren CM, Starr JM, Karlsson M, Lind L, Li JZ, 
Chambers JC, Mori TA, de Geus E, Heath AC, Martin NG, Auvinen J, Buckley BM, de Craen AJM, Waldenberger 
M, Strauch K, Meitinger T, Scott RJ, McEvoy M, Beekman M, Bombieri C, Ridker PM, Mohlke KL, Pedersen NL, 
Morrison AC, Boomsma DI, Whitfield JB, Strachan DP, Hofman A, Vollenweider P, Cucca F, Jarvelin MR, Jukema 
JW, Spector TD, Hamsten A, Zeller T, Uitterlinden AG, Nauck M, Gudnason V, Qi L, Grallert H, Borecki IB, 
Rotter JI, Marz W, Wild PS, Lokki ML, Boyle M, Salomaa V, Melbye M, Eriksson JG, Wilson JF, Penninx B, 
Becker DM, Worrall BB, Gibson G, Krauss RM, Ciullo M, Zaza G, Wareham NJ, Oldehinkel AJ, Palmer LJ, 
Murray SS, Pramstaller PP, Bandinelli S, Heinrich J, Ingelsson E, Deary IJ, Magi R, Vandenput L, van der Harst P, 
Desch KC, Kooner JS, Ohlsson C, Hayward C, Lehtimaki T, Shuldiner AR, Arnett DK, Beilin LJ, Robino A, 
Froguel P, Pirastu M, Jess T, Koenig W, Loos RJF, Evans DA, Schmidt H, Smith GD, Slagboom PE, Eiriksdottir G, 
Morris AP, Psaty BM, Tracy RP, Nolte IM, Boerwinkle E, Visvikis-Siest S, Reiner AP, Gross M, Bis JC, Franke L, 
Franco OH, Benjamin EJ, Chasman DI, Dupuis J, Snieder H, Dehghan A and Alizadeh BZ. Genome Analyses of 
>200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation 
and Complex Disorders. Am J Hum Genet. 2018;103:691-706. 
32. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, Rutten-Jacobs L, Giese AK, van 
der Laan SW, Gretarsdottir S, Anderson CD, Chong M, Adams HHH, Ago T, Almgren P, Amouyel P, Ay H, Bartz 
TM, Benavente OR, Bevan S, Boncoraglio GB, Brown RD, Jr., Butterworth AS, Carrera C, Carty CL, Chasman DI, 
Chen WM, Cole JW, Correa A, Cotlarciuc I, Cruchaga C, Danesh J, de Bakker PIW, DeStefano AL, den Hoed M, 
Duan Q, Engelter ST, Falcone GJ, Gottesman RF, Grewal RP, Gudnason V, Gustafsson S, Haessler J, Harris TB, 
Hassan A, Havulinna AS, Heckbert SR, Holliday EG, Howard G, Hsu FC, Hyacinth HI, Ikram MA, Ingelsson E, 
Irvin MR, Jian X, Jimenez-Conde J, Johnson JA, Jukema JW, Kanai M, Keene KL, Kissela BM, Kleindorfer DO, 
Kooperberg C, Kubo M, Lange LA, Langefeld CD, Langenberg C, Launer LJ, Lee JM, Lemmens R, Leys D, Lewis 
CM, Lin WY, Lindgren AG, Lorentzen E, Magnusson PK, Maguire J, Manichaikul A, McArdle PF, Meschia JF, 
Mitchell BD, Mosley TH, Nalls MA, Ninomiya T, O'Donnell MJ, Psaty BM, Pulit SL, Rannikmae K, Reiner AP, 
Rexrode KM, Rice K, Rich SS, Ridker PM, Rost NS, Rothwell PM, Rotter JI, Rundek T, Sacco RL, Sakaue S, Sale 
MM, Salomaa V, Sapkota BR, Schmidt R, Schmidt CO, Schminke U, Sharma P, Slowik A, Sudlow CLM, Tanislav 
C, Tatlisumak T, Taylor KD, Thijs VNS, Thorleifsson G, Thorsteinsdottir U, Tiedt S, Trompet S, Tzourio C, van 
Duijn CM, Walters M, Wareham NJ, Wassertheil-Smoller S, Wilson JG, Wiggins KL, Yang Q, Yusuf S, Bis JC, 
Pastinen T, Ruusalepp A, Schadt EE, Koplev S, Bjorkegren JLM, Codoni V, Civelek M, Smith NL, Tregouet DA, 
Christophersen IE, Roselli C, Lubitz SA, Ellinor PT, Tai ES, Kooner JS, Kato N, He J, van der Harst P, Elliott P, 
Chambers JC, Takeuchi F, Johnson AD, Sanghera DK, Melander O, Jern C, Strbian D, Fernandez-Cadenas I, 
Longstreth WT, Jr., Rolfs A, Hata J, Woo D, Rosand J, Pare G, Hopewell JC, Saleheen D, Stefansson K, Worrall 
BB, Kittner SJ, Seshadri S, Fornage M, Markus HS, Howson JMM, Kamatani Y, Debette S, Dichgans M, Malik R, 
Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, Rutten-Jacobs L, Giese AK, van der Laan SW, 
Gretarsdottir S, Anderson CD, Chong M, Adams HHH, Ago T, Almgren P, Amouyel P, Ay H, Bartz TM, 
Benavente OR, Bevan S, Boncoraglio GB, Brown RD, Jr., Butterworth AS, Carrera C, Carty CL, Chasman DI, 
Chen WM, Cole JW, Correa A, Cotlarciuc I, Cruchaga C, Danesh J, de Bakker PIW, DeStefano AL, Hoed MD, 
Duan Q, Engelter ST, Falcone GJ, Gottesman RF, Grewal RP, Gudnason V, Gustafsson S, Haessler J, Harris TB, 
22 
 
Hassan A, Havulinna AS, Heckbert SR, Holliday EG, Howard G, Hsu FC, Hyacinth HI, Ikram MA, Ingelsson E, 
Irvin MR, Jian X, Jimenez-Conde J, Johnson JA, Jukema JW, Kanai M, Keene KL, Kissela BM, Kleindorfer DO, 
Kooperberg C, Kubo M, Lange LA, Langefeld CD, Langenberg C, Launer LJ, Lee JM, Lemmens R, Leys D, Lewis 
CM, Lin WY, Lindgren AG, Lorentzen E, Magnusson PK, Maguire J, Manichaikul A, McArdle PF, Meschia JF, 
Mitchell BD, Mosley TH, Nalls MA, Ninomiya T, O'Donnell MJ, Psaty BM, Pulit SL, Rannikmae K, Reiner AP, 
Rexrode KM, Rice K, Rich SS, Ridker PM, Rost NS, Rothwell PM, Rotter JI, Rundek T, Sacco RL, Sakaue S, Sale 
MM, Salomaa V, Sapkota BR, Schmidt R, Schmidt CO, Schminke U, Sharma P, Slowik A, Sudlow CLM, Tanislav 
C, Tatlisumak T, Taylor KD, Thijs VNS, Thorleifsson G, Thorsteinsdottir U, Tiedt S, Trompet S, Tzourio C, van 
Duijn CM, Walters M, Wareham NJ, Wassertheil-Smoller S, Wilson JG, Wiggins KL, Yang Q, Yusuf S, Amin N, 
Aparicio HS, Arnett DK, Attia J, Beiser AS, Berr C, Buring JE, Bustamante M, Caso V, Cheng YC, Choi SH, 
Chowhan A, Cullell N, Dartigues JF, Delavaran H, Delgado P, Dorr M, Engstrom G, Ford I, Gurpreet WS, Hamsten 
A, Heitsch L, Hozawa A, Ibanez L, Ilinca A, Ingelsson M, Iwasaki M, Jackson RD, Jood K, Jousilahti P, Kaffashian 
S, Kalra L, Kamouchi M, Kitazono T, Kjartansson O, Kloss M, Koudstaal PJ, Krupinski J, Labovitz DL, Laurie CC, 
Levi CR, Li L, Lind L, Lindgren CM, Lioutas V, Liu YM, Lopez OL, Makoto H, Martinez-Majander N, Matsuda K, 
Minegishi N, Montaner J, Morris AP, Muino E, Muller-Nurasyid M, Norrving B, Ogishima S, Parati EA, 
Peddareddygari LR, Pedersen NL, Pera J, Perola M, Pezzini A, Pileggi S, Rabionet R, Riba-Llena I, Ribases M, 
Romero JR, Roquer J, Rudd AG, Sarin AP, Sarju R, Sarnowski C, Sasaki M, Satizabal CL, Satoh M, Sattar N, 
Sawada N, Sibolt G, Sigurdsson A, Smith A, Sobue K, Soriano-Tarraga C, Stanne T, Stine OC, Stott DJ, Strauch K, 
Takai T, Tanaka H, Tanno K, Teumer A, Tomppo L, Torres-Aguila NP, Touze E, Tsugane S, Uitterlinden AG, 
Valdimarsson EM, van der Lee SJ, Volzke H, Wakai K, Weir D, Williams SR, Wolfe CDA, Wong Q, Xu H, Yamaji 
T, Sanghera DK, Melander O, Jern C, Strbian D, Fernandez-Cadenas I, Longstreth WT, Jr., Rolfs A, Hata J, Woo D, 
Rosand J, Pare G, Hopewell JC, Saleheen D, Stefansson K, Worrall BB, Kittner SJ, Seshadri S, Fornage M, Markus 
HS, Howson JMM, Kamatani Y, Debette S, Dichgans M, Consortium AF, Cohorts for H, Aging Research in 
Genomic Epidemiology C, International Genomics of Blood Pressure C, Consortium I, Starnet, BioBank Japan 
Cooperative Hospital G, Consortium C, Consortium E-C, Consortium EP-I, International Stroke Genetics C, 
Consortium M, Neurology Working Group of the CC, Network NSG, Study UKYLD, Consortium M and 
Consortium M. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with 
stroke and stroke subtypes. Nat Genet. 2018;50:524-537. 
33. Malik R, Rannikmae K, Traylor M, Georgakis MK, Sargurupremraj M, Markus HS, Hopewell JC, Debette 
S, Sudlow CLM, Dichgans M, consortium M and the International Stroke Genetics C. Genome-wide meta-analysis 
identifies 3 novel loci associated with stroke. Ann Neurol. 2018;84:934-939. 
34. Parisinos CA, Serghiou S, Katsoulis M, George MJ, Patel RS, Hemingway H and Hingorani AD. Variation 
in Interleukin 6 Receptor Gene Associates With Risk of Crohn's Disease and Ulcerative Colitis. Gastroenterology. 
2018;155:303-306 e2. 
35. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, 
McCarthy S, McVean GA and Abecasis GR. A global reference for human genetic variation. Nature. 2015;526:68-
74. 
36. Shim H, Chasman DI, Smith JD, Mora S, Ridker PM, Nickerson DA, Krauss RM and Stephens M. A 
multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 
1868 Caucasians. PLoS One. 2015;10:e0120758. 
37. Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, Timpson NJ, Davey Smith G and Sterne 
JA. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res. 
2012;21:223-42. 
38. Cai T, Zhang Y, Ho YL, Link N, Sun J, Huang J, Cai TA, Damrauer S, Ahuja Y, Honerlaw J, Huang J, 
Costa L, Schubert P, Hong C, Gagnon D, Sun YV, Gaziano JM, Wilson P, Cho K, Tsao P, O'Donnell CJ, Liao KP 
and Program VAMV. Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of 
Interleukin 6 Receptor Blocking Therapy: A Phenome-Wide Association Study. JAMA Cardiol. 2018;3:849-857. 
39. Ferreira RC, Freitag DF, Cutler AJ, Howson JM, Rainbow DB, Smyth DJ, Kaptoge S, Clarke P, Boreham 
C, Coulson RM, Pekalski ML, Chen WM, Onengut-Gumuscu S, Rich SS, Butterworth AS, Malarstig A, Danesh J 
and Todd JA. Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse 
inflammatory diseases. PLoS Genet. 2013;9:e1003444. 
40. Ahola-Olli AV, Wurtz P, Havulinna AS, Aalto K, Pitkanen N, Lehtimaki T, Kahonen M, Lyytikainen LP, 
Raitoharju E, Seppala I, Sarin AP, Ripatti S, Palotie A, Perola M, Viikari JS, Jalkanen S, Maksimow M, Salomaa V, 
Salmi M, Kettunen J and Raitakari OT. Genome-wide Association Study Identifies 27 Loci Influencing 
Concentrations of Circulating Cytokines and Growth Factors. Am J Hum Genet. 2017;100:40-50. 
41. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T, Paige E, 
Surendran P, Oliver-Williams C, Kamat MA, Prins BP, Wilcox SK, Zimmerman ES, Chi A, Bansal N, Spain SL, 
Wood AM, Morrell NW, Bradley JR, Janjic N, Roberts DJ, Ouwehand WH, Todd JA, Soranzo N, Suhre K, Paul 
DS, Fox CS, Plenge RM, Danesh J, Runz H and Butterworth AS. Genomic atlas of the human plasma proteome. 
Nature. 2018;558:73-79. 
42. Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J, Butterworth AS and Staley JR. 
PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics. 2019. 
23 
 
43. de Vries PS, Chasman DI, Sabater-Lleal M, Chen MH, Huffman JE, Steri M, Tang W, Teumer A, Marioni 
RE, Grossmann V, Hottenga JJ, Trompet S, Muller-Nurasyid M, Zhao JH, Brody JA, Kleber ME, Guo X, Wang JJ, 
Auer PL, Attia JR, Yanek LR, Ahluwalia TS, Lahti J, Venturini C, Tanaka T, Bielak LF, Joshi PK, Rocanin-Arjo A, 
Kolcic I, Navarro P, Rose LM, Oldmeadow C, Riess H, Mazur J, Basu S, Goel A, Yang Q, Ghanbari M, Willemsen 
G, Rumley A, Fiorillo E, de Craen AJ, Grotevendt A, Scott R, Taylor KD, Delgado GE, Yao J, Kifley A, 
Kooperberg C, Qayyum R, Lopez LM, Berentzen TL, Raikkonen K, Mangino M, Bandinelli S, Peyser PA, Wild S, 
Tregouet DA, Wright AF, Marten J, Zemunik T, Morrison AC, Sennblad B, Tofler G, de Maat MP, de Geus EJ, 
Lowe GD, Zoledziewska M, Sattar N, Binder H, Volker U, Waldenberger M, Khaw KT, McKnight B, Huang J, 
Jenny NS, Holliday EG, Qi L, McEvoy MG, Becker DM, Starr JM, Sarin AP, Hysi PG, Hernandez DG, Jhun MA, 
Campbell H, Hamsten A, Rivadeneira F, McArdle WL, Slagboom PE, Zeller T, Koenig W, Psaty BM, Haritunians 
T, Liu J, Palotie A, Uitterlinden AG, Stott DJ, Hofman A, Franco OH, Polasek O, Rudan I, Morange PE, Wilson JF, 
Kardia SL, Ferrucci L, Spector TD, Eriksson JG, Hansen T, Deary IJ, Becker LC, Scott RJ, Mitchell P, Marz W, 
Wareham NJ, Peters A, Greinacher A, Wild PS, Jukema JW, Boomsma DI, Hayward C, Cucca F, Tracy R, Watkins 
H, Reiner AP, Folsom AR, Ridker PM, O'Donnell CJ, Smith NL, Strachan DP and Dehghan A. A meta-analysis of 
120 246 individuals identifies 18 new loci for fibrinogen concentration. Hum Mol Genet. 2016;25:358-70. 
44. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, Saleheen D, Kyriakou T, Nelson CP, 
Hopewell JC, Webb TR, Zeng L, Dehghan A, Alver M, Armasu SM, Auro K, Bjonnes A, Chasman DI, Chen S, 
Ford I, Franceschini N, Gieger C, Grace C, Gustafsson S, Huang J, Hwang SJ, Kim YK, Kleber ME, Lau KW, Lu 
X, Lu Y, Lyytikainen LP, Mihailov E, Morrison AC, Pervjakova N, Qu L, Rose LM, Salfati E, Saxena R, Scholz M, 
Smith AV, Tikkanen E, Uitterlinden A, Yang X, Zhang W, Zhao W, de Andrade M, de Vries PS, van Zuydam NR, 
Anand SS, Bertram L, Beutner F, Dedoussis G, Frossard P, Gauguier D, Goodall AH, Gottesman O, Haber M, Han 
BG, Huang J, Jalilzadeh S, Kessler T, Konig IR, Lannfelt L, Lieb W, Lind L, Lindgren CM, Lokki ML, Magnusson 
PK, Mallick NH, Mehra N, Meitinger T, Memon FU, Morris AP, Nieminen MS, Pedersen NL, Peters A, Rallidis 
LS, Rasheed A, Samuel M, Shah SH, Sinisalo J, Stirrups KE, Trompet S, Wang L, Zaman KS, Ardissino D, 
Boerwinkle E, Borecki IB, Bottinger EP, Buring JE, Chambers JC, Collins R, Cupples LA, Danesh J, Demuth I, 
Elosua R, Epstein SE, Esko T, Feitosa MF, Franco OH, Franzosi MG, Granger CB, Gu D, Gudnason V, Hall AS, 
Hamsten A, Harris TB, Hazen SL, Hengstenberg C, Hofman A, Ingelsson E, Iribarren C, Jukema JW, Karhunen PJ, 
Kim BJ, Kooner JS, Kullo IJ, Lehtimaki T, Loos RJF, Melander O, Metspalu A, Marz W, Palmer CN, Perola M, 
Quertermous T, Rader DJ, Ridker PM, Ripatti S, Roberts R, Salomaa V, Sanghera DK, Schwartz SM, Seedorf U, 
Stewart AF, Stott DJ, Thiery J, Zalloua PA, O'Donnell CJ, Reilly MP, Assimes TL, Thompson JR, Erdmann J, 
Clarke R, Watkins H, Kathiresan S, McPherson R, Deloukas P, Schunkert H, Samani NJ and Farrall M. A 
comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 
2015;47:1121-1130. 
45. Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL and Marsh EE, 3rd. 
Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of 
Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41. 
46. Lawlor DA, Harbord RM, Sterne JA, Timpson N and Davey Smith G. Mendelian randomization: using 
genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27:1133-63. 
47. Burgess S, Butterworth A and Thompson SG. Mendelian randomization analysis with multiple genetic 
variants using summarized data. Genet Epidemiol. 2013;37:658-65. 
48. Brion MJ, Shakhbazov K and Visscher PM. Calculating statistical power in Mendelian randomization 
studies. Int J Epidemiol. 2013;42:1497-501. 
49. Swerdlow DI, Kuchenbaecker KB, Shah S, Sofat R, Holmes MV, White J, Mindell JS, Kivimaki M, 
Brunner EJ, Whittaker JC, Casas JP and Hingorani AD. Selecting instruments for Mendelian randomization in the 
wake of genome-wide association studies. Int J Epidemiol. 2016;45:1600-1616. 
50. Hartwig FP, Davey Smith G and Bowden J. Robust inference in summary data Mendelian randomization 
via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46:1985-1998. 
51. Burgess S, Foley CN, Allara E, Staley JR and Howson JM. A robust and efficient method for Mendelian 
randomization with hundreds of genetic variants: unravelling mechanisms linking HDL-cholesterol and coronary 
heart disease. bioRxiv (Pre-print). 2019. 
52. Slob EAW and Burgess S. A Comparison Of Robust Mendelian Randomization Methods Using Summary 
Data. bioRxiv (Pre-print). 2019. 
53. Verbanck M, Chen CY, Neale B and Do R. Detection of widespread horizontal pleiotropy in causal 
relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50:693-
698. 
54. Huber SA, Sakkinen P, Conze D, Hardin N and Tracy R. Interleukin-6 exacerbates early atherosclerosis in 
mice. Arterioscler Thromb Vasc Biol. 1999;19:2364-7. 
55. Ikeda U, Ikeda M, Oohara T, Oguchi A, Kamitani T, Tsuruya Y and Kano S. Interleukin 6 stimulates 
growth of vascular smooth muscle cells in a PDGF-dependent manner. Am J Physiol. 1991;260:H1713-7. 
56. Jenkins BJ, Grail D, Inglese M, Quilici C, Bozinovski S, Wong P and Ernst M. Imbalanced gp130-
dependent signaling in macrophages alters macrophage colony-stimulating factor responsiveness via regulation of c-
fms expression. Mol Cell Biol. 2004;24:1453-63. 
24 
 
57. Wang D, Liu Z, Li Q, Karpurapu M, Kundumani-Sridharan V, Cao H, Dronadula N, Rizvi F, Bajpai AK, 
Zhang C, Muller-Newen G, Harris KW and Rao GN. An essential role for gp130 in neointima formation following 
arterial injury. Circ Res. 2007;100:807-16. 
58. Schieffer B, Selle T, Hilfiker A, Hilfiker-Kleiner D, Grote K, Tietge UJ, Trautwein C, Luchtefeld M, 
Schmittkamp C, Heeneman S, Daemen MJ and Drexler H. Impact of interleukin-6 on plaque development and 
morphology in experimental atherosclerosis. Circulation. 2004;110:3493-500. 
59. Guo F, Dong M, Ren F, Zhang C, Li J, Tao Z, Yang J and Li G. Association between local interleukin-6 
levels and slow flow/microvascular dysfunction. J Thromb Thrombolysis. 2014;37:475-82. 
60. Lindmark E, Diderholm E, Wallentin L and Siegbahn A. Relationship between interleukin 6 and mortality 
in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 
2001;286:2107-13. 
61. Akita K, Isoda K, Sato-Okabayashi Y, Kadoguchi T, Kitamura K, Ohtomo F, Shimada K and Daida H. An 
Interleukin-6 Receptor Antibody Suppresses Atherosclerosis in Atherogenic Mice. Front Cardiovasc Med. 
2017;4:84. 
62. Low A, Mak E, Rowe JB, Markus HS and O'Brien JT. Inflammation and cerebral small vessel disease: A 
systematic review. Ageing Res Rev. 2019;53:100916. 
63. Staszewski J, Piusinska-Macoch R, Brodacki B, Skrobowska E and Stepien A. IL-6, PF-4, sCD40 L, and 
homocysteine are associated with the radiological progression of cerebral small-vessel disease: a 2-year follow-up 
study. Clin Interv Aging. 2018;13:1135-1141. 
64. Shoamanesh A, Preis SR, Beiser AS, Vasan RS, Benjamin EJ, Kase CS, Wolf PA, DeCarli C, Romero JR 
and Seshadri S. Inflammatory biomarkers, cerebral microbleeds, and small vessel disease: Framingham Heart Study. 
Neurology. 2015;84:825-32. 
65. Satizabal CL, Zhu YC, Mazoyer B, Dufouil C and Tzourio C. Circulating IL-6 and CRP are associated 
with MRI findings in the elderly: the 3C-Dijon Study. Neurology. 2012;78:720-7. 
66. Hoshi T, Kitagawa K, Yamagami H, Furukado S, Hougaku H and Hori M. Relations of serum high-
sensitivity C-reactive protein and interleukin-6 levels with silent brain infarction. Stroke. 2005;36:768-72. 
67. Yoshida M, Tomitori H, Machi Y, Katagiri D, Ueda S, Horiguchi K, Kobayashi E, Saeki N, Nishimura K, 
Ishii I, Kashiwagi K and Igarashi K. Acrolein, IL-6 and CRP as markers of silent brain infarction. Atherosclerosis. 
2009;203:557-62. 
68. Fornage M, Chiang YA, O'Meara ES, Psaty BM, Reiner AP, Siscovick DS, Tracy RP and Longstreth WT, 
Jr. Biomarkers of Inflammation and MRI-Defined Small Vessel Disease of the Brain: The Cardiovascular Health 
Study. Stroke. 2008;39:1952-9. 
69. Baune BT, Ponath G, Rothermundt M, Roesler A and Berger K. Association between cytokines and 
cerebral MRI changes in the aging brain. J Geriatr Psychiatry Neurol. 2009;22:23-34. 
70. Jones GT, Tromp G, Kuivaniemi H, Gretarsdottir S, Baas AF, Giusti B, Strauss E, Van't Hof FN, Webb 
TR, Erdman R, Ritchie MD, Elmore JR, Verma A, Pendergrass S, Kullo IJ, Ye Z, Peissig PL, Gottesman O, Verma 
SS, Malinowski J, Rasmussen-Torvik LJ, Borthwick KM, Smelser DT, Crosslin DR, de Andrade M, Ryer EJ, 
McCarty CA, Bottinger EP, Pacheco JA, Crawford DC, Carrell DS, Gerhard GS, Franklin DP, Carey DJ, Phillips 
VL, Williams MJ, Wei W, Blair R, Hill AA, Vasudevan TM, Lewis DR, Thomson IA, Krysa J, Hill GB, Roake J, 
Merriman TR, Oszkinis G, Galora S, Saracini C, Abbate R, Pulli R, Pratesi C, Saratzis A, Verissimo AR, 
Bumpstead S, Badger SA, Clough RE, Cockerill G, Hafez H, Scott DJ, Futers TS, Romaine SP, Bridge K, Griffin 
KJ, Bailey MA, Smith A, Thompson MM, van Bockxmeer FM, Matthiasson SE, Thorleifsson G, Thorsteinsdottir U, 
Blankensteijn JD, Teijink JA, Wijmenga C, de Graaf J, Kiemeney LA, Lindholt JS, Hughes A, Bradley DT, Stirrups 
K, Golledge J, Norman PE, Powell JT, Humphries SE, Hamby SE, Goodall AH, Nelson CP, Sakalihasan N, 
Courtois A, Ferrell RE, Eriksson P, Folkersen L, Franco-Cereceda A, Eicher JD, Johnson AD, Betsholtz C, 
Ruusalepp A, Franzen O, Schadt EE, Bjorkegren JL, Lipovich L, Drolet AM, Verhoeven EL, Zeebregts CJ, 
Geelkerken RH, van Sambeek MR, van Sterkenburg SM, de Vries JP, Stefansson K, Thompson JR, de Bakker PI, 
Deloukas P, Sayers RD, Harrison SC, van Rij AM, Samani NJ and Bown MJ. Meta-Analysis of Genome-Wide 
Association Studies for Abdominal Aortic Aneurysm Identifies Four New Disease-Specific Risk Loci. Circ Res. 
2017;120:341-353. 
71. Harrison SC, Smith AJ, Jones GT, Swerdlow DI, Rampuri R, Bown MJ, Aneurysm C, Folkersen L, Baas 
AF, de Borst GJ, Blankensteijn JD, Price JF, van der Graaf Y, McLachlan S, Agu O, Hofman A, Uitterlinden AG, 
Franco-Cereceda A, Ruigrok YM, van't Hof FN, Powell JT, van Rij AM, Casas JP, Eriksson P, Holmes MV, 
Asselbergs FW, Hingorani AD and Humphries SE. Interleukin-6 receptor pathways in abdominal aortic aneurysm. 
Eur Heart J. 2013;34:3707-16. 
72. Terrades-Garcia N and Cid MC. Pathogenesis of giant-cell arteritis: how targeted therapies are influencing 
our understanding of the mechanisms involved. Rheumatology (Oxford). 2018;57:ii51-ii62. 
73. Evans JM, Bowles CA, Bjornsson J, Mullany CJ and Hunder GG. Thoracic aortic aneurysm and rupture in 
giant cell arteritis. A descriptive study of 41 cases. Arthritis Rheum. 1994;37:1539-47. 
74. Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, Butikofer L, Seitz M and Reichenbach 
S. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-
blind, placebo-controlled trial. Lancet. 2016;387:1921-7. 
25 
 
75. Marcus GM, Whooley MA, Glidden DV, Pawlikowska L, Zaroff JG and Olgin JE. Interleukin-6 and atrial 
fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am Heart J. 2008;155:303-
9. 
76. Amdur RL, Mukherjee M, Go A, Barrows IR, Ramezani A, Shoji J, Reilly MP, Gnanaraj J, Deo R, Roas S, 
Keane M, Master S, Teal V, Soliman EZ, Yang P, Feldman H, Kusek JW, Tracy CM, Raj DS and Investigators CS. 
Interleukin-6 Is a Risk Factor for Atrial Fibrillation in Chronic Kidney Disease: Findings from the CRIC Study. 
PLoS One. 2016;11:e0148189. 
77. Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM and Darbar D. Role of inflammation and oxidative 
stress in atrial fibrillation. Heart Rhythm. 2010;7:438-44. 
78. Ntalla I, Kanoni S, Zeng L, Giannakopoulou O, Danesh J, Watkins H, Samani NJ, Deloukas P, Schunkert 
H and Group UKBCCCW. Genetic Risk Score for Coronary Disease Identifies Predispositions to Cardiovascular 
and Noncardiovascular Diseases. J Am Coll Cardiol. 2019;73:2932-2942. 
79. Schmitt J, Duray G, Gersh BJ and Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a 
systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009;30:1038-45. 
80. Lissilaa R, Buatois V, Magistrelli G, Williams AS, Jones GW, Herren S, Shang L, Malinge P, Guilhot F, 
Chatel L, Hatterer E, Jones SA, Kosco-Vilbois MH and Ferlin WG. Although IL-6 trans-signaling is sufficient to 
drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated 
autoimmunity. J Immunol. 2010;185:5512-21. 
81. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, 
Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T and Collins R. UK biobank: an open 
access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 
2015;12:e1001779. 
82. Franceschini N, Giambartolomei C, de Vries PS, Finan C, Bis JC, Huntley RP, Lovering RC, Tajuddin SM, 
Winkler TW, Graff M, Kavousi M, Dale C, Smith AV, Hofer E, van Leeuwen EM, Nolte IM, Lu L, Scholz M, 
Sargurupremraj M, Pitkanen N, Franzen O, Joshi PK, Noordam R, Marioni RE, Hwang SJ, Musani SK, Schminke 
U, Palmas W, Isaacs A, Correa A, Zonderman AB, Hofman A, Teumer A, Cox AJ, Uitterlinden AG, Wong A, Smit 
AJ, Newman AB, Britton A, Ruusalepp A, Sennblad B, Hedblad B, Pasaniuc B, Penninx BW, Langefeld CD, 
Wassel CL, Tzourio C, Fava C, Baldassarre D, O'Leary DH, Teupser D, Kuh D, Tremoli E, Mannarino E, Grossi E, 
Boerwinkle E, Schadt EE, Ingelsson E, Veglia F, Rivadeneira F, Beutner F, Chauhan G, Heiss G, Snieder H, 
Campbell H, Volzke H, Markus HS, Deary IJ, Jukema JW, de Graaf J, Price J, Pott J, Hopewell JC, Liang J, Thiery 
J, Engmann J, Gertow K, Rice K, Taylor KD, Dhana K, Kiemeney L, Lind L, Raffield LM, Launer LJ, Holdt LM, 
Dorr M, Dichgans M, Traylor M, Sitzer M, Kumari M, Kivimaki M, Nalls MA, Melander O, Raitakari O, Franco 
OH, Rueda-Ochoa OL, Roussos P, Whincup PH, Amouyel P, Giral P, Anugu P, Wong Q, Malik R, Rauramaa R, 
Burkhardt R, Hardy R, Schmidt R, de Mutsert R, Morris RW, Strawbridge RJ, Wannamethee SG, Hagg S, Shah S, 
McLachlan S, Trompet S, Seshadri S, Kurl S, Heckbert SR, Ring S, Harris TB, Lehtimaki T, Galesloot TE, Shah T, 
de Faire U, Plagnol V, Rosamond WD, Post W, Zhu X, Zhang X, Guo X, Saba Y, Consortium M, Dehghan A, 
Seldenrijk A, Morrison AC, Hamsten A, Psaty BM, van Duijn CM, Lawlor DA, Mook-Kanamori DO, Bowden DW, 
Schmidt H, Wilson JF, Wilson JG, Rotter JI, Wardlaw JM, Deanfield J, Halcox J, Lyytikainen LP, Loeffler M, 
Evans MK, Debette S, Humphries SE, Volker U, Gudnason V, Hingorani AD, Bjorkegren JLM, Casas JP and 
O'Donnell CJ. GWAS and colocalization analyses implicate carotid intima-media thickness and carotid plaque loci 
in cardiovascular outcomes. Nat Commun. 2018;9:5141. 
83. Christophersen IE, Rienstra M, Roselli C, Yin X, Geelhoed B, Barnard J, Lin H, Arking DE, Smith AV, 
Albert CM, Chaffin M, Tucker NR, Li M, Klarin D, Bihlmeyer NA, Low SK, Weeke PE, Muller-Nurasyid M, 
Smith JG, Brody JA, Niemeijer MN, Dorr M, Trompet S, Huffman J, Gustafsson S, Schurmann C, Kleber ME, 
Lyytikainen LP, Seppala I, Malik R, Horimoto A, Perez M, Sinisalo J, Aeschbacher S, Theriault S, Yao J, 
Radmanesh F, Weiss S, Teumer A, Choi SH, Weng LC, Clauss S, Deo R, Rader DJ, Shah SH, Sun A, Hopewell JC, 
Debette S, Chauhan G, Yang Q, Worrall BB, Pare G, Kamatani Y, Hagemeijer YP, Verweij N, Siland JE, Kubo M, 
Smith JD, Van Wagoner DR, Bis JC, Perz S, Psaty BM, Ridker PM, Magnani JW, Harris TB, Launer LJ, 
Shoemaker MB, Padmanabhan S, Haessler J, Bartz TM, Waldenberger M, Lichtner P, Arendt M, Krieger JE, 
Kahonen M, Risch L, Mansur AJ, Peters A, Smith BH, Lind L, Scott SA, Lu Y, Bottinger EB, Hernesniemi J, 
Lindgren CM, Wong JA, Huang J, Eskola M, Morris AP, Ford I, Reiner AP, Delgado G, Chen LY, Chen YI, 
Sandhu RK, Li M, Boerwinkle E, Eisele L, Lannfelt L, Rost N, Anderson CD, Taylor KD, Campbell A, Magnusson 
PK, Porteous D, Hocking LJ, Vlachopoulou E, Pedersen NL, Nikus K, Orho-Melander M, Hamsten A, Heeringa J, 
Denny JC, Kriebel J, Darbar D, Newton-Cheh C, Shaffer C, Macfarlane PW, Heilmann-Heimbach S, Almgren P, 
Huang PL, Sotoodehnia N, Soliman EZ, Uitterlinden AG, Hofman A, Franco OH, Volker U, Jockel KH, Sinner MF, 
Lin HJ, Guo X, ISGC MCot, Neurology Working Group of the CC, Dichgans M, Ingelsson E, Kooperberg C, 
Melander O, Loos RJF, Laurikka J, Conen D, Rosand J, van der Harst P, Lokki ML, Kathiresan S, Pereira A, 
Jukema JW, Hayward C, Rotter JI, Marz W, Lehtimaki T, Stricker BH, Chung MK, Felix SB, Gudnason V, Alonso 
A, Roden DM, Kaab S, Chasman DI, Heckbert SR, Benjamin EJ, Tanaka T, Lunetta KL, Lubitz SA, Ellinor PT and 
Consortium AF. Large-scale analyses of common and rare variants identify 12 new loci associated with atrial 
fibrillation. Nat Genet. 2017;49:946-952. 
26 
 
84. Germain M, Chasman DI, de Haan H, Tang W, Lindstrom S, Weng LC, de Andrade M, de Visser MC, 
Wiggins KL, Suchon P, Saut N, Smadja DM, Le Gal G, van Hylckama Vlieg A, Di Narzo A, Hao K, Nelson CP, 
Rocanin-Arjo A, Folkersen L, Monajemi R, Rose LM, Brody JA, Slagboom E, Aissi D, Gagnon F, Deleuze JF, 
Deloukas P, Tzourio C, Dartigues JF, Berr C, Taylor KD, Civelek M, Eriksson P, Cardiogenics C, Psaty BM, 
Houwing-Duitermaat J, Goodall AH, Cambien F, Kraft P, Amouyel P, Samani NJ, Basu S, Ridker PM, Rosendaal 
FR, Kabrhel C, Folsom AR, Heit J, Reitsma PH, Tregouet DA, Smith NL and Morange PE. Meta-analysis of 65,734 





Table 1. Data sources that were used in the analyses for the current study.  
Phenotype Source N (Total or 
Cases/Controls 
Imputation reference panel Ancestry Adjustments 
CRP levels CHARGE Inflammation 
Working Group31 
204,402 HapMap European   age, sex, population structure 
IL-6 levels YFS/FINRISK studies40 8,293 1000 Genomes Phase 1 Finnish age, sex, BMI, population structure 
sIL-6R levels INTERVAL study41 3,301 1000 Genomes Phase 3 European   age, sex, duration between blood draw and 
processing, population structure 
Fibrinogen levels CHARGE Inflammation 
Working Group43 
120,246 1000 Genomes Phase 1 European age, sex, population structure 
Ischemic stroke MEGASTROKE 
Consortium32 
34,217/406,630 1000 Genomes Phase 1 European   age, sex, population structure 
Large artery stroke MEGASTROKE 
Consortium32 
4,373/406,111 1000 Genomes Phase 1 European   age, sex, population structure 
Cardioembolic stroke MEGASTROKE 
Consortium32 
7,193/406,111 1000 Genomes Phase 1 European   age, sex, population structure 
Small vessel stroke MEGASTROKE 
Consortium32 
5,386/406,111 1000 Genomes Phase 1 European   age, sex, population structure 
Coronary artery disease CARDIoGRAMplusC4D 
Consortium44 
60,801/123,504 HapMap European and Asian age, sex, population structure 
Myocardial infarction CARDIoGRAMplusC4D 
Consortium44 
43,676/123,504 HapMap European and Asian age, sex, population structure 
Aortic aneurysm UK Biobank81 1,817/314,325 HRC + UK10K White British age, sex, population structure, genotyping 
platform array 
Carotid plaque CHARGE Consortium82 21,540/26894 1000 Genomes Phase 1 European   age, sex, population structure 
Peripheral artery disease UK Biobank81 3,992/313,725 HRC + UK10K White British age, sex, population structure, genotyping 
platform array 
Heart failure UK Biobank81 8,970/312,436 HRC + UK10K White British age, sex, population structure, genotyping 
platform array 
Atrial fibrillation AFGen Consortium83 18,398/111,433 1000 Genomes Phase 1 European and Asian age, sex, population structure 
Venous thromboembolism INVENT Consortium84 7,507/52,632 1000 Genomes Phase 1 European   age, sex, population structure 
Deep vein thrombosis UK Biobank81 4,135/302,337 HRC + UK10K White British age, sex, population structure, genotyping 
platform array 




Table 2. Single nucleotide polymorphisms (SNP) used in the current analyses for proxying the effects of IL-6 signaling. The betas, 












P-value R2 ‡ F § 
rs73026617 t c 1 0.097 154,369,981 0.0474 0.0068 3.16E-12 3.94E-04 80.5 
rs12083537* a g 1 0.193 154,381,103 0.0643 0.0053 7.14E-34 1.29E-03 263.6 
rs4556348* t c 1 0.148 154,394,296 0.0541 0.0067 6.77E-16 7.38E-04 151.0 
rs2228145* a c 1 0.360 154,426,970 0.0899 0.0042 1.21E-101 3.72E-03 764.1 
rs11264224 a c 1 0.193 154,568,086 0.0465 0.0057 3.41E-16 6.74E-04 137.8 
rs12059682 t c 1 0.196 154,579,585 -0.0441 0.0049 2.26E-19 6.13E-04 125.4 
rs34693607 c g 1 0.184 154,661,369 0.0368 0.0057 1.07E-10 4.07E-04 83.2 
* Variants located within the IL6R gene. 
† Beta coefficients correspond to 1-unit changes in the natural-log-transformed CRP (mg/L) per copy increment in effect allele. 
‡ 𝑅2 =  2 × 𝑀𝐴𝐹 × (1 − 𝑀𝐴𝐹) × 𝑏𝑒𝑡𝑎2, where MAF is the minimum allele frequency and beta is the effect estimate of the SNP on CRP levels.36 
§ F = 
𝑅2×(𝑁−2)
1−𝑅2




Figure 1. Conceptual framework and design of the current Mendelian Randomization 
approach. (A) Shown is a simplified scheme of IL-6 signaling, which is induced by binding of 
IL-6 to the soluble or the membrane-bound form of its receptor (IL-6R). IL-6 signaling results in 
increased C-reactive protein (CRP) and Fibrinogen (Fg) levels and is associated with a higher 
risk of cardiovascular disease. (B) Pharmacological inhibition of IL-6R leads to increases in the 
levels of upstream regulators (IL-6 and sIL-6R), and decreases in the levels of downstream 
effectors (CRP and Fg) of the IL-6 signaling pathway, but its effects on cardiovascular disease 
remain unknown. (C) In the current MR approach, we selected genetic variants within the IL6R 
locus, which significantly associated with lower CRP levels, as instruments (proxies) for a 
downregulated IL-6 signaling, and explored their effects on ischemic stroke, coronary artery 
disease and other cardiovascular disease phenotypes.  
 
 
*  IL-6 signaling was determined by the effects of the instruments on CRP levels. The instruments were further validated by 
exploring their effects on other upstream regulators (IL-6, sIL-6-R) and downstream effectors (Fg) of IL-6 signaling. 





























Figure 2. Effects of pharmacological inhibition of IL-6R and of genetic downregulation of 
IL-6 signaling on circulating levels of IL-6, soluble IL-6R (sIL-6R), and fibrinogen (Fg). 
(A) Effects of pharmacological inhibition of IL-6R on IL-6, sIL-6R, and Fg levels by 
administration of tocilizumab (8 mg/kg), as compared to placebo in a meta-analysis of 4 
randomized clinical trials (RCT). Effects represent the standardized mean differences (SMD) in 
IL-6, sIL-6R, and Fg levels between 8 and 24 weeks after administration of tocilizumab (8 
mg/kg), as compared to placebo. (B) Effects of genetic downregulation of IL-6 signaling on IL-
6, sIL-6R, and Fg levels as determined by Mendelian Randomization (MR) analyses. Effects 
represent SMDs in IL-6, sIL-6R, and Fg levels. 
 
* The SMDs for RCTs are derived from a meta-analysis of 4 studies.20 




Figure 3. Mendelian Randomization associations of genetically downregulated IL-6 
signaling with ischemic stroke. (A) Genetically downregulated IL-6 signaling in association 
with ischemic stroke and coronary artery disease as derived from IVW MR analyses either 
using the full set of genetic instruments (7 SNPs), or the restricted set of instruments (3 SNPs 
located within the IL6R gene). (B) SNP-specific effects regarding the associations of 
genetically downregulated IL-6 signaling with ischemic stroke and results derived from the 
IVW MR analysis. (C) Distributions of the effects of 7 randomly selected CRP-decreasing 
SNPs on risk of ischemic stroke and the position of the IL-6 signaling downregulating effect (7 
SNPs included in our analyses).  
 




Figure 4. Mendelian Randomization associations of genetically downregulated IL-6 
signaling with ischemic stroke etiological subtypes. The effects represent Odds Ratios (OR) 
derived from inverse-variance-weighted MR analyses. 
 
 





Figure 5. Mendelian Randomization associations of genetically downregulated IL-6 
signaling with other cardiovascular outcomes. The effects represent Odds Ratios (OR) 
derived from inverse-variance-weighted MR analyses. 
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BACKGROUND: Drug effects can be investigated through natural 
variation in the genes for their protein targets. The present study aimed 
to use this approach to explore the potential side effects and repurposing 
potential of antihypertensive drugs, which are among the most commonly 
used medications worldwide.
METHODS: Genetic proxies for the effect of antihypertensive drug 
classes were identified as variants in the genes for the corresponding 
targets that associated with systolic blood pressure at genome-wide 
significance. Mendelian randomization estimates for drug effects on 
coronary heart disease and stroke risk were compared with randomized, 
controlled trial results. A phenome-wide association study in the 
UK Biobank was performed to identify potential side effects and 
repurposing opportunities, with findings investigated in the Vanderbilt 
University biobank (BioVU) and in observational analysis of the UK 
Biobank.
RESULTS: Suitable genetic proxies for angiotensin-converting enzyme 
inhibitors, β-blockers, and calcium channel blockers (CCBs) were 
identified. Mendelian randomization estimates for their effect on coronary 
heart disease and stroke risk, respectively, were comparable to results 
from randomized, controlled trials against placebo. A phenome-wide 
association study in the UK Biobank identified an association of the CCB 
standardized genetic risk score with increased risk of diverticulosis (odds 
ratio, 1.02 per standard deviation increase; 95% CI, 1.01–1.04), with a 
consistent estimate found in BioVU (odds ratio, 1.01; 95% CI, 1.00–1.02). 
Cox regression analysis of drug use in the UK Biobank suggested that this 
association was specific to nondihydropyridine CCBs (hazard ratio 1.49 
considering thiazide diuretic agents as a comparator; 95% CI, 1.04–2.14) 
but not dihydropyridine CCBs (hazard ratio, 1.04; 95% CI, 0.83–1.32).
CONCLUSIONS: Genetic variants can be used to explore the efficacy 
and side effects of antihypertensive medications. The identified potential 
effect of nondihydropyridine CCBs on diverticulosis risk could have clinical 
implications and warrants further investigation.
© 2019 The Authors. Circulation is 
published on behalf of the American 
Heart Association, Inc., by Wolters 
Kluwer Health, Inc. This is an open 
access article under the terms of the 
Creative Commons Attribution License, 
which permits use, distribution, and 
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In 2015, the 874 million adults worldwide estimated to have a systolic blood pressure (SBP) of ≥140 mm Hg accounted for 106 deaths per 100 000 and loss of 
143 million disability-adjusted life-years,1 making hy-
pertension a leading cause of mortality and morbidity. 
Blood pressure lowering through lifestyle modification 
or pharmacological treatment can significantly decrease 
cardiovascular risk, with every 10 mm Hg reduction es-
timated to decrease risk of all-cause mortality by 13%.2
The pharmacological treatment of hypertension is 
founded on strong evidence, underpinned by a large 
number of outcome-based randomized, controlled tri-
als (RCTs) that have identified several drug classes to be 
effective for lowering blood pressure.3 However, RCTs 
based on clinical outcomes have limitations4; they are 
largely restricted to older or high-risk patients and have 
a relatively short duration of follow-up, rarely beyond 5 
years.5 Therefore, recommendations for treatment are 
often based on extrapolation of the available evidence, 
with known side effects frequently limited to relative-
ly common outcomes captured in RCTs.6 At the same 
time, particular drug treatments for hypertension may 
have beneficial effects beyond their blood pressure–
lowering properties,6 thus offering potential for repur-
posing. However, observational research used to study 
such opportunities suffers from well-characterized bi-
ases, including confounding by indication.7
With the growing availability of genome-wide asso-
ciation study (GWAS) meta-analyses, it is becoming in-
creasingly feasible to study drug effects by investigating 
genetic variants in the genes of their protein targets, 
as has previously been applied to lipid-lowering drugs.7 
In this study, human genetic variants within genes cor-
responding to the targets of common pharmacological 
agents for hypertension were first identified to serve 
as a proxy for the effects of these treatments. Second, 
the validity of this approach for studying the effects of 
these drugs was investigated by exploring consistency 
in mendelian randomization (MR) estimates for their ef-
fect on coronary heart disease (CHD) and stroke risk 
with corresponding RCT findings. Finally, to offer in-
sight into their adverse effect profiles and repurposing 
potential, phenome-wide association study (PheWAS) 
analyses were undertaken with replication in an exter-
nal dataset, as well as further investigation in observa-
tional analysis of drug use.
METHODS
All supporting data are available within the article, the online-
only Data Supplement, and the web links provided. UK Biobank 
data were accessed through application 236. Relevant ethical 
approval and participant consent were already obtained in all 
studies that contributed data to this work. Statistical analysis 
was undertaken with R version 3.4.1 (The R Foundation for 
Statistical Computing) and Stata 14.2 (StataCorp LP).
Genetic Variant Selection
Common antihypertensive drugs were selected for study 
on the basis of recent consensus guidelines6: angiotensin-
converting enzyme (ACE) inhibitors, angiotensin receptor 
blockers, β-blockers (BB), calcium channel blockers (CCB) and 
thiazide diuretic agents. Genes encoding the targets of these 
drugs related to effects on blood pressure were identified 
using the DrugBank database,8 with promoter and enhancer 
regions identified using the GeneHancer database in the 
GeneCards online platform (version 4.7).9 Genetic association 
estimates for SBP were obtained from a GWAS meta-analysis 
of 757 601 individuals with European ancestry drawn from 
the UK Biobank and the International Consortium of Blood 
Pressure GWAS meta-analysis,10 where correction was made 
for antihypertensive medication use by adding 15 mm Hg to 
the SBP of participants receiving medication, with further 
adjustment for body mass index.10 In sensitivity analyses, a 
GWAS of SBP on ≈337 000 white British individuals in the UK 
Biobank was also used, without correction for medication 
use or adjustment for body mass index .11 Genetic variants to 
serve as proxies (ie, instruments) for the effect of lower SBP 
through antihypertensive drug targets were selected as sin-
gle-nucleotide polymorphisms (SNPs) in corresponding genes, 
promoter regions, or enhancers that were associated with 
SBP at genome-wide significance (P<5×10–8) and clumped 
to a linkage disequilibrium (LD) threshold of r2<0.1 using the 
1000G European reference panel. This approach does not 
distinguish between selection of loss-of-function variants 
or those related to gene expression. The R2 and F statistics 
Clinical Perspective
What Is New?
• This work identifies genetic variants that serve as 
proxies for the effect of angiotensin-converting 
enzyme inhibitor, β-blocker, and calcium channel 
blocker antihypertensive drugs.
• Mendelian randomization using the genetic prox-
ies for each respective drug class provides estimates 
consistent with those of randomized, controlled tri-
als against placebo for effects on risk of coronary 
heart disease and stroke.
• Phenome-wide association study identifies diver-
ticulosis as a previously unreported possible side 
effect of calcium channel blockers, with observa-
tional analysis further supporting an association 
between nondihydropyridine calcium channel 
blocker use and increased risk of diverticulosis.
What Are the Clinical Implications?
• Any increase in the risk of diverticulosis related to 
use of nondihydropyridine calcium channel block-
ers could have notable consequences and warrants 
further study.
• No other potential side effects of angiotensin-con-
verting enzyme inhibitors, β-blockers, or calcium 
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were used to estimate the variance in SBP explained and the 
strength of each SNP, respectively.12
Statistical Analysis
Mendelian Randomization
MR uses randomly allocated genetic variants related to an 
exposure of interest to study the effect of that exposure on a 
given outcome. In this study, the exposure of interest was SBP 
lowering through a particular antihypertensive drug class. All 
antihypertensive drug classes for which SNPs were identified 
as proxies using the larger SBP GWAS were taken forward to 
MR analysis investigating their effect on CHD and stroke risk. 
Genetic association estimates for CHD were obtained from the 
CARDIoGRAMplusC4D (Coronary Artery Disease Genome-
wide Replication and Meta-analysis [CARDIOGRAM] plus the 
Coronary Artery Disease [C4D] Genetics) Consortium’s 1000 
Genomes–based transethnic meta-analysis of 60 801 case 
subjects and 123 504 control subjects.13 Estimates for stroke 
risk were obtained from the MEGASTROKE Consortium’s 
transethnic meta-analysis of 67 162 cases of any stroke and 
454 450 control subjects.14 Details for the MR analyses are 
provided in the online-only Data Supplement Methods. To 
allow comparison with RCT results, all MR estimates were 
scaled to the SBP-lowering effect of their respective drug class 
as measured in these RCTs.3
Investigation of Genetic Pleiotropy 
Unrelated to Drug Effect
The MR estimates can be biased if any of the genetic vari-
ants used affect the outcome under consideration through 
a pleiotropic pathway that is independent of the drug effect 
for which they serve as proxies. The PhenoScanner curated 
database of publicly available SNP-phenotype associations 
(accessed on March 30, 2018) was used to explore whether 
any of the selected SNPs or proxies with LD r2>0.8 (using a 
1000G reference panel) were also associated at genome-wide 
significance (P<5×10−8) with traits that may potentially be 
exerting such pleiotropy,15 and any such SNPs were excluded 
in sensitivity analyses. PhenoScanner includes SNP-phenotype 
associations identified in analysis of UK Biobank data.11 
Statistical evaluations of pleiotropy were also incorporated 
where multiple genetic variants were available to serve as 
proxies for the drug effect16 and are detailed in the Methods 
in the online-only Data Supplement.
Phenome-Wide Association Study
The UK Biobank, a prospective study comprising approxi-
mately half a million middle-aged individuals,17 served as 
the cohort for the PheWAS investigating drug side effects 
and repurposing opportunities. The participants provided 
self-reported information, with blood samples collected for 
biochemical tests and genotyping and physical measure-
ments performed as described previously.17 Individuals were 
linked retrospectively and prospectively to the National Health 
Service’s Hospital Episode Statistics database.
PheWAS was restricted to participants of self-reported 
European descent, with random exclusion of 1 participant 
from each pair of relatives based on a kinship coefficient 
>0.0884. For antihypertensive drugs for which genetic vari-
ants were identified to serve as proxies, PLINK was used 
to construct a genetic risk score (GRS) for each individual, 
weighted for the SBP-lowering effect of each participating 
SNP,18 and standardized to have a mean of 0 and an SD of 
1 across all individuals. The 9th and 10th revisions of the 
International Classification of Diseases were used to define 
cases based on inpatient Hospital Episode Statistics data. The 
phecode grouping system was used to align diagnoses used 
in clinical practice with genomic analysis.19 A series of case-
control groups were generated for each phecode, with con-
trol subjects identified as individuals with no record of the 
respective outcome and its related phecodes.19 Analysis was 
performed with logistic regression after adjustment for age, 
sex, and first 4 genetic principal components. Only outcomes 
that had a minimum of 200 cases were considered, to main-
tain sufficient statistical power to identify associations with 
common variants.20 A 5% threshold with the false-discovery 
rate method was used in ascertaining the statistical signifi-
cance of associations, to correct for multiple testing of corre-
lated phenotypes. As for the MR analysis, sensitivity analyses 
were performed using genetic association estimates derived 
from the SBP GWAS that did not correct for medication use 
or adjust for body mass index, and after the exclusion of any 
SNPs with potentially pleiotropic associations at genome-wide 
significance that were identified with PhenoScanner.15
PheWAS associations for noncardiovascular conditions 
were investigated for relation to SBP more generally using a 
permutation-based approach that repeated association analy-
ses 1000 times, with the standardized GRS created on each 
instance using a matched number of randomly sampled SBP-
related SNPs from throughout the genome (ie, associated with 
SBP at genome-wide significance and clumped to LD r2<0.001; 
Table I in the online-only Data Supplement). Compared with 
the investigation of antihypertensive drug targets, a more 
stringent LD threshold was used, because variants for SBP 
were selected from throughout the genome rather than any 
particular locus. The proportion of such permutation analyses 
that have a consistent direction of effect and P value lower 
than in the main PheWAS analysis would serve as an adjusted 
P value of the null hypothesis. Further study of any PheWAS 
associations significant at a false-discovery rate threshold of 
5% for noncardiovascular conditions was also undertaken in 
the Vanderbilt University Biobank (BioVU), for which genetic 
data on ≈50 000 individuals are linked to a deidentified elec-
tronic health record system.21 Similar to the main PheWAS, 
a standardized GRS was constructed, and logistic regres-
sion with the outcome was performed after adjustment for 
age, sex, and first 3 principal components. The analysis was 
restricted to individuals identified as white, with control sub-
jects based on the same exclusions as the main PheWAS. 
Results between the UK Biobank and BioVU analysis were 
pooled by use of a fixed-effects meta-analysis model.
Observational Analysis of Drug Use
PheWAS associations significant at a 5% false-discovery rate 
for noncardiovascular conditions related to any antihyper-
tensive class were further explored in observational analy-
sis of drug use among individuals in the UK Biobank. This 
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and nondihydropyridine CCB subclasses, which was not pos-
sible when using genetic proxies because of overlap in the 
genes for their corresponding protein targets. Cox regression 
analysis was used to compare time to first incident outcome 
between individuals orally taking different antihypertensive 
drug classes at baseline. Individuals who died during the 
follow-up period before a relevant diagnosis were censored. 
The categories of antihypertensive drug treatment considered 
were ACE inhibitors alone, angiotensin receptor blockers 
alone, BBs alone, dihydropyridine CCBs alone, nondihydro-
pyridine CCBs alone, thiazide diuretic agents alone, a com-
bination of medications from any 2 antihypertensive classes, 
and a combination of medications from 3 or more antihy-
pertensive classes. In a separate model, individuals who were 
taking any subclass of CCBs were pooled into a single cat-
egory. Adjustment was made for age, sex, body mass index, 
Townsend Deprivation Index, smoking status, previous cancer 
diagnosis, number of noncancer diagnoses, and number of 
previous surgical operations. Individuals with a diagnosis of 




The genes and enhancer and promoter regions cor-
responding to the targets of each antihypertensive 
drug class are shown in Table II in the online-only Data 
Supplement. There was 1 gene identified for each drug 
target for ACE inhibitors (ACE), angiotensin receptor 
blockers (AGTR1), BBs (ADRB1), and thiazide diuretic 
agents (SLC12A3), and 11 genes for CCBs (CACNA1D, 
CACNA1F, CACNA2D1, CACNA2D2, CACNA1S, CAC-
NB1, CACNB2, CACNB3, CACNB4, CACNG1, and CAC-
NA1C) encoding the different calcium channel subunits 
related to effects on blood pressure. The CACNA1F 
gene is located on the X chromosome, and SNPs cor-
responding to this region were not available. Using the 
predefined selection criteria, there was 1 SNP identified 
for ACE inhibitors, 6 for BBs, and 24 for CCBs (Tables 
III through V in the online-only Data Supplement). The 
larger number of SNPs and correspondingly greater 
proportion of variation in SBP explained for CCBs was 
related to the availability of more genes from which to 
identify variants. The F statistic for SNPs ranged from 
54 to 534 (Tables III through V in the online-only Data 
Supplement), consistent with a low risk of weak instru-
ment bias.12
Mendelian Randomization
To allow comparison with RCT meta-analysis effect 
estimates, MR results for each drug class were scaled 
to their respective SBP-lowering effect in these stud-
ies. Thus, for ACE inhibitors, MR estimates are given 
per 21.14 mm Hg decrease, for BBs per 9.51 mm Hg 
decrease, and for CCBs per 8.90 mm Hg decrease.3 MR 
analysis using the single genetic variant identified for 
ACE inhibitors showed a protective effect on stroke (rel-
ative risk [RR], 0.21; 95% CI, 0.06–0.72; P=0.01) but 
not CHD risk (RR, 0.67; 95% CI, 0.16–2.56; P=0.58). 
The main MR analysis using the 6 variants for BBs iden-
tified a protective effect on CHD risk (RR, 0.62; 95% CI, 
0.47–0.81; P=4×10−4) but not stroke risk (RR, 0.91; 95% 
CI, 0.73–1.14; P=0.41). For CCBs, the main MR analysis 
using the 24 SNPs identified a protective effect on both 
CHD risk (RR, 0.73; 95% CI, 0.64–0.84; P=6×10−6) and 
stroke risk (RR, 0.75; 95% CI, 0.66–0.84; P=1×10−6). 
Similar results for all drug classes were obtained when 
the incidence of CHD and stroke was considered to be 
1%, 5%, and 10% (Table VI in the online-only Data 
Supplement). The MR estimates had overlapping 95% 
CIs to those from RCTs of these drugs versus placebo3 
(Figure 1). Individual MR estimates for each BB and CCB 
SNP are given in Figures I through IV in the online-only 
Data Supplement. Consistent MR results were found in 
sensitivity analyses, as detailed in the online-only Data 
Supplement (Results, Tables VII through IX, and Figures 
V through VIII).
Phenome-Wide Association Study
After quality control and mapping of International 
Classification of Diseases, 9th Revision and 10th Revi-
sion, to phecodes, data for 424 439 individuals across 
909 distinct phenotypes were available for PheWAS 
analysis. Details of the number of phenotypes and cas-
es per disease category are provided in the Table, with 
the number of cases and controls for each outcome in 
Tables X through XVI in the online-only Data Supple-
ment. Using the ACE inhibitor, BB, and CCB standard-
ized GRS, the respective PheWAS analyses revealed 
associations with hypertension and related cardiovas-
cular disease (Figures 2–4 and Tables X through XII in 
the online-only Data Supplement). CCBs additionally 
showed an association with higher risk of diverticu-
losis (odds ratio per SD increase in standardized GRS, 
1.02; 95% CI, 1.01–1.04, P=2×10−4). Similar results 
were obtained in PheWAS sensitivity analyses (Tables 
XIII through XVI in the online-only Data Supplement 
). Random sampling of 24 SBP SNPs from throughout 
the genome (Table I in the online-only Data Supple-
ment) to create standardized GRSs and measurement 
of associations with diverticulosis risk in permutation 
analyses (N=1000) showed effect estimates centered 
close to the null (mean odds ratio per SD increase in 
standardized GRS, 1.00; 95% CI, 0.98–1.02, P=0.79; 
Figure IX in the online-only Data Supplement). Of the 
1000 permutation analyses, only 10 had a consistent 
direction of effect and P value lower than that ob-
served for the association of the standardized CCB 
GRS with diverticulosis in PheWAS, thus generating 
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Data for 45 517 individuals were available in BioVU 
to further investigate novel PheWAS findings for traits 
unrelated to hypertension. General cohort characteris-
tics for the considered populations from the UK Bio-
bank and BioVU are detailed in Table XVII in the online-
only Data Supplement. The prevalence of diverticulosis 
in BioVU was 12%, comparable to the 10% observed 
in the UK Biobank. In BioVU, the CCB standardized GRS 
association with diverticulosis had an odds ratio per SD 
increase of 1.01 (95% CI, 1.00–1.02; P=0.17). The 
meta-analyses of UK Biobank and BioVU estimates had 
an odds ratio of 1.02 (95% CI, 1.01–1.03; P=3×10−4; 
Figure 5).
Observational Analysis of Drug Use
For the observational analysis of antihypertensive drug 
use in the UK Biobank, there were 1408 incident di-
verticulosis diagnoses up to February 13, 2016, in the 
54 612 individuals taking any of the considered antihy-
pertensive drug classes at recruitment (March 13, 2006, 
to October 1, 2010), with a mean follow-up of 2538 
days. In adjusted Cox regression (with use of thiazide 
diuretic antihypertensive medications alone as the ref-
erence category), there was no evidence for an associa-
tion between use of any CCB and risk of diverticulosis 
(hazard ratio, 1.10; 95% CI, 0.88–1.35; P=0.43). Con-
sidering CCB subclasses, there was evidence for an as-
sociation with risk of diverticulosis for nondihydropyri-
dine CCB use (hazard ratio, 1.49; 95% CI, 1.03–2.14; 
P=0.03) but not dihydropyridine CCB use (hazard ratio, 
1.01; 95% CI, 0.80–1.28; P=0.91) or any other antihy-
pertensive drug class (Table XVIII in the online-only Data 
Supplement).
DISCUSSION
This work leveraged large-scale GWAS data from 
>750 000 individuals and generated genetic proxies 
for the effect of ACE inhibitors, BBs, and CCBs, 3 of 
the most commonly used medications worldwide. The 
MR estimates for risk of CHD and stroke were compa-
rable to those observed in RCTs against placebo, which 
supports the validity of the approach. PheWAS on 909 
outcomes corroborated the known efficacy of these 
agents in preventing hypertension and related vascular 
diseases, thus further supporting the robustness of the 
genetic variants used.
The PheWAS investigation also revealed an increased 
risk of diverticulosis associated with the standardized 
Figure 1. MR estimates for the effect of genetically lower systolic blood pressure through the ACE inhibitor, β-blocker, and calcium channel blocker 
variants, respectively, on risk of coronary heart disease and stroke, compared with randomized, controlled trial meta-analysis results.3  
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GRS for CCBs. No significant association with diverticu-
losis risk was identified when SBP SNPs were explored 
more generally, which makes effects through systemic 
SBP lowering unlikely to account for this. A consistent as-
sociation between the standardized CCB GRS and diver-
ticulosis risk was found in BioVU, which contained fewer 
cases and had a correspondingly wider CI that crossed 
the null. The finding was further supported by observa-
Table. Number of Phenotypes and Cases per Disease Category in the UK Biobank Phenome-Wide Association Study Analysis
Disease Category Phenotypes, n
Cases, n
Minimum Median Mean Maximum
Circulatory system 98 202 1048 6308 133 749
Congenital anomalies 19 211 442 557 1823
Dermatologic 43 218 799 4765 82 669
Digestive 116 228 1455 4817 79 488
Endocrine/metabolic 49 208 773 4076 45 303
Genitourinary 106 203 1376 4153 103 829
Hematopoietic 22 201 569 2690 12 759
Infectious diseases 25 219 1012 2237 10 752
Injuries and poisonings 59 222 536 1513 16 683
Mental disorders 36 202 710 3280 29 405
Musculoskeletal 57 213 925 4164 53 823
Neoplasms 82 215 1124 4261 90 826
Neurological 44 204 567 2286 40 703
Pregnancy complications 17 208 1113 1854 9534
Respiratory 56 200 1124 3837 62 168
Sense organs 64 210 774 2443 39 998
Symptoms 16 304 2341 7036 42 311
Figure 2. Phenome-wide association study of the standardized genetic risk score for angiotensin-converting enzyme inhibitors. 
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tional analysis suggesting that nondihydropyridine CCB 
treatment at baseline in the UK Biobank was associated 
with increased risk of diverticulosis. Dihydropyridine and 
nondihydropyridine CCBs have different pharmacologi-
cal effects, and it also follows that their side effect pro-
files vary.22 In terms of a possible mechanism, constipa-
tion is an established side effect of nondihydropyridine 
CCBs, related to their role in reducing bowel contractil-
ity,23 and it may be through a similar process that the 
risk of diverticulosis is increased. Alternatively, there may 
be specific effects on the vasa recta vessels that pene-
trate the muscle layer of the colon, thus giving rise to 
weak points where diverticulae consequently form.24 
Complications related to diverticulosis are a common 
reason for hospital admission25 and have a rising inci-
dence.26 Given that more than one-tenth of the world’s 
adults have hypertension, and CCBs are recommended 
as a first-line pharmacological agent, with nondihydro-
pyridine drugs in particular recommended for individuals 
with concurrent atrial fibrillation,1,6 the clinical implica-
tions of these findings merit consideration. For example, 
individuals with or at increased risk of developing diver-
ticulosis might benefit from alternative pharmacologi-
cal treatments for hypertension. The genetic proxies for 
ACE inhibitors, BBs, and CCBs did not show detrimen-
tal associations with any of the other traits examined in 
PheWAS. Although absence of evidence is not evidence 
of absence, this does provide some assurance that long-
term pharmacological inhibition of these drug targets is 
generally safe, with other side effects that require hospi-
talization being smaller or rarer.
A major strength of our work is that it uses genetic 
variants to investigate the effect of antihypertensive 
drugs using existing data obtained from large-scale 
studies, thus avoiding the time and resource constraints 
associated with such study through RCTs4 and over-
coming the limitations of potential confounding and 
reverse causation from use of standard observational 
methods.7 A range of sensitivity analyses supported 
the robustness of this approach, with PheWAS allow-
ing rapid investigation of hundreds of clinically relevant 
traits across the phenome. Additionally, observational 
analysis allowed for consideration of CCB subclasses 
and further replication of novel findings.
Concerning the limitations of the study, the MR and 
PheWAS results estimate the cumulative effect of life-
long exposure to genetic variants, rather than the con-
sequence of a clinical intervention. Furthermore, there 
may be unknown pleiotropic effects of the genetic 
variants that bias the association estimates.16 Although 
less stringent criteria for selecting instruments (such as 
a more relaxed P value threshold for association with 
SBP, or a more lenient LD criterion for clumping) might 
have increased the number of variants available, this 
could also have reduced the sensitivity and specificity 
of the analysis because of the introduction of weak 
Figure 3. Phenome-wide association study of the standardized genetic risk score for β-blockers. 
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instrument bias and invalid instruments, respective-
ly. Similarly, information on gene expression was not 
incorporated in this work, and although such an ap-
proach could offer an additional strategy for identifying 
genetic variants that serve as proxies for drug effects,7 
this would be restricted to the cells or tissues in which 
gene expression was measured, limiting applicability 
for exploration of general side effects or repurposing 
opportunities. Although the PheWAS analysis was per-
formed to explore clinically relevant outcomes identi-
fied using harmonized Hospital Episode Statistics data 
in UK Biobank participants, there is also the potential 
to extend this approach to other cohorts and summary-
level genetic data.15 Finally, although the observational 
analysis of drug use in the UK Biobank did support an 
association between nondihydropyridine CCB use and 
risk of diverticulosis, it is not clear whether this find-
ing may in part relate to ascertainment bias or residual 
confounding. Diverticulosis can be incidental in asymp-
tomatic individuals, and as such, increased interaction 
with healthcare services could lead to a greater chance 
of diagnosis.
In conclusion, this work has identified genetic vari-
ants that serve as proxies for the effect of the ACE in-
Figure 4. Phenome-wide association study of the standardized genetic risk score for calcium channel blockers. 
The horizontal line depicts the 5% false-discovery rate threshold.
Figure 5. Estimates for genetic association 
between calcium channel blockers and 
diverticulosis risk derived from PheWAS 
analyses in the UK Biobank and BioVU, 
respectively, and their fixed-effects pooled 
estimate.  
BioVU indicates Vanderbilt University Bio-
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hibitor, BB, and CCB classes of antihypertensive medi-
cation. In MR and PheWAS, our instrumental variable 
approaches corroborated the established associations 
of these agents with a range of traits related to hy-
pertension. Additionally, this study identified an appar-
ent, previously unreported detrimental effect of nondi-
hydropyridine CCBs on risk of diverticulosis, a finding 
that requires further replication before it should alter 
clinical practice. No other potential side effects of any 
drug class were identified to suggest a lack of long-
term safety. This study demonstrates that the use of 
genetic variants offers a powerful complement to exist-
ing RCT and observational approaches for investigating 
the efficacy, side effects, and repurposing potential of 
antihypertensive agents.
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ABSTRACT  1 
Objective: We employed Mendelian Randomization to explore whether the effects of blood 2 
pressure (BP) and BP lowering through different antihypertensive drug classes on stroke risk 3 
vary by stroke etiology.  4 
Methods: We selected genetic variants associated with systolic and diastolic BP and BP-5 
lowering variants in genes encoding antihypertensive drug targets from a GWAS on 757,601 6 
individuals. Applying two-sample Mendelian randomization, we examined associations with any 7 
stroke (67,162 cases; 454,450 controls), ischemic stroke and its subtypes (large artery, 8 
cardioembolic, small vessel stroke), intracerebral hemorrhage (ICH, deep and lobar), and the 9 
related small vessel disease phenotype of WMH. 10 
Results: Genetic predisposition to higher systolic and diastolic BP was associated with higher risk 11 
of any stroke, ischemic stroke, and ICH. We found associations between genetically determined 12 
BP and all ischemic stroke subtypes with a higher risk of large artery and small vessel stroke 13 
compared to cardioembolic stroke, as well as associations with deep, but not lobar ICH. Genetic 14 
proxies for calcium channel blockers, but not beta blockers, were associated with lower risk of any 15 
stroke and ischemic stroke. Proxies for CCBs showed particularly strong associations with small 16 
vessel stroke and the related radiological phenotype of WMH. 17 
Conclusions: This study supports a causal role of hypertension in all major stroke subtypes 18 
except lobar ICH. We find differences in the effects of BP and BP lowering through 19 
antihypertensive drug classes between stroke subtypes and identify calcium channel blockade as 20 





Stroke ranks among the leading causes of death and disability worldwide.1,2 High blood pressure 2 
(BP) is the major risk factor for both ischemic and hemorrhagic stroke, accounting for ~50% of 3 
the population attributable risk worldwide.3-6  BP lowering reduces stroke risk with known 4 
differences between antihypertensive drug classes.7,8 Randomized-controlled trials (RCTs) found 5 
calcium channel blockers (CCBs) to be superior to other drug classes, and specifically beta-6 
blockers (BB), in lowering stroke risk.7,9,10 However, it remains unknown whether the effects of 7 
BP or BP lowering through specific drug classes vary between stroke etiologies. In light of 8 
largely variable mechanisms between large artery stroke (LAS), cardioembolic stroke (CES), 9 
small vessel stroke (SVS), and deep and lobar intracerebral hemorrhage (ICH),11,12 differences 10 
seem possible and might have relevance for therapeutic decisions. 11 
Mendelian Randomization (MR) uses genetic variants as proxies for traits of interest and is by 12 
design less prone to confounding and reverse causation than observational studies.13 As such, 13 
MR has been proven valuable in exploring causality and in predicting the effects of 14 
interventions,13-17 as we recently showed for the effects of antihypertensive drugs on vascular 15 
outcomes.18 The large samples in genome-wide association studies (GWAS) further permit 16 
exploration of outcomes for which there are no adequate data from RCTs, as is the case for BP 17 
lowering and stroke subtypes. Here, leveraging genetic data on BP19 and stroke20 we employed 18 
MR to examine the effects of genetically determined BP and genetic proxies for antihypertensive 19 
drug classes on stroke subtypes, as well as on white matter hyperintensities (WMH), a 20 








This study was conducted in accordance with the Guidelines for strengthening the reporting of 3 
Mendelian randomization studies (STROBE-MR).21 4 
 5 
Genetic instrument selection 6 
Data sources are detailed in Table 1. All data were derived from studies that had already 7 
obtained ethical review board approvals. We used summary statistics from the discovery GWAS 8 
meta-analysis of the International Consortium for Blood Pressure (ICBP) and the UK Biobank 9 
(UKB), based on 757,601 individuals of European ancestry.19 In the pooled sample, mean 10 
systolic (SBP) and diastolic BP (DBP) were 138.4 (SD: 21.5) and 82.8 (SD: 11.4) mmHg, 11 
respectively. As genetic instruments for SBP and DBP, we selected single-nucleotide 12 
polymorphisms (SNPs) associated with SBP or DBP at genome-wide significance level (p<5x10-13 
8) and clumped for linkage disequilibrium (LD) to r2<0.001 based on the European 1000 14 
Genomes panel. We estimated the proportion of variance in SBP and DBP explained by each 15 
instrument22 and calculated F-statistics to measure instrument strength (data available from 16 
dryad, Tables e-1 and e-2,  doi: https://doi.org/10.5061/dryad.dfn2z34wj).23  17 
We further selected genetic variants as proxies for the SBP-lowering effects of common 18 
antihypertensive drug classes (Figure 1). According to our previously described strategy,18 we 19 
identified the genes encoding pharmacological targets related to BP-lowering for common 20 
antihypertensive drug classes in DrugBank24 and screened the genomic regions corresponding to 21 
these genes and their regulatory regions (promoters and enhancers).25 For the main analyses, we 22 
selected SNPs associated with SBP at genome-wide significance (p<5x10-8) that were at 23 




analyses using a more stringent LD threshold (r2<0.1) (data available from dryad, Table e-3,  1 
doi: https://doi.org/10.5061/dryad.dfn2z34wj). The genes and the specific genomic regions 2 
screened for identification of genetic proxies for each antihypertensive drug class are detailed in 3 
Table e-4 (data available from dryad, doi: https://doi.org/10.5061/dryad.dfn2z34wj). 4 
 5 
Primary outcomes and etiologically related phenotypes 6 
The primary outcomes for our analyses were any stroke, ischemic stroke and its TOAST-defined 7 
subtypes (LAS, CES, SVS),29 ICH and its location-specific subtypes, i.e. lobar (originating at 8 
cerebral cortex or cortical-subcortical junction) and deep (originating at thalamus, internal 9 
capsule, basal ganglia, deep periventricular white matter, cerebellum, or brainstem).30 Genetic 10 
association estimates for any stroke, ischemic stroke and its subtypes were obtained from the 11 
MEGASTROKE multi-ethnic GWAS meta-analysis of 67,162 cases (60,341 ischemic stroke, 12 
6,688 LAS, 9,006 CES, 11,710 SVS) and 454,450 controls.20,31 For ICH, we used the summary 13 
statistics from the ISGC meta-analysis by Woo et al. including 1,545 cases (664 lobar, 881 deep) 14 
and 1,481 controls.30 In addition, we performed MR analyses for the radiological phenotype of 15 
WMH volume, a manifestation of cerebral SVD etiologically related to SVS and ICH. We 16 
performed a genome-wide association study (GWAS) analysis for total volume of WMH, 17 
derived from T1 and T2-FLAIR images in the UK Biobank data following a previously 18 
described approach,32 as detailed in eMethods (data available from dryad, doi: 19 
https://doi.org/10.5061/dryad.dfn2z34wj).  20 
 21 
Statistical analysis 22 
For SBP and DBP, we calculated individual MR estimates and standard errors from the SNP-23 




second-order weights were used.33 The MR associations for SBP and DBP with the primary 1 
outcomes were estimated by pooling individual MR estimates using fixed-effects inverse-2 
variance weighted (IVW) meta-analyses.33 All MR associations between SBP, DBP, and stroke 3 
were scaled to 10 mmHg increment in SBP and 5 mmHg in DBP. 4 
For the antihypertensive drug classes, including instruments at moderate to low LD (r2<0.4), we 5 
applied generalized linear regression analyses weighted for the correlation between the 6 
instruments, as previously described.26 This relatively lenient LD correlation threshold allows for 7 
an increase in proportion of variance explained and thus in statistical power.26,27 In sensitivity 8 
analyses we restricted our instrument selection to a lower LD correlation threshold (r2<0.1) and 9 
applied fixed-effects IVW. All MR associations between antihypertensive drug classes and 10 
stroke were scaled to 10 mmHg decrease in SBP. 11 
MR analyses might be biased due to pleiotropic instruments. As measures of pleiotropy, we 12 
assessed heterogeneity across MR estimates with I2 and the Cochran’s Q test (I2>50% and 13 
p<0.05 were considered statistically significant)34 and the intercept obtained from MR-Egger 14 
regression (p<0.05 considered statistically significant).35 We further used alternative methods 15 
(weighted-median estimator,36 MR-Egger,35 weighted-modal estimator37) with relaxing 16 
assumptions regarding pleiotropic variants. The weighted median estimator requires that at least 17 
half of the information for the MR analysis comes from valid instruments.36 MR-Egger 18 
regression requires that the strengths of potential pleiotropic instruments are independent of their 19 
direct associations with the outcome.35 The weighted modal estimator provides correct estimates 20 
under the assumption that a plurality of genetic variants are valid instruments.37 We further 21 
tested for the presence of pleiotropic outlier variants using the Mendelian randomization 22 
pleiotropy residual sum and outlier (MR- PRESSO) test38 and in sensitivity IVW MR analyses 23 




The genetic association estimates used in the analyses for BP were corrected for antihypertensive 1 
medication use and were adjusted for body mass index,19 thus introducing potential bias due to 2 
medication non-compliance or collider effects, respectively. Thus, we performed sensitivity 3 
analyses using unadjusted estimates for BP from a UK Biobank GWAS (317,756 individuals).39  4 
To minimize ancestral mismatch with the European population used in the BP GWAS, in 5 
sensitivity analyses we further restricted our MR analyses for stroke to the MEGASTROKE 6 
European subset.   7 
Statistical significance for all analyses was set at a two-sided p-value <0.05. To examine whether 8 
BP differentially associated with stroke subtypes or whether there were differential effects of 9 
antihypertensive drugs on stroke risk, we compared the derived ORs by computing z-score for 10 
the differences of their natural logarithms. All statistical analyses were undertaken in R (v3.5.0; 11 
The R Foundation for Statistical Computing) using the MendelianRandomization, 12 
TwoSampleMR, and the MRPRESSO packages. 13 
 14 
Data availability statement 15 
This study was based on summary statistics. The GWAS data from the ICBP and UKB meta-16 
analysis are publicly available through the GRASP repository of the National Heart, Lung, and 17 
Blood Institute (https://grasp.nhlbi.nih.gov/FullResults.aspx). The data from the GWAS studies 18 
for stroke and ICH are publicly available and may be accessed through the MEGASTROKE 19 
(http://www.megastroke.org/download.html) and the ISGC 20 
(http://cerebrovascularportal.org/informational/downloads) websites, respectively. Data from the 21 
UK Biobank GWAS for WMH volume may be accessed through an application to the UK 22 








Genetically determined BP and risk of stroke subtypes 5 
We first examined the relationship between genetically determined BP and the risk of stroke and 6 
stroke subtypes. We identified 462 genetic variants associated with SBP and 460 variants 7 
associated with DBP. F-statistic was >10 for all variants indicating low risk of weak instrument 8 
bias (data available from dryad, Tables e-1 and e-2, doi: 9 
https://doi.org/10.5061/dryad.dfn2z34wj). MR analyses showed statistically significant 10 
associations of both SBP and DBP with risk of any stroke, ischemic stroke and all of its major 11 
subtypes (LAS, CES, SVS), ICH, and deep ICH, but not lobar ICH (Figure 2). The effects of 12 
genetically determined BP were larger for LAS and SVS compared to CES (p for LAS-CES 13 
comparisons of ORs=2x10-8 for SBP and 0.004 for DBP; p for SVS-CES comparisons of ORs 14 
=0.001 for SBP and 9x10-4 for DBP), and for deep compared to lobar ICH (p for comparisons of 15 
ORs =0.016 for SBP and 0.009 for DBP), as depicted in Figure 2. 16 
The effect estimates remained stable in the weighted median, MR-Egger, and weighted-modal 17 
analyses, analyses excluding outliers detected with MR-PRESSO, European-restricted analyses, 18 
and analyses based on unadjusted BP estimates (data available from dryad, Table e-5, doi: 19 
https://doi.org/10.5061/dryad.dfn2z34wj). Tests for heterogeneity and the MR-Egger intercepts 20 
were not significant in any of the analyses (I2<50% and p>0.05, respectively) providing no 21 





Genetic proxies for antihypertensive drugs and risk of stroke subtypes 1 
Next, we selected BP-lowering variants in genes encoding drug targets as proxies for the effects 2 
of antihypertensive drug classes, as detailed in Figure 1 and as has been previously described,18 3 
and examined their effects on stroke in MR analyses. We identified 8 proxies (variants) for BBs 4 
and 60 proxies for CCBs (data available from dryad, Table e-3, doi: 5 
https://doi.org/10.5061/dryad.dfn2z34wj). We further identified a single proxy for ACE 6 
inhibitors, which we did not consider in the following analyses given the lack of power. A 10-7 
mmHg reduction in SBP through variants in genes encoding targets of CCBs, but not BBs, was 8 
associated with a significantly lower risk of any stroke and ischemic stroke (Figure 3). In 9 
analyses for ischemic stroke subtypes, we found a 10-mmHg reduction in SBP through CCB 10 
variants to be associated with significantly lower risks of LAS, CES, and SVS. The effect for 11 
SVS was stronger than that for both LAS (p for comparison of ORs=0.002) and CES (p for 12 
comparison of ORs=6x10-4) (Figure 3). BB variants were not associated with any of the 13 
ischemic stroke subtypes. We found no significant associations for any of the drug classes for 14 
ICH and its subtypes, which is probably related to limited power (data available from dryad, 15 
Table e-6, doi: https://doi.org/10.5061/dryad.dfn2z34wj). 16 
Sensitivity analyses for BBs and CCBs restricted to the set of variants with a more stringent LD 17 
threshold (r2<0.1) showed consistent association estimates with the primary analyses for all of 18 
the examined phenotypes (data available from dryad, Table e-6, doi: 19 
https://doi.org/10.5061/dryad.dfn2z34wj). For CCBs, we found no evidence for pleiotropy 20 
(heterogeneity: I2<50%; p of MR-Egger intercepts>0.05). There was heterogeneity in the 21 
associations of BBs with any stroke (I2=59%), ischemic stroke (I2=67%), and SVS (I2=66%), 22 
which was however attenuated following exclusion of 2 outlier SNPs in MR-PRESSO (I2=0%, 23 
following exclusion of outlier SNPs), while the association estimates remained stable (data 24 




remained consistent across the alternative MR methods (data available from dryad, Table e-6, 1 
doi: https://doi.org/10.5061/dryad.dfn2z34wj).  2 
Genetically determined BP and WMH volume 3 
To gain additional insight in the relationship between genetically determined BP and cerebral 4 
SVD, we next calculated MR estimates for the associations of BP with WMH volume. We found 5 
genetically elevated SBP and DBP to be significantly associated with higher WMH volume 6 
(Figure 4A). Examining the effects of genetic proxies for antihypertensive drug classes (Figure 7 
4B), we found significant associations of CCBs with lower WMH volume (β=-0.491, 95%CI=-8 
0.591 to -0.391, p=3.5x10-7), whereas proxies for BBs were not associated with WMH volume. 9 




We investigated the relationship between the leading modifiable risk factor for stroke and 14 
etiologically defined stroke subtypes by leveraging large-scale genetic data. We found genetic 15 
predisposition to higher BP to be associated with greater risk of any stroke, ischemic stroke, each 16 
of its main subtypes, and deep but not lobar ICH. Risk was higher for LAS and SVS compared to 17 
CES. Using genetic proxies for different antihypertensive drug classes we found BP-lowering 18 
through CCBs, but not BBs to be associated with lower risk of stroke and ischemic stroke. CCB 19 
variants were associated with a lower risk of all major ischemic stroke subtypes showing 20 
particularly strong effects on SVS and the related phenotype of WMH. 21 
Our study provides evidence for a causal effect of higher BP on LAS, CES, and SVS, thus 22 
demonstrating a broad involvement of BP in the pathogenesis of ischemic stroke. Of note, 23 




Specifically, risk was more pronounced for LAS and SVS than for CES and was restricted to 1 
deep ICH. Unlike deep ICH, lobar ICH is often related to cerebral amyloid angiopathy and the 2 
absence of an association signal between BP and lobar ICH is consistent with observational 3 
data.40,41 As demonstrated by our drug target analyses, the effects of specific antihypertensive 4 
drug classes also differed according to stroke subtype. Collectively, these data emphasize the 5 
need to consider stroke etiologies when studying the effects of BP on stroke risk in observational 6 
and interventional studies.  7 
Among the major findings is a benefit of BP lowering through genetic proxies for CCBs over 8 
BBs for SVS and the related phenotype of WMH. In contrast, we found no disparity in effects 9 
between genetic proxies for CCBs and BBs for LAS and CES. This suggests that CCBs may be 10 
particularly effective in preventing manifestations of cerebral small vessel disease. The 11 
mechanisms underlying this observation are currently unknown but may include direct effects of 12 
CCBs on cerebral microvessels or systemic effects for instance from the established influence of 13 
CCBs on BP variability.9,10,42  14 
Patients with cerebral small vessel disease mark a population at increased risk for stroke, 15 
dementia and death.43 Small vessel disease manifestations are highly prevalent in the ageing 16 
population with figures reaching up to 90% in patients aged 65 years and above.44 Yet, there 17 
have been no informative trials on specific antihypertensive agents for the prevention of SVS, 18 
WMH or other manifestations of small vessel disease.45-47 Our MR results suggest that BP 19 
lowering with CCBs should be tested in clinical trials for prevention of SVS and other outcomes 20 
related to small vessel disease. 21 
The consistency of our results for stroke obtained from genetic proxies for different drug classes 22 
with those from previous RCTs7,9,10 is worth noting and lends confidence to our findings on 23 
etiological stroke subtypes for which no data from RCTs exist. The disparity in treatment effects 24 




BP variability; CCBs decrease whereas BBs increase BP variability.9,10 However, whether the 1 
effects of BP variability on stroke risk vary by stroke etiology is unresolved and deserves further 2 
investigation. 3 
Our study has several methodological strengths. We used large datasets offering sufficient 4 
statistical power for most analyses and applied multiple methods to exclude pleiotropic effects 5 
and other biases. We also examined phenotypes etiologically related to stroke subtypes and 6 
performed mediation analyses that allowed inferences on mechanistic aspects regarding the 7 
association of BP with stroke. Finally, we used genetic proxies for antihypertensive drug classes 8 
that have been previously validated and have shown comparable effects to those derived from 9 
RCTs.18  10 
Our study also has limitations. First, MR examines the lifetime effects of genetically determined 11 
BP, which might differ from the effect of a clinical intervention for BP lowering. Second, based 12 
on our selection criteria we identified only a single genetic proxy for ACE inhibitors that did not 13 
offer sufficient statistical power to perform meaningful analyses. Future studies encompassing 14 
larger GWAS datasets for BP might identify such variants and might thus offer deeper insights 15 
into differential effects between different classes of BP-lowering agents including ACE 16 
inhibitors, angiotensin-receptor blockers, and thiazide diuretics on stroke and stroke subtypes. 17 
Third, by design, we could not examine non-linear associations between BP and stroke risk.48 18 
However, current evidence suggests that the association of mid-life SBP and DBP with stroke 19 
seems to follow a linear pattern.49 Fourth, our results apply stroke incidence and not stroke 20 
recurrence. While we found high BP to not be associated with risk of lobar ICH, hypertension 21 
has been shown in observational studies to increase the risk for both deep and lobar ICH 22 
recurrence,50 which could not be examined in the context of the current study. Fifth, the small 23 
sample size for the ICH GWAS did not offer sufficient power to examine the effects of 24 




restricted to individuals of European ancestry which could limit generalizability of our findings 1 
to this population. This might specifically apply for ICH 30 given the evidence from 2 
observational studies for differential associations of BP with lobar ICH depending on ethnicity.51 3 
Furthermore, there is evidence for differential responses to antihypertensive drug classes by 4 
ethnicity, which could not be examined in the current study.52 The availability of large-scale 5 
GWAS data from more diverse populations with higher representation of non-European 6 
ethnicities will enable future MR studies to explore potential ethnic disparities in more detail. 7 
Finally, it was not possible to disentangle the effects of dihydropyridine and non-dihydropyridine 8 
CCBs with MR, because the differences in the subunits of the voltage-gated calcium channels 9 
that are the targets of these drug subclasses in the vessels and the heart, respectively, are encoded 10 
by the same genes but are the result of alternative splicing.53 11 
In conclusion, we provide evidence for a causal association of higher BP with risk of any stroke 12 
and all stroke subtypes except lobar ICH, with a higher risk of large artery and small vessel 13 
stroke compared to cardioembolic stroke. Our findings support CCBs, but not BBs, to lower 14 
ischemic stroke risk. Genetic proxies for the effects of CCBs showed particularly strong 15 
associations with SVS and WMH, highlighting calcium channel blockade as a promising strategy 16 
for the prevention of cerebral small vessel disease. 17 
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Figure 1. Selection strategy for genetic variants used as proxies for antihypertensive drug 







Figure 2. Mendelian randomization associations between genetically determined blood pressure and risk of stroke and stroke subtypes. 






Figure 3. Mendelian randomization associations between genetic proxies for 
antihypertensive drug classes and risk of stroke and stroke subtypes. Shown are the results 






Figure 4. Mendelian randomization associations of (A) genetically determined blood 
pressure and (B) genetic proxies for antihypertensive drug classes with WMH volume. (A) 
Shown are the results from the fixed-effects IVW analysis. (B) Shown are the results from the 






Table 1. Descriptive characteristics of the genome-wide association study (GWAS) meta-analyses that were 
included in this Mendelian randomization study.  
Study stage GWAS Phenotype Sample size Ancestry Adjustmentsa 
Instrument selection 
ICBP & UK 
Biobank19 
SBP, DBP  757,601 individuals European age, sex, BMI 
Use of instruments for 
sensitivity analysis 
UK Biobank (Neale 
lab analysis)39  
SBP, DBP 317,756 individuals European none 
Primary outcome MEGASTROKE20 
Any stroke, IS and subtypes 






Primary outcome ISGC ICH GWAS30 
ICH and subtypes (lobar, 
deep ICH) 
1,545 cases/ 1,481 
controls 
European age, sex 
Etiologically related 
outcome 
UK Biobank  WMH volume 10,597 individuals European age, sex 
 
a All GWAS studies have further adjusted for principal components. 
BMI, body mass index; CES, cardioembolic stroke; DBP, diastolic blood pressure; ICBP, International Consortium for Blood Pressure; ICH, intracerebral hemorrhage; 
LAS, large artery stroke; SBP, systolic blood pressure; SVS, small vessel stroke; WMH, white matter hyperintensities. 
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Genetic determinants of blood lipids and
cerebral small vessel disease: role of
high-density lipoprotein cholesterol
Marios K. Georgakis,1,2 Rainer Malik,1 Christopher D. Anderson,3,4,5,6 Klaus G. Parhofer,7
Jemma C. Hopewell8 and Martin Dichgans1,9,10
Blood lipids are causally involved in the pathogenesis of atherosclerosis, but their role in cerebral small vessel disease remains
largely elusive. Here, we explored associations of genetic determinants of blood lipid levels, lipoprotein particle components, and
targets for lipid-modifying drugs with small vessel disease phenotypes. We selected genetic instruments for blood levels of high-
density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides, for cholesterol and trigly-
cerides components of size-defined lipoprotein particles, and for lipid-modifying drug targets based on published genome-wide
association studies (up to 617 303 individuals). Applying two-sample Mendelian randomization approaches we investigated asso-
ciations with ischaemic and haemorrhagic manifestations of small vessel disease [small vessel stroke: 11 710 cases, 287 067 con-
trols; white matter hyperintensities (WMH): 10 597 individuals; intracerebral haemorrhage: 1545 cases, 1481 controls]. We applied
the inverse-variance weighted method and multivariable Mendelian randomization as our main analytical approaches. Genetic
predisposition to higher HDL-C levels was associated with lower risk of small vessel stroke [odds ratio (OR) per standard
deviation = 0.85, 95% confidence interval (CI) = 0.78–0.92] and lower WMH volume (b = –0.07, 95% CI = –0.12 to –0.02),
which in multivariable Mendelian randomization remained stable after adjustments for LDL-C and triglycerides. In analyses of
lipoprotein particle components by size, we found these effects to be specific for cholesterol concentration in medium-sized high-
density lipoprotein, and not large or extra-large high-density lipoprotein particles. Association estimates for intracerebral haem-
orrhage were negatively correlated with those for small vessel stroke and WMH volume across all lipid traits and lipoprotein
particle components. HDL-C raising genetic variants in the gene locus of the target of CETP inhibitors were associated with lower
risk of small vessel stroke (OR: 0.82, 95% CI = 0.75–0.89) and lower WMH volume (b = –0.08, 95% CI = –0.13 to –0.02), but a
higher risk of intracerebral haemorrhage (OR: 1.64, 95% CI = 1.26–2.13). Genetic predisposition to higher HDL-C, specifically to
cholesterol in medium-sized high-density lipoprotein particles, is associated with both a lower risk of small vessel stroke and lower
WMH volume. These analyses indicate that HDL-C raising strategies could be considered for the prevention of ischaemic small
vessel disease but the net benefit of such an approach would need to be tested in a randomized controlled trial.
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Introduction
Cerebral small vessel disease (SVD) accounts for 20% of
all ischaemic strokes (Sudlow and Warlow, 1997) and most
cases of intracerebral haemorrhage (ICH) (Qureshi et al.,
2001, 2009). SVD is the leading cause of vascular dementia
(O’Brien and Thomas, 2015; Iadecola et al., 2019) and an
independent predictor of mortality (Debette et al., 2019;
Georgakis et al., 2019). Manifestations of SVD on MRI
are highly prevalent in the ageing population with figures
reaching 90% for white matter hyperintensities (WMH) in
patients aged 65 years and above (de Leeuw et al., 2001;
Pantoni, 2010; Wardlaw et al., 2019). However, the mech-
anisms underlying SVD are poorly understood, thus imped-
ing the development of effective strategies for prevention.
Blood lipids are a well-established risk factor for large
artery atherosclerosis (Collins et al., 2016) and lipid-mod-
ifying therapies have shown benefits in reducing risk of
both coronary artery disease and stroke [Cholesterol
Treatment Trialists’ (CTT) Collaboration et al., 2010;
Chou et al., 2016]. Yet, their role in SVD remains largely
elusive. Current guidelines for secondary stroke prevention
recommend treatment with statins after ischaemic stroke or
transient ischaemic attack [European Stroke Organisation
(ESO) Executive Committee and ESO Writing Committee,
2008; Kernan et al., 2014; Intercollegiate Stroke Working
Party, 2016; Stroke Foundation, 2017) referring to clinical
trials data and meta-analyses (Amarenco et al., 2006;
Amarenco and Labreuche, 2009; Manktelow and Potter,
2009). However, most trials provided no sub-analyses for
ischaemic stroke subtypes. The J-STARS trial, the only
study providing sub-analyses, found statins to reduce recur-
rence of large artery stroke but not small vessel stroke
(SVS) (Hosomi et al., 2015). Results from the SPARCL
trial suggest that statins may increase the risk of ICH in
patients with stroke or transient ischaemic attack
(Amarenco et al., 2006), especially in patients with SVS
as an entry event (Goldstein et al., 2008).
Mendelian randomization makes use of genetic variants
that are associated with an exposure or risk factor as
instruments, and investigates their associations with disease
outcomes thus overcoming some of the key limitations of
observational studies such as confounding and reverse caus-
ation (Hopewell and Clarke, 2016; Holmes et al., 2017).
Hence, Mendelian randomization analyses can assess the
causal relevance of a risk factor for disease and facilitate
prioritization of interventions to be tested in clinical trials
(Holmes et al., 2017; O’Donnell and Sabatine, 2018) as has
specifically been demonstrated for lipid-modifying drugs
(Khera and Kathiresan, 2017; Ference et al., 2018). In
fact, there are several examples where Mendelian random-
ization studies have predicted the success or failure of clin-
ical trials (Ference et al., 2015, 2016, 2017b, 2019b; Gill
et al., 2019; Ray et al., 2019). The availability of large scale
genome-wide association studies (GWAS) for an expanding
range of phenotypes and the development of two-sample
Mendelian randomization approaches enable the exploration
of associations for which there is a paucity of evidence from
clinical trials, as is the case for lipids and cerebral SVD.
Here, we leveraged data from the largest GWAS cur-
rently available on blood lipid levels (617 303 individuals)
(Willer et al., 2013; Klarin et al., 2018) and on both is-
chaemic (SVS, WMH volume) and haemorrhagic (ICH)
manifestations of cerebral SVD (Woo et al., 2014; Malik
et al., 2018a; Rutten-Jacobs et al., 2018) with the aim to:
(i) examine the effects of genetic determinants of blood
levels of high-density lipoprotein cholesterol (HDL-C),
low-density lipoprotein cholesterol (LDL-C), and triglycer-
ides on SVD manifestations; (ii) explore associations be-
tween genetic determinants of size-defined lipoprotein
particle fractions with these phenotypes; and (iii) determine
the effects of genetic predisposition to HDL-C raising,
LDL-C lowering, and triglyceride lowering through vari-
ants in genes encoding targets of lipid-modifying drugs on
SVD manifestations.
Materials and methods
This study follows the guidelines for strengthening the report-
ing of Mendelian randomization studies (STROBE-MR)
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(Davey Smith et al., 2019). We applied two-sample Mendelian
randomization analyses, which allow selection of genetic vari-
ants as instruments for a risk factor (blood lipid traits) in one
sample and explore associations of theses variants with out-
comes (manifestations of SVD) in another sample (Davey
Smith and Hemani, 2014; Burgess et al., 2015). By overcoming
the requirement for assessing the exposure and outcome in the
same dataset, this approach enables the exploration of associ-
ations in publicly available summary statistics from large
GWASs with a corresponding increase in power. Also, two-
sample Mendelian randomization is less prone to the winner’s
curse bias than one-sample Mendelian randomization (Davey
Smith and Hemani, 2014; Taylor et al., 2014).
Study design and data sources
The data sources used for this study are detailed in
Supplementary Table 1. In Mendelian randomization analyses,
we examined associations of blood lipid levels, size-defined lipo-
protein particle fractions, and lipid-modifying drug targets, with
ischaemic and haemorrhagic SVD phenotypes. We selected gen-
etic instruments from the GWAS summary statistics of the
Million Veteran Program (MVP) (Klarin et al., 2018), the
Global Lipids Genetics Consortium (GLGC) (Willer et al.,
2013), and from a GWAS on nuclear magnetic resonance
(NMR) measured circulating metabolites (Kettunen et al.,
2016). We then examined associations of the selected instru-
ments with SVS in the GWAS summary statistics of the
MEGASTROKE Consortium (Malik et al., 2018a), with
WMH volume in a GWAS analysis that we undertook in the
UK Biobank neuroimaging dataset (Alfaro-Almagro et al.,
2018), and with ICH in the International Stroke Genetics
Consortium (ISGC) GWAS meta-analysis (Woo et al., 2014).
Genetic instrument selection
Blood lipid levels
We selected genetic instruments for the blood levels of HDL-C,
LDL-C, and triglycerides, based on the results of the GWAS
multi-ethnic meta-analysis of the MVP and the GLGC samples
(617 303 individuals) (Klarin et al., 2018). Specifically, we
used independent genetic variants that reached genome-wide
level of significance (P5 5  10–8) for their associations with
HDL-C, LDL-C and triglycerides, in the conditional GWAS
meta-analyses as instruments. We identified 312 instruments
for HDL-C, 219 for LDL-C, and 253 for triglycerides
(Supplementary Table 2). In our primary analyses, we
weighted the instruments based on the joint regression coeffi-
cients from the conditional GWAS meta-analysis of MVP and
GLGC. As the GLGC further excluded participants on lipid-
lowering treatment (Willer et al., 2013), to exclude sources of
biases related to treatment-mediated effects on blood lipids in
the MVP dataset, we performed sensitivity analyses weighting
the instruments using the GLGC effect sizes only. Both MVP
and GLGC were imputed to the 1000 Genomes Project (Phase
3 and Phase 1, respectively) (1000 Genomes Project
Consortium et al., 2012) and included adjustments for age,
age2, sex, and population structure.
In a secondary approach, we restricted our selection of in-
struments to HDL-C-, LDL-C-, and triglyceride-specific vari-
ants. In particular, we used the GLGC dataset (188 577
individuals), for which we had access to the full GWAS sum-
mary statistics (Willer et al., 2013), and identified those inde-
pendent genetic variants associated with HDL-C, LDL-C, or
triglycerides at genome-wide significance (P5 5  10–8), but
showed associations of P40.01 with the other two traits.
We found 19 HLD-C-specific, 25 LDL-C-specific, and four
triglyceride-specific variants (Supplementary Table 3) and per-
formed sensitivity analyses using them as instruments.
Size-defined lipoprotein particle fractions
We then selected genetic instruments for cholesterol and trigly-
ceride concentrations in size-defined lipoprotein particles avail-
able from a GWAS for NMR-measured circulating metabolites
on 24 925 European individuals (Kettunen et al., 2016). The
GWAS analyses were imputed to the 1000 Genomes Project
(Phase 1) and adjusted for age, sex, time from last meal, and
population structure (Kettunen et al., 2016). Based on sum-
mary statistics for each trait, we extracted variants after
clumping for linkage disequilibrium (LD) at r2 5 0.1 that
reached genome-wide significance (P55  10–8). The identi-
fied instruments for each metabolite are available in
Supplementary Table 4.
Variants in genes encoding known lipid-modifying
drug targets
Next, we selected variants clumped for linkage disequilibrium
at r2 5 0.1 within a region of 100 kb upstream or down-
stream from genes encoding known drug targets that were
associated with the respective lipid trait at a genome-wide sig-
nificant level (P55  10–8) in the GLGC dataset (Willer et al.,
2013). Specifically, we searched for genetic variants in the
CETP locus (encoding the target of CETP inhibitors) asso-
ciated with HDL-C levels; variants in the loci of HMGCR
(target of statins), NPC1L1 (target of ezetimibe), PCSK9
(target of PCSK9 inhibitors), ABCG5 and ABCG8 (targets
of bile acid resins), and LDLR (therapeutic target of the
LDL receptor) associated with LDL-C levels; and variants in
the PPARA locus (target for fibrates) associated with triglycer-
ide levels, in accordance with similar approaches applied by
other studies (Ference et al., 2012, 2015, 2017b, 2019a;
Anderson et al., 2016; Harrison et al., 2018; Nowak and
Arnlov, 2018). We identified 24 HDL-C raising variants in
CETP, and for LDL-C lowering targets, four variants in
HMGCR, three in NPC1L1, 11 in PCSK9, six in ABCG5/
G8, and eight in LDLR (Supplementary Table 5). No trigly-
ceride-lowering variants were identified in the PPARA locus
based on our selection criteria for instruments.
For each genetic instrument, we estimated the proportion of
variance explained for the respective phenotype and measured
instrument strength with F-statistics (Supplementary Tables
2–5). F was 410 for all selected instruments, indicating a
low probability for weak instrument bias (Palmer et al.,
2012). Furthermore, we performed power calculations
(Burgess, 2014) to identify the range of association estimates
that we had 480% power (1 – b) to detect at  = 0.05
(Supplementary Table 6).
Associations with outcomes
The outcomes examined in this study were ischaemic and
haemorrhagic manifestations of SVD including SVS, WMH
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volume, and ICH. Genetic association estimates for SVS—
defined according to the TOAST (Trial of Org 10172 in
Acute Stroke Treatment) criteria (Adams et al., 1993)—were
obtained from the MEGASTROKE multi-ethnic GWAS meta-
analysis (Malik et al., 2018a, b) on 11 710 cases and 287 067
controls. For WMH volume, we performed a GWAS analysis
in the UK Biobank Imaging dataset (10 597 individuals of
White-British ancestry), based on the measurements of WMH
volume in T1 and T2 FLAIR MRI sequences, as previously
described, following adjustments for age, sex, and the first
10 principal components (Rutten-Jacobs et al., 2018). We fur-
ther examined ICH, as well as ICH subtypes defined according
to haemorrhage location (deep and lobar). We used summary
statistics from the ISGC GWAS meta-analysis including 1545
cases of spontaneous ICH defined by acute neurological onset
and compatible neuroimaging showing intraparenchymal
haemorrhage (664 lobar, 881 deep) and 1481 controls of
European ancestry (Woo et al., 2014).
Statistical analysis
Main analyses
We applied two-sample Mendelian randomization analyses
based on association estimates derived from the abovemen-
tioned sources. Following extraction of the association esti-
mates between the instruments and the outcomes and
harmonization of the direction of estimates by effect alleles,
we computed Mendelian randomization estimates for each in-
strument with the Wald estimator and standard errors with the
Delta method. All Mendelian randomization estimates were
scaled to 1 – SD (standard deviation) increment in the lipid
levels or the lipoprotein particle fractions. We then pooled
individual Mendelian randomization estimates using random-
effects inverse-variance weighted (IVW) meta-analyses. IVW is
the most widely used main method for Mendelian randomiza-
tion analysis because it provides robust causal estimates under
absence of directional pleiotropy (Burgess et al., 2013).
Given the correlation between HDL-C, LDL-C, and triglycer-
ide levels, and between cholesterol and triglyceride concentra-
tions in specific size-defined lipoprotein particles, we further
performed multivariable Mendelian randomization to disentangle
their independent associations with SVD phenotypes (Burgess
and Thompson, 2015). For HDL-C, LDL-C, and triglyceride
blood levels, we used the respective instruments and adjusted
for their effects on the other two traits from the GLGC dataset.
For cholesterol concentration in HDL particles, we combined all
unique variants associated with either total HDL-C levels or size-
defined HDL cholesterol concentration and adjusted for their
effects on blood LDL-C and triglyceride levels. Similarly, for
cholesterol concentration in LDL and larger particles, we com-
bined all variants associated with either total LDL-C levels or
size-defined LDL and larger particle cholesterol concentrations
and adjusted for their effects on HDL-C and triglyceride levels.
Finally, we combined instruments for either total circulating tri-
glyceride levels or for particle-specific triglyceride concentrations
and adjusted for their effects on HDL-C and LDL-C.
For all analyses, we corrected for multiple comparisons with
the false discovery rate (FDR) approach and set statistical sig-
nificance at a q-value 5 0.05. Associations not reaching this
threshold, but showing a P50.05, were considered suggestive
of an association.
Assessment of pleiotropy and sensitivity analyses
The IVW method was our primary Mendelian randomization
analysis approach, but the derived estimates might be biased in
case of directional pleiotropy. As a measure of pleiotropy, we
assessed heterogeneity across the Mendelian randomization es-
timates for each instrument in the IVW Mendelian randomiza-
tion analyses with the Cochran’s Q statistic (Bowden et al.,
2018). Under presence of nominal heterogeneity (P from
Cochran’s Q50.10) we further applied alternative
Mendelian randomization methods, which are more robust
to the use of pleiotropic instruments. These were the weighted
median estimator and the Mendelian randomization (MR)-
Egger regression. The weighted median estimator allows the
use of invalid instruments under the assumption that at least
half of the instruments used in the Mendelian randomization
analysis are valid (Hartwig et al., 2017). The MR-Egger re-
gression allows for the estimation of an intercept term, which
can be used as an indicator of unbalanced directional plei-
otropy (Bowden et al., 2015). MR-Egger provides less
precise estimates and relies on the assumption that the
strengths of potential pleiotropic instruments are independent
of their direct associations with the outcome (Bowden et al.,
2015). The intercept obtained from MR-Egger regression was
used as a measure of directional pleiotropy (P5 0.05 indicated
statistical significance) (Bowden et al., 2015).
In case of evidence of directional pleiotropy (as assessed by
both the Cochran’s Q statistic and the intercept in the MR-
Egger regression) and inconsistent results between the different
approaches, we further applied the generalized summary data-
based Mendelian randomization (GSMR) approach. This
method uses all variants reaching genome-wide significance
as instruments by accounting for linkage disequilibrium correl-
ation between them and further identifies and eliminates out-
liers that exert apparent pleiotropic effects on both the risk
factor and the outcome using the HEIDI-outlier method
(Zhu et al., 2018). GSMR further provides a measure of re-
maining global heterogeneity following exclusion of outliers
that also takes into account the low linkage disequilibrium
across the used instruments.
All analyses were performed in R (v3.5.0; The R Foundation
for Statistical Computing) using the MendelianRandomization
and the gsmr packages.
Data availability
The data used for the current study are publicly available and
may also become available from the corresponding author on
reasonable request.
Results
Genetic determinants of blood lipid
levels and ischaemic small vessel
disease
The primary results of the IVW Mendelian randomization
analyses for the associations between genetic determinants
of blood lipid levels and SVS and WMH volume are pre-
sented in Fig. 1. Genetic predisposition to elevated HDL-C
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levels were associated with both a lower risk of SVS [odds
ratio (OR): 0.85, 95% CI: 0.78–0.92, P = 5  10–4] and
lower WMH volume (b: –0.07, 95% CI: –0.12 to –0.02,
P = 0.004). We further found genetic predisposition to
higher triglyceride levels to be associated with higher risk
of SVS and a suggestive association between genetic predis-
position to higher LDL-C levels and SVS risk. In multivari-
able Mendelian randomization, the associations between
genetic determinants of HDL-C levels and SVS and
WMH volume remained stable and statistically significant
(Fig. 1). In contrast, the association between genetic deter-
minants of triglyceride levels and SVS was attenuated when
adjusting for HDL-C and LDL-C.
The Mendelian randomization results were stable when
weighting the genetic instruments for the three lipid traits
based on their association estimates in the GLGC dataset,
which excluded individuals on lipid-modifying treatment
(Supplementary Figs 1 and 2). In Mendelian randomization
analyses restricted to the instruments specifically associated
with HDL-C, LDL-C, or triglycerides, the association esti-
mates of genetic determinants of HDL-C for both risk of
SVS (OR: 0.78, 95% CI: 0.62–0.98) and WMH volume (b:
–0.27, 95% CI: –0.45 to –0.08) were even stronger
(Supplementary Fig. 3). GSMR-HEIDI, which identifies
and excludes pleiotropic outlier variants, also showed sig-
nificant associations between genetic predisposition to
higher HDL-C and both lower SVS risk and lower WMH
volume (Supplementary Figs 1 and 2).
Genetic determinants of size-defined
lipoprotein particle fractions and
ischaemic small vessel disease
To obtain a deeper understanding of the observed associ-
ations, we next selected genetic instruments for cholesterol
and triglyceride concentrations in size-defined lipoprotein
particles and examined their associations with SVS and
WMH volume (Fig. 2 and Supplementary Table 7). We
found genetic predisposition to higher cholesterol concen-
tration in the medium-sized, but not in the large- or extra-
large sized HDL particles, to be associated with both lower
SVS risk (OR: 0.84, 95% CI: 0.73–0.96, P = 0.007) and
lower WMH volume (b: –0.09, 95% CI: –0.16 to –0.02,
P = 0.009). There was no heterogeneity and the associ-
ations remained significant when adjusting for the effects
of the instruments on circulating LDL-C and triglyceride
levels (Fig. 2 and Supplementary Table 8).
Because of evidence for heterogeneity (Cochran’s Q
P50.10) and inconsistent results for the associations of
genetic determinants of total HDL-C with SVS risk and
WMH volume across sensitivity analyses (weighted
median and MR-Egger) (Fig. 3 and Supplementary Figs 1
and 2), we next restricted the set of instruments for total
HDL-C to those associated with medium-sized HDL-C
(P55  10–8). These analyses revealed stronger associ-
ation estimates between genetic predisposition to higher
HDL-C and both lower risk of SVS (OR: 0.69, 95% CI:
0.56–0.84, P = 4  10–4) and lower WMH volume (b:
–0.23, 95% CI: –0.35 to –0.10, P = 2  10–4) (Fig. 3).
Moreover, the estimates were highly consistent in alterna-
tive Mendelian randomization approaches with no evidence
for heterogeneity, thus suggesting that heterogeneity in the
overall analyses was driven by non-medium sized HDL-C
increasing variants.
To explore whether the observed associations were specific
to genetic predisposition to higher cholesterol concentration
in the medium-sized HDL, we next expanded our analyses
to other components of the HDL particles (Supplementary
Fig. 4). In this post hoc analysis, we found similar associ-
ation estimates between genetic determinants of the concen-
tration of any of the medium-sized HDL particle
components (total cholesterol, cholesterol-esters, free choles-
terol, total lipids, and phospholipids) and SVS risk as well as
WMH volume suggesting that the associations are driven by
the medium-sized HDL particles as a whole.
Regarding other lipoprotein particle components, we fur-
ther found genetic predisposition to higher concentration of
triglycerides in the small-sized HDL particles to be asso-
ciated with higher risk of SVS (Fig. 2 and Supplementary
Tables 7–9).
Genetic variants in loci of
lipid-modifying drug targets and
ischaemic small vessel disease
We next selected genetic variants in genes encoding known
HDL-C-raising or LDL-C-lowering drug targets and exam-
ined their associations with ischaemic SVD phenotypes.
HDL-C-raising variants in the CETP locus were associated
with lower risk of SVS (OR: 0.82, 95% CI = 0.75–0.89,
P = 9  10–6) and lower WMH volume (b = –0.08, 95%
CI = –0.13 to –0.02, P = 0.008) (Figs 4, 5A and B). While
there was heterogeneity in the association between CETP
variants and SVS (P = 0.03), the results remained significant
in the weighted median and MR-Egger approaches
(Supplementary Table 10). As previous analyses from the
REVEAL trial (HPS3/TIMI55–REVEAL Collaborative
Group et al., 2017) had shown the beneficial effects of
cholesteryl-ester transfer protein (CETP) inhibitors on vas-
cular disease to be mainly driven by their LDL-C lowering
and not their HDL-C raising capacity, we further explored
the associations between genetic predisposition to LDL-C
lowering through CETP variants and ischaemic SVD
manifestations. While genetic predisposition to LDL-C low-
ering was associated with lower risk of SVS and lower
WMH volume in univariable IVW Mendelian randomiza-
tion analyses, these effects were entirely reversed after ad-
justing for the HDL-C raising effects of the variants in
multivariable Mendelian randomization (Supplementary
Table 11). Analyses for genetic variants in LDL-C lowering
drug target loci showed no statistically significant results
(Fig. 4).
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Genetic associations of lipid traits
with intracerebral haemorrhage
IVW-Mendelian randomization analyses showed no signifi-
cant associations of genetic determinants of HDL-C, LDL-
C, and triglycerides with risk of ICH (Fig. 6). When
examining lipoprotein particle fractions, we found associ-
ations of the opposite direction, as compared to both SVS
and WMH volume (Fig. 7). However, confidence intervals
were wide, likely due to lack of statistical power
(Supplementary Fig. 5 and Supplementary Tables 6 and
12). Across drug target loci (Supplementary Fig. 6) we
found HDL-C raising variants in the CETP locus to be
associated with a higher risk of ICH (OR: 1.64, 95% CI:
1.26–2.13, P = 2.6  10–4) (Fig. 5C). This effect was signifi-
cant for both deep (OR: 2.01, 95% CI: 1.27–3.18,
P = 0.003) and lobar ICH (OR: 1.78, 95% CI: 1.06–2.89,
P = 0.028) (Supplementary Fig. 7).
Discussion
The main findings from this study can be summarized as
follows: (i) we found significant associations between gen-
etic predisposition to higher HDL-C levels and both lower
risk of SVS and lower WMH volume; (ii) associations were
specific for cholesterol concentrations in the medium and
not large or extra-large sized HDL particles; (iii) exploring
genetic variants at loci for targets of lipid-modifying drugs,
we found HDL-C raising variants in CETP to be associated
with a lower SVS risk and lower WMH volume; and (iv)
we found these HDL-C raising variants in CETP to be
associated with a higher risk of ICH, with consistent results
for both lobar and deep ICH.
Our Mendelian randomization results provide evidence
for a protective role of HDL-C on ischaemic SVD. This
agrees with findings from two small observational studies.
In the Women’s Healthy Ageing Project, midlife HDL-C
levels among 135 females were inversely associated with
WMH volume after 20 years, independently of other vas-
cular risk factors (Aljondi et al., 2018). Similarly, in a
cross-sectional study of 817 participants aged 550 years,
higher HDL-C levels were associated with lower volumes of
both deep and periventricular WMH after adjusting for
vascular risk factors (Yin et al., 2018). The mechanisms
underlying the observed inverse association between
HDL-C levels and ischaemic SVD are unknown but may
involve protective effects on the vascular endothelium
(Sorrentino et al., 2010; Prosser et al., 2012; Tran-Dinh
et al., 2013; Monette et al., 2016). Endothelial cells, includ-
ing those of the brain microvasculature (Lapergue et al.,
2010; Fung et al., 2017), express receptors, which upon
HDL binding, induce intracellular signalling eventually
leading to vasodilatory (Yuhanna et al., 2001; Spieker
et al., 2002; Nofer et al., 2004), anti-inflammatory
(Cockerill et al., 1995; Nicholls et al., 2005; Murphy
et al., 2008), antioxidative (Garner et al., 1998; Lee
et al., 2005; Terasaka et al., 2007), and anti-thrombotic
effects (Viswambharan et al., 2004; Calkin et al., 2009).
Our findings contrast with Mendelian randomization
analyses on atherosclerotic phenotypes supporting no asso-
ciation of genetic determinants of HDL-C levels with
Figure 1 Mendelian randomization associations of genetic determinants of blood lipid levels (HDL-C, LDL-C, triglycerides)
with risk of small vessel stroke and WMH volume. Shown are the results derived from random-effects IVW (inverse-variance weighted)
Mendelian randomization and multivariable Mendelian randomization (MVMR) analyses adjusting for the effects of the genetic variants on all the
three blood lipid traits. SD = standard deviation; TG = triglycerides.
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coronary artery disease (Voight et al., 2012; Holmes et al.,
2015; White et al., 2016) and large artery stroke (Hindy
et al., 2018) thus suggesting differential effects of HDL-C
on cerebral SVD and large artery atherosclerosis. A dispar-
ity in the effect of lipid levels between small and large
vessel pathologies has also been reported for LDL-C:
previous Mendelian randomization studies found strong ef-
fects of genetic predisposition to higher LDL-C on the risk
of coronary artery disease, large artery stroke, and periph-
eral artery disease (Holmes et al., 2015; Hindy et al., 2018;
Valdes-Marquez et al., 2019; Emanuelsson et al., 2019),
but no effect on risk of retinopathy and neuropathy,
Figure 2 Mendelian randomization associations of genetic determinants of cholesterol (C) and triglyceride (TG) concentra-
tions in size-defined lipoprotein particles with risk of small vessel stroke and WMH volume. Shown are the results derived from
random-effects inverse-variance weighted (IVW) Mendelian randomization and multivariable Mendelian randomization (MVMR) analyses. MVMR
for cholesterol in HDL particles adjusted for LDL-C and triglycerides; for cholesterol in LDL and larger particles adjusted for HDL-C and
triglycerides; and for triglycerides in any particles adjusted for HDL-C and LDL-C. IDL = intermediate density lipoprotein; L = large; M = medium;
S = small; VLDL = very low density lipoprotein; XL = extra-large.
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which are typically related to small vessel pathology
(Emanuelsson et al., 2019). Future studies should explore
potentially distinct mechanisms through which blood lipids
influence the risk of small versus large vessel disease.
Analysing size-defined lipoprotein particle subfractions
we found that the protective effects of HDL-C on ischaemic
SVD are specific for medium-sized, and not larger HDL
particles. In additional analyses, this effect seemed to be
not specific to a particular component of the HDL particles
but rather uniform across the different components, thus
suggesting that medium-sized HDL particles as a whole
could underlie this observation. HDL comprises a hetero-
geneous pool of lipoprotein particles (Kontush and
Chapman, 2010) and the few observational studies that
have performed analyses stratified by particle size indeed
found differential effects on vascular outcomes (Martin
et al., 2015; Wurtz et al., 2015; Joshi et al., 2016;
Holmes et al., 2018). There are technical challenges related
to different methods of HDL subfractioning (Superko et al.,
2012), making it challenging to compare our results with
those from previous studies. Still, our results agree with the
general notion that the favourable effects observed for
HDL are predominantly exerted by the smaller and
denser HDL particles (Yu et al., 2003; Williams, 2012;
Martin et al., 2014). Of note, previous Mendelian random-
ization studies on blood lipids that showed no significant
associations between HDL-C levels and atherosclerotic
phenotypes did not consider particle subfractions (Holmes
et al., 2015; White et al., 2016; Hindy et al., 2018).
Conceivably, disregarding subfractions might result in
Figure 3 Mendelian randomization (MR) associations of genetic determinants of HDL-C with risk of small vessel stroke and
WMH volume. Shown are the results from random-effects inverse-variance weighted (IVW), weighted median and MR-Egger analyses when (A)
using the full set of genetic instruments and (B) restricting the analyses to instruments also associated with cholesterol concentration in medium-
sized HDL.
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masking causal effects of potential biological relevance. As
such, our findings highlight the importance of sub-analyses
stratifying by lipoprotein particle size, but the complexity
of the potential underlying mechanisms necessitates further
study of our observations.
Importantly, we found HDL-C raising genetic variants in
the CETP locus to also associate with lower SVS risk and
WMH volume. Pharmacological CETP inhibition leads to
an increase in the circulating pool of HDL particles
(Armitage et al., 2019). While initial randomized trials
investigating CETP inhibitors on top of statins found no
benefit of CETP inhibition on vascular risk (Barter et al.,
2007; Schwartz et al., 2012; Lincoff et al., 2017), the most
recent REVEAL trial showed a reduced risk for major cor-
onary events (HPS3/TIMI55–REVEAL Collaborative
Group et al., 2017). In light of the relatively small effect
(relative risk reduction in REVEAL: 9%) it seems unlikely
that CETP inhibitors will achieve approval for prevention
of cardiovascular disease (Hegele, 2017; Badimon, 2018).
However, none of these trials explicitly reported effects on
risk of SVS or other SVD manifestations. Our Mendelian
randomization results suggest that post hoc analyses should
consider stratifying for stroke subtypes, and that HDL-C
raising approaches might show promise as a strategy for
lowering the burden of ischaemic SVD.
The exact mechanism by which CETP inhibition might
reduce risk of SVS and WMH volume is poorly under-
stood. In the REVEAL trial, the reduction in vascular risk
by CETP inhibition was mediated by a reduction in LDL-C
rather than an increase in HDL-C (HPS3/TIMI55–REVEAL
Collaborative Group et al., 2017). In our analyses, most of
the HDL-C raising CETP variants also showed strong as-
sociations with lower LDL-C levels. Yet, in multivariable
Mendelian randomization analyses adjusting for the effects
of the variants on both HDL-C and LDL-C, we found only
the effects of genetic predisposition to higher HDL-C
Figure 5 Mendelian randomization associations between HDL-C raising genetic variants in the CETP locus and (A) risk of SVS,
(B) WMH volume, and (C) risk of ICH. Shown are the results from the random-effects inverse-variance weighted (IVW) Mendelian
randomization approach. The results are scaled per 1 SD increment in circulating HDL-C levels.
Figure 4 Mendelian randomization associations of HDL-C-raising and LDL-C-lowering genetic variants in the loci of known
lipid-modifying drug targets with risk of SVS and WMH volume. Shown are the results derived from random-effects inverse-variance
weighted (IVW) Mendelian randomization analyses. The results are scaled per 1 SD increment in circulating HDL-C levels (HDL-C-raising drug
targets) and per 1 SD increment in circulating LDL-C levels (LDL-C-lowering drug targets).
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through these CETP variants to remain consistent in terms
of magnitude and directionality. Thus, although we were
not sufficiently powered to entirely disentangle the effects
of the two traits, our results suggest that in contrast with
the REVEAL trial results, the effects of CETP variants on
SVD manifestations might be primarily exerted by HDL-C
raising. Administration of CETP inhibitors increases HDL
particle size (Brousseau et al., 2004) and genetic predispos-
ition to higher CETP concentration is associated with
increased concentrations of medium- and large-sized, but
not smaller HDL particles (Blauw et al., 2019). However,
whether the expected effects of CETP inhibition on SVS
and WMH volume are mediated through increases in the
pool of specific HDL subparticles would need to be
explored in future studies.
Previous observational and genetic studies found high
HDL-C and low LDL-C levels to be associated with a
higher risk of ICH (Wang et al., 2013; Anderson et al.,
2016; Sun et al., 2019). Also, clinical trials have shown
that LDL-C lowering with statins might increase risk for
ICH (Amarenco et al., 2006; Goldstein et al., 2008). We
found HDL-C raising variants in the CETP locus to be
associated with a higher risk of both deep and lobar
ICH, which relate to different vascular pathologies.
Specifically, deep ICH has been associated with hyperten-
sive SVD, whereas lobar ICH is typically related to cerebral
amyloid angiopathy (Martini et al., 2012). While specula-
tive, low serum LDL-C and high HDL-C levels may be
associated with a fragile vascular endothelium, eventually
leading to vessel permeability and a higher susceptibility to
rupture (Konishi et al., 1993).
The main analytical approaches used in the current
study, IVW and multivariable Mendelian randomization,
are sensitive to directional pleiotropy (Lawlor et al.,
2008; Burgess and Thompson, 2015). Specifically, if the
single nucleotide polymorphisms used as genetic instru-
ments for blood lipid levels associate with manifestations
of SVD through pathways independent of blood lipid
levels, the results could be biased. To ameliorate this risk,
we performed a series of sensitivity analyses, which are
based on statistical models that are more robust to plei-
otropy, are focused on a subset of genetic instruments
that are more specifically associated with the blood lipid
traits under study, or excluded outlier single nucleotide
polymorphisms with out of average effects on SVD mani-
festations, which are more likely to exert pleiotropic effects.
Importantly, our results for an association between genetic
determinants of HDL-C levels with risk of SVS and WMH
volume were robust across these sensitivity analyses, thus
supporting the results of the main analyses.
Our study has several strengths. The use of large genetic
datasets enabled us to explore associations with a range of
phenotypes, covering key manifestations of cerebral SVD.
Also, the use of GWAS data for NMR-derived measure-
ments enabled analyses stratified for lipoprotein particle
subfractions. We further performed multiple tests for the
detection of unbalanced pleiotropy and used multiple sen-
sitivity analyses including advanced approaches such as
GSMR-HEIDI. These analyses showed consistent results,
thus minimizing the possibility of bias in the Mendelian
randomization analyses. Finally, we explored the effects
of HDL-C raising or LDL-C lowering genetic variants in
genes encoding known lipid-modifying drug targets; this
approach has previously been validated with the
Mendelian randomization effects being comparable to
those derived from randomized controlled trials.
Our study also has limitations. First, Mendelian random-
ization examines the lifetime effect of genetic determinants
of blood lipid levels, which might differ from the effects of
clinical lipid-modifying interventions. Second, we were not
sufficiently powered to identify significant associations for
ICH, and especially for ICH subtypes. Similarly, the non-
significant, but still suggestive associations between LDL-C
levels and SVS risk should be tested in larger datasets offer-
ing greater statistical power. Third, we had no access to the
full summary statistics from the meta-analysis of the MVP
and the GLGC studies. Hence, some analyses were re-
stricted to the smaller GLGC dataset. Fourth, we are not
aware of any sufficiently powered GWAS on cerebral
microbleeds that would more accurately capture the spec-
trum of haemorrhagic SVD pathology than the currently
used phenotype of ICH. While SVD is an important
cause of ICH as a severe clinical manifestation, SVD
more frequently manifests with subclinical cerebral micro-
bleeds. Future GWAS on cerebral microbleeds will facilitate
Mendelian randomization analyses on the relationship with
Figure 6 Mendelian randomization associations of genetic
determinants of blood lipid levels (HDL-C, LDL-C, trigly-
cerides) with risk of intracerebral haemorrhage. Shown are
the results derived from random-effects inverse-variance weighted
(IVW) Mendelian randomization and multivariable Mendelian ran-
domization (MVMR) analyses. MVMR for cholesterol in HDL par-
ticles adjusted for LDL-C and triglycerides; for cholesterol in LDL
and larger particles adjusted for HDL-C and triglycerides; and for
triglycerides in any particles adjusted for HDL-C and LDL-C. TG =
triglycerides.
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blood lipids. Finally, we could not identify valid triglycer-
ide-lowering variants in the locus of the target for fibrates.
Hence, we could not explore their associations with SVD
phenotypes. Future studies leveraging even larger GWAS
datasets on blood lipid levels might identify genetic instru-
ments for the full range of lipid-modifying drug classes.
In conclusion, our results suggest causal associations be-
tween higher HDL-C levels and both a lower risk of SVS
and lower WMH volume, which were driven by cholesterol
concentrations in medium-sized, and not larger HDL par-
ticles. HDL-C raising strategies might be of benefit for the
prevention of ischaemic SVD. Considering the predicted
increase in risk of ICH, the net benefit of such an approach
would need to be tested in a randomized controlled trial.
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Summary of the findings 
In this thesis, I used large-scale genetic data to identify novel risk factors and drug targets 
for cerebrovascular disease. Applying Mendelian randomization, this thesis provides 
evidence that genetic predisposition to higher MCP-1 levels and to upregulated IL-6 
signaling are associated with higher risk of ischemic stroke and other cardiovascular 
phenotypes. These results for MCP-1 were further replicated in a meta-analysis of 
observational population-based cohort studies, where MCP-1 levels among stroke-free 
individuals were associated with a higher risk of incident ischemic stroke over a 16-year 
follow-up period. Interestingly, circulating MCP-1 and IL-6 levels were both associated 
with ischemic stroke risk, independently of each other, thus indicating that targeting the 
two pathways might offer complementary benefits in reducing stroke risk. These results 
highlight the potential of targeting inflammatory mechanisms for the treatment of 
atherosclerosis. 
By leveraging GWAS data I further examined the associations of genetic predisposition to 
well-established risk factors for stroke with manifestations of cerebral SVD. Specifically, 
genetic predisposition to high blood pressure was found to be associated with a higher 
risk of small vessel stroke, deep ICH, and the radiological phenotype of WMH volume. My 
collaborators and I further showed that genetically determined higher HDL cholesterol 
levels, and particularly cholesterol levels in medium-sized HDL particles, are associated 
with a lower risk of ischemic manifestations of cerebral SVD (small vessel stroke, WMH 
volume). By focusing on genetic variants in genes encoding drug targets, we were able to 
identify genetic proxies for the effects of common blood pressure-lowering and lipid-
modifying drugs drug classes. Interestingly, we found BP-lowering variants at loci for 
targets of calcium channel blockers and HDL-C-raising variants at loci for targets of CETP 
(cholesterol-ester transfer protein) inhibitors to be associated with significantly lower 
risk of small vessel stroke and lower WMH volume. These findings demonstrate that the 
use of genetics might offer a powerful approach for investigating the efficacy and 
repurposing potential of commonly used pharmacological agents for cerebral SVD. 
| 148 
 
Cytokines as drug targets for cerebrovascular disease 
Although inflammation has long been identified as a key contributor to atherosclerosis, it 
was only recetnly that the results of a large-scale clinical trial provided evidence for the 
efficacy of anti-inflammatory approaches for lowering vascular risk. Yet, the discrepancy 
in the results of the CANTOS trial testing a monoclonal antibody against IL-1β (Ridker et 
al., 2017; Aday and Ridker, 2019; Ridker, 2019; Ridker et al., 2019a) and CIRT (Ridker et 
al., 2019a), which tested low-dose methotrexate, highlight the importance of targeting 
specific inflammatory cytokines and pathways for lowering vascular risk (Ridker et al., 
2017; Aday and Ridker, 2019; Ridker, 2019; Ridker et al., 2019a). 
In the MR analyses, we systematically explored the associations between genetic 
predisposition to circulating levels of 41 cytokines with the risk of stroke, aiming to 
identify specific mediators with the highest potential to be tested as drug targets for 
lowering stroke risk. Across these cytokines, genetic predisposition to higher lifetime 
MCP-1 levels came up as showing the strongest association with the risk of stroke, and 
specifically large artery stroke. We then confirmed and extended these results in a meta-
analysis of 6 population-based cohort studies with long-term follow-up involving 17,180 
stroke-free individuals. Again, high MCP-1 levels in midlife were associated with a higher 
risk of incident ischemic stroke over follow-up independently of conventional vascular 
risk factors. The results were remarkably consistent between the two approaches: with 
MR the odds ratio for stroke was 1.06 per SD increment in genetically determined MCP-1 
levels, which is almost identical to the hazard ratio for incident stroke observed in the 
current meta-analysis of observational studies. 
Besides the evidence from genetic and observational studies provided in the current 
thesis, experimental studies in animal models of atherosclerosis further suggest MCP-1 as 
a key molecule in atherogenesis and atheroprogression. By binding to its receptor CCR2, 
MCP-1 is the prototypical CC family chemokine that is upregulated by chronic 
inflammatory conditions and attracts monocytes to the subendothelial space of the 
atherogenic arterial wall (Lin et al., 2014). Mice lacking MCP-1 (Gu et al., 1998; 
Combadiere et al., 2008) or CCR2 (Boring et al., 1998) are less susceptible to 
atherosclerosis and anti-MCP-1 gene therapy (Inoue et al., 2002), MCP-1 inhibitors 
(Grassia et al., 2009), MCP-1 competitors (Liehn et al., 2010), and CCR2 antagonists 
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(Yamashita et al., 2002; Okamoto et al., 2012; Bot et al., 2017; Winter et al., 2018) reduce 
plaque size and inhibit plaque progression and destabilization in experimental 
atherosclerosis. In contrast, overexpression of MCP-1 promotes oxidized lipid 
accumulation, macrophage infiltration, and smooth muscle cell proliferation, thus 
accelerating atherosclerosis (Aiello et al., 1999) .  
When viewed together with the existing experimental data (Boring et al., 1998; Gu et al., 
1998; Combadiere et al., 2008; Liehn et al., 2010; Bot et al., 2017), the data presented here 
from two different approaches in humans (MR and population-based cohort studies) 
provide triangulation of evidence regarding a role of MCP-1 as a causal risk factor for 
ischemic stroke. This thesis thus provides strong evidence for the candidacy of the MCP-
1/CCR2 as a target for lowering risk of ischemic stroke. The MCP-1/CCR2 pathway has to 
our knowledge only been targeted in a small phase II clinical trial in 108 patients with risk 
factors for atherosclerosis and elevated circulating CRP levels. MLN1202, a humanized 
monoclonal antibody against CCR2 reduced CRP levels after 4 and 12 weeks (Gilbert et al., 
2011). However, effects on clinical endpoints were not assessed (Gilbert et al., 2011) and 
would need to be determined in a larger trial.  
In addition to MCP-1, we identified variants at the locus of IL6R that could be used as 
proxies for genetically downregulated IL-6 signaling. Exploring the associations of these 
variants with ischemic stroke and its subtypes, we found significant reductions in the risk 
of large artery and small vessel stroke. The MR association between genetically 
downregulated IL-6 signaling and lower risk of large artery stroke extends previous 
clinical (Ridker et al., 2000; Kaptoge et al., 2014; Ridker et al., 2018a), genetic (Il R. 
Genetics Consortium Emerging Risk Factors Collaboration et al., 2012; Interleukin-6 
Receptor Mendelian Randomisation Analysis Consortium et al., 2012), and experimental 
(Ikeda et al., 1991; Huber et al., 1999) data demonstrating a key role of IL-6 signaling in 
atherosclerosis. Moreover, pharmacological inhibition of IL-6R has been shown to 
attenuate atherosclerotic lesions in an experimental model of atherosclerosis (Akita et al., 
2017). Our finding of an effect of genetic predisposition to downregulated IL-6 signaling 
on multiple atherosclerotic phenotypes (large artery stroke, coronary artery disease, 
myocardial infarction, aortic aneurysm, atrial fibrillation, carotid plaque) provides 
further support that IL-6 signaling is critically implicated in atherogenesis and 
atheroprogression and might represent a valid therapeutic target. 
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Notably, genetically downregulated IL-6 signaling was further associated with small 
vessel stroke. There is only limited evidence regarding a role of inflammation in general 
and of IL-6 signaling in particular in cerebral SVD (Low et al., 2019). In a small prospective 
study of 123 patients with manifestations of cerebral SVD, IL-6 circulating levels were 
associated with a higher risk of incident lacunes, a marker of SVD on brain magnetic 
resonance imaging (Staszewski et al., 2018). However, cross-sectional analyses from 
larger population-based studies showed inconsistent findings for lacunes, silent brain 
infarcts and other SVD manifestations (Hoshi et al., 2005; Fornage et al., 2008; Baune et 
al., 2009; Yoshida et al., 2009; Satizabal et al., 2012; Shoamanesh et al., 2015). While the 
specific mechanisms underlying our MR results remain unknown, our findings suggest 
that inhibition of IL-6 signaling aside from being a candidate treatment for atherosclerosis 
might also lower the risk of small vessel stroke. 
The CANTOS trial targeted IL-1β rather than IL-6R and thus provided only indirect 
evidence for a benefit of interfering with IL-6 signaling (Ridker et al., 2018a; Ridker, 
2019). Interestingly, the study further showed that part of the residual vascular risk after 
IL-1β inhibition could be explained by IL-6 levels, thus providing evidence that direct IL-
6 signaling inhibition might represent a more effective strategy (Ridker et al., 2019b). 
Also, CANTOS was based on a population of individuals with coronary artery disease and 
explored a combined vascular endpoint rather than offering information on individual 
cardiovascular outcomes. With respect to stroke, there was a 7% reduction in incident 
stroke events in the IL-1β arm, which however did not reach statistical significance, 
possibly because of insufficient power (Ridker et al., 2017). Our MR results provide 
evidence for directionally consistent effects of IL-6 signaling in multiple cardiovascular 
outcomes. Thus, our findings offer a solid basis for future clinical trials exploring the 
benefit of pharmacological IL-6R inhibition for the range of phenotypes examined here. 
Secondary analyses from the CANTOS trial showed that the reductions in vascular event 
rates after IL-1β inhibition were restricted to individuals with a substantial decrease in 
IL-6 or hsCRP levels (Ridker et al., 2018a; Ridker et al., 2018b). Intriguingly, the risk 
estimates for stroke by MCP-1 levels in our meta-analysis of observational studies 
remained stable after additional adjustments for the baseline levels of IL-6, hsCRP, and 
both IL-6 and hsCRP. This observation provides indirect evidence suggesting that 
elevated levels of MCP-1 might influence risk of stroke independently of the IL-1β/IL-
6/CRP axis. Thus, targeting the MCP-1/CCR2 pathway might serve as an alternative anti-
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inflammatory strategy with independent and complementary effects in reducing vascular 
event rates on top of current approaches. 
 
Identifying novel drug targets for cerebral small vessel disease 
Manifestations of cerebral SVD are highly prevalent in the ageing population with figures 
reaching up to 90% in patients aged 65 years and above (de Leeuw et al., 2001) and 
patients with these manifestations mark a population at increased risk for stroke, 
dementia and death (Debette et al., 2018; Georgakis et al., 2019). However, the risk factors 
for cerebral SVD remain elusive and to date there have been no informative trials 
exploring the efficacy of specific interventions for the prevention of outcomes related to 
SVD (Group et al., 2013; Croall et al., 2018; van Middelaar et al., 2018). With the MR studies 
presented here, I explored the associations of blood pressure and blood lipid levels, two 
major risk factors for large vessel disease, with manifestations of cerebral SVD. I further 
aimed to explore if genetic variants at loci of the targets of common antihypertensive and 
lipid-modifying drugs associate with the risk of cerebral SVD.  
As expected, we found genetic predisposition to higher blood pressure to associate with 
a higher risk of small vessel stroke, WMH volume, and deep ICH. Unlike deep ICH, lobar 
ICH is often related to cerebral amyloid angiopathy and the absence of an association 
signal between BP and lobar ICH is consistent with observational data (Jackson and 
Sudlow, 2006; Martini et al., 2012). Most interestingly, we also found a benefit of BP 
lowering through genetic proxies for CCBs over BBs for SVS and the related phenotype of 
WMH. In contrast, we found no disparity in effects between genetic proxies for CCBs and 
BBs for other stroke subtypes. This might suggest that CCBs may be particularly effective 
in preventing manifestations of cerebral SVD. The mechanisms underlying this 
observation are currently unknown, but might be related to the established influence of 
CCBs on BP variability (Rothwell et al., 2010; Webb et al., 2010; Yamaguchi et al., 2014).  
Our MR analyses for blood lipids further provide evidence for a protective role of HDL-C 
on ischemic SVD (small vessel stroke and WMH volume), which is in agreement with 
findings from small observational studies (Aljondi et al., 2018; Yin et al., 2018). The 
mechanisms underlying this observation may involve protective effects of HDL particles 
on the vascular endothelium (Sorrentino et al., 2010; Prosser et al., 2012; Tran-Dinh et al., 
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2013; Monette et al., 2016). Endothelial cells of the brain microvasculature (Lapergue et 
al., 2010; Fung et al., 2017), express receptors which upon HDL binding induce 
intracellular signaling eventually leading to vasodilatory (Yuhanna et al., 2001; Spieker et 
al., 2002; Nofer et al., 2004), anti-inflammatory (Cockerill et al., 1995; Nicholls et al., 2005; 
Murphy et al., 2008), anti-oxidative(Garner et al., 1998; Lee et al., 2005; Terasaka et al., 
2007), and anti-thrombotic effects (Viswambharan et al., 2004; Calkin et al., 2009). The 
observed effect was specific for cholesterol concentrations in medium-sized HDL 
particles, which agrees with the general notion that the favorable effects observed for HDL 
are predominantly exerted by the smaller and denser HDL particles (Yu et al., 2003; 
Williams, 2012; Martin et al., 2014). The elucidation of the mechanisms by which HDL-C 
and particularly medium-sized HDL particles influence the risk of cerebral SVD might 
offer novel insights into the mechanisms of cerebral SVD. 
HDL-C raising genetic variants in the CETP locus were also associated with lower SVS risk 
and WMH volume. Pharmacological CETP inhibition leads to an increase in the circulating 
pool of HDL particles (Armitage et al., 2019). While a number of randomized trials have 
investigated the efficacy of CETP inhibition on top of statins for reducing vascular risk 
(Barter et al., 2007; Schwartz et al., 2012; HPS3/TIMI55–REVEAL Collaborative Group et 
al., 2017; Lincoff et al., 2017), none of them explicitly reported effects on risk of small 
vessel stroke or other SVD manifestations. On the basis of our MR results, post hoc 
analyses should consider stratifying for stroke subtypes. In the REVEAL trial, the 
reduction in vascular risk by CETP inhibition was mediated by a reduction in LDL-C rather 
than an increase in HDL-C (HPS3/TIMI55–REVEAL Collaborative Group et al., 2017). Yet, 
our multivariable MR results suggest, that in contrast with the REVEAL trial, the effects of 
CETP variants on SVD manifestations might be primarily exerted by HDL-C raising and 
not LDL-C lowering. 
Our results suggest opposite effects of the blood lipid traits on risk of ischemic SVD 
phenotypes (small vessel stroke, WMH volume), as compared with ICH. This agrees with 
previous observational, genetic, and clinical studies that have found high HDL-C and low 
LDL-C levels to be associated with a higher risk of ICH (Amarenco et al., 2006; Goldstein 
et al., 2008; Wang et al., 2013; Anderson et al., 2016; Sun et al., 2019). Here, HDL-C raising 
variants in the CETP locus were also associated with a higher risk of both deep and lobar 
ICH. Thus, HDL-C raising strategies might decrease the risk for small vessel stroke and 
153 |  
 
WMH volume, but such effects should be counterbalanced to potential increases in the 
risk of ICH.  
Collectively, with the MR analyses presented in the current thesis, I provide evidence that 
BP-lowering and HDL-raising approaches might be effective strategies for decreasing the 
risk of ischemic SVD manifestations. More specifically, our findings support that BP-
lowering through calcium channel blockade and HDL-C-raising through CETP inhibition 
might be promising approaches in preventing ischemic manifestations of cerebral SVD, 
worth exploring in future clinical trials. 
 
Methodological considerations 
The validity of MR analyses is based on specific assumptions. First, the variants used as 
instruments need to represent valid genetic determinants of the risk factor under study 
and be strongly associated with it. In our MR for cytokine levels, instrument selection was 
based on a single discovery GWAS that adjusted for BMI. While the associations remained 
consistent when using unweighted allele scores, it cannot be excluded that the BMI 
adjustment led to collider bias during instrument selection. The genetic instruments used 
in all other MR analyses were selected from GWAS meta-analyses including both 
discovery and replication samples. In all occasions, we were very strict with our statistical 
significance thresholds for instrument selection to preclude both selection of invalid 
instruments and introduction of weak instrument bias. Second, the genetic variants used 
as instruments must exert any of their effects on the clinical outcomes only through the 
risk factors under study and not through alternative pathways. The use of horizontally 
pleiotropic variants may violate this assumption. To decrease the possibility of pleiotropy 
we either (1) focused our analyses on variants in specific loci closely related to the risk 
factor under study (e.g. IL6R for IL-6 signaling or genes encoding the drug targets when 
studying drug effects), or (2) performed sensitivity analyses that control for this type of 
bias (e.g. MR-Egger, weighted median approach, MR-PRESSO). Yet, for MCP-1, it was not 
possible to identify genetic variants located in the vicinity of the CCL2 gene thus 
precluding analyses restricted to SNPs within this locus. Consequently, while no statistical 
evidence for pleiotropy was found, nonspecific effects of the MCP-1 trans-acting 
instruments cannot be entirely excluded.  
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MR analyses exploring drug effects estimate the cumulative effects of lifelong exposure to 
genetic variants, which might differ from those of a clinical intervention. Still, the 
estimates of the associations between the identified genetic instruments for 
antihypertensive drug classes and vascular endpoints were comparable to those from 
clinical trials. Similarly, using CRP levels as a proxy for downstream IL-6 signaling enabled 
the scaling of the respective association estimates to the effects of tocilizumab, as 
determined from previous trials, thus providing clinically meaningful estimates. Indeed, 
when exploring the effects of the selected proxies on upstream regulators (IL-6 and 
soluble IL-6R) and downstream effectors (fibrinogen) of IL-6 signaling for validation, we 
found consistent estimates with the effects observed with pharmacological inhibition of 
IL-6R.  
With regards to the meta-analysis of observational studies, the different assays used by 
individual studies to quantify circulating MCP-1 levels and the different sample sources 
(plasma vs. serum) resulted in substantial variations in MCP-1 levels. Although our 
analyses standardized MCP-1 levels across studies, it was not possible to explore 
associations between absolute MCP-1 values and risk of stroke. Finally, I should note that 
most of the datasets analysed in the current thesis were based on individuals of primarily 
European origin, and might thus not apply to other ethnic groups. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
Cerebrovascular disease remains a major cause of mortality and disability worldwide. In 
the context of lack of specific neuroprotective treatments, current efforts are focused on 
prevention of its clinical consequences. This requires a deep understanding of underlying 
pathophysiological mechanisms and the identification of modifiable risk factors that 
could be targeted in the context of preventive strategies. However, the etiological 
heterogeneity of cerebrovascular disease and the inherent limitations of observational 
studies to explore its causes hamper progress regarding identification of risk factors and 
drug targets. With this thesis I aimed to address this issue by using large-scale genetic 
data and the approach of Mendelian randomization that enables exploration of causal 
inference in a more robust framework.  
I provide support for a key role of inflammatory mechanisms in ischemic stroke and for 
the potential of anti-inflamatory approaches for lowering ischemic stroke risk. Based on 
genetic studies and population-based cohorts, our findings suggest circulating MCP-1 
levels as a novel risk factor for ischemic stroke. Similarly, I provide evidence for a key role 
of IL-6 signaling in ischemic stroke and other cardiovascular phenotypes. These results 
extend and corroborate previous experimental and clinical evidence supporting the MCP-
1 and IL-6 signaling pathways to play a causal role in the progression of atherosclerosis 
and the pathogenesis of stroke. Future clinical trials should explore whether taregting 
MCP-1 or IL-6R signaling could represent valid therapeutic targets for lowering ischemic 
stroke risk. 
I further explored in large-scale genetic data how blood pressure and blood lipid levels 
associate with manifestations of cerebral SVD. I provide evidence for causal associations 
of genetically determined higher BP with all major manifestations of cerebral SVD (small 
vessel stroke, WMH, deep ICH), except for lobar ICH. Our findings further support that 
genetically determined lower HDL-C levels are associated with higher risk of small vessel 
stroke and higher WMH volume. Genetic proxies for calcium channel blockers and CETP 
inhibitors showed strong associations with small vessel stroke and WMH. Thus, calcium 
channel blockade and CETP inhibition might comprise promising strategy for the 
prevention of ischemic manifestations of cerebral SVD and its clinical sequalae and would 
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Analysis of the UK Biobank data 
We used the June 2017 release of the imputed genetic data from UK Biobank (downloaded on 
July 13, 2017). Details on the design of the arrays, sample processing and quality control have 
been previously described (1). In brief, two closely related arrays from Affymetrix, the UK 
BiLEVE Axiom array (9.9% of individuals) and the UK Biobank Axiom array were used to 
genotype approximately 805,426 markers with good genome-wide coverage. Phasing was 
performed using SHAPEIT3 and imputation to a merged HRC reference panel (39,131,578 
autosomal SNPs) and UK10K & 1000 Genomes Phase 3 panel was carried out using the 
IMPUTE4 package. Imputed genotypes were available for 488,369 individuals (1). From the 
resulting dataset, we excluded individuals of self-reported ancestry other than White-British, 
related individuals (pi-hat >0.1875), individuals with high levels heterozygosity and missingness 
(>5%), and individuals whose reported sex was inconsistent with sex inferred from the genetic 
data. In addition, only SNPs imputed from the HRC panel were included in this analysis. Stroke in 
UK Biobank was based on self-reported medical history, and linkage to hospitalization and 
mortality data. We used the stroke variables provided by UK Biobank that have been created using 
algorithmic definitions. Details of the stroke algorithm have been described previously and are 
available on the UK Biobank website (“Definitions of stroke and main stroke pathological types 
for UK Biobank phase 1 outcomes adjudication”, Version 1, http://www.ukbiobank.ac.uk). 
Individuals with stroke based on self-report only were excluded from the analysis. 
 
Search strategy for meta-analysis 
Medline was searched via PubMed using the following combination of search terms: 
 (CCL2 OR MCP1 OR CCL-2 OR MCP-1 OR “monocyte chemoattractant protein 1” OR “small 
inducible cytokine A2” OR “chemokine (C-C motif) ligand 2” OR “C-C motif ligand 2”) AND 
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(stroke OR cerebrovascular OR (coronary AND artery AND disease) OR (ischemic AND heart 
AND disease) OR (myocardial AND infarction)) 
 
1. Bycroft C, Freeman C, Petkova D, et al. Genome-wide genetic data on ~500,000 UK Biobank 




Supplemental Table 1. Descriptive characteristics of the genome-wide association studies (GWAS) that were included in the Mendelian randomization study.  
GWAS Phenotype Sample size Ancestry Adjustments a Use in this MR study URL for data download 
FINRISK/ CRYFS 
Circulating levels of 41 
cytokines and growth factors 
8,293 
individuals 
Finnish age, sex, BMI 
Exposure variable in all 





Any stroke, any ischemic stroke 










Woo et al, 2014 ICH 
1,545 cases/ 
1,481 controls 
European age, sex 











Primary outcome in 
validation analysis 
http://www.ukbiobank.ac.uk/  






European age, sex 














(search for variants of interest) 



















UK Biobank  
(Neale lab analysis) 








a All GWAS studies have further adjusted for principal components. 
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GWAS names: AGFen, Atrial Fibrillation Genetics; CARDIoGRAMplusC4D, Coronary ARtery DIsease Genome-wide Replication and Meta-analysis (CARDIoGRAM) 
plus The Coronary Artery Disease (C4D) Genetics; CRYFS, Cardiovascular Risk in Young Finns Study; GLGC, global lipids genetics consortium; DIAGRAM, DIAbetes 
Genetics Replication And Meta-analysis. 
Phenotypes: AF, atrial fibrillation; CAD, coronary artery disease; CES, cardioembolic stroke; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; 
ICH, intracerebral hemorrhage; LAS, large artery stroke; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; SBP, systolic blood pressure; SVS, small 
vessel stroke; T2D, type 2 diabetes; TGL, triglycerides
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Supplemental Table 2. Cytokines and growth factors examined by the original GWAS study and 
number of genetic instruments (SNPs) identified from our approach.  













































Supplemental Table 3. Characteristics of the genetic instruments selected for the circulating levels of 
cytokines and growth factors. Variance explained by the selected instruments, power of the 
instruments assessed by the F-statistic and power calculations for the Mendelian randomization study 






























BNGF 1 0.012 37 1.107 1.112 1.318 1.275 1.242 2.477 
CTACK 14 0.161 27 [24-142] 1.029 1.031 1.087 1.075 1.066 1.288 
Eotaxin 22 0.112 28 [22-94] 1.037 1.035 1.104 1.089 1.079 1.354 
GRO-a 10 0.162 28 [22-183] 1.029 1.031 1.086 1.074 1.066 1.287 
HGF 2 0.017 49 [41-58] 1.090 1.094 1.268 1.229 1.204 2.155 
IL-2ra 5 0.143 41 [24-168] 1.031 1.033 1.093 1.079 1.070 1.308 
IL-5 1 0.012 38 1.107 1.112 1.318 1.275 1.242 2.477 
IL-10 3 0.012 26 [25-37] 1.107 1.112 1.318 1.275 1.242 2.477 
IL-12p70 7 0.025 25 [23-35] 1.074 1.077 1.220 1.190 1.168 1.890 
IL-16 5 0.123 30 [25-131] 1.034 1.035 1.099 1.085 1.076 1.336 
IL-17 1 0.006 39 1.153 1.160 1.450 1.390 1.346 3.508 
IL-18 26 0.352 25 [21-96] 1.020 1.021 1.059 1.051 1.045 1.187 
IP-10 4 0.036 27 [26-31] 1.062 1.065 1.185 1.158 1.140 1.703 
MCP-1 38 0.147 25 [21-92] 1.031 1.031 1.091 1.078 1.069 1.303 
MIF 1 0.012 39 1.107 1.112 1.318 1.275 1.242 2.477 
MIG 8 0.077 27 [24-42] 1.042 1.044 1.126 1.108 1.095 1.441 
MIP-1b 237 1.000c 25 [17-789] 1.012 1.013 1.035 1.030 1.027 1.107 
PDGF-bb 25 0.118 29 [23-102] 1.034 1.036 1.101 1.087 1.077 1.344 
SCF 4 0.023 31 [27-48] 1.077 1.081 1.230 1.197 1.175 1.940 
SCGF-b 11 0.174 35 [24-98] 1.028 1.030 1.083 1.072 1.064 1.276 
TNF-b 4 0.174 108 [35-123] 1.028 1.030 1.083 1.072 1.064 1.276 
TRAIL 41 0.454 35 [21-370] 1.018 1.018 1.052 1.045 1.040 1.163 
VEGF 19 0.094 25 [21-63] 1.038 1.040 1.113 1.098 1.086 1.392 
Shown are the Odds Ratios per 1 SD increase in circulating levels of the cytokine/growth factor, for which there is power (β) 
≥80% to detect an existed association at a type I error of α <0.05. 
a 𝑅2 = (𝑏𝑒𝑡𝑎 𝑥 √2 𝑥 𝑀𝐴𝐹(1 − 𝑀𝐴𝐹))2, where MAF is the minimum allele frequency and beta is the effect of the SNP on 
the respective cytokine levels (Park et al 2010, Nat. Genet. 42, 570–575). Total variance was calculated in an additive model 
assuming no interaction between the individual SNPs.  
b F = beta² / SE², where beta is the effect estimate of the SNP and SE its standard error on the respective cytokine levels (Li 
& Martin 2002, Comput Stat Data Anal, 40, 21-26). 




Supplemental Table 4. SNPs that were used as instruments for the circulating levels of MCP-1. 







Betaa SE p-value 
rs56212190 HIVEP3 1 42168539 c t 0.95 -0.181 0.0373 9.85E-07 
rs145155829 KDM4A 1 44165646 c t 0.96 0.2153 0.0463 3.72E-06 
rs10888395 CTSK 1 150762171 c t 0.63 0.0814 0.0163 5.98E-07 
rs7519506 MNDA 1 158859138 c t 0.68 0.0987 0.0191 2.44E-07 
rs12727764 IFI16 1 158982477 g t 0.83 -0.0971 0.0213 5.02E-06 
rs2281300 CADM3 1 159156285 c t 0.77 0.0889 0.017 1.71E-07 
rs115936758 LOC100131825 1 159170343 c t 0.94 0.1775 0.0349 5.74E-07 
rs35333710 CADM3 1 159172854 g a 0.9 -0.1476 0.0268 3.71E-08 
rs12047264 APCS 1 159535626 g a 0.19 0.0929 0.0191 1.87E-06 
rs7527322 APCS 1 159579533 g a 0.79 0.0805 0.0171 1.54E-06 
rs12073356 LOC148696 1 208007848 g a 0.93 0.1426 0.0311 4.17E-06 
rs111995966 LIMS1 2 109174969 g t 0.03 -0.1452 0.031 2.53E-06 
rs11926788 SEC22C 3 42623498 g c 0.04 0.1887 0.0363 2.06E-07 
rs56300632 NKTR 3 42685911 g a 0.4 -0.0772 0.0165 3.04E-06 
rs4682860 CCBP2 3 42863804 g a 0.61 -0.0811 0.0157 2.31E-07 
rs116425179 LARS2 3 45598703 g a 0.07 0.1476 0.0255 5.68E-09 
rs75265958 SACM1L 3 45758020 g t 0.05 -0.1231 0.0271 5.16E-06 
rs1386930 LZTFL1 3 45884003 c t 0.54 -0.0903 0.0157 7.86E-09 
rs75826707 CCR9 3 45908859 g a 0.97 -0.1676 0.0369 5.51E-06 
rs3774641 CCR9 3 45937833 g t 0.81 -0.1324 0.0191 5.04E-12 
rs2036297 CCR1 3 46172903 g a 0.63 -0.119 0.016 1.09E-13 
rs41338844 CCR3 3 46272951 g a 0.98 -0.2195 0.0462 3.22E-06 
rs138591554 CCR3 3 46289206 t a 0.1 0.3171 0.0331 7.94E-22 
rs112313229 CCR2 3 46364860 g a 0.96 0.1646 0.0313 1.43E-07 
rs62242985 CCR2 3 46385638 g a 0.4 0.1013 0.0164 5.54E-10 
rs35060576 CCRL2 3 46434525 g a 0.58 -0.0955 0.0162 3.79E-09 
rs11720094 LRRC2 3 46559911 g c 0.53 0.1058 0.0157 1.54E-11 
rs141676607 LOC100132146 3 46653244 c t 0.98 -0.3128 0.064 9.48E-07 
rs142043796 LOC100132146 3 46679831 g c 0.98 0.2414 0.0487 8.30E-07 
rs34190208 ALS2CL 3 46736217 c t 0.75 -0.1076 0.022 9.91E-07 
rs78629618 PRSS42 3 46880130 c t 0.12 -0.1188 0.0259 4.23E-06 
rs11710798 PFKFB4 3 48570686 c a 0.11 -0.0924 0.0197 2.87E-06 
rs2712431 RPN1 3 128316890 c a 0.32 0.0787 0.0172 4.76E-06 
rs7019112 FLJ35282 9 23028336 g t 0.21 0.2126 0.0471 7.12E-06 
rs10744620 EFCAB4B 12 3739094 c t 0.62 -0.0788 0.0161 9.91E-07 
rs10145849 SEL1L 14 82941991 g a 0.6 0.0755 0.0162 3.41E-06 
rs7197349 WWOX 16 78687219 g a 0.13 -0.0968 0.0206 2.62E-06 
rs146522229 C5AR1 19 47798480 c t 0.98 0.5976 0.1177 3.56E-07 
rs191688264 SF3A1 22 30745361 c a 0.99 0.4834 0.0991 1.10E-06 
a Beta refers to 1 standard deviation increase in circulating MCP-1 levels.  




Supplemental Table 5. Characteristics of the observational case-control studies that were included in the meta-analysis of circulating MCP-1 levels and 
risk of stroke.  
Study Place  
(study period) 






















Losy et al, 
2001 
Poznan, Poland First-ever ischemic 
stroke 
Individuals with tension 
headache 
23 15 ELISA 269 72.2 NR 17 52 NR NR Age, gender 
Sánchez-
Moreno et al, 
2004 
Boston, USA Ischemic stroke Outpatients without 
neurological disorders 





Ischemic stroke Individuals without 
history of stroke and 
myocardial infarction 
40 40 ELISA 312 59.8 70 4 25 NR NR - 
Zaremba et 
al, 2006 




27 20 ELISA 182 65.5 40 15 34 NR NR Age, gender 




Ischemic stroke and 
diabetes 
Healthy controls 90 45 ELISA  185 
 





First-time or recurrent 
ischemic stroke 
Individuals with normal 
MRI 
100 90 Multiplex 
assay 
139 66.1 52 29 50 NR 38 Age  





Ischemic stroke Individuals without 
cerebrovascular or 
cardiovascular disease 
58 32 ELISA 226 71.6 51 11 63 25.7 46 - 
Khurana et 
al, 2013 
Chandigarh, India Ischemic stroke with 
carotid plaque 
Individuals without 
stroke or carotid plaque 
57 15 ELISA  4.25 59.3 50 29 73 NR 5 - 
Gao et al, 
2014  
Meta-analysis of 
8 Asian studies 
Ischemic stroke Health controls 716 425 ELISA NR 62.6 59 NR NR NR NR - 





Cardioembolic stroke Individuals without 
cardiovascular disease 
11 11 ELISA 165 69.5 
 
82 NR NR 26.3 18 Age, gender 






Supplemental Table 6. Characteristics of the observational cohort studies that were included in the meta-analysis of circulating MCP-1 levels and risk of 
stroke.  
Study Place  
(study period) 
























Haim et al, 
2005 (BIP) 
Israel  Patients with 
myocardial 
infarction in the 
last 5 years (part 




6.2 466 123 ELISA 319 61.1 94 11.5 34.5 26.7 NR age, sex, smoking, circulating 
lipoprotein concentrations at 
baseline, diabetes mellitus, 
hypertension, and history of 
myocardial infarction, 
fibrinogen, soluble ICAM-1 
Canoui-














10 285 95 Multiplex 
bioassay 
82 55.5 100 4.9 47.7 26.7 NR age, sex, hypertension, 
smoking, diabetes, body mass 
index, high-density lipoprotein 
and total cholesterol, 
triglycerides, high sensitivity 
C-reactive protein, and 
fibrinogen 







stroke in the 
previous 6-12 






5 2176 482 ELISA 116 62.9 61.4 17.2 62.5 27.4 NR age, sex, race, treatment group, 
entry event (stroke or transient 
ischemic attack), time since 
entry event, geographic region, 
smoking, diabetes, systolic 
blood pressure, hypertension 
treatment, high-density 
lipoprotein cholesterol, and 
apolipoprotein A1 





Supplemental Figure 1. Forest plots of SNP-specific Mendelian randomization 
associations between circulating MCP-1 levels with the odds of (A) any stroke, (B) any 
ischemic stroke, (C) large artery stroke, (D) cardioembolic stroke, (E) small-vessel stroke, 
and (F) intracerebral hemorrhage. The results are expressed as Odds Ratios (OR) with their 
95% Confidence Intervals (95%CI) for the effect of 1 SD increase in circulating MCP-1 
levels and are based on the MEGASTROKE data. 
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Supplemental Figure 2. Mendelian randomization associations of the circulating levels of cytokines 
and growth factors in with any stroke and stroke subtypes restricted to individuals of European 
ancestry in the MEGASTROKE data. The results are derived from the fixed-effects inverse-variance 























* Significant heterogeneity (I2>25% or  
Cochran Q-derived p <0.05) 
† Bonferroni-corrected threshold for number of cytokines 





























































































Any stroke                        
Any ischemic stroke              
 
         
Large artery stroke                        
Cardioembolic stroke                       
 
Small vessel stroke                        
Intracerebral hemorrhage                        
SNPs (N) 1 14 22 10 2 5 1 3 7 5 1 26 4 38 1 8 237 25 4 11 4 41 19 
Higher levels decrease riskHigher levels increase risk
*Significant heterogeneity (I2>25% or Cochran Q-derived p <0.05)
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Supplemental Figure 3. Mendelian randomization associations of the circulating levels of 
cytokines and growth factors with any stroke and stroke subtypes, using a GWAS threshold of 
p <5 x 10-8 for the selection of genetic instruments in the MEGASTROKE data. The results are 

























* Significant heterogeneity (I2>25% or Cochran Q-derived p <0.05) 
† Bonferroni-corrected threshold for number of cytokines 





























































































Any stroke                        
Any ischemic stroke              * 
         
Large artery stroke                        
Cardioembolic stroke                       
 
Small vessel stroke                        
Intracerebral hemorrhage                        
SNPs (N) 1 6 10 4 2 3 1 0 0 1 0 10 2 9 1 1 83 10 2 8 4 23 4 
Higher levels decrease riskHigher levels increase risk
*Significant heterogeneity (I2>25% or Cochran Q-derived p <0.05)
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Supplemental Figure 4. (A) Protein-protein interactions between MCP-1 and proteins encoded 
by genes in the vicinity of the genetic instruments for MCP-1. (B) Results from the Mendelian 
randomization analysis restricted to the respective genetic instruments at CCR1, CCR2, CCR3, 





The protein-protein interaction network has been produced by the STRING database. The Mendelian 
randomization has been conducted within the MEGASTROKE database and has been based on the fixed-effects 

















  1.271 3.69
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Supplemental Figure 5. Forest plots of SNP-specific Mendelian randomization 
associations between circulating MCP-1 levels with the odds of (A) any stroke, and (B) 
any ischemic stroke in the UK Biobank. The results are expressed as Odds Ratios (OR) 






















































































































































































































































Supplemental Figure 6. Flowchart of the study selection process in the meta-analysis of MCP-



























Records identified through databases  

























Records identified through reference 







Full-text articles assessed 
for eligibility 
(n = 116) 
Records screened  
(n = 1211) 
Records excluded 
(n = 1095) 
Full-text articles excluded, with reasons 
(n = 96) 
 
No assessment of stroke risk (n=78) 
Specific populations (n=9) 
No quantification of the association (n=4) 
Quantification of stroke only together 
with other outcomes (n=5) 
Case-control studies 
(n = 17) 
Articles meeting eligibility 
criteria 
(n = 20) 
Prospective cohort studies 
(n = 3) 
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Supplemental Figure 7. Forest plots of the meta-analyses of circulating MCP-1 levels (1 SD 
increase) and risk of any ischemic stroke, as derived from published observational studies. (A) 








































































Ganz et al 2017 (SPARCL)
Haim et al 2005 (BIP)
Subtotal  (I-squared = 31.6%, p = 0.227)
Incident ischemic stroke
Canoui-Poitrine et al 2011 (PRIME)



































Georgakis et al. Circulating monocyte chemoattractant protein-1 and risk of stroke: a meta-analysis of 
population-based studies involving 17,180 individuals. 
 
Appendix I. Search strategy. 
Online Table I. Summary of the study design, population characteristics, methods used for quantifying 
circulating MCP-1 levels, stroke outcome definitions, and assessments in the cohorts included in the 
meta-analysis. 
Online Table II. Quality characteristics of the included studies according to the Newcastle-Ottawa Scale. 
Online Table III. Associations between baseline circulating MCP-1 levels and risk of any stroke. Shown 
are the results from random-effects meta-analyses across the different models in the pooled sample 
consisting of six population-based studies. 
Online Table IV. Associations between baseline circulating MCP-1 levels and risk of ischemic stroke. 
Shown are the results from random-effects meta-analyses across the different models in the pooled 
sample consisting of six population-based studies. 
Online Table V. Associations between baseline circulating MCP-1 levels and risk of hemorrhagic stroke. 
Shown are the results from random-effects meta-analyses across the different models in the pooled 
sample consisting of six population-based studies. 
Online Table VI. Meta-regression analyses for the effect of different study characteristics on the 
association between ln-transformed MCP-1 circulating levels at baseline (1 SD increment) with any 
stroke and etiological stroke subtypes (ischemic and hemorrhagic stroke).   
Online Table VII. Associations between baseline circulating hsCRP, IL-6, and MCP-1 levels and risk of 
any stroke, ischemic stroke, and hemorrhagic stroke. Shown are the results from random-effects meta-
analyses of the pooled sample consisting of four population-based studies, where both hsCRP and IL-6 
levels were available. 
Online Figure I. Flowchart of the study selection for the systematic review. 
Online Figure II. Study-specific and pooled hazard ratios for incident any stroke per standard deviation 
increase in ln-transformed circulating MCP-1 levels and across MCP-1 level quartiles. Shown are the 
results from random-effects meta-analyses.  
Online Figure III. Study-specific and pooled hazard ratios for incident ischemic stroke per standard 
deviation increase in ln-transformed circulating MCP-1 levels and across MCP-1 level quartiles. Shown 
are the results from random-effects meta-analyses (Model 2).  
Online Figure IV. Study-specific and pooled hazard ratios for incident hemorrhagic stroke per standard 
deviation increase in ln-transformed circulating MCP-1 levels and across MCP-1 level quartiles. Shown 
are the results from random-effects meta-analyses (Model 2).  
Online Figure V. Pooled hazard ratios for incident fatal and non-fatal stroke per circulating MCP-1 
levels, as derived from random-effects meta-analyses (Model 2). 
Online Figure VI. Pooled hazard ratios for incident any stroke per standard deviation increase in ln-
transformed circulating MCP-1 levels and across MCP-1 level quartiles in sensitivity analyses omitting 
one study per time. Shown are the results from random-effects meta-analyses.  
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Online Figure VII. Pooled hazard ratios for incident ischemic stroke per standard deviation increase in 
ln-transformed circulating MCP-1 levels and across MCP-1 level quartiles in sensitivity analyses omitting 
one study per time. Shown are the results from random-effects meta-analyses.  
Online Figure VIII. Pooled hazard ratios for incident hemorrhagic stroke per standard deviation increase 
in ln-transformed circulating MCP-1 levels and across MCP-1 level quartiles in sensitivity analyses 
omitting one study per time. Shown are the results from random-effects meta-analyses.  
Online Figure IX. Pooled hazard ratios for incident ischemic stroke per standard deviation increase in ln-
transformed circulating MCP-1 levels, as derived from random-effects meta-analyses stratified by pre-
defined study variables. 
Online References.  
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Appendix I. Search strategy. 
(CCL2 OR MCP1 OR CCL-2 OR MCP-1 OR “monocyte chemoattractant protein 1” OR “small inducible 
cytokine A2” OR “chemokine (C-C motif) ligand 2” OR “C-C motif ligand 2”) AND (stroke OR 
cerebrovascular OR (coronary AND artery AND disease) OR (ischemic AND heart AND disease) OR 
(myocardial AND infarction)) 




Online Table I. Summary of the study design, population characteristics, methods used for quantifying circulating MCP-1 levels, stroke outcome definitions, and 
assessments in the cohorts included in the meta-analysis. 
Cohort Study design Population characteristics MCP-1 quantification Definition-assessment of stroke 
Atherosclerosis Risk in 
Communities (ARIC) 
A sub-sample of the population-based 
prospective ARIC cohort study with 
available measurements on MCP-11  
 
Inhabitants of 4 US communities 
(Forsyth County, North Carolina; 
Jackson, Mississippi; the 
northwestern suburbs of 
Minneapolis, Minnesota; and 
Washington County, Maryland) 
aged 45-64 years 
Duplicate measurements using direct 
sandwich ELISA (Amersham 
Pharmacia Biotech Inc., Piscataway, 
NJ, USA) in fasting plasma samples 
(stored at -70 °C) 
Non-fatal and fatal stroke were defined through linkage with the 
hospital records for possible stroke‐related hospitalizations 
(International Classification of Diseases, Ninth Revision [ICD‐9] 
codes 430–438 until 1997 and codes 430–436 afterwards) and the 
National Death Index for stroke deaths; physician reviewers 
adjudicated all possible strokes and classified them as definite or 
probable ischemic and hemorrhagic events2 
Dallas Heart Study (DHS) 
A sub-sample of a population-based 
prospective cohort study designed to study 
cardiovascular disease with available 
measurements on MCP-13 
Multi-ethnic stratified random 
sample of Dallas County, US, 
residents aged 30-65 years 
Duplicate measurements using 
immunoassay (BIOSITE Inc., San 
Diego, CA) on a high-throughput 
robotic platform (TECAN Genesis 
RSP 200/8) in fasting plasma samples 
(stored at -80 °C) 
Non-fatal stroke was defined by either assessment of medical 
records during annual follow-up assessments or by tracking 
hospital admissions through the Dallas–Fort Worth Hospital 
Council Data Initiative database (coverage 90% of the study 
region) using the ICD 9 codes 430-438; fatal stroke was defined by 
death certification using the National Death Index according to the 
ICD 10 codes I60-I694  
European Prospective 
Investigation of Cancer (EPIC) - 
Norfolk study 
Secondary analysis of a nested case-
control study within the prospective 
population-based EPIC-Norfolk cohort of 
cases with coronary artery disease and 
healthy controls5 
Inhabitants of Norfolk, UK, aged 
45-79 years who were free of stroke 
and myocardial infarction at 
baseline 
Multiplex assay using the Bioplex 
Suspension Array (Bio-Rad, 
Veenendaal, the Netherlands) in non-
fasting serum samples (stored at -80 
°C) 
Non-fatal stroke was defined by hospital admission record linkage 
with the NHS hospital information system and ENCORE (East 
Norfolk COmmission Record; fatal stroke was defined by death 
certification derived from the Office of National Statistics, and was 
defined according to the ICD 9 codes 430-438, or the ICD 10 
codes I60-I696  
Framingham Heart Study (FHS) - 
Offspring Cohort 
Participants of the community-based 
prospective cohort FHS study who 
attended the examination cycle 7 (1998-
2001)7 
Offspring of the participants of the 
Original Cohort of the FHS and 
their spouses aged 33-90 years 
Duplicate measurements using a 
commercially available ELISA (R&D 
Systems) in fasting serum samples 
(stored at -70 °C)8 
Stroke was defined as rapidly developing signs of focal neurologic 
disturbance of presumed vascular etiology lasting more than 24 
hours as part of an ongoing clinic and hospital surveillance 
including medical record review; laboratory testing; imaging; 
autopsy findings; and collaboration with general practitioners, 
emergency departments, and imaging facilities in the area9 
Monitoring of Trends and 
Determinants in Cardiovascular 
Disease sub-cohort of the 
Cooperative Health Research in 
the Region of Augsburg 
(MONICA/ KORA) 
Secondary analysis of a case-cohort study 
within the prospective population-based 
MONICA/KORA cohort of incident cases 
with coronary artery disease and a 
representative sub-cohort of 
MONICA/KORA sample10 
Inhabitants of Augsburg and 
surrounding counties, Germany, 
aged 25-74 years  
Luminex multiplex technology using 
a Luminex 100 analyzer (Luminex 
Corporation, Austin, TX, recombinant 
proteins and antibodies purchased 
from R&D systems) in non-fasting 
serum samples (stored at -80 °C) 
Non-fatal stroke was defined by self-report validated by cross-
linkage with hospital records and information gathered from the 
treating physicians of the participants; fatal stroke was defined by 
death certification derived from local health authorities and was 
defined according to the ICD 9 codes 430-434 (German modified 
version)11  
Malmö Diet and Cancer Study 
(MDCS) - Cardiovascular (CV) 
sub-cohort  
A random 50% sub-sample of the 
population-based prospective cohort 
MDCS study were included in the MDCS-
CV sub-cohort designed to examine 
cardiovascular disease12 
Inhabitants of Malmö, Sweden, 
aged 45-64 years  
Proximity Extension Assay technique 
using the Proseek Multiplex 
CVD96x96 reagents kit (Olink 
Bioscience) in fasting plasma samples 
(stored at -80 °C) 
Non-fatal and fatal stroke were defined by record linkage with the 
National Inpatient Register, the Swedish Causes of Death Register, 
and the Stroke Register of Malmö (STROMA) and was defined 





Online Table II. Quality characteristics of the included studies according to the Newcastle-Ottawa Scale. 






Selection items       
Representativeness of exposed cohort (general population study) * * * * * * 
Selection of the non-exposed cohort (patients selected independently of MCP-1 levels) * * * * * * 
Ascertainment of exposure (serum/plasma MCP-1 levels assessed with validated assay) * * * * * * 
Outcome not present a start of study (exclusion of prevalent stroke cases from analysis) * * * * * * 
Comparability items       
Adjustments on age, sex, race * * * * * * 
Adjustments on vascular risk factors * * * * * * 
Outcome items       
Assessment of outcome (assessment through medical records, hospital admission records, 
and death certificates) 
* * * * * * 
Length of follow-up (>5 years) * * * * * * 
Adequacy of follow-up cohorts (<10% lost to follow-up rates) * * * * * * 




Online Table III. Associations between baseline circulating MCP-1 levels and risk of any stroke. Shown are the results from random-effects meta-analyses across the 
different models in the pooled sample consisting of six population-based studies. 
  Model 1    Model 2    
Alternative 
Model 2 
   Model 3  
Variables in the models HR 95%CI p  HR 95%CI p  HR 95%CI p  HR 95%CI p 
Age (1-yr increment) 1.09 (1.07-1.12) 7E-13  1.08 (1.05-1.11) 7E-8  1.07 (1.04-1.11) 2E-6  1.08 (1.05-1.11) 2E-7 
Sex (males vs. females) 1.26 (0.98-1.62) 0.067  1.21 (1.00-1.48) 0.056  1.13 (0.93-1.36) 0.214  1.22 (1.00-1.48) 0.051 
Hypertension (yes vs. no)     1.80 (1.58-2.04) 2E-19      1.78 (1.57-2.03) 1E-20 
SBP (10 mmHg-increment)         1.16 (1.12-1.19) 3E-18     
Intake of antihypertensive medication         1.47 (1.29-1.67) 5E-9     
Diabetes (yes vs. no)     1.739 (1.27-2.38) 0.001      1.79 (1.26-2.53) 0.001 
Fasting glucose levels (10 mg/dl increment)         1.03 (1.00-1.07) 0.04     
Intake of glucose-lowering medication         1.33 (0.93-1.91) 0.117     
Smoking (current vs. non-current)     1.594 (0.99-2.56) 0.054  1.52 (0.94-2.46) 0.086  1.51 (0.98-2.34) 0.062 
Hypercholesterolemia (yes vs. no)     1.021 (0.88-1.19) 0.784      1.02 (0.89-1.16) 0.804 
LDL-C levels (10 mg/dl increment)         1.01 (0.99-1.02) 0.406     
HDL-C levels (5 mg/dl increment)         0.98 (0.95-1.01) 0.269     
Intake of lipid-lowering medication         1.05 (0.82-1.35) 0.694     
Chronic kidney disease (yes vs. no)     1.00 (0.89-1.12) 0.999      0.97 (0.89-1.06) 0.546 
eGFR (10 ml/min/1.73 m2 increment)         1.00 (0.99-1.00) 0.48     
BMI (5 kg/m2 increment)     1.01 (0.91-1.11) 0.896  0.96 (0.87-1.05) 0.336  0.97 (0.95-1.00) 0.044 
Heart failure (yes vs. no)      1.18 (0.80-1.73) 0.402  1.35 (0.91-1.99) 0.134  1.18 (0.80-1.76) 0.405 
Coronary artery disease (yes vs. no)     1.80 (1.38-2.34) 2E-5  1.74 (1.32-2.29) 8E-5  1.76 (1.35-2.31) 4E-5 
Atrial fibrillation (yes vs. no)     1.50 (0.94-2.39) 0.091  1.48 (0.92-2.36) 0.106  1.51 (0.94-2.41) 0.086 
ln-hsCRP (1-SD increment)             1.12 (1.05-1.19) 0.0003 
ln-MCP1 (1-SD increment) 1.10 (1.01-1.19) 0.018  1.07 (1.01-1.14) 0.028  1.07 (1.00-1.15) 0.035  1.07 (1.00-1.14) 0.053 
1st quartile  reference    reference    reference    Reference  
2nd quartile 1.17 (1.00-1.37) 0.058  1.16 (0.99-1.36) 0.075  1.16 (0.98-1.38) 0.079  1.18 (1.00-1.38) 0.048 
3rd quartile 1.35 (1.16-1.57) 0.0001  1.31 (1.12-1.53) 0.001  1.35 (1.14-1.58) 0.0003  1.32 (1.13-1.55) 0.0004 
4th quartile 1.43 (1.10-1.86) 0.004  1.33 (1.05-1.68) 0.008  1.37 (1.09-1.72) 0.005  1.34 (1.08-1.65) 0.007 
All models are additionally adjusted for race, but following study-specific classifications that precluded meta-analysis for this variable. 
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; BMI, body mass 





Online Table IV. Associations between baseline circulating MCP-1 levels and risk of ischemic stroke. Shown are the results from random-effects meta-analyses across 
the different models in the pooled sample consisting of six population-based studies. 
  Model 1    Model 2    
Alternative 
Model 2 
   Model 3  
Variables in the models HR 95%CI p  HR 95%CI p  HR 95%CI p  HR 95%CI p 
Age (1-yr increment) 1.10 (1.07-1.12) 4E-13  1.08 (1.05-1.11) 7E-7  1.08 (1.04-1.11) 7E-6  1.08 (1.05-1.11) 4E-7 
Sex (males vs. females) 1.28 (1.00-1.64) 0.050  1.22 (1.02-1.45) 0.029  1.12 (0.94-1.34) 0.193  1.23 (1.03-1.46) 0.022 
Hypertension (yes vs. no)     1.80 (1.57-2.06) 3E-17      1.78 (1.55-2.05) 4E-16 
SBP (10 mmHg-increment)         1.15 (1.10-1.20) 3E-11     
Intake of antihypertensive medication         1.52 (1.32-1.75) 3E-9     
Diabetes (yes vs. no)     1.88 (1.33-2.64) 0.0003      1.90 (1.32-2.72) 0.001 
Fasting glucose levels (10 mg/dl increment)         1.04 (1.01-1.07) 0.013     
Intake of glucose-lowering medication         1.33 (0.90-1.96) 0.154     
Smoking (current vs. non-current)     1.55 (0.95-2.54) 0.082  1.47 (0.89-2.44) 0.137  1.48 (0.93-2.34) 0.097 
Hypercholesterolemia (yes vs. no)     1.09 (0.92-1.28) 0.314      1.09 (0.94-1.26) 0.260 
LDL-C levels (10 mg/dl increment)         1.01 (1.00-1.03) 0.112     
HDL-C levels (5 mg/dl increment)         0.98 (0.96-1.01) 0.243     
Intake of lipid-lowering medication         1.12 (0.86-1.47) 0.404     
Chronic kidney disease (yes vs. no)     0.97 (0.85-1.11) 0.664      0.94 (0.85-1.03) 0.198 
eGFR (10 ml/min/1.73 m2 increment)         1.00 (0.99-1.00) 0.268     
BMI (5 kg/m2 increment)     1.01 (0.90-1.13) 0.877  0.95 (0.84-1.07) 0.412  0.99 (0.92-1.06) 0.721 
Heart failure (yes vs. no)      1.16 (0.76-1.77) 0.501  1.29 (0.84-2.00) 0.246  1.16 (0.75-1.81) 0.508 
Coronary artery disease (yes vs. no)     1.74 (1.22-2.48) 0.002  1.64 (1.13-2.38) 0.009  1.55 (0.97-2.48) 0.068 
Atrial fibrillation (yes vs. no)     1.54 (0.94-2.54) 0.088  1.53 (0.93-2.54) 0.097  1.56 (0.95-2.56) 0.083 
ln-hsCRP (1-SD increment)             1.14 (1.07-1.22) 0.0002 
ln-MCP1 (1-SD increment) 1.12 (1.03-1.23) 0.007  1.11 (1.02-1.21) 0.009  1.11 (1.02-1.21) 0.011  1.10 (1.01-1.21) 0.018 
1st quartile  reference    reference    reference    reference  
2nd quartile 1.19 (1.01-1.41) 0.039  1.19 (1.00-1.42) 0.047  1.17 (0.97-1.41) 0.089  1.22 (1.03-1.45) 0.022 
3rd quartile 1.38 (1.17-1.63) 0.0001  1.35 (1.14-1.59) 0.0004  1.38 (1.16-1.65) 0.0003  1.36 (1.15-1.60) 0.0003 
4th quartile 1.43 (1.11-1.85) 0.003  1.38 (1.07-1.77) 0.008  1.39 (1.10-1.76) 0.006  1.38 (1.10-1.74) 0.004 
All models are additionally adjusted for race, but following study-specific classifications that precluded meta-analysis for this variable. 
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; BMI, body mass 
index; hsCRP, high-sensitivity C-reactive protein; MCP-1, monocyte-chemoattractant protein 1; HR, hazard ratio; SD, standard deviation.
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Online Table V. Associations between baseline circulating MCP-1 levels and risk of hemorrhagic stroke. Shown are the results from random-effects meta-analyses 
across the different models in the pooled sample consisting of six population-based studies. 
  Model 1    Model 2    
Alternative 
Model 2 
   Model 3  
Variables in the models HR 95%CI p  HR 95%CI p  HR 95%CI p  HR 95%CI p 
Age (1-yr increment) 1.08 (1.06-1.10) 0  1.08 (1.05-1.10) 7E-10  1.06 (1.03-1.09) 7E-5  1.07 (1.03-1.11) 0.0001 
Sex (males vs. females) 1.05 (0.62-1.78) 0.847  1.04 (0.63-1.71) 0.879  0.82 (0.49-1.37) 0.446  0.89 (0.64-1.22) 0.453 
Hypertension (yes vs. no)     1.94 (1.39-2.71) 0.0001      1.95 (1.39-2.73) 0.0001 
SBP (10 mmHg-increment)         1.23 (1.14-1.34) 3E-7     
Intake of antihypertensive medication         1.32 (0.82-2.13) 0.250     
Diabetes (yes vs. no)     1.05 (0.67-1.65) 0.832      1.05 (0.66-1.65) 0.842 
Fasting glucose levels (10 mg/dl increment)         0.95 (0.88-1.03) 0.224     
Intake of glucose-lowering medication         2.81 (0.94-8.38) 0.065     
Smoking (current vs. non-current)     1.57 (0.90-2.73) 0.110  1.49 (0.82-2.72) 0.193  1.36 (0.96-1.92) 0.087 
Hypercholesterolemia (yes vs. no)     0.83 (0.59-1.17) 0.286      0.80 (0.56-1.13) 0.199 
LDL-C levels (10 mg/dl increment)         0.98 (0.94-1.03) 0.465     
HDL-C levels (5 mg/dl increment)         1.05 (0.93-1.18) 0.417     
Intake of lipid-lowering medication         1.05 (0.48-2.32) 0.905     
Chronic kidney disease (yes vs. no)     1.17 (0.76-1.81) 0.474      1.17 (0.75-1.82) 0.487 
eGFR (10 ml/min/1.73 m2 increment)         1.00 (0.92-1.10) 0.937     
BMI (5 kg/m2 increment)     0.93 (0.75-1.15) 0.493  0.94 (0.71-1.23) 0.645  0.94 (0.83-1.07) 0.330 
Heart failure (yes vs. no)      6.93 (1.65-29.2) 0.008  12.0 (3.46-41.7) 9E-5  6.52 (1.24-34.2) 0.027 
Coronary artery disease (yes vs. no)     1.30 (0.49-3.48) 0.601  1.37 (0.50-3.76) 0.547  1.42 (0.53-3.86) 0.488 
Atrial fibrillation (yes vs. no)     3.97 (0.94-16.7) 0.061  3.83 (0.89-16.4) 0.071  3.90 (0.93-16.4) 0.064 
ln-hsCRP (1-SD increment)             1.13 (0.96-1.34) 0.140 
ln-MCP1 (1-SD increment) 1.05 (0.84-1.30) 0.669  1.02 (0.82-1.29) 0.833  1.04 (0.79-1.37) 0.776  1.02 (0.80-1.31) 0.844 
1st quartile  reference    reference    reference    reference  
2nd quartile 0.96 (0.62-1.50) 0.873  0.95 (0.61-1.47) 0.807  0.97 (0.60-1.57) 0.907  0.96 (0.62-1.49) 0.860 
3rd quartile 1.27 (0.84-1.92) 0.251  1.25 (0.82-1.91) 0.293  1.31 (0.80-2.15) 0.276  1.27 (0.84-1.93) 0.252 
4th quartile 1.09 (0.71-1.66) 0.692  1.02 (0.66-1.56) 0.945  1.07 (0.67-1.71) 0.768  1.02 (0.67-1.57) 0.921 
All models are additionally adjusted for race, but following study-specific classifications that precluded meta-analysis for this variable. The Dallas Heart Study (DHS) is not included in any of the analyses for hemorrhagic stroke due 
to the low number of events. The Atherosclerosis Risk in Community (ARIC) study is not included in the quartile analyses. 
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; BMI, body mass 
index; hsCRP, high-sensitivity C-reactive protein; MCP-1, monocyte-chemoattractant protein 1; HR, hazard ratio; SD, standard deviation.
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Online Table VI. Meta-regression analyses for the effect of different study characteristics on the association between ln-
transformed MCP-1 circulating levels at baseline (1 SD increment) with any stroke and etiological stroke subtypes 
(ischemic and hemorrhagic stroke).   














Age (1y-increment) 0.993 (0.979-1.007) 0.24 0.989 (0.974-1.005) 0.12 1.002 (0.914-1.099) 0.95 
Males (5%-increment) 1.003 (0.941-1.068) 0.91 0.994 (0.919-1.075) 0.85 1.063 (0.950-1.190) 0.18 
SBP (10 mmHg-increment) 0.932 (0.814-1.066) 0.22 0.897 (0.774-1.040) 0.11 1.065 (0.540-2.097) 0.79 
Diabetes (5%-increment) 0.987 (0.903-1.079) 0.71 0:983 (0.877-1.102) 0.69 1.063 (0.857-1.320) 0.43 
LDL-C (10 mg/dl-increment) 0.984 (0.933-1.037) 0.43 0.968 (0.919-1.020) 0.16 1.054 (0.833-1.335) 0.53 
BMI (5kg/m2-increment) 1.160 (0.776-1.734) 0.36 1.298 (0.856-1.970) 0.16 0.978 (0.098-9.707) 0.98 
Current smokers (5%-increment) 0.997 (0.937-1.061) 0.91 0.994 (0.917-1.077) 0.84 1.076 (0.950-1.219) 0.16 
eGFR (10ml/min/1.73m2-increment) 1.064 (0.971-1.166) 0.13 1.090 (0.987-1.203) 0.07 1.016 (0.592-1.743) 0.93 
Coronary artery disease (5%-increment) 1.033 (0.870-1.227) 0.63 1.058 (0.877-1.277) 0.45 0.830 (0.510-1.351) 0.31 
hsCRP (1 unit-increment in ln(hsCRP)) 1.028 (0.696-1.517) 0.84 1.125 (0.643-1.971) 0.55 0.992 (0.102-9.615) 0.99 
Sample (serum vs. plasma) 0.985 (0.800-1.247) 0.88 0.943 (0.704-1.262) 0.61 1.043 (0.443-2.457) 0.89 
 
Abbreviations: BMI, body mass index; hsCRP, high-sensitivity C-reactive protein; eGFR, estimated glomerular filtration rate; LDL, low-density liporprotein; MCP-






Online Table VII. Associations between baseline circulating hsCRP, IL-6, and MCP-1 levels and risk of any stroke, ischemic stroke, and hemorrhagic stroke. Shown are 
the results from random-effects meta-analyses of the pooled sample consisting of four population-based studies, where both hsCRP and IL-6 levels were available. 
      Any stroke  Ischemic stroke  Hemorrhagic stroke * 
Variables in the models Population Follow-up (y) Events HR 95%CI p  Events HR 95%CI p  Events HR 95%CI p 
Model adjusted for age, sex, race, vascular risk factors† 
ln-MCP1 (1-SD increment) 12686 15.6 777 1.08 (1.00-1.16) 0.056  634 1.12 (1.02-1.24) 0.020  108 0.90 (0.74-1.10) 0.298 
1st quartile 3184 15.7 145  reference   114  reference   26  reference  
2nd quartile 3162 15.7 177 1.09 (0.87-1.37) 0.468  144 1.12 (0.87-1.43) 0.390  24 0.95 (0.51-1.79) 0.876 
3rd quartile 3177 15.6 212 1.21 (0.98-1.50) 0.080  175 1.27 (1.01-1.62) 0.044  31 1.15 (0.58-2.28) 0.692 
4th quartile 3163 15.3 243 1.33 (1.05-1.69) 0.014  201 1.43 (1.04-1.97) 0.022  27 0.91 (0.52-1.60) 0.745 
Model adjusted for age, sex, race, vascular risk factors†, hsCRP levels 
ln-hsCRP (1-SD increment) 12519 15.6 773 1.11 (1.03-1.20) 0.009  616 1.14 (1.05-1.24) 0.003  107 1.03 (0.83-1.26) 0.803 
ln-MCP1 (1-SD increment) 12519 15.6 773 1.06 (0.98-1.14) 0.098  616 1.12 (1.00-1.26) 0.048  107 0.91 (0.74-1.10) 0.321 
1st quartile 3155 15.7 142  reference   110  reference   25  reference  
2nd quartile 3128 15.7 178 1.09 (0.87-1.36) 0.449  143 1.12 (0.87-1.44) 0.374  24 0.95 (0.51-1.77) 0.870 
3rd quartile 3138 15.6 213 1.22 (0.98-1.51) 0.073  174 1.28 (1.01-1.63) 0.041  31 1.16 (0.59-2.29) 0.661 
4th quartile 3098 15.3 240 1.32 (1.02-1.72) 0.039  189 1.42 (1.03-1.99) 0.037  27 0.92 (0.52-1.62) 0.777 
Model adjusted for age, sex, race, vascular risk factors†, IL-6 levels 
ln-IL-6 (1-SD increment) 12516 15.6 758 1.12 (1.04-1.21) 0.003  614 1.17 (1.02-1.35) 0.025  107 1.12 (0.92-1.36) 0.251 
ln-MCP1 (1-SD increment) 12516 15.6 769 1.05 (0.98-1.4) 0.146  614 1.12 (0.99-1.28) 0.064  107 0.88 (0.72-1.08) 0.210 
1st quartile 3168 15.7 142  reference   109  reference   25  reference  
2nd quartile 3148 15.7 177 1.09 (0.87-1.36) 0.465  142 1.10 (0.86-1.42) 0.445  24 0.96 (0.49-1.88) 0.901 
3rd quartile 3160 15.6 212 1.20 (0.96-1.49) 0.098  174 1.24 (0.97-1.58) 0.079  31 1.13 (0.56-2.27) 0.736 
4th quartile 3141 15.3 238 1.31 (0.97-1.76) 0.086  189 1.39 (0.99-1.96) 0.052  27 0.86 (0.48-1.53) 0.611 
Model adjusted for age, sex, race, vascular risk factors†, hsCRP, and IL-6 levels 
ln-hsCRP (1-SD increment) 12516 15.6 758 1.08 (1.00-1.19) 0.058  610 1.12 (1.02-1.23) 0.018  107 0.88 (0.79-1.23) 0.877 
ln-IL-6 (1-SD increment) 12516 15.6 758 1.09 (1.00-1.19) 0.041  610 1.13 (0.96-1.35) 0.137  107 1.13 (0.92-1.40) 0.248 
ln-MCP1 (1-SD increment) 12516 15.6 758 1.05 (0.98-1.13) 0.178  610 1.12 (0.98-1.29) 0.078  107 0.88 (0.72-1.08) 0.234 
1st quartile 3168 15.7 141  reference   107  reference   25  reference  
2nd quartile 3148 15.7 176 1.10 (0.88-1.37) 0.422  141 1.12 (0.87-1.44) 0.398  24 0.96 (0.49-1.88) 0.914 
3rd quartile 3160 15.6 211 1.21 (0.98-1.51) 0.078  173 1.26 (0.99-1.61) 0.059  31 1.14 (0.56-2.30) 0.718 
4th quartile 3141 15.3 230 1.30 (0.97-1.76) 0.096  189 1.39 (0.98-1.99) 0.063  27 0.88 (0.49-1.56) 0.660 
The Atherosclerosis Risk in Community (ARIC) and the European Prospective Investigation of Cancer-Norfolk (EPIC-Norfolk) studies are not included in these analyses because of non-availability of data on IL-6 levels. 
* The Dallas Heart Study (DHS) is not included in any of the analyses for hemorrhagic stroke due to the low number of events.  
† Vascular risk factors included the models are: body mass index (1 kg/m2 increment), smoking (current vs. non-current), estimated glomerular filtration rate (1 mL/min/1.73 m² increment), history of coronary artery disease, diabetes 
mellitus, hypertension, hypercholesterolemia, atrial fibrillation, and heart failure at baseline. 




Online Figure I. Flowchart of the study selection for the systematic review. 
 
   
Screened by title/abstract
(n = 1,321)
Excluded (n = 1,247)
Assessed for eligibility by full-text
(n = 74)
Excluded (n = 67):
• Not population-based studies (n = 25)
• Associations with outcomes after CAD/MI (n = 16)
• Associations with outcomes after stroke (n = 13)
• Associations with recurrent stroke/MI events (n = 9)
• Only assessing mortality as an outcome (n = 2)
• Reviews (n = 2)
• Overlap (n = 1)






Excluded (n = 1):
• Did not provide data (n = 1)
Studies included in meta-analysis (n = 6)
• ARIC: 1234 individuals, 23 yrs of follow-up 
153 incident stroke events
• DHS: 2931 individuals, 11 yrs of follow-up, 64 
incident stroke events
• EPIC-Norfolk: 3182 individuals, 17 yrs of 
follow-up, 503 incident stroke events
• FHS Offspring: 3069 individuals, 14 yrs of 
follow-up, 172 incident stroke events
• MONICA/KORA: 2055 individuals, 16 yrs of 
follow-up, 116 incident stroke events
• MDCS-CV: 4709 individuals, 20 yrs of follow-
up, 427 incident stroke events
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Online Figure II. Study-specific and pooled hazard ratios for incident any stroke per standard 
deviation increase in ln-transformed circulating MCP-1 levels and across MCP-1 level 




The results are derived from Cox proportional hazard models adjusted for age, sex, race, body mass index (1 kg/m2 increment), 
smoking (current vs. non-current), estimated glomerular filtration rate (1 mL/min/1.73 m² increment), history of coronary artery 
disease, diabetes mellitus, hypertension, hypercholesterolemia, atrial fibrillation, and heart failure at baseline. 
Analyses for 1 SD increment correspond to ln-transformed MCP-1 levels.  
The gray squares around the point estimates correspond to the weight of the included studies in the meta-analysis.  
Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; DHS, Dallas Heart Study; EPIC, European Prospective 
Investigation of Cancer; FHS Framingham Heart Study; KORA, Kooperative Gesundheitsforschung in der Region Augsburg; 


















































































































































































Online Figure III. Study-specific and pooled hazard ratios for incident ischemic stroke per 
standard deviation increase in ln-transformed circulating MCP-1 levels and across MCP-1 level 
quartiles. Shown are the results from random-effects meta-analyses (Model 2).  
 
 
The results are derived from Cox proportional hazard models adjusted for age, sex, race, body mass index (1 kg/m2 increment), 
smoking (current vs. non-current), estimated glomerular filtration rate (1 mL/min/1.73 m² increment), history of coronary artery 
disease, diabetes mellitus, hypertension, hypercholesterolemia, atrial fibrillation, and heart failure at baseline. 
Analyses for 1 SD increment correspond to ln-transformed MCP-1 levels.  
The gray squares around the point estimates correspond to the weight of the included studies in the meta-analysis.  
Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; DHS, Dallas Heart Study; EPIC, European Prospective 
Investigation of Cancer; FHS Framingham Heart Study; KORA, Kooperative Gesundheitsforschung in der Region Augsburg; 



















































































































































































Online Figure IV. Study-specific and pooled hazard ratios for incident hemorrhagic stroke per 
standard deviation increase in ln-transformed circulating MCP-1 levels and across MCP-1 level 
quartiles. Shown are the results from random-effects meta-analyses (Model 2).  
 
 
The results are derived from Cox proportional hazard models adjusted for age, sex, race, body mass index (1 kg/m2 increment), 
smoking (current vs. non-current), estimated glomerular filtration rate (1 mL/min/1.73 m² increment), history of coronary artery 
disease, diabetes mellitus, hypertension, hypercholesterolemia, atrial fibrillation, and heart failure at baseline. 
Analyses for 1 SD increment correspond to ln-transformed MCP-1 levels.  
The Dallas Heart Study (DHS) is not included in any of the analyses for hemorrhagic stroke due to the low number of events. 
The Atherosclerosis Risk in Community (ARIC) study is not included in the quartile analyses due to the low number of events. 
The gray squares around the point estimates correspond to the weight of the included studies in the meta-analysis.  
Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; EPIC, European Prospective Investigation of Cancer; FHS 









































































































































Online Figure V. Pooled hazard ratios for incident fatal and non-fatal stroke per circulating MCP-1 levels, 
as derived from random-effects meta-analyses. 
 
Analyses correspond to 1 SD increment in ln-transformed MCP-1 levels and represent pooled results of meta-analyses of all six studies. 
The results are derived from Cox proportional hazard models adjusted for age, sex, race, body mass index (1 kg/m2 increment), smoking 
(current vs. non-current), estimated glomerular filtration rate (1 mL/min/1.73 m² increment), history of coronary artery disease, diabetes 











































Online Figure VI. Pooled hazard ratios for incident any stroke per standard deviation increase in ln-
transformed circulating MCP-1 levels and across MCP-1 level quartiles in sensitivity analyses omitting one 
study per time. Shown are the results from random-effects meta-analyses.  
 
 
(A) 1 SD increment         (B) Q2 vs. Q1 
  
(C) Q3 vs. Q1          (D) Q4 vs. Q1 
   
The results are derived from Cox proportional hazard models adjusted for age, sex, race, body mass index (1 kg/m2 increment), smoking (current vs. non-current), 
estimated glomerular filtration rate (1 mL/min/1.73 m² increment), history of coronary artery disease, diabetes mellitus, hypertension, hypercholesterolemia, atrial 
fibrillation, and heart failure at baseline. 
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Online Figure VII. Pooled hazard ratios for incident ischemic stroke per standard deviation increase in ln-
transformed circulating MCP-1 levels and across MCP-1 level quartiles in sensitivity analyses omitting 
one study per time. Shown are the results from random-effects meta-analyses.  
 
 
(B) 1 SD increment         (B) Q2 vs. Q1 
  
(D) Q3 vs. Q1          (D) Q4 vs. Q1 
   
The results are derived from Cox proportional hazard models adjusted for age, sex, race, body mass index (1 kg/m2 increment), smoking (current vs. non-current), 
estimated glomerular filtration rate (1 mL/min/1.73 m² increment), history of coronary artery disease, diabetes mellitus, hypertension, hypercholesterolemia, atrial 
fibrillation, and heart failure at baseline. 
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Online Figure VIII. Pooled hazard ratios for incident hemorrhagic stroke per standard deviation increase 
in ln-transformed circulating MCP-1 levels and across MCP-1 level quartiles in sensitivity analyses 
omitting one study per time. Shown are the results from random-effects meta-analyses.  
 
 
(C) 1 SD increment         (B) Q2 vs. Q1 
  
(E) Q3 vs. Q1          (D) Q4 vs. Q1 
   
The results are derived from Cox proportional hazard models adjusted for age, sex, race, body mass index (1 kg/m2 increment), smoking (current vs. non-current), 
estimated glomerular filtration rate (1 mL/min/1.73 m² increment), history of coronary artery disease, diabetes mellitus, hypertension, hypercholesterolemia, atrial 
fibrillation, and heart failure at baseline. 


































































Online Figure IX. Pooled hazard ratios for incident ischemic stroke per standard deviation increase in 
ln-transformed circulating MCP-1 levels, as derived from random-effects meta-analyses stratified by pre-
defined study variables. 
 
 
The p-values (p) correspond to the results of the random-effects meta-analyses and test statistical significance for the hazard ratios, whereas the 
p-values for heterogeneity (p-het) correspond to the Cochran Q test and test for statistical significance for the presence of heterogeneity in the 
respective meta-analysis. The results of heterogeneity between the pooled effects across the different variable categories are presented under the 
results for each variable. 
The gray squares around the point estimates correspond to the weight of the included studies in the meta-analysis.  
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instruments for IL-6 signaling and precise location of the identified single 
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IL-6 signaling with ischemic stroke and coronary artery disease (positive 
control), as derived from fixed-effects inverse-variance-weighted (IVW), 
weighted median, contamination mixture (Con-Mix) and MR Pleiotropy 
Residual Sum and Outlier (MR-PRESSO) analyses. 
Figure S3 Mendelian Randomization associations of genetically downregulated IL-6 
signaling and CRP levels with ischemic stroke and coronary artery disease. 
The effects represent Odds Ratios (OR) derived from inverse-variance-
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Figure S4 Distribution of the effects of randomly selected sets of 7 CRP-decreasing 
SNPs on risk of coronary artery disease. The red line represents the effect of 
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Pleiotropy Residual Sum and Outlier (MR-PRESSO) analyses. 
Figure S6 Distribution of the effects of randomly selected sets of 7 CRP-decreasing 
SNPs on risk of (A) large artery, (B) cardioembolic, and (C) small vessel 
stroke. The red lines represent the effect of the 7 SNPs used as instruments 
for IL-6 signaling downregulation in the current study. 
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Supplementary Methods. Secondary outcomes derived from the UK Biobank. 
 
For some of the etiologically related outcomes, we examined the associations with the genetic variants 
in the IL6R gene that were used as instruments based on data from the UK Biobank. These included 
aortic aneurysm, peripheral artery disease, heart failure, deep vein thrombosis, and pulmonary 
embolism. To determine prevalent and incident cases for these phenotypes in the UK Biobank, we 
used diagnoses based on electronic health and hospital procedure codes, coded according to the 10th 
Edition of the International Classification of Diseases (ICD-10). Specifically, we extracted the ICD-10 
codes from the fields “41270”, “41202”, and “41204” in the UK Biobank database. Aortic aneurysm 
was defined by the codes I71.1, I71.2, I71.3, and I71.4; peripheral artery disease by I73.8 and I73.9; 
heart failure by I11.0, I13.0, I13.2, and I.50; deep vein thrombosis by I80.2; and pulmonary embolism 
by I26. We then excluded related participants (pi-hat >0.0884 and participants of non-White-British 
descent and fit logistic regression models exploring the associations between the SNPs of interest and 
the respective outcomes. The models were further adjusted for age at baseline, sex, the first 10 




Table S1. Power calculations for the Mendelian randomization analyses performed in the current 
study. 
Phenotype N total % cases Detectable OR* at 80% power 
Coronary artery disease 184,305 33.0 ≤0.93 or ≥1.09 
Ischemic stroke 440,328 7.8 ≤0.92 or ≥1.11 
Large artery stroke 410,484 1.1 ≤0.82 or ≥1.36 
Cardioembolic stroke 413,304 1.7 ≤0.84 or ≥1.28 
Small vessel stroke 411,497 1.3 ≤0.84 or ≥1.31 
Myocardial infarction 167,180 26.1 ≤0.92 or ≥1.1 
Aortic aneurysm 316,142 0.6 ≤0.75 or ≥1.92 
Carotid plaque 48,434 44.5 ≤0.86 or ≥1.16 
Peripheral artery disease 317,717 1.3 ≤0.81 or ≥1.41 
Heart failure 321,406 2.8 ≤0.86 or ≥1.23 
Atrial fibrillation 129,831 14.2 ≤0.89 or ≥1.16 
Venous thromboembolism 60,139 12.5 ≤0.84 or ≥1.27 
Deep vein thrombosis 306,472 1.3 ≤0.81 or ≥1.43 
Pulmonary embolism 307,586 1.8 ≤0.83 or ≥1.32 
Power calculation were based on the online application “mRnd: Power calculations for Mendelian 
Randomization” (http://cnsgenomics.com/shiny/mRnd/). 
R2 was estimated using an additive model, after estimating the variance explained for each of the 7 variants from 
the associations estimates with CRP levels, according to the formula: b 𝑅2 =  2 × 𝑀𝐴𝐹 × (1 − 𝑀𝐴𝐹) × 𝑏𝑒𝑡𝑎2  , 
where MAF is the minimum allele frequency for the respective variant and beta the association estimate with 
circulating ln-CRP levels. 





Figure S1. The genomic region that was screened for identification of genetic instruments for IL-6 signaling and precise location of the identified single nucleotide 
polymorphisms (SNPs).  
 
The region was selected as 300 kB upstream or downstream from the IL6R gene according to GRCh37/hg19 (chr1: 154,077,669-154,741,926). Gene name 
annotations are presented according to GENCODE (version 28) and accessed through the Integrative Genomics Viewer (https://igv.org/app/)1.  
































































Figure S2. Mendelian Randomization (MR) associations of genetically downregulated IL-6 signaling 
with ischemic stroke and coronary artery disease (positive control), as derived from fixed-effects 
inverse-variance-weighted (IVW), weighted median, contamination mixture (Con-Mix) and MR 
Pleiotropy Residual Sum and Outlier (MR-PRESSO) analyses. 
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Figure S3. Mendelian Randomization associations of genetically downregulated IL-6 signaling and 
CRP levels with ischemic stroke and coronary artery disease. The effects represent Odds Ratios (OR) 
derived from inverse-variance-weighted MR analyses. 
 





Figure S4. Distribution of the effects of randomly selected sets of 7 CRP-decreasing SNPs on risk of 
coronary artery disease. The red line represents the effect of the 7 SNPs used as instruments for IL-6 
signaling downregulation in the current study. 
 




Figure S5. Mendelian Randomization (MR) associations of genetically downregulated IL-6 signaling 
with large artery stroke, cardioembolic stroke, and small vessel stroke, as derived from fixed-effects 
inverse-variance-weighted (IVW), weighted median, contamination mixture (Con-Mix) and MR 
Pleiotropy Residual Sum and Outlier (MR-PRESSO) analyses.  
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Figure S6. Mendelian Randomization associations of genetically downregulated IL-6 signaling and 
CRP levels with ischemic stroke subtypes. The effects represent Odds Ratios (OR) derived from 
inverse-variance-weighted MR analyses. 
 




Figure S7. Distribution of the effects of randomly selected sets of 7 CRP-decreasing SNPs on risk of 
(A) large artery, (B) cardioembolic, and (C) small vessel stroke. The red lines represent the effects of 
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I. Supplemental Methods 
Mendelian randomization (MR) 
In the main MR analysis, estimates for each single-nucleotide polymorphism (SNP) were derived 
using the Wald ratio method, with standard errors estimated using second order weights to allow for 
measurement error in both the exposure and outcome estimates (1). For drug targets with more 
than one related SNP, overall MR estimates were calculated by pooling individual MR estimates for 
each SNP using fixed-effects inverse-variance weighted (IVW) meta-analysis (1), and were scaled to 
the estimated effect of the corresponding drug target on systolic blood pressure (SBP) in randomized 
controlled trials (RCTs) (2), in order to reflect drug effect. After conversion of odds ratio estimates to 
relative risk (RR) using baseline incidences of CHD and stroke of 0.042 and 0.041 respectively from a 
systematic review of 613,815 participants enrolled in blood pressure lowering trials (3), MR results 
were compared with estimates from a recent Cochrane systematic review and meta-analysis of RCTs 
that investigated the effect of common antihypertensive drugs against placebo (2). Sensitivity 
analyses were also performed using MR RR estimates derived from baseline CHD and stroke 
incidences of 1%, 5% and 10%. 
 
Investigation of pleiotropy 
Heterogeneity in the MR estimates generated by different SNPs can be used to indicate such 
pleiotropy (4), which was identified through a significant Cochran’s Q test (P<0.05) or an I2 measure 
of heterogeneity >30%. MR statistical sensitivity analyses that are more robust to the inclusion of 
pleiotropic variants were also performed. Firstly, the weighted median estimator was used, which 
obtains an overall MR estimate by ordering individual SNP MR estimates by their magnitude 
weighted for their precision, and is reliable when more than half the information for the analysis 
comes from valid instruments (5). Secondly, the MR-Egger technique was performed, which 
regresses the SNP-outcome estimates against the SNP-exposure estimates, weighted for the 
precision of the SNP-outcome estimates to give a reliable MR estimate and test for the presence of 
directional pleiotropy in scenarios where any pleiotropic effect of the genetic variants is 
independent of their association with the exposure (6). Finally, MR-PRESSO was conducted, which 
performs a zero-intercept regression of the SNP-outcome estimates against the SNP-exposure 
estimates to test, using residual errors, whether there are outlier SNPs (P<0.05), and whether 
removing these changes the MR estimates generated (7). MR-PRESSO generally requires that at least 
half of the genetic variants used do not relate to the outcome independently of the exposure (7). 
Statistical sensitivity analyses in MR suffer from low power (4), and as such no formal statistical 
significance threshold was set for these. 
 
II. Supplemental Results 
Mendelian randomization 
The main variants used to proxy drug class effect were based on genetic association estimates that 
corrected for antihypertensive medication use and adjusted for body mass index (BMI) (8). To avoid 
possible bias related to medication non-compliance or introduction of collider effects respectively, 
sensitivity analyses were performed using the UK Biobank SBP GWAS that did not correct for 
medication use or adjust for BMI (9). No suitable variants were identified for ACEI, two SNPs were 
identified as variants for BB (Supplementary Table 7), and six SNPs as variants for CCB 
(Supplementary Table 8). IVW MR produced estimates that were comparable to the main analysis, 
but with wider confidence intervals (Supplementary Figures 5-8). Searching PhenoScanner (10), 
possible pleiotropic effects were identified for one BB SNP and five CCB SNPs (details are provided in 
Supplementary Table 9). Repeating the IVW MR analysis after excluding these SNPs also produced 
similar estimates to the main analysis (Supplementary Figures 5-8). 
There was only evidence of heterogeneity, suggesting possible bias related to pleiotropic SNPs, in 
the MR analysis of BBs on stroke risk (I2 59%, Cochran’s Q P=0.03). The MR-Egger intercept was not 
significant for directional pleiotropy for either BBs (CHD P=0.87 and stroke P=0.89) or CCBs (CHD 
P=0.89 and stroke P=0.51). MR-PRESSO only detected outlier SNPs in the analysis of BBs on stroke 
risk (2 outliers), with MR-PRESSO estimates that excluded these SNPs consistent with the main 
analysis results (Supplementary Figure 6). Estimates using MR-Egger regression, the weighted 
median approach and MR-PRESSO also produced similar estimates to the main IVW MR analyses 
(Supplementary Figures 5-8). 
 
III. Supplemental Figures 
Supplementary Figure 1. Individual ratio method MR estimates for the analysis of BBs and CHD risk. 
 




Supplementary Figure 3. Individual ratio method MR estimates for the analysis of CCBs and CHD risk. 
 
  




Supplementary Figure 5. MR sensitivity analyses for the analysis of BBs and CHD risk 
 
  
Supplementary Figure 6. MR sensitivity analyses for the analysis of BBs and stroke risk 
 
  
Supplementary Figure 7. MR sensitivity analyses for the analysis of CCBs and CHD risk 
 
  
Supplementary Figure 8. MR sensitivity analyses for the analysis of CCBs and stroke risk 
 
  
Supplementary Figure 9. Permutation analysis randomly sampling 24 SBP SNPs and investigating 
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Genome-wide association analysis for WMH volume in the UK Biobank individual-level data 
We performed a genome-wide association study (GWAS) analysis for total volume of white matter 
hyperintensities (WMH), derived from T1 and T2-FLAIR images in the UK Biobank data. Total WMH volume 
definition was based on the field 25781 from the UK Biobank dataset. We followed the methodology, as has 
been previously described.1 Specifically, we log-transformed WMH volume to approximate a normal 
distribution. For the GWAS, we excluded related participants (pi-hat >0.1875) and participants of non-White-
British descent. This resulted in 10,597 individuals with available data on WMH volume, who were included 
in the analyses. SNPs with MAF <0.01 were excluded, as were SNPs not imputed from the HRC panel. We 
fit a linear regression model with log(WMHV) ~ SNP + age at MRI + sex + PCs1-10 + genotyping chip for 
each SNP. 
 
1. Rutten-Jacobs LCA, Tozer DJ, Duering M, et al. Genetic Study of White Matter Integrity in UK 




Table e-1. Genome-wide significant (p<5x10-8) and independent (r2<0.001) single nucleotide polymorphisms (SNP) that 
were used as instruments for systolic blood pressure (SBP). 






EAF beta SE p-value R2 a Fb 
rs488834 1 10767902 t c 0.765 -0.380 0.037 2.4E-25 3.8E-04 272.5 
rs10776752 1 113044328 t g 0.081 0.821 0.058 4.6E-46 3.4E-04 247.8 
rs59980837 1 115827266 t g 0.018 1.100 0.116 3.3E-21 1.1E-04 77.7 
rs6699618 1 11881441 c g 0.840 0.912 0.041 1.7E-109 6.7E-04 497.1 
rs11585169 1 150572037 a t 0.577 0.180 0.031 5.3E-09 2.4E-04 175.5 
rs76719272 1 156129796 t c 0.131 -0.274 0.046 3.0E-09 1.7E-04 126.5 
rs75461554 1 15810172 t c 0.201 -0.302 0.038 1.2E-15 2.7E-04 196.3 
rs1889785 1 16348729 a g 0.455 0.178 0.030 4.4E-09 2.4E-04 179.3 
rs7796 1 1684169 c g 0.511 0.339 0.031 5.0E-27 4.6E-04 338.1 
rs12731646 1 169090660 t c 0.409 -0.189 0.031 7.2E-10 2.5E-04 185.2 
rs1043069 1 180859368 t g 0.616 0.234 0.031 5.3E-14 3.0E-04 224.7 
rs4651224 1 184585182 t c 0.447 0.199 0.031 9.0E-11 2.7E-04 199.0 
rs12042924 1 197297417 t c 0.528 -0.181 0.030 2.6E-09 2.5E-04 182.7 
rs11120093 1 207211326 t c 0.408 -0.179 0.031 5.1E-09 2.4E-04 175.7 
rs2724377 1 207974818 a g 0.530 0.194 0.030 1.3E-10 2.7E-04 195.9 
rs7555285 1 209970355 c g 0.801 0.229 0.038 1.1E-09 2.0E-04 148.3 
rs263532 1 2164116 t c 0.576 0.180 0.031 4.7E-09 2.4E-04 177.5 
rs68085857 1 217737629 t c 0.234 0.274 0.036 1.7E-14 2.7E-04 199.3 
rs72742507 1 221265336 t c 0.300 -0.205 0.033 3.8E-10 2.4E-04 174.9 
rs708117 1 228199902 a g 0.520 0.287 0.030 1.6E-21 3.9E-04 291.1 
rs699 1 230845794 a g 0.593 -0.375 0.031 5.6E-34 5.0E-04 358.8 
rs1565440 1 243387788 a g 0.375 0.175 0.031 1.9E-08 2.2E-04 166.1 
rs4926499 1 249155909 c g 0.826 0.297 0.044 1.3E-11 2.3E-04 166.4 
rs404100 1 25366987 t c 0.451 0.194 0.030 1.7E-10 2.6E-04 194.2 
rs34079867 1 27407850 t c 0.266 0.199 0.035 1.8E-08 2.1E-04 157.6 
rs4908348 1 28706949 t g 0.694 0.237 0.033 8.1E-13 2.8E-04 203.5 
rs2493296 1 3327032 t c 0.143 0.418 0.044 3.1E-21 2.8E-04 203.5 
rs11210029 1 41865293 a g 0.632 -0.203 0.031 8.9E-11 2.6E-04 191.3 
rs1408945 1 42364877 t g 0.424 -0.320 0.030 8.3E-26 4.3E-04 316.4 
rs1209384 1 43765089 a g 0.388 0.256 0.031 2.8E-16 3.3E-04 244.8 
rs778124 1 56606206 a g 0.374 0.297 0.031 1.5E-21 3.8E-04 281.6 
rs61772592 1 56979681 a g 0.875 -0.318 0.046 2.9E-12 1.9E-04 141.7 
rs12063372 1 59621911 a g 0.385 0.199 0.032 3.9E-10 2.6E-04 190.8 
rs10779795 1 6677064 a g 0.661 0.219 0.032 7.4E-12 2.7E-04 196.9 
rs12136922 1 67007389 a g 0.495 0.203 0.030 2.7E-11 2.8E-04 200.3 
rs658780 1 78555928 t g 0.745 -0.203 0.035 5.3E-09 2.1E-04 156.2 
rs786923 1 89242954 t c 0.624 -0.308 0.031 2.8E-23 4.0E-04 293.1 
rs7514579 1 94051350 a c 0.771 0.224 0.036 5.5E-10 2.2E-04 160.6 
rs1006545 10 102553647 t g 0.887 0.685 0.048 3.5E-46 3.8E-04 278.1 
rs11191580 10 104906211 t c 0.918 1.100 0.055 7.7E-89 4.6E-04 337.4 
rs117464403 10 107158054 a g 0.018 0.864 0.120 5.8E-13 8.5E-05 62.1 
rs12255372 10 114808902 t g 0.288 0.236 0.034 1.9E-12 2.7E-04 194.1 
rs1801253 10 115805056 c g 0.734 0.463 0.034 2.8E-41 5.0E-04 366.8 
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rs72842207 10 121433675 t c 0.214 -0.203 0.037 3.1E-08 1.9E-04 138.7 
rs11592107 10 122968964 a g 0.310 0.302 0.033 1.5E-20 3.6E-04 262.3 
rs7093894 10 124234880 a c 0.151 0.236 0.043 3.2E-08 1.7E-04 122.9 
rs7912283 10 133773019 a g 0.647 -0.214 0.032 2.9E-11 2.7E-04 198.2 
rs1133400 10 134459388 a g 0.786 -0.298 0.038 2.5E-15 2.8E-04 198.8 
rs1623474 10 18471794 t c 0.330 0.383 0.032 7.7E-33 4.7E-04 343.6 
rs12258967 10 18727959 c g 0.705 0.633 0.034 1.1E-78 7.2E-04 533.8 
rs3802517 10 28233469 a t 0.462 0.253 0.030 4.6E-17 3.5E-04 254.9 
rs12264186 10 32289986 t c 0.187 0.214 0.039 3.6E-08 1.8E-04 131.8 
rs11252324 10 4124568 t g 0.077 -0.416 0.057 3.6E-13 1.6E-04 120.2 
rs4948643 10 45379759 t c 0.282 0.226 0.034 2.4E-11 2.5E-04 185.2 
rs34130368 10 48411796 t g 0.117 -0.302 0.050 1.3E-09 1.7E-04 126.1 
rs4245599 10 60365755 a g 0.458 -0.179 0.031 4.0E-09 2.4E-04 180.7 
rs57946343 10 63499951 t c 0.853 0.716 0.043 2.1E-63 4.9E-04 364.0 
rs2236295 10 64564892 t g 0.398 -0.303 0.031 1.0E-22 4.0E-04 294.4 
rs2177843 10 75409877 t c 0.151 0.439 0.043 2.8E-24 3.1E-04 228.0 
rs10749572 10 82136664 t g 0.544 -0.203 0.030 1.9E-11 2.8E-04 204.3 
rs111866816 10 94441507 t c 0.071 0.357 0.060 2.3E-09 1.3E-04 95.3 
rs2689690 10 95899706 t c 0.368 -0.270 0.032 1.1E-17 3.5E-04 251.3 
rs2274224 10 96039597 c g 0.432 -0.452 0.030 6.0E-50 6.1E-04 449.4 
rs604723 11 100610546 t c 0.276 -0.655 0.034 2.5E-83 7.2E-04 530.2 
rs7926110 11 107086143 t g 0.673 0.260 0.032 5.7E-16 3.1E-04 232.4 
rs641620 11 117074229 t c 0.855 -0.319 0.044 3.7E-13 2.2E-04 159.0 
rs573455 11 117267884 a g 0.461 0.199 0.030 4.8E-11 2.7E-04 200.8 
rs11222084 11 130273230 a t 0.638 -0.336 0.032 1.8E-26 4.3E-04 314.9 
rs7944927 11 130490917 t c 0.782 0.224 0.039 1.2E-08 2.1E-04 154.4 
rs2014408 11 16365282 t c 0.209 0.517 0.037 1.3E-43 4.7E-04 346.5 
rs7926335 11 16917869 t c 0.269 0.314 0.034 2.5E-20 3.4E-04 249.5 
rs569550 11 1887068 t g 0.604 -0.577 0.032 1.3E-73 7.6E-04 544.8 
rs74048190 11 2114221 t c 0.952 -0.440 0.076 6.1E-09 1.1E-04 79.1 
rs17762 11 22492454 a g 0.078 0.412 0.057 5.6E-13 1.6E-04 119.7 
rs1382472 11 27273967 a g 0.404 -0.192 0.031 4.5E-10 2.5E-04 187.3 
rs871004 11 28512458 a g 0.348 0.234 0.032 1.6E-13 2.9E-04 215.1 
rs1340030 11 30182068 t c 0.635 0.194 0.031 5.8E-10 2.5E-04 182.2 
rs11604310 11 45351420 t c 0.166 -0.278 0.041 1.5E-11 2.1E-04 155.7 
rs7107356 11 47676170 a g 0.496 -0.460 0.030 1.6E-52 6.3E-04 466.6 
rs2904315 11 48109948 a g 0.313 -0.208 0.033 1.6E-10 2.5E-04 181.6 
rs7125196 11 61272565 t c 0.882 0.442 0.047 7.3E-21 2.5E-04 186.6 
rs2306363 11 65405600 t g 0.205 -0.436 0.038 5.2E-31 3.9E-04 287.7 
rs7395791 11 69262916 a g 0.442 -0.216 0.031 2.2E-12 2.9E-04 216.4 
rs10501410 11 72088806 a g 0.069 0.412 0.061 1.1E-11 1.5E-04 107.7 
rs7927515 11 76125330 a c 0.346 0.227 0.032 1.0E-12 2.8E-04 206.2 
rs2289124 11 89224477 a g 0.167 -0.308 0.042 1.1E-13 2.4E-04 173.9 
rs360153 11 9762274 t c 0.417 -0.345 0.031 1.7E-29 4.6E-04 339.8 
rs67885470 11 99998431 t c 0.209 -0.209 0.038 4.1E-08 1.9E-04 140.0 
rs10207726 2 112744260 t c 0.296 -0.214 0.033 8.1E-11 2.5E-04 181.1 
rs6737318 2 114083120 a g 0.778 0.235 0.036 1.1E-10 2.2E-04 164.5 
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rs2580350 2 121996007 a g 0.561 0.177 0.031 8.4E-09 2.4E-04 176.6 
rs17257081 2 135630498 a g 0.807 0.227 0.039 6.4E-09 2.0E-04 140.9 
rs55944332 2 145726621 a g 0.763 -0.261 0.036 1.8E-13 2.6E-04 191.6 
rs62170470 2 146989797 t c 0.602 0.197 0.032 7.7E-10 2.6E-04 189.3 
rs62187653 2 162469128 t c 0.903 0.329 0.051 1.2E-10 1.6E-04 116.9 
rs4667454 2 164867726 a g 0.671 0.264 0.032 2.6E-16 3.2E-04 236.3 
rs73029563 2 165008166 c g 0.455 -0.514 0.030 4.2E-64 7.0E-04 516.7 
rs11694601 2 174949358 a g 0.597 -0.191 0.031 6.4E-10 2.5E-04 184.3 
rs34727427 2 177016728 t c 0.683 -0.235 0.032 4.0E-13 2.8E-04 206.7 
rs1882212 2 182981968 a g 0.779 0.275 0.036 3.3E-14 2.6E-04 191.9 
rs13412750 2 191634958 a g 0.271 -0.289 0.034 2.3E-17 3.1E-04 228.9 
rs17760259 2 19744462 t c 0.572 -0.265 0.030 2.3E-18 3.6E-04 263.6 
rs12693982 2 204085635 t c 0.402 0.258 0.031 7.5E-17 3.4E-04 250.3 
rs3845811 2 208521512 c g 0.566 -0.294 0.031 1.9E-21 4.0E-04 292.9 
rs12694277 2 213188795 t c 0.295 -0.202 0.034 1.8E-09 2.3E-04 170.2 
rs2161967 2 218680529 t g 0.428 0.284 0.031 2.9E-20 3.8E-04 281.8 
rs3828282 2 218779144 c g 0.428 0.186 0.032 5.3E-09 2.5E-04 184.2 
rs10804330 2 227185749 t c 0.567 0.235 0.031 1.6E-14 3.2E-04 233.6 
rs1044822 2 230629138 t c 0.148 -0.248 0.042 5.2E-09 1.7E-04 127.0 
rs28365916 2 231280791 t c 0.415 -0.171 0.031 2.2E-08 2.3E-04 168.5 
rs139354822 2 242344695 t c 0.970 0.612 0.098 3.5E-10 9.7E-05 69.5 
rs2384063 2 25187115 t c 0.761 0.327 0.036 6.3E-20 3.3E-04 240.9 
rs1275988 2 26914364 t c 0.611 -0.541 0.031 4.4E-69 7.1E-04 521.9 
rs13420463 2 37517566 a g 0.773 0.314 0.036 2.7E-18 3.0E-04 220.9 
rs4952609 2 40555733 a g 0.744 0.212 0.035 9.6E-10 2.2E-04 164.0 
rs115262049 2 43196694 a t 0.913 0.589 0.055 1.3E-26 2.6E-04 189.6 
rs12464602 2 43397614 a g 0.621 -0.244 0.032 1.0E-14 3.2E-04 232.8 
rs13016772 2 55779476 t c 0.765 0.252 0.036 1.2E-12 2.5E-04 183.9 
rs2249105 2 65287896 a g 0.632 0.293 0.031 7.6E-21 3.7E-04 273.2 
rs10188003 2 66773469 t c 0.393 0.188 0.031 8.8E-10 2.5E-04 182.0 
rs6731373 2 68503044 a g 0.349 0.191 0.033 4.2E-09 2.4E-04 176.2 
rs6732123 2 69534650 c g 0.417 -0.174 0.031 1.5E-08 2.3E-04 171.4 
rs4577304 2 73403040 t c 0.523 -0.177 0.030 5.0E-09 2.4E-04 178.9 
rs72847885 2 86326717 a g 0.663 0.241 0.032 3.1E-14 3.0E-04 218.5 
rs9848170 3 11495983 c g 0.597 0.323 0.031 7.0E-26 4.3E-04 315.5 
rs12637573 3 121682388 a g 0.472 -0.173 0.030 9.9E-09 2.4E-04 174.8 
rs6438857 3 124557643 t c 0.577 0.274 0.031 3.1E-19 3.7E-04 270.9 
rs9880098 3 133949366 a g 0.395 0.308 0.031 1.6E-23 4.0E-04 298.7 
rs1199330 3 138101529 a g 0.882 -0.265 0.047 1.7E-08 1.5E-04 110.5 
rs9876694 3 141152017 t c 0.058 0.471 0.065 4.6E-13 1.4E-04 105.0 
rs11925504 3 14943965 a g 0.572 -0.290 0.031 1.8E-21 3.9E-04 287.8 
rs4408839 3 153729768 a g 0.743 -0.230 0.035 2.4E-11 2.4E-04 178.2 
rs79539362 3 154680449 t c 0.899 0.400 0.050 2.1E-15 2.0E-04 147.2 
rs17684859 3 158213841 t c 0.734 -0.224 0.034 4.2E-11 2.4E-04 177.8 
rs3980686 3 168697602 t g 0.108 -0.500 0.049 1.0E-24 2.6E-04 194.6 
rs1290784 3 169096900 t c 0.448 0.412 0.030 3.0E-42 5.6E-04 412.9 
rs2111557 3 169325621 t c 0.468 0.176 0.030 5.2E-09 2.4E-04 178.2 
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rs4955575 3 169534538 a c 0.746 0.216 0.035 5.6E-10 2.2E-04 165.9 
rs262986 3 183435713 a g 0.470 -0.237 0.031 7.7E-15 3.2E-04 239.7 
rs13091418 3 185329756 c g 0.666 -0.223 0.033 6.1E-12 2.7E-04 201.4 
rs9869437 3 196228360 a c 0.352 -0.200 0.032 3.2E-10 2.5E-04 185.0 
rs189267552 3 20073193 a t 0.013 -0.866 0.139 4.6E-10 6.2E-05 45.6 
rs2643826 3 27562988 t c 0.451 0.447 0.031 1.7E-48 6.1E-04 449.5 
rs68115553 3 27704702 a g 0.980 -0.645 0.114 1.7E-08 6.9E-05 50.3 
rs743395 3 37598382 t c 0.383 0.260 0.032 2.6E-16 3.4E-04 248.8 
rs6788984 3 41107173 a g 0.856 0.300 0.043 3.8E-12 2.0E-04 149.7 
rs1052501 3 41925398 t c 0.833 0.226 0.041 4.1E-08 1.7E-04 126.3 
rs6771917 3 48108442 t c 0.248 -0.379 0.036 1.4E-26 3.9E-04 286.9 
rs7615099 3 53143901 a g 0.668 0.189 0.032 3.9E-09 2.3E-04 170.1 
rs6445583 3 53562894 a g 0.747 0.277 0.035 1.9E-15 2.9E-04 213.0 
rs3772219 3 56771251 a c 0.682 0.273 0.032 3.1E-17 3.3E-04 240.4 
rs7618284 3 66422246 c g 0.339 -0.189 0.033 1.1E-08 2.3E-04 171.8 
rs4499560 3 70920485 a t 0.317 -0.220 0.033 1.5E-11 2.6E-04 193.0 
rs9857362 3 74710462 a c 0.529 0.173 0.031 1.6E-08 2.4E-04 170.6 
rs1375564 3 85656311 t c 0.640 0.258 0.032 2.8E-16 3.3E-04 240.6 
rs13107325 4 103188709 t c 0.074 -0.909 0.059 4.2E-53 3.4E-04 251.3 
rs11097909 4 106911321 t c 0.147 -0.363 0.043 3.4E-17 2.5E-04 184.1 
rs1493132 4 108861082 t c 0.660 -0.177 0.032 2.7E-08 2.2E-04 160.1 
rs1814951 4 111408718 a g 0.879 -0.323 0.047 3.9E-12 1.9E-04 139.4 
rs4834792 4 120555696 a t 0.480 0.197 0.030 7.2E-11 2.7E-04 199.0 
rs7439567 4 138464842 t c 0.411 0.254 0.031 2.3E-16 3.4E-04 247.8 
rs72719160 4 144051276 a t 0.683 -0.224 0.032 4.3E-12 2.7E-04 196.3 
rs2353940 4 145740898 t c 0.751 -0.208 0.036 6.8E-09 2.1E-04 156.4 
rs73855810 4 148383424 a g 0.141 0.273 0.043 3.0E-10 1.8E-04 134.0 
rs7683728 4 156402654 t c 0.531 -0.365 0.030 2.4E-33 5.0E-04 364.4 
rs12643599 4 156639846 a g 0.640 0.313 0.031 1.2E-23 4.0E-04 293.2 
rs17035181 4 157678511 t g 0.855 0.307 0.043 7.6E-13 2.1E-04 154.2 
rs869396 4 169688000 a c 0.466 -0.212 0.031 4.1E-12 2.9E-04 213.3 
rs2610990 4 18008232 a g 0.264 -0.290 0.034 2.9E-17 3.1E-04 228.0 
rs34535756 4 2246927 t c 0.039 0.478 0.079 1.2E-09 9.9E-05 73.3 
rs1290933 4 2668217 a c 0.692 -0.285 0.033 3.2E-18 3.3E-04 246.3 
rs55924432 4 26812737 t c 0.401 0.265 0.032 5.7E-17 3.5E-04 257.0 
rs2498323 4 3451109 a g 0.098 0.317 0.052 8.5E-10 1.5E-04 113.4 
rs2291434 4 38387244 t g 0.534 -0.262 0.030 5.1E-18 3.6E-04 263.8 
rs12511987 4 46595623 t g 0.823 -0.233 0.040 5.4E-09 1.9E-04 137.9 
rs62309747 4 48713862 a g 0.473 -0.224 0.030 1.6E-13 3.1E-04 226.7 
rs60991988 4 54801228 t g 0.893 0.379 0.050 2.8E-14 2.0E-04 145.1 
rs13107261 4 63768826 a g 0.369 -0.178 0.031 1.6E-08 2.3E-04 166.1 
rs10008637 4 77414144 t c 0.541 0.216 0.030 9.2E-13 2.9E-04 217.4 
rs12509595 4 81182554 t c 0.708 -0.837 0.033 2.6E-138 9.5E-04 701.9 
rs60909079 4 83830244 c g 0.249 -0.211 0.035 1.7E-09 2.2E-04 159.8 
rs17010957 4 86719165 t c 0.854 -0.534 0.043 1.8E-35 3.7E-04 269.6 
rs10028284 4 89752913 a t 0.818 0.294 0.040 1.7E-13 2.4E-04 176.2 
rs11241313 5 114428167 t c 0.311 -0.207 0.033 2.2E-10 2.4E-04 180.1 
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rs1624822 5 122475437 t c 0.620 -0.336 0.031 5.1E-27 4.4E-04 321.7 
rs9327297 5 122835051 c g 0.668 0.275 0.032 8.1E-18 3.4E-04 247.4 
rs758180 5 127354423 a t 0.225 0.208 0.037 1.3E-08 2.0E-04 146.8 
rs6892983 5 127845030 a c 0.402 0.343 0.031 7.1E-29 4.5E-04 334.0 
rs10069690 5 1279790 t c 0.258 0.310 0.037 4.5E-17 3.3E-04 230.8 
rs702395 5 140086677 t c 0.437 0.232 0.031 3.2E-14 3.1E-04 231.1 
rs2913920 5 141726983 t c 0.765 0.242 0.036 1.6E-11 2.4E-04 175.7 
rs7725413 5 15695987 t c 0.770 -0.199 0.036 3.1E-08 1.9E-04 142.5 
rs1957563 5 157474590 t c 0.265 0.363 0.034 2.3E-26 3.9E-04 285.7 
rs11960210 5 157817634 t c 0.625 0.473 0.031 1.3E-51 6.1E-04 443.1 
rs13358657 5 157938070 a g 0.867 -0.388 0.045 3.0E-18 2.5E-04 181.0 
rs3860770 5 173301427 a g 0.292 -0.266 0.033 1.2E-15 3.0E-04 221.7 
rs12153395 5 179411477 a g 0.115 -0.330 0.049 1.1E-11 1.8E-04 135.4 
rs12656497 5 32831939 t c 0.403 -0.638 0.031 7.1E-96 8.4E-04 621.9 
rs10941043 5 33194751 t g 0.710 -0.259 0.033 6.4E-15 2.9E-04 216.1 
rs4957026 5 361148 a g 0.340 0.198 0.032 8.1E-10 2.4E-04 179.7 
rs2113077 5 50799442 a g 0.430 0.210 0.031 6.1E-12 2.8E-04 208.3 
rs1694068 5 53283630 a t 0.614 0.266 0.031 1.2E-17 3.5E-04 255.6 
rs13179413 5 55868097 t c 0.282 0.224 0.035 1.1E-10 2.5E-04 183.6 
rs34496659 5 61798934 a g 0.070 0.455 0.062 1.5E-13 1.6E-04 120.4 
rs6870654 5 63831964 t c 0.745 0.214 0.035 7.6E-10 2.2E-04 162.7 
rs4286632 5 66291370 a g 0.731 0.211 0.034 7.6E-10 2.3E-04 168.5 
rs7703560 5 67678506 a g 0.700 -0.225 0.033 1.5E-11 2.6E-04 189.1 
rs246973 5 68007803 t c 0.288 0.248 0.034 1.5E-13 2.8E-04 206.1 
rs6452769 5 87389027 a g 0.205 -0.314 0.038 7.8E-17 2.8E-04 207.8 
rs76443575 5 96211594 c g 0.036 -0.523 0.082 1.4E-10 1.0E-04 73.4 
rs1871190 5 97953719 t g 0.335 0.195 0.032 1.7E-09 2.4E-04 176.4 
rs9486916 6 109013930 t c 0.198 0.266 0.039 5.4E-12 2.3E-04 169.1 
rs961764 6 117522156 c g 0.425 -0.191 0.031 3.7E-10 2.6E-04 189.4 
rs1630736 6 12295987 t c 0.465 -0.171 0.031 3.5E-08 2.3E-04 172.0 
rs10782230 6 126228512 a g 0.485 0.211 0.030 2.9E-12 2.9E-04 213.5 
rs9401913 6 127159982 a g 0.439 0.520 0.031 3.7E-65 7.0E-04 520.0 
rs9349379 6 12903957 a g 0.593 0.266 0.031 1.3E-17 3.5E-04 260.6 
rs9285476 6 134159976 c g 0.707 0.184 0.033 3.1E-08 2.1E-04 155.0 
rs13204703 6 140692862 t c 0.751 0.197 0.035 1.9E-08 2.0E-04 149.2 
rs8180684 6 143200936 t c 0.290 0.213 0.034 1.8E-10 2.4E-04 177.9 
rs7765526 6 147713764 a g 0.463 0.201 0.031 5.9E-11 2.7E-04 202.5 
rs17080102 6 151004770 c g 0.069 -0.809 0.059 3.5E-42 2.9E-04 211.9 
rs1293969 6 151959945 t c 0.748 -0.199 0.035 1.0E-08 2.1E-04 151.9 
rs509833 6 159711515 a g 0.139 0.329 0.044 7.1E-14 2.2E-04 159.2 
rs2745599 6 1613686 a g 0.552 0.216 0.032 9.0E-12 2.9E-04 214.3 
rs12661036 6 163737476 t c 0.775 -0.210 0.037 1.8E-08 2.0E-04 148.7 
rs7744902 6 166176722 a g 0.077 -0.409 0.059 5.6E-12 1.6E-04 113.4 
rs9368222 6 20686996 a c 0.269 0.228 0.034 1.8E-11 2.5E-04 181.9 
rs9393231 6 22123695 a c 0.492 -0.215 0.031 3.4E-12 3.0E-04 217.6 
rs7753826 6 26042239 a t 0.190 0.428 0.039 1.0E-28 3.6E-04 267.0 
rs2596498 6 31322688 t c 0.638 -0.233 0.034 4.9E-12 3.0E-04 204.8 
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rs3132442 6 31839494 t c 0.520 0.393 0.030 2.6E-38 5.4E-04 392.7 
rs7763558 6 43349215 a g 0.324 0.336 0.032 1.2E-25 4.0E-04 299.0 
rs11967262 6 43760327 c g 0.513 -0.172 0.031 3.4E-08 2.4E-04 172.0 
rs78648104 6 50683009 t c 0.908 -0.429 0.054 2.4E-15 2.0E-04 145.4 
rs1575290 6 7715689 t c 0.473 0.197 0.030 5.6E-11 2.7E-04 199.6 
rs1984195 6 79657391 a g 0.489 0.241 0.030 1.8E-15 3.3E-04 241.6 
rs9361836 6 82235408 t c 0.317 0.220 0.032 1.2E-11 2.6E-04 193.0 
rs6921291 6 97066242 t c 0.191 0.358 0.039 1.6E-20 3.0E-04 223.9 
rs2392929 7 106414069 t g 0.797 -0.751 0.038 2.0E-87 6.7E-04 491.9 
rs34072724 7 130432469 a g 0.489 -0.242 0.030 1.4E-15 3.3E-04 244.9 
rs35680304 7 130973495 t c 0.593 0.269 0.031 3.8E-18 3.6E-04 263.1 
rs75672964 7 131321010 t c 0.042 0.589 0.084 2.3E-12 1.3E-04 92.3 
rs6957161 7 131361319 a g 0.262 0.206 0.035 2.2E-09 2.2E-04 161.2 
rs73727605 7 149474622 a g 0.066 0.362 0.062 6.6E-09 1.2E-04 89.4 
rs3918226 7 150690176 t c 0.081 0.664 0.058 8.5E-31 2.7E-04 199.0 
rs10224210 7 151413194 t c 0.721 -0.383 0.034 1.6E-29 4.2E-04 312.7 
rs1870735 7 155744303 c g 0.453 0.206 0.031 3.6E-11 2.8E-04 206.9 
rs3807925 7 18543250 a g 0.650 -0.186 0.032 5.4E-09 2.3E-04 171.2 
rs28688791 7 19039605 t c 0.802 -0.322 0.038 2.3E-17 2.8E-04 207.8 
rs6978112 7 1966841 t c 0.411 0.229 0.031 1.3E-13 3.0E-04 223.7 
rs112509803 7 24735004 c g 0.114 -0.264 0.048 3.2E-08 1.5E-04 108.1 
rs10282122 7 2529623 t c 0.668 -0.302 0.033 2.5E-20 3.7E-04 270.5 
rs3735533 7 27245893 t c 0.074 -0.910 0.058 5.3E-56 3.4E-04 253.7 
rs6961048 7 27328187 c g 0.896 -0.530 0.050 1.4E-26 2.7E-04 199.5 
rs11977526 7 46008110 a g 0.401 -0.321 0.031 6.6E-25 4.2E-04 310.7 
rs73049928 7 4669949 a g 0.806 -0.238 0.039 1.2E-09 2.0E-04 150.8 
rs12668436 7 47548893 t c 0.754 -0.215 0.035 7.9E-10 2.2E-04 161.9 
rs848445 7 77572461 t c 0.285 -0.203 0.034 2.3E-09 2.3E-04 167.5 
rs67617547 7 90297177 c g 0.670 0.180 0.032 2.4E-08 2.2E-04 161.5 
rs42032 7 92237426 a g 0.264 -0.323 0.035 7.4E-21 3.5E-04 254.1 
rs79069610 8 105921209 t c 0.950 -0.401 0.073 3.7E-08 1.0E-04 77.2 
rs35783704 8 105966258 a g 0.104 -0.462 0.051 8.8E-20 2.4E-04 174.7 
rs1821002 8 10640065 c g 0.411 0.379 0.031 5.2E-35 5.0E-04 372.7 
rs7830607 8 110097287 a g 0.305 -0.206 0.033 3.1E-10 2.4E-04 177.1 
rs2470004 8 120358445 t c 0.818 -0.345 0.039 1.3E-18 2.8E-04 209.1 
rs6986368 8 126513197 a t 0.673 -0.213 0.033 9.6E-11 2.6E-04 187.5 
rs2608029 8 129170126 c g 0.665 0.181 0.032 1.6E-08 2.2E-04 162.9 
rs4260863 8 129386613 c g 0.616 0.191 0.031 1.2E-09 2.5E-04 180.3 
rs7012866 8 135616959 t g 0.499 -0.233 0.030 1.2E-14 3.2E-04 235.6 
rs4440615 8 141057641 a g 0.632 -0.220 0.031 1.9E-12 2.8E-04 207.7 
rs4961293 8 141812374 t c 0.451 0.227 0.030 7.4E-14 3.1E-04 227.9 
rs7463212 8 143991858 a t 0.545 -0.275 0.031 1.8E-19 3.8E-04 273.6 
rs71499040 8 1711918 c g 0.708 0.222 0.034 5.6E-11 2.5E-04 184.6 
rs7844887 8 23402482 a g 0.221 0.266 0.036 2.4E-13 2.5E-04 185.9 
rs7821832 8 25889446 t g 0.745 0.422 0.035 6.7E-34 4.4E-04 322.1 
rs77375686 8 26043622 a g 0.888 -0.347 0.049 8.4E-13 1.9E-04 139.6 
rs1906672 8 38130025 a g 0.232 0.297 0.036 1.2E-16 2.9E-04 214.4 
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rs4873492 8 51947549 t c 0.172 0.343 0.040 1.6E-17 2.7E-04 198.7 
rs2354862 8 64501744 a c 0.641 0.251 0.032 2.4E-15 3.2E-04 231.4 
rs13253358 8 68920135 t c 0.298 0.213 0.033 1.1E-10 2.4E-04 180.5 
rs2126474 8 76878957 t g 0.413 -0.260 0.031 1.9E-17 3.5E-04 255.4 
rs9918876 8 77681097 a c 0.104 -0.298 0.050 2.3E-09 1.5E-04 112.2 
rs148401029 8 81386066 a c 0.035 -0.462 0.085 5.0E-08 8.6E-05 63.7 
rs10091532 8 82853793 a c 0.417 -0.207 0.031 1.3E-11 2.8E-04 203.9 
rs843093 8 92528310 a g 0.709 -0.209 0.034 7.0E-10 2.4E-04 174.4 
rs2613203 8 95253197 a t 0.815 -0.268 0.039 5.8E-12 2.2E-04 164.2 
rs10980408 9 113249071 t c 0.964 -0.761 0.083 3.8E-20 1.4E-04 107.9 
rs7026176 9 116670743 t g 0.512 -0.187 0.030 4.0E-10 2.6E-04 191.5 
rs34025993 9 123516572 a g 0.414 0.223 0.031 4.7E-13 3.0E-04 221.5 
rs4838021 9 125657099 t c 0.129 -0.301 0.045 3.1E-11 1.9E-04 136.9 
rs13289468 9 128180332 a c 0.574 0.249 0.031 3.9E-16 3.3E-04 249.1 
rs6271 9 136522274 t c 0.074 -0.555 0.061 1.2E-19 2.1E-04 153.0 
rs11145807 9 139520789 a g 0.406 0.214 0.032 3.5E-11 2.8E-04 204.2 
rs9886665 9 22942770 t c 0.267 0.205 0.034 2.5E-09 2.2E-04 162.2 
rs4553000 9 34223553 t c 0.514 -0.204 0.030 1.1E-11 2.8E-04 208.4 
rs76452347 9 35906471 t c 0.205 -0.297 0.040 7.1E-14 2.7E-04 198.2 
rs927315 9 4117713 t c 0.471 0.169 0.030 2.4E-08 2.3E-04 172.3 
rs60191654 9 753648 a g 0.812 -0.238 0.039 5.9E-10 2.0E-04 149.2 
rs1410222 9 77239540 t c 0.817 0.217 0.039 2.2E-08 1.8E-04 133.4 
rs1332813 9 9350706 t c 0.351 0.220 0.031 2.3E-12 2.8E-04 205.9 
rs7045409 9 95201540 a t 0.367 -0.186 0.031 2.5E-09 2.4E-04 176.4 
rs5742643 12 102837863 t c 0.249 -0.223 0.035 1.5E-10 2.3E-04 169.9 
rs7310615 12 111865049 c g 0.482 0.585 0.031 1.3E-81 8.0E-04 592.1 
rs1896326 12 115342956 a g 0.229 -0.280 0.037 4.4E-14 2.7E-04 202.0 
rs35444 12 115552437 a g 0.614 0.437 0.031 3.5E-45 5.7E-04 420.0 
rs6490019 12 115920472 a g 0.380 -0.290 0.031 6.6E-21 3.7E-04 279.8 
rs1169078 12 122416254 c g 0.688 -0.197 0.033 1.7E-09 2.3E-04 173.3 
rs2024385 12 12888438 a t 0.424 -0.264 0.031 5.9E-18 3.5E-04 264.6 
rs117206641 12 133086888 t c 0.111 0.315 0.050 2.7E-10 1.7E-04 123.9 
rs1010064 12 20000315 a c 0.816 0.357 0.039 3.0E-20 2.9E-04 219.6 
rs73075659 12 20373541 a g 0.665 0.396 0.032 5.5E-35 4.8E-04 361.2 
rs3819532 12 2436837 t c 0.391 -0.188 0.031 9.4E-10 2.5E-04 182.9 
rs2129869 12 26457650 a t 0.778 -0.264 0.036 2.4E-13 2.5E-04 186.8 
rs78998485 12 434755 c g 0.744 -0.245 0.035 1.5E-12 2.6E-04 190.8 
rs61917655 12 48210787 t c 0.101 0.343 0.051 2.7E-11 1.7E-04 128.0 
rs57342147 12 50129422 a g 0.903 0.279 0.051 4.2E-08 1.3E-04 100.4 
rs12426261 12 50573037 a g 0.379 0.378 0.031 2.3E-34 4.9E-04 364.4 
rs7134440 12 53450097 t c 0.082 0.479 0.056 1.6E-17 2.0E-04 148.1 
rs7134677 12 54441498 t c 0.298 -0.385 0.033 4.5E-31 4.4E-04 329.8 
rs7306710 12 66376091 t c 0.481 -0.243 0.030 1.0E-15 3.3E-04 248.6 
rs4143175 12 67782397 t c 0.241 0.219 0.035 5.1E-10 2.2E-04 163.7 
rs7963801 12 79685226 t c 0.422 -0.236 0.031 2.9E-14 3.2E-04 235.9 
rs6539467 12 79955306 a g 0.166 0.265 0.040 5.6E-11 2.0E-04 150.5 
rs113695818 12 8837407 t c 0.303 -0.184 0.033 2.6E-08 2.1E-04 158.9 
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rs17249754 12 90060586 a g 0.168 -0.845 0.040 1.3E-97 6.5E-04 483.5 
rs10777213 12 90349999 a g 0.524 -0.179 0.030 2.5E-09 2.4E-04 182.6 
rs9549627 13 113652369 a g 0.118 0.285 0.050 1.2E-08 1.6E-04 118.3 
rs7331680 13 115000650 t g 0.149 0.410 0.042 3.4E-22 2.9E-04 212.5 
rs483071 13 22294117 t c 0.625 0.271 0.031 5.1E-18 3.5E-04 260.0 
rs9507885 13 27951090 t c 0.095 -0.321 0.054 3.2E-09 1.5E-04 112.6 
rs7338758 13 30137828 t c 0.245 0.355 0.035 7.0E-24 3.6E-04 266.1 
rs4274337 13 41967193 a g 0.170 -0.297 0.041 2.5E-13 2.3E-04 171.5 
rs7491248 13 47180671 a g 0.224 0.216 0.036 2.4E-09 2.1E-04 152.4 
rs9526707 13 51489186 a g 0.322 -0.204 0.032 2.8E-10 2.4E-04 182.1 
rs75961402 13 56398286 a g 0.153 0.266 0.042 1.9E-10 1.9E-04 141.6 
rs17245822 13 73131694 a c 0.627 -0.190 0.031 1.2E-09 2.4E-04 182.1 
rs78474310 13 73826901 a g 0.955 -0.470 0.073 1.5E-10 1.1E-04 82.4 
rs6562778 13 74223828 a g 0.459 0.178 0.030 5.0E-09 2.4E-04 181.0 
rs17562391 14 100133250 t c 0.419 0.197 0.031 1.3E-10 2.6E-04 196.3 
rs75016974 14 100197940 t c 0.142 -0.251 0.044 1.0E-08 1.7E-04 125.6 
rs12885878 14 104007555 a g 0.234 -0.229 0.037 4.3E-10 2.3E-04 168.0 
rs365990 14 23861811 a g 0.634 0.225 0.031 6.0E-13 2.9E-04 214.0 
rs8904 14 35871217 a g 0.368 0.306 0.031 1.7E-22 3.9E-04 289.5 
rs7493678 14 39400917 a t 0.651 -0.189 0.032 2.3E-09 2.4E-04 176.0 
rs72683923 14 50735947 t c 0.979 0.959 0.110 3.1E-18 1.1E-04 81.3 
rs35413927 14 53420358 a g 0.695 -0.300 0.033 5.3E-20 3.5E-04 261.1 
rs12883810 14 68032235 t c 0.146 -0.238 0.043 2.7E-08 1.6E-04 120.4 
rs57786342 14 69260028 a g 0.206 0.232 0.037 5.6E-10 2.1E-04 155.3 
rs8003103 14 71451265 a g 0.345 -0.176 0.032 3.6E-08 2.2E-04 162.5 
rs3815460 14 73422259 c g 0.898 -0.285 0.050 1.2E-08 1.4E-04 106.7 
rs11159091 14 75074316 a g 0.462 0.198 0.030 6.8E-11 2.7E-04 198.9 
rs7154723 14 98590629 a g 0.385 0.253 0.031 2.7E-16 3.3E-04 245.3 
rs4606697 15 100087596 a g 0.104 -0.320 0.052 9.7E-10 1.6E-04 121.3 
rs8030856 15 40314967 c g 0.605 -0.176 0.031 1.2E-08 2.3E-04 172.6 
rs28866311 15 41442195 t g 0.526 -0.276 0.030 5.5E-20 3.8E-04 282.4 
rs4775769 15 48939888 t g 0.095 -0.416 0.052 7.8E-16 2.0E-04 146.0 
rs3098186 15 50810621 t c 0.516 -0.242 0.030 1.4E-15 3.3E-04 248.0 
rs2652812 15 63406170 t c 0.754 -0.252 0.035 1.0E-12 2.6E-04 190.9 
rs28429256 15 66931617 a g 0.334 0.215 0.033 3.9E-11 2.6E-04 195.6 
rs11636952 15 75114322 t c 0.314 0.531 0.033 4.2E-59 6.3E-04 458.2 
rs2627313 15 81006712 t c 0.445 0.321 0.030 3.6E-26 4.4E-04 321.2 
rs1994158 15 86064327 a g 0.819 0.251 0.039 1.2E-10 2.0E-04 152.1 
rs17807723 15 90023558 a g 0.138 -0.272 0.044 8.4E-10 1.8E-04 131.3 
rs4932373 15 91429287 a c 0.674 -0.635 0.033 2.5E-83 7.7E-04 556.0 
rs12906962 15 95312071 t c 0.676 -0.265 0.033 3.3E-16 3.2E-04 237.3 
rs2589218 15 96785017 t c 0.730 -0.226 0.034 2.5E-11 2.4E-04 182.1 
rs11075030 16 11976414 a c 0.594 -0.175 0.031 1.7E-08 2.3E-04 168.7 
rs11641374 16 1347717 a c 0.600 -0.194 0.031 3.3E-10 2.6E-04 190.2 
rs77924615 16 20392332 a g 0.199 -0.408 0.039 1.1E-25 3.6E-04 265.6 
rs12596630 16 2065666 t c 0.090 0.428 0.055 5.0E-15 1.9E-04 139.7 
rs7186298 16 21088031 t c 0.430 -0.232 0.030 1.9E-14 3.1E-04 232.6 
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rs8044992 16 24811207 t c 0.712 0.214 0.033 1.1E-10 2.4E-04 179.6 
rs7189884 16 4145164 a g 0.115 -0.314 0.048 4.2E-11 1.7E-04 130.5 
rs12446456 16 4922201 t c 0.427 -0.300 0.030 3.0E-23 4.0E-04 301.4 
rs34941092 16 50550137 a g 0.150 -0.323 0.043 3.2E-14 2.3E-04 168.4 
rs4784541 16 51704452 t c 0.475 -0.202 0.031 4.9E-11 2.8E-04 205.7 
rs35098810 16 60635748 a c 0.768 0.197 0.036 3.2E-08 1.9E-04 143.6 
rs146550789 16 66781040 t c 0.958 -0.482 0.078 5.6E-10 1.1E-04 79.0 
rs62047964 16 70729954 t c 0.062 0.512 0.069 9.3E-14 1.6E-04 120.8 
rs1012089 16 74171973 c g 0.475 -0.192 0.030 2.0E-10 2.6E-04 196.3 
rs4888408 16 75432824 a g 0.586 0.365 0.031 1.4E-32 4.9E-04 363.1 
rs12926550 16 81510155 a g 0.316 -0.255 0.032 3.4E-15 3.0E-04 225.7 
rs8054587 16 86170044 t c 0.527 0.167 0.030 3.4E-08 2.3E-04 169.9 
rs3950627 16 86436343 a c 0.531 0.185 0.031 1.8E-09 2.5E-04 187.2 
rs6540119 16 87984477 a t 0.334 0.202 0.032 3.9E-10 2.5E-04 183.9 
rs908951 16 89697625 t c 0.438 -0.226 0.032 7.1E-13 3.1E-04 224.6 
rs8079811 17 1371473 c g 0.348 -0.210 0.033 1.0E-10 2.6E-04 193.7 
rs4925159 17 18185510 a g 0.425 0.217 0.031 9.7E-13 2.9E-04 215.4 
rs7211535 17 19922364 a g 0.476 -0.178 0.030 4.6E-09 2.4E-04 179.9 
rs2760748 17 2001604 a t 0.098 0.363 0.051 1.1E-12 1.8E-04 131.3 
rs1551355 17 30032420 t c 0.233 0.210 0.036 3.9E-09 2.1E-04 153.9 
rs9899540 17 30777924 a t 0.400 0.201 0.032 1.9E-10 2.7E-04 197.6 
rs7213273 17 43155914 a g 0.655 -0.400 0.032 6.2E-37 5.0E-04 370.7 
rs17608766 17 45013271 t c 0.856 -0.690 0.043 2.5E-57 4.7E-04 346.1 
rs3764400 17 46123932 t c 0.864 0.375 0.045 3.7E-17 2.4E-04 180.9 
rs9897429 17 47518378 a g 0.520 0.265 0.032 1.2E-16 3.6E-04 270.3 
rs1000423 17 59475642 t c 0.732 0.414 0.035 6.5E-33 4.5E-04 329.3 
rs56288724 17 60767135 a g 0.583 -0.218 0.031 2.0E-12 2.9E-04 216.8 
rs62076622 17 61090958 a g 0.801 0.236 0.038 3.8E-10 2.1E-04 154.3 
rs6504213 17 62381714 t c 0.418 -0.298 0.031 1.2E-21 4.0E-04 297.1 
rs113086489 17 7171356 t c 0.553 0.325 0.031 3.8E-26 4.4E-04 329.0 
rs4511593 17 7455536 t c 0.653 -0.288 0.032 1.3E-19 3.6E-04 264.8 
rs1436138 17 75316880 a g 0.637 0.312 0.032 4.7E-23 4.0E-04 295.4 
rs9302885 17 76799898 a g 0.445 0.224 0.030 1.0E-13 3.0E-04 226.7 
rs79930761 17 7815712 t c 0.087 -0.469 0.056 4.9E-17 2.1E-04 153.0 
rs11655604 17 79365861 t c 0.358 -0.203 0.033 1.1E-09 2.6E-04 179.7 
rs62082230 18 22676071 a t 0.277 -0.188 0.035 4.7E-08 2.1E-04 154.6 
rs1154214 18 24546824 t g 0.396 -0.203 0.031 3.3E-11 2.7E-04 198.9 
rs56407827 18 42179819 t c 0.269 0.360 0.034 2.8E-26 3.9E-04 289.9 
rs11874246 18 42596789 t c 0.296 0.286 0.033 3.2E-18 3.3E-04 244.2 
rs7236548 18 43097750 a c 0.185 0.343 0.039 8.5E-19 2.8E-04 211.9 
rs1437649 18 48132646 a g 0.235 -0.219 0.036 8.6E-10 2.2E-04 161.1 
rs665445 18 51842682 a c 0.279 -0.191 0.033 1.2E-08 2.1E-04 157.6 
rs10048404 18 54578482 t c 0.370 -0.261 0.032 1.9E-16 3.3E-04 248.9 
rs10460108 18 73034151 a g 0.480 0.214 0.030 1.1E-12 2.9E-04 219.1 
rs34413141 18 777282 a t 0.182 -0.353 0.039 2.5E-19 2.9E-04 215.7 
rs3816865 19 11507855 a g 0.080 0.309 0.057 4.4E-08 1.3E-04 92.4 
rs167479 19 11526765 t g 0.473 -0.564 0.033 7.2E-67 7.7E-04 522.5 
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rs698748 19 1424888 a g 0.421 0.187 0.033 8.9E-09 2.5E-04 181.0 
rs8106184 19 17159779 a c 0.745 -0.237 0.035 8.3E-12 2.5E-04 184.7 
rs149339216 19 2144046 t c 0.957 -0.691 0.078 6.9E-19 1.6E-04 114.2 
rs4319878 19 21924452 t c 0.561 0.169 0.031 3.8E-08 2.3E-04 170.9 
rs8108027 19 22115901 c g 0.295 0.195 0.033 3.7E-09 2.2E-04 166.0 
rs28572357 19 31867447 a c 0.602 -0.273 0.031 6.3E-19 3.6E-04 266.8 
rs1433121 19 32591878 t c 0.691 -0.228 0.033 2.7E-12 2.7E-04 199.7 
rs33836 19 34008600 t c 0.462 0.177 0.030 6.6E-09 2.4E-04 180.0 
rs10420519 19 45298461 t g 0.035 -0.492 0.089 2.9E-08 9.1E-05 66.9 
rs7255933 19 45766729 a g 0.257 0.231 0.035 2.4E-11 2.4E-04 180.7 
rs11672660 19 46180184 t c 0.200 0.221 0.038 6.3E-09 1.9E-04 143.2 
rs571689 19 49207554 t c 0.520 0.228 0.030 6.8E-14 3.1E-04 230.6 
rs73046792 19 49605705 a g 0.159 -0.355 0.043 7.2E-17 2.6E-04 192.4 
rs68096471 19 5175709 a g 0.266 -0.210 0.034 9.3E-10 2.3E-04 167.9 
rs12985940 19 7262734 t c 0.841 0.464 0.043 1.1E-26 3.4E-04 246.5 
rs2423514 20 10693337 a g 0.541 0.301 0.030 1.8E-23 4.1E-04 306.6 
rs6108787 20 10967214 t g 0.530 -0.427 0.030 5.4E-46 5.9E-04 435.5 
rs6078093 20 11168669 a g 0.428 -0.185 0.030 1.2E-09 2.5E-04 185.3 
rs8125763 20 17883531 a c 0.472 0.176 0.030 4.8E-09 2.4E-04 179.9 
rs17812022 20 19007099 t c 0.096 -0.361 0.053 5.6E-12 1.7E-04 128.1 
rs6058088 20 30139886 t g 0.844 0.283 0.042 1.1E-11 2.1E-04 153.0 
rs79384779 20 31214944 t c 0.151 0.318 0.043 1.1E-13 2.2E-04 167.3 
rs6029756 20 40266681 a g 0.323 -0.271 0.033 1.9E-16 3.3E-04 242.6 
rs6031431 20 42795152 a g 0.538 -0.262 0.030 7.0E-18 3.6E-04 266.0 
rs2598 20 47241618 a g 0.533 0.168 0.030 2.9E-08 2.3E-04 171.4 
rs6090907 20 47410231 a g 0.147 -0.385 0.043 1.3E-19 2.7E-04 198.1 
rs234623 20 57488964 a g 0.504 -0.180 0.030 2.4E-09 2.5E-04 183.8 
rs6026744 20 57742388 a t 0.877 -0.713 0.046 7.0E-54 4.2E-04 313.3 
rs28374392 20 61189717 t c 0.623 0.192 0.034 1.2E-08 2.5E-04 168.4 
rs6062324 20 62446351 a g 0.236 -0.329 0.036 1.2E-19 3.3E-04 241.5 
rs6054139 20 6327810 a g 0.606 0.209 0.031 8.2E-12 2.7E-04 205.0 
rs2776037 21 16317933 t c 0.415 -0.185 0.031 2.1E-09 2.5E-04 183.7 
rs1882961 21 16556367 t c 0.309 0.244 0.033 6.7E-14 2.9E-04 213.8 
rs2833834 21 33814378 a c 0.277 0.218 0.034 1.2E-10 2.4E-04 176.6 
rs12627651 21 44760603 a g 0.287 0.350 0.034 1.0E-24 3.9E-04 292.0 
rs34487963 21 44838330 a c 0.019 -0.882 0.124 1.4E-12 8.8E-05 63.0 
rs7278003 21 44966069 t c 0.438 -0.188 0.030 6.6E-10 2.5E-04 189.1 
rs2238787 22 19976406 a g 0.292 0.255 0.033 1.5E-14 2.9E-04 215.7 
rs12321 22 29453193 c g 0.433 -0.229 0.030 3.8E-14 3.1E-04 230.7 
rs112854918 22 30588910 c g 0.975 -0.558 0.100 2.8E-08 7.6E-05 56.7 
rs8142376 22 32001037 t c 0.491 0.168 0.030 2.2E-08 2.3E-04 171.7 
rs148140538 22 50228044 t c 0.081 -0.325 0.056 7.4E-09 1.3E-04 98.5 
rs28578714 22 50727921 t c 0.606 0.207 0.033 2.5E-10 2.7E-04 193.3 
a 𝑅2 =  
2×𝐸𝐴𝐹×(1−𝐸𝐴𝐹)×𝑏𝑒𝑡𝑎2
𝑆𝐷2
  , 𝑤ℎere EAF is the effect allele frequency and beta is the effect estimate of the SNP on SBP (Shim 2015, PLoS 
One;10(4):e0120758). 
b F = 
𝑅2×(𝑁−2)
1−𝑅2
  where R2 is the variance of SBP explained by the specific SNP (as explained above) and N the number of individuals in the GWAS 
analysis (Palmer 2012, Stat Methods Med Res;21(3):223-42). 
CHR: chromosome; EAF: effect allele frequency; SE: standard error; SNP: single nucleotide polymorphism.  
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Table e-2. Genome-wide significant (p<5x10-8) and independent (r2<0.001) single nucleotide polymorphisms (SNP) 








EAF beta SE p-value R2 a Fb 
rs488834 1 10767902 t c 0.764 -0.193 0.021 1.9E-20 1.9E-04 142.4 
rs10776752 1 1.13E+08 t g 0.081 0.457 0.033 1.2E-43 1.9E-04 141.0 
rs57748895 1 1.16E+08 a t 0.982 -0.663 0.067 2.5E-23 6.4E-05 48.4 
rs55857306 1 11895795 a g 0.160 -0.522 0.024 5.1E-109 3.9E-04 292.0 
rs72704264 1 1.46E+08 c g 0.217 0.117 0.021 3.6E-08 1.1E-04 82.8 
rs1819663 1 1.54E+08 a g 0.507 0.115 0.017 4.6E-11 1.6E-04 118.0 
rs11578696 1 1.56E+08 a g 0.866 0.146 0.026 1.7E-08 9.3E-05 70.5 
rs1889785 1 16348729 a g 0.455 0.126 0.017 5.6E-13 1.7E-04 129.6 
rs7524019 1 1.67E+08 t c 0.492 0.104 0.017 2.6E-09 1.4E-04 107.8 
rs12405515 1 1.72E+08 t g 0.570 -0.170 0.017 1.9E-22 2.3E-04 172.8 
rs34645159 1 1724366 a g 0.501 -0.133 0.017 2.1E-14 1.8E-04 138.5 
rs150816167 1 1.8E+08 t c 0.955 -0.287 0.045 1.2E-10 6.8E-05 51.5 
rs1999996 1 1.85E+08 a g 0.559 -0.112 0.018 1.7E-10 1.5E-04 112.4 
rs882624 1 2.02E+08 t c 0.333 -0.157 0.019 2.3E-17 1.9E-04 143.6 
rs2169137 1 2.04E+08 c g 0.729 0.159 0.019 3.2E-16 1.7E-04 130.7 
rs1502358 1 2.17E+08 a g 0.681 -0.113 0.019 1.1E-09 1.3E-04 101.8 
rs68085857 1 2.18E+08 t c 0.234 0.191 0.021 9.8E-21 1.9E-04 142.6 
rs35981664 1 2.19E+08 a t 0.688 -0.161 0.019 2.0E-17 1.9E-04 143.4 
rs2760061 1 2.28E+08 a t 0.480 0.177 0.018 1.0E-23 2.4E-04 183.9 
rs699 1 2.31E+08 a g 0.593 -0.236 0.018 1.3E-40 3.1E-04 231.8 
rs3943093 1 2.43E+08 t c 0.323 0.248 0.018 3.9E-41 3.0E-04 225.7 
rs4926499 1 2.49E+08 c g 0.826 0.169 0.025 9.4E-12 1.3E-04 97.8 
rs6686889 1 25030470 t c 0.253 0.192 0.020 6.9E-22 2.0E-04 151.1 
rs12728150 1 27268737 a g 0.919 -0.205 0.032 1.3E-10 8.4E-05 63.4 
rs2493296 1 3327032 t c 0.142 0.250 0.025 7.5E-23 1.7E-04 124.2 
rs2146315 1 42050366 t c 0.232 -0.120 0.021 5.0E-09 1.2E-04 88.6 
rs710249 1 43869235 c g 0.426 0.150 0.017 6.4E-18 2.0E-04 152.9 
rs4926901 1 48025824 a g 0.355 0.098 0.018 4.8E-08 1.2E-04 93.8 
rs4926923 1 48109225 t c 0.912 0.192 0.031 4.7E-10 8.5E-05 63.6 
rs78256308 1 50814474 t g 0.981 0.411 0.066 3.7E-10 4.3E-05 32.5 
rs10493408 1 66992054 a c 0.133 0.158 0.026 5.1E-10 1.0E-04 75.3 
rs34517439 1 78450517 a c 0.120 -0.251 0.028 2.0E-19 1.5E-04 110.2 
rs786921 1 89286673 a g 0.596 -0.115 0.018 8.6E-11 1.5E-04 113.3 
rs17396055 1 94730954 a g 0.332 -0.115 0.018 4.1E-10 1.4E-04 105.1 
rs1006545 10 1.03E+08 t g 0.888 0.363 0.028 8.0E-40 2.0E-04 151.1 
rs2273654 10 1.03E+08 t c 0.561 0.117 0.018 2.8E-11 1.6E-04 118.2 
rs12414028 10 1.05E+08 a t 0.088 -0.514 0.031 1.6E-60 2.3E-04 172.0 
rs2067831 10 1.06E+08 c g 0.272 -0.128 0.020 5.1E-11 1.4E-04 105.6 
rs2484294 10 1.16E+08 a g 0.733 0.317 0.020 1.2E-58 3.4E-04 258.2 
rs72842207 10 1.21E+08 t c 0.215 -0.211 0.021 1.1E-23 2.0E-04 148.4 
rs11592107 10 1.23E+08 a g 0.309 0.120 0.019 1.2E-10 1.4E-04 107.0 
rs10490923 10 1.24E+08 a g 0.126 0.153 0.026 5.0E-09 9.3E-05 70.1 
rs9419374 10 1.34E+08 a g 0.354 0.116 0.019 3.4E-10 1.5E-04 110.6 
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rs1133400 10 1.34E+08 a g 0.785 -0.132 0.022 8.3E-10 1.2E-04 90.7 
rs6602177 10 17167141 t c 0.707 -0.120 0.021 6.5E-09 1.4E-04 103.6 
rs1623474 10 18471794 t c 0.330 0.223 0.018 6.2E-34 2.7E-04 205.7 
rs12258967 10 18727959 c g 0.704 0.354 0.019 3.3E-75 4.1E-04 306.7 
rs3802517 10 28233469 a t 0.462 0.129 0.017 9.3E-14 1.8E-04 133.1 
rs1265842 10 28924901 t c 0.483 0.111 0.017 1.7E-10 1.5E-04 115.7 
rs2487926 10 30300787 a g 0.571 0.097 0.018 3.3E-08 1.3E-04 99.2 
rs3006583 10 31280845 t c 0.811 -0.130 0.022 4.7E-09 1.1E-04 83.0 
rs11252324 10 4124568 t g 0.077 -0.234 0.033 1.0E-12 9.1E-05 69.2 
rs4948643 10 45379759 t c 0.282 0.159 0.019 2.3E-16 1.8E-04 134.0 
rs34130368 10 48411796 t g 0.117 -0.203 0.028 8.8E-13 1.2E-04 87.1 
rs72831343 10 63515681 t g 0.858 0.494 0.025 4.8E-88 3.3E-04 249.0 
rs2236295 10 64564892 t g 0.399 -0.207 0.018 1.4E-31 2.7E-04 206.8 
rs35506078 10 65210552 t c 0.663 -0.135 0.018 1.5E-13 1.7E-04 125.4 
rs12247028 10 75410052 a g 0.632 -0.140 0.019 1.2E-13 1.8E-04 132.8 
rs2274224 10 96039597 c g 0.433 -0.279 0.017 1.2E-57 3.8E-04 284.6 
rs604723 11 1.01E+08 t c 0.275 -0.385 0.019 2.3E-87 4.2E-04 319.4 
rs66682451 11 1.07E+08 a g 0.725 0.135 0.019 3.4E-12 1.5E-04 111.8 
rs7106104 11 1.12E+08 t c 0.719 -0.119 0.019 7.7E-10 1.3E-04 99.8 
rs12790943 11 1.2E+08 t c 0.421 -0.100 0.018 1.1E-08 1.3E-04 101.7 
rs12574332 11 1.23E+08 t c 0.123 0.207 0.027 6.1E-15 1.2E-04 92.9 
rs4936099 11 1.3E+08 a c 0.599 0.175 0.018 1.2E-22 2.3E-04 174.1 
rs7107711 11 13255538 c g 0.778 0.126 0.021 1.7E-09 1.2E-04 90.3 
rs7123705 11 14255043 c g 0.816 -0.147 0.023 7.9E-11 1.2E-04 91.7 
rs28570096 11 1616088 t c 0.309 0.140 0.019 1.1E-13 1.6E-04 124.2 
rs10832586 11 16304089 a c 0.798 -0.308 0.022 2.5E-46 2.7E-04 206.7 
rs7926335 11 16917869 t c 0.270 0.180 0.020 2.0E-20 2.0E-04 147.6 
rs79889784 11 1702117 t g 0.018 -0.394 0.072 3.9E-08 3.7E-05 25.8 
rs569550 11 1887068 t g 0.605 -0.269 0.018 1.2E-49 3.5E-04 260.6 
rs147081004 11 1919980 a c 0.856 0.141 0.026 4.1E-08 9.6E-05 70.9 
rs10500932 11 22501446 a g 0.074 0.278 0.033 5.8E-17 1.1E-04 79.6 
rs962369 11 27734420 t c 0.699 0.168 0.019 6.0E-19 1.9E-04 146.0 
rs7933758 11 31000774 t c 0.305 -0.114 0.019 2.6E-09 1.3E-04 100.3 
rs10838702 11 47410888 t g 0.388 0.238 0.018 1.3E-40 3.1E-04 234.1 
rs10839259 11 49321410 t c 0.763 0.145 0.021 2.1E-12 1.4E-04 109.1 
rs751984 11 61278246 t c 0.883 0.394 0.028 1.4E-46 2.2E-04 167.6 
rs35927325 11 63882495 t c 0.061 0.222 0.036 1.0E-09 7.0E-05 53.1 
rs2306363 11 65405600 t g 0.205 -0.264 0.022 1.6E-34 2.4E-04 179.3 
rs11228613 11 69068492 t g 0.784 0.174 0.021 2.1E-16 1.6E-04 121.5 
rs504217 11 72006086 t c 0.074 0.275 0.034 2.5E-16 1.0E-04 77.1 
rs7115331 11 76218590 t g 0.714 -0.127 0.019 3.9E-11 1.4E-04 107.6 
rs11021221 11 95308854 a t 0.167 -0.188 0.023 6.9E-16 1.4E-04 108.6 
rs61909958 11 96151677 c g 0.812 0.128 0.023 2.2E-08 1.1E-04 81.0 
rs360153 11 9762274 t c 0.417 -0.220 0.018 4.4E-36 2.9E-04 222.6 
rs28377357 2 1.13E+08 a g 0.294 -0.124 0.019 6.0E-11 1.4E-04 107.2 
rs62158170 2 1.14E+08 a g 0.783 0.165 0.021 6.6E-15 1.5E-04 116.2 
rs13021015 2 1.27E+08 a c 0.160 0.152 0.024 2.3E-10 1.1E-04 84.7 
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rs4954192 2 1.36E+08 t c 0.387 -0.123 0.018 8.1E-12 1.6E-04 118.5 
rs55944332 2 1.46E+08 a g 0.763 -0.237 0.020 3.3E-31 2.3E-04 178.0 
rs12990959 2 1.49E+08 t c 0.688 -0.127 0.019 1.1E-11 1.5E-04 113.7 
rs2444769 2 1.58E+08 a c 0.795 0.158 0.022 4.8E-13 1.4E-04 107.0 
rs7572130 2 1.64E+08 a g 0.896 -0.180 0.029 4.1E-10 9.2E-05 69.8 
rs73029563 2 1.65E+08 c g 0.455 -0.259 0.017 5.8E-50 3.5E-04 267.4 
rs6735275 2 1.74E+08 t c 0.729 0.123 0.019 2.6E-10 1.3E-04 100.8 
rs6715901 2 1.8E+08 a g 0.496 -0.138 0.017 2.8E-15 1.9E-04 141.7 
rs12693302 2 1.83E+08 a g 0.652 -0.238 0.018 2.2E-39 3.0E-04 224.8 
rs7576060 2 1.88E+08 t c 0.350 -0.102 0.018 2.1E-08 1.3E-04 96.3 
rs7592578 2 1.91E+08 t g 0.194 -0.200 0.022 4.7E-19 1.7E-04 129.8 
rs1373780 2 19501029 c g 0.185 0.125 0.022 2.6E-08 1.0E-04 77.7 
rs824523 2 19707855 a c 0.334 0.123 0.018 2.3E-11 1.5E-04 113.6 
rs11692619 2 2.05E+08 t c 0.361 -0.128 0.018 3.3E-12 1.6E-04 122.9 
rs1263671 2 2.08E+08 t c 0.837 -0.139 0.024 4.7E-09 1.0E-04 79.2 
rs4675682 2 2.08E+08 t c 0.538 -0.141 0.017 4.5E-16 1.9E-04 145.9 
rs1035673 2 2.19E+08 t c 0.397 0.163 0.018 3.0E-20 2.1E-04 162.0 
rs13004222 2 2.2E+08 c g 0.949 0.294 0.039 7.1E-14 7.8E-05 59.3 
rs1039897 2 2.2E+08 a g 0.650 -0.109 0.018 3.3E-09 1.4E-04 102.8 
rs10804330 2 2.27E+08 t c 0.567 0.133 0.018 4.6E-14 1.8E-04 135.7 
rs1044822 2 2.31E+08 t c 0.149 -0.133 0.024 4.1E-08 9.3E-05 70.4 
rs4507125 2 2.4E+08 a c 0.786 -0.124 0.021 3.6E-09 1.1E-04 87.0 
rs11687089 2 25082926 t c 0.583 0.174 0.018 2.8E-23 2.3E-04 176.1 
rs1275988 2 26914364 t c 0.611 -0.295 0.018 1.9E-62 3.8E-04 291.5 
rs1468816 2 37595696 a c 0.772 0.124 0.021 4.6E-09 1.2E-04 89.7 
rs11124595 2 37887589 t g 0.260 0.111 0.020 2.4E-08 1.2E-04 89.1 
rs2160236 2 40557276 c g 0.379 -0.142 0.018 4.3E-15 1.8E-04 137.5 
rs76326501 2 43167878 a c 0.909 0.362 0.031 2.2E-32 1.6E-04 124.6 
rs4952668 2 43386568 a g 0.624 -0.192 0.018 1.1E-26 2.5E-04 187.7 
rs2586970 2 55829967 a g 0.436 -0.149 0.018 1.6E-17 2.0E-04 149.9 
rs2421200 2 61711815 t g 0.488 -0.110 0.017 2.6E-10 1.5E-04 114.1 
rs1876490 2 73052351 a g 0.717 0.136 0.019 1.2E-12 1.5E-04 115.2 
rs6546810 2 73389716 t c 0.648 -0.120 0.018 3.2E-11 1.5E-04 114.1 
rs311564 2 86293498 a g 0.346 -0.133 0.018 4.2E-13 1.7E-04 125.2 
rs62155750 2 96491456 a g 0.693 -0.218 0.020 8.3E-29 2.5E-04 192.1 
rs112393817 2 9807226 c g 0.783 0.116 0.021 3.8E-08 1.1E-04 82.1 
rs11923667 3 1.01E+08 a t 0.407 0.118 0.018 3.1E-11 1.6E-04 118.0 
rs28675079 3 1.12E+08 a g 0.187 -0.144 0.022 8.3E-11 1.2E-04 91.3 
rs347585 3 11286220 t c 0.701 0.151 0.019 1.6E-15 1.7E-04 131.2 
rs12152463 3 1.22E+08 t c 0.425 0.101 0.017 8.0E-09 1.4E-04 102.4 
rs4141663 3 1.25E+08 t c 0.422 -0.150 0.018 1.4E-17 2.0E-04 151.7 
rs4077158 3 1.34E+08 t c 0.471 -0.183 0.017 3.1E-26 2.5E-04 190.1 
rs9289557 3 1.38E+08 t c 0.260 -0.119 0.021 8.7E-09 1.3E-04 95.1 
rs6763931 3 1.41E+08 a g 0.444 0.138 0.017 1.5E-15 1.9E-04 142.2 
rs1687295 3 14889756 t c 0.270 0.206 0.019 3.0E-26 2.2E-04 169.3 
rs1527797 3 1.54E+08 t c 0.740 -0.141 0.020 8.7E-13 1.5E-04 112.7 
rs78809139 3 1.55E+08 a g 0.101 -0.228 0.029 2.6E-15 1.1E-04 86.5 
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rs78151625 3 1.58E+08 t c 0.834 -0.187 0.023 1.0E-15 1.4E-04 107.6 
rs62234672 3 16592069 a c 0.175 0.125 0.023 4.9E-08 9.9E-05 75.1 
rs16853198 3 1.69E+08 a g 0.924 0.339 0.033 4.4E-25 1.3E-04 99.3 
rs1528293 3 1.69E+08 a t 0.492 0.276 0.017 1.5E-57 3.8E-04 287.0 
rs62294352 3 1.69E+08 t c 0.216 -0.161 0.022 6.1E-13 1.5E-04 110.0 
rs6779368 3 1.85E+08 a g 0.658 -0.179 0.018 2.3E-22 2.2E-04 167.9 
rs147501096 3 1.86E+08 c g 0.072 -0.196 0.034 9.9E-09 7.2E-05 54.4 
rs4244200 3 1.96E+08 c g 0.280 -0.122 0.019 3.2E-10 1.3E-04 101.8 
rs6777317 3 1.97E+08 a g 0.290 0.125 0.020 1.5E-10 1.4E-04 105.7 
rs2643826 3 27562988 t c 0.451 0.186 0.018 2.8E-26 2.5E-04 191.5 
rs7427249 3 37572489 a g 0.580 -0.110 0.018 4.3E-10 1.5E-04 111.4 
rs114714860 3 41882905 c g 0.168 0.330 0.024 1.4E-44 2.5E-04 192.1 
rs6442105 3 48182326 a g 0.327 -0.249 0.019 3.1E-41 3.0E-04 227.9 
rs61018691 3 50538600 c g 0.135 0.160 0.026 3.4E-10 1.0E-04 77.9 
rs1401494 3 53696955 t c 0.473 -0.138 0.017 1.8E-15 1.9E-04 142.0 
rs3772219 3 56771251 a c 0.681 0.175 0.019 2.9E-21 2.1E-04 158.8 
rs11130602 3 57947168 a g 0.443 0.147 0.018 4.3E-17 2.0E-04 150.7 
rs3774702 3 63856870 a g 0.177 0.147 0.023 1.2E-10 1.2E-04 89.1 
rs6795735 3 64705365 t c 0.411 -0.144 0.018 3.1E-16 1.9E-04 143.1 
rs7623706 3 74712754 a g 0.565 0.098 0.018 2.8E-08 1.3E-04 98.6 
rs11923343 3 85668570 a g 0.360 -0.114 0.018 3.1E-10 1.4E-04 108.9 
rs13107325 4 1.03E+08 t c 0.074 -0.675 0.034 3.7E-88 2.5E-04 192.3 
rs12503341 4 1.07E+08 a g 0.039 -0.299 0.046 9.4E-11 6.2E-05 46.8 
rs4245930 4 1.09E+08 a g 0.632 -0.122 0.018 1.1E-11 1.6E-04 117.6 
rs13118687 4 1.11E+08 a g 0.470 -0.150 0.018 1.4E-17 2.0E-04 154.2 
rs66887589 4 1.21E+08 t c 0.522 -0.161 0.017 1.8E-20 2.2E-04 166.6 
rs9286351 4 1.38E+08 a g 0.581 -0.141 0.018 1.6E-15 1.9E-04 142.4 
rs72719149 4 1.44E+08 t c 0.684 -0.128 0.019 6.3E-12 1.5E-04 114.7 
rs13124515 4 1.45E+08 t c 0.313 -0.105 0.019 2.0E-08 1.2E-04 93.8 
rs1123037 4 1.57E+08 a t 0.477 -0.161 0.017 1.6E-20 2.2E-04 167.1 
rs13139571 4 1.57E+08 a c 0.237 -0.241 0.020 2.3E-32 2.4E-04 181.1 
rs1425486 4 1.58E+08 t c 0.321 -0.133 0.019 1.1E-12 1.6E-04 118.0 
rs16896276 4 18015156 a t 0.263 -0.131 0.020 3.8E-11 1.4E-04 105.1 
rs61789369 4 2265295 a g 0.957 -0.304 0.044 3.1E-12 6.9E-05 52.7 
rs28667801 4 26785356 a t 0.593 -0.162 0.018 1.9E-19 2.2E-04 162.2 
rs11721984 4 38343935 t c 0.453 -0.141 0.018 1.9E-15 1.9E-04 143.0 
rs62301873 4 40603821 a g 0.894 -0.173 0.028 1.1E-09 9.0E-05 68.2 
rs11945489 4 56463775 t c 0.291 -0.139 0.019 4.0E-13 1.6E-04 119.4 
rs13152154 4 77417756 t c 0.729 -0.119 0.020 1.2E-09 1.3E-04 96.4 
rs12509595 4 81182554 t c 0.708 -0.497 0.019 1.6E-148 5.7E-04 428.0 
rs72976750 4 86725684 t c 0.860 -0.172 0.025 7.4E-12 1.1E-04 85.5 
rs7694000 4 95324968 a t 0.539 -0.097 0.018 3.5E-08 1.3E-04 99.5 
rs9326869 5 1.12E+08 t c 0.249 0.110 0.020 4.0E-08 1.1E-04 85.3 
rs335170 5 1.22E+08 a c 0.408 0.113 0.018 1.6E-10 1.5E-04 112.3 
rs1582931 5 1.23E+08 a g 0.475 0.216 0.018 4.5E-35 3.0E-04 224.1 
rs17677603 5 1.28E+08 a g 0.616 -0.200 0.018 3.9E-29 2.6E-04 196.7 
rs10069690 5 1279790 t c 0.258 0.162 0.021 1.4E-14 1.7E-04 123.6 
17 
 
rs11745207 5 1.32E+08 c g 0.742 0.113 0.020 1.3E-08 1.2E-04 90.2 
rs1212061 5 1.42E+08 c g 0.732 0.128 0.020 7.9E-11 1.4E-04 104.1 
rs3776299 5 1.43E+08 a g 0.456 0.127 0.018 5.1E-13 1.7E-04 128.8 
rs78909293 5 1.48E+08 t c 0.955 0.321 0.043 7.3E-14 7.6E-05 57.1 
rs2921604 5 14867948 t c 0.537 -0.096 0.018 4.5E-08 1.3E-04 99.4 
rs3117736 5 1.57E+08 t c 0.266 0.237 0.020 9.7E-34 2.5E-04 192.3 
rs11960210 5 1.58E+08 t c 0.625 0.247 0.018 3.4E-43 3.2E-04 237.9 
rs13358657 5 1.58E+08 a g 0.867 -0.224 0.026 1.7E-18 1.4E-04 107.3 
rs6556384 5 1.58E+08 a c 0.811 -0.152 0.022 5.9E-12 1.3E-04 96.8 
rs114503346 5 1.72E+08 t c 0.046 -0.268 0.043 3.1E-10 6.5E-05 48.8 
rs55993676 5 1.73E+08 t g 0.292 -0.210 0.019 3.8E-28 2.4E-04 179.7 
rs1177764 5 32829975 c g 0.405 -0.307 0.018 1.4E-67 4.1E-04 307.9 
rs10941043 5 33194751 t g 0.709 -0.127 0.019 2.5E-11 1.4E-04 108.9 
rs4645335 5 3704761 a g 0.336 0.114 0.019 7.0E-10 1.4E-04 106.0 
rs1467049 5 42440062 t g 0.805 0.124 0.022 1.4E-08 1.1E-04 81.3 
rs6875967 5 50878292 a g 0.352 0.134 0.018 1.2E-13 1.7E-04 127.7 
rs10054208 5 55688992 t c 0.362 0.119 0.019 1.5E-10 1.5E-04 114.0 
rs12515541 5 57095011 t g 0.607 0.116 0.018 6.2E-11 1.5E-04 114.8 
rs1848510 5 57754005 a g 0.362 0.126 0.018 4.1E-12 1.6E-04 119.9 
rs10062049 5 61553881 t c 0.136 0.221 0.026 4.5E-18 1.4E-04 106.8 
rs2307111 5 75003678 t c 0.603 -0.174 0.018 1.6E-22 2.3E-04 169.7 
rs4704514 5 77820081 t c 0.283 0.109 0.019 1.7E-08 1.2E-04 91.9 
rs62380354 5 89484911 a c 0.890 0.183 0.029 3.7E-10 9.8E-05 74.2 
rs13355146 5 92023661 t c 0.383 0.122 0.018 6.4E-12 1.6E-04 120.5 
rs55770741 5 96220087 t c 0.561 -0.128 0.018 2.2E-13 1.7E-04 131.4 
rs1871190 5 97953719 t g 0.334 0.108 0.019 6.6E-09 1.3E-04 99.8 
rs72613227 6 1.06E+08 a t 0.873 -0.188 0.029 3.9E-11 1.1E-04 80.1 
rs7767235 6 1.16E+08 a c 0.353 -0.118 0.018 7.9E-11 1.5E-04 112.4 
rs509067 6 1.17E+08 t c 0.414 -0.144 0.018 2.6E-16 1.9E-04 145.1 
rs11153730 6 1.19E+08 t c 0.509 0.155 0.017 2.6E-19 2.1E-04 161.0 
rs76785130 6 1.22E+08 a g 0.980 -0.429 0.066 9.4E-11 4.6E-05 34.4 
rs13215166 6 1.27E+08 a g 0.559 -0.309 0.017 1.8E-70 4.2E-04 317.8 
rs9399137 6 1.35E+08 t c 0.738 0.115 0.020 5.8E-09 1.2E-04 92.3 
rs636202 6 1.4E+08 t c 0.482 0.102 0.017 4.4E-09 1.4E-04 106.2 
rs9791312 6 1.43E+08 a c 0.655 -0.123 0.018 2.9E-11 1.5E-04 115.2 
rs62434124 6 1.51E+08 t c 0.071 -0.485 0.034 7.8E-47 1.8E-04 133.5 
rs9478282 6 1.52E+08 t c 0.112 -0.199 0.028 8.7E-13 1.1E-04 82.2 
rs2569882 6 1620147 t c 0.566 0.120 0.018 4.3E-11 1.6E-04 122.5 
rs9365555 6 1.64E+08 a g 0.674 0.125 0.019 2.0E-11 1.5E-04 114.6 
rs11961593 6 1.66E+08 t c 0.069 -0.316 0.035 1.5E-19 1.1E-04 81.6 
rs1322639 6 1.7E+08 a g 0.777 -0.158 0.021 3.9E-14 1.5E-04 114.3 
rs67077402 6 20658978 a c 0.683 -0.108 0.019 6.3E-09 1.3E-04 97.2 
rs6934891 6 22139729 a g 0.426 0.128 0.018 5.2E-13 1.7E-04 129.6 
rs2744133 6 22392260 a g 0.725 0.144 0.019 1.2E-13 1.6E-04 119.1 
rs9467545 6 25638464 a t 0.843 -0.255 0.024 7.4E-27 1.9E-04 140.4 
rs198851 6 26104632 t g 0.150 0.389 0.024 2.9E-57 2.7E-04 203.6 
rs6922353 6 26465768 a t 0.852 -0.164 0.024 1.4E-11 1.1E-04 86.5 
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rs389883 6 31947460 t g 0.686 0.249 0.019 4.8E-40 2.9E-04 220.2 
rs115447786 6 34354073 t c 0.043 0.290 0.046 1.7E-10 6.5E-05 49.1 
rs10947786 6 39156410 a g 0.221 -0.138 0.021 4.6E-11 1.3E-04 98.8 
rs6905288 6 43758873 a g 0.568 0.176 0.018 7.8E-23 2.4E-04 178.4 
rs881858 6 43806609 a g 0.694 0.155 0.019 4.7E-16 1.8E-04 136.2 
rs2397060 6 51611470 t c 0.860 -0.161 0.025 1.5E-10 1.1E-04 79.1 
rs1114347 6 51834297 a g 0.518 -0.179 0.017 3.3E-25 2.5E-04 186.3 
rs62413546 6 56012664 t c 0.085 -0.188 0.032 4.6E-09 8.0E-05 60.5 
rs504691 6 72206620 a c 0.400 -0.118 0.018 3.1E-11 1.6E-04 117.4 
rs1984195 6 79657391 a g 0.488 0.174 0.017 1.4E-23 2.4E-04 178.7 
rs9406076 6 8023804 t c 0.328 0.101 0.019 4.6E-08 1.2E-04 92.7 
rs16875357 6 85652904 t g 0.757 -0.121 0.020 2.7E-09 1.2E-04 91.3 
rs3798293 6 97033370 a g 0.784 -0.133 0.021 2.7E-10 1.2E-04 93.8 
rs4556017 7 1.01E+08 t c 0.852 -0.160 0.025 9.7E-11 1.1E-04 83.3 
rs2191046 7 1.08E+08 t g 0.735 0.118 0.020 1.8E-09 1.3E-04 95.9 
rs73033340 7 1195692 a g 0.964 0.531 0.053 5.1E-24 1.0E-04 72.7 
rs11556924 7 1.3E+08 t c 0.383 -0.181 0.018 1.8E-23 2.4E-04 175.8 
rs13237249 7 1.31E+08 t c 0.398 0.137 0.018 1.0E-14 1.8E-04 136.3 
rs75511781 7 1.31E+08 a g 0.958 -0.372 0.047 2.5E-15 8.3E-05 60.8 
rs7800558 7 1.4E+08 t c 0.578 0.096 0.018 4.5E-08 1.3E-04 97.5 
rs1044608 7 1.51E+08 c g 0.923 -0.202 0.034 2.8E-09 7.9E-05 59.3 
rs3918226 7 1.51E+08 t c 0.081 0.612 0.033 5.3E-77 2.5E-04 188.6 
rs310597 7 1.51E+08 a g 0.631 -0.115 0.018 2.2E-10 1.5E-04 111.6 
rs6464165 7 1.51E+08 t c 0.719 -0.217 0.020 7.3E-29 2.4E-04 182.6 
rs1534338 7 1.56E+08 a g 0.603 -0.114 0.018 1.2E-10 1.5E-04 113.9 
rs17432462 7 18548613 t c 0.623 -0.104 0.018 7.3E-09 1.3E-04 101.2 
rs12699415 7 1909479 a g 0.413 0.124 0.018 3.3E-12 1.6E-04 124.4 
rs4507656 7 22156538 c g 0.693 -0.149 0.020 8.7E-14 1.7E-04 124.3 
rs2906152 7 2523003 a g 0.630 -0.187 0.018 5.5E-25 2.4E-04 181.0 
rs7805035 7 25965890 a t 0.412 0.134 0.018 2.4E-14 1.8E-04 135.2 
rs3735533 7 27245893 t c 0.074 -0.487 0.033 6.3E-49 1.8E-04 139.1 
rs6961048 7 27328187 c g 0.896 -0.273 0.029 1.3E-21 1.4E-04 105.2 
rs342977 7 35459888 a g 0.772 -0.158 0.021 1.7E-14 1.5E-04 115.8 
rs2854746 7 45960645 c g 0.400 0.113 0.018 3.3E-10 1.5E-04 112.0 
rs17454517 7 50915776 a g 0.494 0.122 0.017 2.7E-12 1.7E-04 125.2 
rs58407878 7 7260161 a t 0.150 0.157 0.024 1.2E-10 1.1E-04 83.4 
rs1178979 7 72856430 t c 0.805 0.150 0.022 1.0E-11 1.3E-04 97.2 
rs3807101 7 80393418 t c 0.123 -0.174 0.027 4.6E-11 1.0E-04 78.1 
rs1449596 7 96395096 c g 0.355 -0.109 0.018 1.9E-09 1.4E-04 103.4 
rs7788746 7 99612405 t g 0.669 -0.164 0.018 3.2E-19 2.0E-04 151.4 
rs2978098 8 1.02E+08 a c 0.547 0.155 0.018 1.3E-18 2.1E-04 157.9 
rs142449193 8 1.03E+08 t c 0.046 -0.257 0.043 1.5E-09 6.2E-05 47.0 
rs2957468 8 1.06E+08 a g 0.335 0.138 0.019 8.4E-14 1.7E-04 127.6 
rs35091929 8 10693492 t c 0.397 0.183 0.018 6.5E-25 2.4E-04 182.2 
rs722783 8 1.2E+08 a g 0.222 -0.209 0.021 9.0E-24 2.0E-04 150.4 
rs9918907 8 1.25E+08 a g 0.784 -0.119 0.021 1.6E-08 1.1E-04 83.8 
rs7012891 8 1.27E+08 t c 0.763 -0.139 0.021 1.2E-11 1.4E-04 103.5 
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rs4909314 8 1.36E+08 a t 0.395 0.134 0.018 3.4E-14 1.8E-04 133.2 
rs4074812 8 1.42E+08 a g 0.554 -0.134 0.018 2.1E-14 1.8E-04 135.9 
rs3802230 8 1.44E+08 a c 0.545 -0.161 0.017 2.8E-20 2.2E-04 165.6 
rs62503324 8 23400615 t c 0.240 0.203 0.020 2.1E-23 2.0E-04 152.5 
rs951914 8 25878995 c g 0.713 0.190 0.019 5.1E-23 2.1E-04 162.2 
rs17832905 8 26038759 a c 0.072 0.192 0.035 2.8E-08 7.0E-05 53.0 
rs17321041 8 26445194 t c 0.063 0.231 0.036 1.8E-10 7.5E-05 57.0 
rs1906672 8 38130025 a g 0.232 0.140 0.021 8.5E-12 1.4E-04 104.2 
rs10087280 8 49391836 a g 0.832 0.138 0.023 2.5E-09 1.1E-04 80.5 
rs4873492 8 51947549 t c 0.173 0.140 0.023 1.3E-09 1.1E-04 83.3 
rs2442618 8 6379832 t c 0.572 -0.132 0.018 1.2E-13 1.8E-04 133.9 
rs11778153 8 64503942 t c 0.643 0.119 0.018 5.8E-11 1.5E-04 112.6 
rs6983239 8 72507296 t g 0.219 0.116 0.021 3.7E-08 1.1E-04 81.4 
rs148401029 8 81386066 a c 0.035 -0.312 0.049 1.3E-10 5.8E-05 44.1 
rs56345595 8 82814156 a g 0.585 0.133 0.018 5.2E-14 1.8E-04 134.2 
rs73276406 8 96021760 c g 0.146 0.156 0.025 2.0E-10 1.1E-04 81.1 
rs4743021 9 1.09E+08 t c 0.685 -0.108 0.019 2.4E-08 1.3E-04 95.7 
rs10980408 9 1.13E+08 t c 0.964 -0.375 0.048 4.2E-15 7.1E-05 53.8 
rs10759697 9 1.17E+08 a g 0.491 0.131 0.017 3.9E-14 1.8E-04 135.9 
rs2133386 9 1.28E+08 a c 0.433 -0.132 0.018 5.2E-14 1.8E-04 135.0 
rs507666 9 1.36E+08 a g 0.187 -0.285 0.022 2.3E-37 2.4E-04 178.9 
rs6271 9 1.37E+08 t c 0.074 -0.431 0.035 1.7E-34 1.6E-04 121.2 
rs11145807 9 1.4E+08 a g 0.406 0.155 0.018 4.1E-17 2.1E-04 152.0 
rs4615669 9 21818674 a g 0.560 -0.114 0.017 6.1E-11 1.5E-04 117.0 
rs10491713 9 2506236 t g 0.198 -0.122 0.022 2.0E-08 1.1E-04 80.4 
rs1243876 9 35693104 t c 0.701 -0.106 0.019 2.1E-08 1.2E-04 92.7 
rs76452347 9 35906471 t c 0.205 -0.225 0.023 9.4E-23 2.0E-04 152.2 
rs12337056 9 628670 t c 0.176 0.136 0.023 2.2E-09 1.1E-04 82.4 
rs11141731 9 89888472 t c 0.228 -0.126 0.021 1.3E-09 1.2E-04 92.0 
rs1332812 9 9350986 a t 0.647 -0.115 0.018 2.7E-10 1.4E-04 108.9 
rs11112548 12 1.06E+08 a t 0.956 0.274 0.044 5.8E-10 6.4E-05 48.4 
rs116063464 12 1.1E+08 a g 0.060 0.202 0.037 4.7E-08 6.3E-05 47.3 
rs7137828 12 1.12E+08 t c 0.518 -0.503 0.018 4.8E-180 6.9E-04 516.9 
rs35443 12 1.16E+08 c g 0.386 -0.266 0.018 1.2E-50 3.5E-04 262.6 
rs7299936 12 1.16E+08 a g 0.578 0.176 0.018 1.1E-23 2.4E-04 178.7 
rs1790123 12 1.24E+08 t c 0.803 0.199 0.022 6.9E-20 1.7E-04 131.1 
rs2271139 12 1.25E+08 a c 0.286 -0.125 0.019 8.2E-11 1.4E-04 105.7 
rs61912333 12 19554817 c g 0.496 0.119 0.018 1.1E-11 1.6E-04 123.6 
rs4306343 12 20190630 a t 0.279 -0.317 0.019 8.2E-61 3.5E-04 265.5 
rs6487076 12 20470857 a g 0.777 0.174 0.021 8.7E-17 1.7E-04 125.6 
rs12229480 12 26472908 t c 0.723 0.136 0.019 2.1E-12 1.5E-04 113.2 
rs1669907 12 42777933 t g 0.303 0.116 0.019 1.4E-09 1.3E-04 101.6 
rs61917655 12 48210787 t c 0.101 0.225 0.030 3.7E-14 1.1E-04 85.0 
rs7967705 12 50511408 t c 0.380 0.269 0.018 1.5E-51 3.5E-04 264.5 
rs7134440 12 53450097 t c 0.083 0.228 0.032 1.8E-12 9.5E-05 71.9 
rs75507123 12 5417856 t g 0.127 -0.143 0.026 3.9E-08 8.8E-05 66.4 
rs6580970 12 54434277 t c 0.299 -0.166 0.019 4.0E-18 1.9E-04 143.3 
20 
 
rs6581101 12 57136374 a c 0.604 -0.126 0.018 2.0E-12 1.7E-04 125.5 
rs7959649 12 67783108 t c 0.242 0.117 0.020 8.1E-09 1.2E-04 89.2 
rs521033 12 69951428 a g 0.864 -0.180 0.025 1.1E-12 1.2E-04 88.4 
rs710698 12 70369918 a g 0.587 0.106 0.018 1.9E-09 1.4E-04 105.8 
rs7132012 12 8832203 a g 0.675 0.156 0.019 3.2E-17 1.9E-04 142.9 
rs2681485 12 90025622 a g 0.598 0.295 0.018 1.3E-62 3.9E-04 295.0 
rs11108209 12 96109855 t c 0.907 -0.190 0.030 2.4E-10 8.8E-05 66.9 
rs544012 13 1.11E+08 t g 0.266 0.114 0.020 1.4E-08 1.2E-04 92.6 
rs36169093 13 1.14E+08 a g 0.504 0.123 0.018 5.6E-12 1.7E-04 127.7 
rs7321688 13 1.15E+08 a c 0.233 0.151 0.021 2.0E-13 1.5E-04 111.6 
rs682681 13 22294062 t c 0.334 -0.145 0.019 4.5E-15 1.8E-04 134.4 
rs61948065 13 25255052 a c 0.879 -0.174 0.027 1.2E-10 1.0E-04 76.9 
rs7338758 13 30137828 t c 0.244 0.194 0.020 1.7E-21 2.0E-04 147.3 
rs56256111 13 41478963 a g 0.144 0.193 0.026 2.6E-13 1.3E-04 98.0 
rs7992292 13 41968013 a g 0.824 0.137 0.023 3.2E-09 1.1E-04 82.6 
rs9526707 13 51489186 a g 0.322 -0.122 0.019 6.6E-11 1.5E-04 110.5 
rs9563529 13 58316637 t g 0.204 0.122 0.022 1.4E-08 1.1E-04 82.6 
rs3861113 13 72364382 a c 0.083 0.213 0.032 3.9E-11 8.8E-05 66.2 
rs12866098 13 73119617 a g 0.342 0.103 0.019 2.7E-08 1.3E-04 96.7 
rs1215469 13 80707408 a c 0.230 -0.138 0.021 5.2E-11 1.3E-04 101.6 
rs55684003 13 97988689 a g 0.696 0.122 0.019 1.0E-10 1.4E-04 107.5 
rs8014182 14 1.04E+08 t c 0.132 -0.194 0.026 3.9E-14 1.2E-04 92.6 
rs7350752 14 21841154 a g 0.124 -0.150 0.027 2.0E-08 9.0E-05 68.0 
rs17880989 14 23313633 a g 0.026 0.401 0.059 1.1E-11 5.6E-05 40.3 
rs1950500 14 24830850 t c 0.292 0.140 0.019 2.2E-13 1.6E-04 120.2 
rs4424827 14 35110857 t c 0.567 -0.098 0.018 2.1E-08 1.3E-04 100.3 
rs7155504 14 36158828 t c 0.912 0.229 0.032 5.2E-13 1.0E-04 75.4 
rs72683923 14 50735947 t c 0.979 0.533 0.064 5.0E-17 6.1E-05 45.9 
rs35413927 14 53420358 a g 0.695 -0.127 0.019 1.8E-11 1.5E-04 112.4 
rs194742 14 69287483 t c 0.169 0.128 0.023 3.2E-08 9.9E-05 74.9 
rs227426 14 70456664 t g 0.562 0.112 0.018 1.7E-10 1.5E-04 114.6 
rs2239268 14 72469591 a g 0.701 0.110 0.019 7.4E-09 1.3E-04 95.7 
rs4903064 14 73279420 t c 0.765 0.154 0.021 7.8E-14 1.5E-04 115.4 
rs10873612 15 26105602 t c 0.596 -0.110 0.018 9.5E-10 1.5E-04 109.6 
rs11070245 15 40317792 t g 0.468 -0.129 0.017 1.6E-13 1.8E-04 132.0 
rs2925345 15 41311799 t c 0.468 0.189 0.017 1.6E-27 2.6E-04 195.7 
rs2305654 15 42136977 a c 0.345 0.171 0.019 4.0E-20 2.1E-04 156.5 
rs7169864 15 53902901 t c 0.232 -0.113 0.021 3.4E-08 1.1E-04 83.9 
rs28429256 15 66931617 a g 0.334 0.164 0.019 2.8E-18 2.0E-04 151.2 
rs2469141 15 66967398 t c 0.837 0.135 0.024 1.4E-08 1.0E-04 76.4 
rs3743111 15 71587373 a g 0.613 0.152 0.018 1.6E-17 2.0E-04 149.9 
rs11636952 15 75114322 t c 0.313 0.400 0.019 5.2E-99 4.7E-04 349.6 
rs57708073 15 79066653 a g 0.739 0.191 0.021 4.7E-19 2.0E-04 137.9 
rs2627313 15 81006712 t c 0.446 0.151 0.018 5.9E-18 2.1E-04 153.6 
rs17807723 15 90023558 a g 0.138 -0.176 0.026 7.4E-12 1.1E-04 86.0 
rs4932373 15 91429287 a c 0.674 -0.366 0.019 7.7E-84 4.4E-04 325.9 
rs3743369 15 92707569 a g 0.628 0.104 0.018 6.8E-09 1.3E-04 100.9 
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rs12906962 15 95312071 t c 0.677 -0.238 0.019 8.7E-37 2.9E-04 215.8 
rs2589218 15 96785017 t c 0.730 -0.121 0.020 6.9E-10 1.3E-04 98.7 
rs77924615 16 20392332 a g 0.198 -0.316 0.022 3.7E-45 2.8E-04 208.8 
rs12596630 16 2065666 t c 0.091 0.261 0.031 1.0E-16 1.2E-04 86.9 
rs9937801 16 21088130 t c 0.569 0.155 0.017 4.8E-19 2.1E-04 158.5 
rs80095680 16 30902353 a g 0.737 -0.157 0.020 2.8E-15 1.7E-04 126.5 
rs917522 16 4097222 t c 0.885 0.167 0.027 1.0E-09 9.3E-05 70.4 
rs12446456 16 4922201 t c 0.427 -0.181 0.018 4.0E-25 2.4E-04 184.5 
rs7192407 16 49783926 t c 0.472 0.102 0.017 4.5E-09 1.4E-04 105.8 
rs62030049 16 50572709 a g 0.760 0.134 0.021 1.5E-10 1.3E-04 101.5 
rs9932220 16 51758116 a g 0.218 -0.159 0.021 3.8E-14 1.5E-04 112.8 
rs12919839 16 56859216 t c 0.284 -0.110 0.019 1.0E-08 1.2E-04 93.0 
rs45474499 16 66914492 t c 0.047 0.356 0.042 8.5E-18 8.8E-05 66.8 
rs28544928 16 69329268 t g 0.747 0.154 0.020 9.1E-15 1.6E-04 121.6 
rs12444212 16 71437689 t c 0.817 0.129 0.023 1.1E-08 1.1E-04 80.2 
rs11859505 16 74195719 a g 0.420 -0.104 0.018 9.8E-09 1.4E-04 103.8 
rs8046697 16 75442144 t c 0.417 -0.129 0.018 6.1E-13 1.7E-04 130.0 
rs12929303 16 81602264 a g 0.533 0.157 0.017 1.6E-19 2.2E-04 163.0 
rs79286081 16 86555837 a g 0.102 -0.163 0.030 4.8E-08 8.2E-05 61.9 
rs908951 16 89697625 t c 0.437 -0.198 0.018 7.7E-28 2.7E-04 200.0 
rs9893005 17 16225506 c g 0.535 -0.121 0.018 7.9E-12 1.6E-04 124.7 
rs12938803 17 19204432 a c 0.189 -0.160 0.022 8.8E-13 1.3E-04 100.1 
rs4362428 17 2090341 a c 0.409 -0.113 0.018 1.5E-10 1.5E-04 113.4 
rs76954792 17 30033514 t c 0.232 0.121 0.021 5.1E-09 1.2E-04 90.1 
rs28661492 17 30609932 t c 0.202 -0.136 0.022 9.6E-10 1.2E-04 91.2 
rs9895032 17 3951946 t c 0.498 0.107 0.018 1.2E-09 1.5E-04 111.5 
rs2239917 17 43165887 t c 0.425 0.173 0.018 9.7E-23 2.3E-04 176.0 
rs55671319 17 43548424 a g 0.817 0.137 0.023 5.4E-09 1.1E-04 84.2 
rs8078510 17 47045862 a g 0.269 -0.128 0.020 9.8E-11 1.4E-04 104.6 
rs9889262 17 47398070 a t 0.367 0.228 0.018 7.1E-37 2.9E-04 220.5 
rs3785837 17 59468942 a g 0.764 0.145 0.021 9.6E-12 1.4E-04 107.9 
rs6504163 17 61545779 t c 0.624 -0.184 0.018 6.3E-24 2.4E-04 179.5 
rs1867624 17 62387091 t c 0.615 0.141 0.018 2.1E-15 1.8E-04 139.3 
rs55868524 17 7170665 a g 0.611 0.144 0.018 5.5E-16 1.9E-04 142.8 
rs1436138 17 75316880 a g 0.637 0.199 0.018 7.3E-28 2.5E-04 191.5 
rs7217916 17 76769434 a g 0.385 0.111 0.018 5.6E-10 1.4E-04 109.6 
rs138420351 17 7700063 t c 0.016 0.557 0.085 7.1E-11 4.8E-05 35.2 
rs74439044 17 7781019 t c 0.902 -0.350 0.029 1.4E-32 1.7E-04 129.0 
rs11077961 17 81012749 a g 0.632 0.107 0.019 8.5E-09 1.4E-04 102.3 
rs11665020 18 10879503 c g 0.322 -0.142 0.019 2.8E-14 1.7E-04 129.2 
rs11664194 18 20021031 a t 0.460 -0.108 0.018 8.7E-10 1.5E-04 111.4 
rs10164193 18 31161426 t g 0.922 -0.220 0.033 1.9E-11 8.6E-05 65.5 
rs11661473 18 42177123 a g 0.268 0.201 0.020 1.5E-24 2.2E-04 163.6 
rs4890499 18 42585761 a g 0.255 0.113 0.020 1.3E-08 1.2E-04 89.4 
rs58693787 18 48141710 a g 0.754 0.158 0.020 3.8E-15 1.6E-04 122.1 
rs1523871 18 51950877 c g 0.566 -0.119 0.018 1.5E-11 1.6E-04 121.3 
rs10048404 18 54578482 t c 0.369 -0.110 0.018 2.0E-09 1.4E-04 106.2 
22 
 
rs7235890 18 55732115 t g 0.896 -0.169 0.029 4.1E-09 8.7E-05 65.9 
rs1903752 18 7129327 t c 0.539 -0.099 0.018 3.2E-08 1.3E-04 102.0 
rs4891258 18 72995537 a g 0.683 -0.116 0.019 5.7E-10 1.4E-04 104.6 
rs7227492 18 772064 t c 0.818 0.181 0.023 1.4E-15 1.5E-04 112.3 
rs387865 19 11284539 t c 0.306 -0.106 0.019 3.2E-08 1.2E-04 92.5 
rs167479 19 11526765 t g 0.472 -0.362 0.019 1.7E-82 5.0E-04 340.5 
rs73504817 19 17167723 t c 0.713 0.177 0.019 1.7E-20 2.0E-04 151.3 
rs72999033 19 19366632 t c 0.066 0.279 0.036 5.9E-15 9.4E-05 70.9 
rs7257694 19 30314666 t c 0.400 0.184 0.018 6.3E-25 2.4E-04 182.3 
rs1353532 19 31867132 a t 0.602 -0.127 0.018 1.1E-12 1.7E-04 125.4 
rs1433121 19 32591878 t c 0.691 -0.135 0.019 6.9E-13 1.6E-04 120.3 
rs73036520 19 45749484 c g 0.254 0.156 0.020 1.3E-14 1.6E-04 122.4 
rs2548459 19 49209339 t c 0.481 -0.132 0.018 5.9E-14 1.8E-04 135.0 
rs73046792 19 49605705 a g 0.159 -0.152 0.025 5.9E-10 1.1E-04 83.3 
rs10424224 19 7240481 t c 0.358 0.104 0.018 1.0E-08 1.3E-04 99.8 
rs7258382 19 7262569 t c 0.839 0.262 0.025 3.0E-26 1.9E-04 142.9 
rs2009733 19 8398714 a g 0.500 0.122 0.018 5.1E-12 1.7E-04 123.9 
rs693974 20 10557252 t c 0.604 -0.185 0.018 1.8E-25 2.4E-04 184.1 
rs1327235 20 10969030 a g 0.529 -0.302 0.017 4.8E-68 4.1E-04 313.3 
rs6078393 20 11908101 t g 0.589 0.121 0.018 7.7E-12 1.6E-04 121.3 
rs6081555 20 19245723 t g 0.343 -0.102 0.018 3.1E-08 1.3E-04 95.3 
rs2376997 20 30319199 a c 0.249 -0.139 0.022 1.9E-10 1.4E-04 108.0 
rs13042148 20 32298286 t c 0.154 -0.167 0.024 7.2E-12 1.2E-04 90.7 
rs7265695 20 40043096 t c 0.804 0.197 0.022 2.5E-19 1.7E-04 129.3 
rs6031431 20 42795152 a g 0.538 -0.115 0.018 4.9E-11 1.6E-04 119.0 
rs2598 20 47241618 a g 0.533 0.139 0.018 1.9E-15 1.9E-04 143.8 
rs79044887 20 47427831 c g 0.852 0.243 0.025 4.0E-23 1.7E-04 127.2 
rs234623 20 57488964 a g 0.504 -0.119 0.017 8.6E-12 1.6E-04 123.2 
rs6026739 20 57739469 a t 0.877 -0.503 0.027 1.5E-79 3.0E-04 224.1 
rs79208229 20 62516236 t g 0.088 0.213 0.033 6.5E-11 9.3E-05 70.4 
rs35213536 20 62694319 t g 0.247 0.204 0.021 2.5E-23 2.1E-04 154.2 
rs6108168 20 8626271 a c 0.255 -0.190 0.020 1.1E-21 2.0E-04 150.2 
rs1882961 21 16556367 t c 0.309 0.127 0.019 1.4E-11 1.5E-04 113.1 
rs2070527 21 40067495 a c 0.249 -0.147 0.020 3.1E-13 1.5E-04 113.4 
rs12627514 21 44759440 c g 0.710 -0.216 0.020 2.0E-28 2.4E-04 184.7 
rs34487963 21 44838330 a c 0.019 -0.573 0.071 8.2E-16 5.7E-05 41.6 
rs7278003 21 44966069 t c 0.439 -0.129 0.018 1.8E-13 1.7E-04 132.4 
rs5992929 22 18451977 t c 0.283 0.168 0.019 3.1E-18 1.9E-04 142.4 
rs134041 22 28056338 t c 0.436 0.122 0.018 3.1E-12 1.7E-04 125.1 
rs12321 22 29453193 c g 0.433 -0.149 0.018 1.4E-17 2.0E-04 152.6 
rs5753630 22 31861950 a g 0.562 0.107 0.018 8.8E-10 1.4E-04 109.7 
 
a 𝑅2 =  
2×𝐸𝐴𝐹×(1−𝐸𝐴𝐹)×𝑏𝑒𝑡𝑎2
𝑆𝐷2
  , 𝑤ℎere EAF is the effect allele frequency and beta is the effect estimate of the SNP on SBP (Shim 2015, PLoS 
One;10(4):e0120758). 
b F = 
𝑅2×(𝑁−2)
1−𝑅2
  where R2 is the variance of SBP explained by the specific SNP (as explained above) and N the number of individuals in the GWAS 
analysis (Palmer 2012, Stat Methods Med Res;21(3):223-42). 
CHR: chromosome; EAF: effect allele frequency; SE: standard error; SNP: single nucleotide polymorphism.  
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Table e-3. Single nucleotide polymorphisms (SNP) that fulfilled our selection criteria to be used as proxies for the effects 







EAF Beta SE p-value R2 a F b 
ACE inhibitors 
 
        
rs4291 17 61554194 ACE a 0.615 -0.2839 0.0312 8.65E-20 3.7E-04 275.5 
Beta blockers          
rs11196549 c 10 115707298 ADRB1 a 0.042 0.6884 0.0784 1.58E-18 1.5E-04 113.7 
rs460718 c 10 115721364 ADRB1 a 0.326 -0.2764 0.0324 1.36E-17 3.3E-04 246.7 
rs11196597 c 10 115788094 ADRB1 a 0.133 0.2858 0.0458 4.23E-10 1.8E-04 133.5 
rs79850079 10 115790006 ADRB1 a 0.031 -0.5804 0.0905 1.45E-10 9.8E-05 72.2 
rs17875473 c 10 115800294 ADRB1 t 0.087 0.3283 0.0552 2.66E-09 1.4E-04 105.9 
rs2429511 10 115801253 ADRB1 t 0.520 -0.3728 0.0303 7.39E-35 5.1E-04 377.7 
rs1801253 c 10 115805056 ADRB1 c 0.733 0.4626 0.0344 2.84E-41 5.0E-04 366.8 
rs4359161 c 10 115826508 ADRB1 a 0.181 -0.2662 0.0391 9.46E-12 2.2E-04 160.3 
Calcium channel blockers   
      
rs116556102 12 2303850 CACNA1C c 0.983 -0.6853 0.1252 4.42E-08 6.0E-05 43.8 
rs2239046 c 12 2434419 CACNA1C a 0.681 0.2082 0.0322 9.58E-11 2.5E-04 185.2 
rs714277 c 12 2514270 CACNA1C t 0.283 0.1986 0.0333 2.38E-09 2.2E-04 165.4 
rs2488136 c 10 18334521 CACNB2 a 0.287 0.2261 0.0334 1.22E-11 2.5E-04 187.9 
rs1888693 c 10 18440444 CACNB2 a 0.344 0.3858 0.0317 4.69E-34 4.8E-04 352.8 
rs17604757 10 18442940 CACNB2 a 0.932 -0.5022 0.0606 1.12E-16 1.7E-04 126.8 
rs12571593 10 18443222 CACNB2 a 0.907 -0.3996 0.0521 1.71E-14 1.8E-04 136.2 
rs12414844 10 18451994 CACNB2 t 0.266 0.2790 0.0342 3.15E-16 3.0E-04 220.8 
rs7076319 c 10 18459450 CACNB2 a 0.733 -0.3210 0.0341 5.07E-21 3.4E-04 254.0 
rs17662793 10 18465479 CACNB2 a 0.712 0.2363 0.0338 2.65E-12 2.7E-04 196.5 
rs10828295 10 18466094 CACNB2 a 0.747 -0.3397 0.0349 2.18E-22 3.5E-04 257.6 
rs16916922 10 18467744 CACNB2 a 0.858 -0.3662 0.0433 2.86E-17 2.4E-04 180.5 
rs61278674 c 10 18481737 CACNB2 a 0.906 -0.3298 0.0540 1.03E-09 1.5E-04 113.6 
rs4748444 10 18494482 CACNB2 t 0.663 0.1939 0.0327 3.13E-09 2.4E-04 175.1 
rs1539680 10 18502889 CACNB2 c 0.792 -0.3259 0.0375 3.37E-18 2.9E-04 214.6 
rs1779209 c 10 18514561 CACNB2 t 0.287 0.2736 0.0336 4.23E-16 3.1E-04 224.8 
rs1757213 10 18537594 CACNB2 a 0.112 0.3084 0.0507 1.15E-09 1.7E-04 124.3 
rs10828399 c 10 18553968 CACNB2 a 0.521 -0.1947 0.0302 1.10E-10 2.7E-04 197.2 
rs10828452 c 10 18592450 CACNB2 a 0.793 0.3046 0.0388 4.20E-15 2.7E-04 202.6 
rs17610275 10 18621630 CACNB2 t 0.926 0.3868 0.0613 2.87E-10 1.4E-04 106.4 
rs10828542 c 10 18627285 CACNB2 a 0.613 0.1817 0.0311 5.18E-09 2.4E-04 174.8 
rs112701401 10 18644811 CACNB2 c 0.969 0.5026 0.0921 4.92E-08 8.2E-05 60.3 
rs7072277 10 18658707 CACNB2 a 0.471 -0.1746 0.0301 6.88E-09 2.4E-04 176.6 
rs11013938 10 18669271 CACNB2 c 0.255 -0.3265 0.0350 1.17E-20 3.4E-04 251.6 
rs12780039 c 10 18678987 CACNB2 c 0.121 0.2852 0.0470 1.26E-09 1.7E-04 123.1 
rs79253631 c 10 18694223 CACNB2 a 0.986 -0.7774 0.1392 2.32E-08 5.7E-05 41.4 
rs112133583 c 10 18695681 CACNB2 t 0.029 -0.5546 0.0973 1.18E-08 8.8E-05 65.2 
rs7909027 c 10 18695892 CACNB2 t 0.649 -0.3312 0.0318 2.01E-25 4.1E-04 302.8 
rs10828662 10 18703097 CACNB2 t 0.558 -0.2879 0.0304 2.54E-21 3.9E-04 288.1 
rs982003 10 18707296 CACNB2 t 0.756 -0.2414 0.0351 6.21E-12 2.4E-04 180.3 
rs1325990 10 18707352 CACNB2 a 0.470 -0.3873 0.0302 1.09E-37 5.3E-04 391.6 
rs11014170 c 10 18710991 CACNB2 a 0.020 -0.6701 0.1150 5.61E-09 7.4E-05 54.4 
rs72786085 10 18713206 CACNB2 c 0.079 -0.5309 0.0595 4.46E-19 2.1E-04 156.9 
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rs10828689 10 18721957 CACNB2 c 0.443 -0.3634 0.0304 6.94E-33 4.9E-04 364.1 
rs67214975 10 18727251 CACNB2 a 0.456 -0.4144 0.0307 1.42E-41 5.7E-04 416.8 
rs7923191 c 10 18727901 CACNB2 a 0.791 -0.3690 0.0376 1.10E-22 3.3E-04 246.5 
rs12258967 c 10 18727959 CACNB2 c 0.704 0.6327 0.0337 1.08E-78 7.2E-04 533.8 
rs72786098 c 10 18729855 CACNB2 a 0.032 -0.5033 0.0883 1.18E-08 8.6E-05 63.5 
rs116936375 10 18737135 CACNB2 a 0.040 -0.5739 0.0810 1.40E-12 1.2E-04 90.4 
rs12256244 10 18750045 CACNB2 a 0.626 0.4246 0.0315 2.09E-41 5.5E-04 402.8 
rs1998822 c 10 18755664 CACNB2 a 0.723 -0.1958 0.0343 1.15E-08 2.2E-04 156.6 
rs7070582 10 18755942 CACNB2 t 0.383 0.2502 0.0317 2.86E-15 3.3E-04 239.8 
rs7076100 10 18759537 CACNB2 a 0.406 -0.3569 0.0308 5.51E-31 4.7E-04 349.1 
rs7076247 10 18759629 CACNB2 t 0.388 0.2557 0.0309 1.33E-16 3.3E-04 246.6 
rs11014494 10 18780705 CACNB2 a 0.492 0.1676 0.0304 3.37E-08 2.3E-04 170.0 
rs10828784 10 18788273 CACNB2 c 0.663 0.2021 0.0345 4.49E-09 2.5E-04 182.9 
rs12416030 10 18789075 CACNB2 t 0.796 -0.2088 0.0381 4.32E-08 1.9E-04 136.9 
rs12416052 10 18789267 CACNB2 t 0.594 0.1987 0.0311 1.59E-10 2.6E-04 194.1 
rs4748476 10 18792875 CACNB2 t 0.777 0.2166 0.0365 2.89E-09 2.1E-04 152.2 
rs150857355 c 12 49209340 CACNB3 c 0.021 0.9406 0.1122 5.20E-17 1.1E-04 80.3 
rs312487 3 53545622 CACNA1D t 0.478 0.2194 0.0307 9.65E-13 3.0E-04 222.2 
rs3821843 c 3 53558012 CACNA1D a 0.680 0.3373 0.0335 6.56E-24 4.0E-04 296.6 
rs9311502 3 53560321 CACNA1D t 0.760 -0.2463 0.0355 3.87E-12 2.5E-04 181.8 
rs1547950 3 53568283 CACNA1D t 0.537 -0.2151 0.0307 2.33E-12 2.9E-04 217.0 
rs11709630 3 53577164 CACNA1D t 0.637 0.1931 0.0320 1.61E-09 2.5E-04 180.9 
rs114987861 c 3 53605712 CACNA1D a 0.028 0.5289 0.0958 3.36E-08 8.0E-05 59.1 
rs113210396 c 3 53612327 CACNA1D t 0.045 -0.4338 0.0770 1.76E-08 1.0E-04 75.7 
rs3774475 3 53650483 CACNA1D a 0.417 0.1854 0.0307 1.60E-09 2.5E-04 183.0 
rs7340705 c 3 53734443 CACNA1D t 0.673 -0.2425 0.0322 4.87E-14 2.9E-04 216.5 
rs2633731 3 53738424 CACNA1D t 0.396 -0.1963 0.0309 2.21E-10 2.6E-04 190.6 
  
a 𝑅2 =  
2×𝐸𝐴𝐹×(1−𝐸𝐴𝐹)×𝑏𝑒𝑡𝑎2
𝑆𝐷2
  , 𝑤ℎere EAF is the effect allele frequency and beta is the effect estimate of the SNP on SBP (Shim 2015, 
PLoS One;10(4):e0120758). 
b F = 
𝑅2×(𝑁−2)
1−𝑅2
  where R2 is the variance of SBP explained by the specific SNP (as explained above) and N the number of individuals in the GWAS 
analysis (Palmer 2012, Stat Methods Med Res;21(3):223-42). 
C SNPs also included in the sensitivity analyses of the instruments correlated at a lower LD threshold (r2<0.1). 




Table e-4. Genomic regions of encoding genes and regulatory regions (promoters or enhances) of 
known antihypertensive drug targets, as identified via GeneHancer. These regions were screened for 
instrument selection of single nucleotide polymorphisms (SNP) that were associated with systolic 
blood pressure at genome-wide significance. 
Drug Gene Genomic region (GRCh37/hg19) Function 
ACEIs ACE chr17:61554422-61599205 Encoding gene 
ACEIs ACE chr17:61551058-61556950 Promoter/Enhancer 
ACEIs ACE chr17:61562201-61562303 Promoter/Enhancer 
ACEIs ACE chr17:61508611-61515166 Promoter/Enhancer 
ACEIs ACE chr17:61626418-61630304 Promoter/Enhancer 
ACEIs ACE chr17:61431510-61431613 Enhancer  
ACEIs ACE chr17:62090924-62103850 Promoter/Enhancer 
ACEIs ACE chr17:61497048-61498662 Enhancer  
ACEIs ACE chr17:61505277-61506104 Enhancer  
ACEIs ACE chr17:61689560-61689960 Enhancer  
ACEIs ACE chr17:61594421-61594870 Enhancer  
ACEIs ACE chr17:61502881-61503030  Enhancer  
ACEIs ACE chr17:61656647-61657871  Enhancer  
ACEIs ACE chr17:61500762-61501161 Enhancer  
ACEIs ACE chr17:60855121-60860435 Enhancer  
ACEIs ACE chr17:61574731-61577281 Enhancer  
ACEIs ACE chr17:60972606-60973907 Enhancer  
ARBs AGTR1 chr3:148415571-148460795 Encoding gene 
ARBs AGTR1 chr3:148415061-148416388 Promoter/Enhancer 
ARBs AGTR1 chr3:148366071-148367473 Enhancer  
ARBs AGTR1 chr3:148441102-148442130 Enhancer  
ARBs AGTR1 chr3:148360847-148362186  Enhancer  
ARBs AGTR1 chr3:148360520-148360788 Enhancer  
ARBs AGTR1 chr3:148899476-148899525 Enhancer  
BBs ADRB1 chr10:115803806-115806667 Enhancer  
BBs ADRB1 chr10:115802241-115807338  Promoter/Enhancer 
BBs ADRB1 chr10:115716558-115722360  Enhancer 
BBs ADRB1 chr10:115706609-115708137  Enhancer 
BBs ADRB1 chr10:115824009-115824850  Enhancer 
BBs ADRB1 chr10:115548188-115549279  Enhancer 
BBs ADRB1 chr10:115833610-115834154  Enhancer 
BBs ADRB1 chr10:115704333-115705870  Enhancer 
BBs ADRB1 chr10:116441242-116446390  Promoter/Enhancer 
BBs ADRB1 chr10:115842035-115843254  Enhancer 
BBs ADRB1 chr10:115784258-115788102  Enhancer 
BBs ADRB1 chr10:115725160-115725959  Enhancer 
BBs ADRB1 chr10:115697701-115697810  Enhancer 
BBs ADRB1 chr10:115741347-115744110  Enhancer 
BBs ADRB1 chr10:115782141-115782270  Enhancer 
BBs ADRB1 chr10:115559441-115559610  Enhancer 
BBs ADRB1 chr10:115841821-115841970  Enhancer 
BBs ADRB1 chr10:115826224-115827332  Enhancer 
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BBs ADRB1 chr10:115827575-115828874  Enhancer 
BBs ADRB1 chr10:115910708-115912162  Enhancer 
BBs ADRB1 chr10:115752960-115753842  Enhancer 
BBs ADRB1 chr10:115651401-115651550  Enhancer 
BBs ADRB1 chr10:115683621-115684573  Enhancer 
BBs ADRB1 chr10:115758960-115759559  Enhancer 
BBs ADRB1 chr10:116457630-116458961  Enhancer 
BBs ADRB1 chr10:115561321-115561530  Enhancer 
BBs ADRB1 chr10:115625638-115626159  Enhancer 
BBs ADRB1 chr10:116437959-116439282  Enhancer 
BBs ADRB1 chr10:115789385-115790216  Enhancer 
BBs ADRB1 chr10:115800822-115802086  Enhancer 
BBs ADRB1 chr10:115799814-115800507  Enhancer 
CCBs CACNA1S chr1:201008640-201081694 Encoding gene 
CCBs CACNA1S chr1:201082861-201084129 Promoter/Enhancer 
CCBs CACNA1S chr1:201079942-201082115 Enhancer 
CCBs CACNA1S chr1:201122647-201124394 Promoter/Enhancer 
CCBs CACNA1S chr1:201274996-201282487 Enhancer 
CCBs CACNA1S chr1:201012141-201012270 Enhancer 
CCBs CACNA1S chr1:201263489-201273426 Enhancer 
CCBs CACNA1S chr1:200941201-200941350 Enhancer 
CCBs CACNA1S chr1:201106054-201107629 Enhancer 
CCBs CACNA1S chr1:201056384-201057751 Enhancer 
CCBs CACNA1S chr1:201057880-201061411 Enhancer 
CCBs CACNA1S chr1:201111781-201111890 Enhancer 
CCBs CACNA1S chr1:201063580-201070116 Enhancer 
CCBs CACNA1S chr1:201071203-201078371 Enhancer 
CCBs CACNA1S chr1:201032066-201032442 Enhancer 
CCBs CACNA1D chr3:53528683-53847760 Encoding gene 
CCBs CACNA1D chr3:53526751-53529027 Promoter/Enhancer 
CCBs CACNA1D chr3:53529053-53530500 Promoter/Enhancer 
CCBs CACNA1D chr3:53361979-53363570  Enhancer 
CCBs CACNA1D chr3:53551784-53554581 Enhancer 
CCBs CACNA1D chr3:53558098-53559174 Enhancer 
CCBs CACNA1D chr3:53379987-53382717 Promoter/Enhancer 
CCBs CACNA1D chr3:53859957-53860202 Enhancer 
CCBs CACNA1D chr3:53384627-53385227 Enhancer 
CCBs CACNA1D chr3:53388806-53389878 Enhancer 
CCBs CACNA1D chr3:53354541-53355561 Enhancer 
CCBs CACNA1D chr3:53511553-53514862 Enhancer 
CCBs CACNA1D chr3:53457125-53457810 Enhancer 
CCBs CACNA1D chr3:53539797-53541150 Enhancer 
CCBs CACNA1D chr3:53531730-53534232 Enhancer 
CCBs CACNA1D chr3:53405028-53405227 Enhancer 
CCBs CACNA1D chr3:53559666-53560346 Enhancer 
CCBs CACNA1D chr3:53698941-53699090 Enhancer 
CCBs CACNA1D chr3:53604273-53605793 Enhancer 
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CCBs CACNA1D chr3:53742028-53742227  Enhancer 
CCBs CACNA1D chr3:53664741-53664930 Enhancer 
CCBs CACNA1D chr3:53714181-53714330 Enhancer 
CCBs CACNA1D chr3:53664161-53664290 Enhancer 
CCBs CACNA1D chr3:53647109-53647870 Enhancer 
CCBs CACNA1D chr3:53568043-53568300 Enhancer 
CCBs CACNA1D chr3:53707221-53707290 Enhancer 
CCBs CACNA1D chr3:53723669-53724036 Enhancer 
CCBs CACNA1D chr3:53741428-53741627 Enhancer 
CCBs CACNA1D chr3:53787436-53788581  Enhancer 
CCBs CACNA1D chr3:53793207-53793702 Enhancer 
CCBs CACNA1D chr3:53796777-53798080 Enhancer 
CCBs CACNA1D chr3:53798222-53799233 Enhancer 
CCBs CACNA1D chr3:53810959-53811945 Enhancer 
CCBs CACNA1D chr3:53809709-53810892 Enhancer 
CCBs CACNA1D chr3:53817819-53818839 Enhancer 
CCBs CACNA1D chr3:53828693-53829307 Enhancer 
CCBs CACNA1D chr3:53829341-53829430 Enhancer 
CCBs CACNA1D chr3:53838172-53842050 Enhancer 
CCBs CACNA1D chr3:53744028-53744627 Enhancer 
CCBs CACNA1D chr3:53759658-53759955 Enhancer 
CCBs CACNA1D chr3:53843873-53844716 Enhancer 
CCBs CACNA1D chr3:53802862-53803908 Enhancer 
CCBs CACNA1D chr3:53806640-53808437 Enhancer 
CCBs CACNA1D chr3:53799850-53800909 Enhancer 
CCBs CACNA1D chr3:53801465-53802329 Enhancer 
CCBs CACNA1D chr3:53782002-53784852  Enhancer 
CCBs CACNA1D chr3:53777569-53779058 Enhancer 
CCBs CACNA1D chr3:53764428-53765080 Enhancer 
CCBs CACNA1D chr3:53766775-53767435 Enhancer 
CCBs CACNA2D1 chr7:81575760-82073114 Encoding gene  
CCBs CACNA2D1 chr7:82071056-82074330 Promoter/Enhancer 
CCBs CACNA2D1 chr7:82039597-82041108 Enhancer 
CCBs CACNA2D1 chr7:82223184-82225724 Enhancer 
CCBs CACNA2D1 chr7:82171489-82172576 Enhancer 
CCBs CACNA2D1 chr7:82164161-82164310 Enhancer 
CCBs CACNA2D1 chr7:82063702-82063952 Enhancer 
CCBs CACNA2D1 chr7:81584968-81585322 Enhancer 
CCBs CACNA2D1 chr7:81858656-81858971 Enhancer 
CCBs CACNA2D1 chr7:82057141-82058356 Enhancer 
CCBs CACNA2D1 chr7:82059961-82060110 Enhancer 
CCBs CACNA2D1 chr7:82013345-82013689 Enhancer 
CCBs CACNA2D1 chr7:81785601-81785750 Enhancer 
CCBs CACNA2D1 chr7:81948701-81949880 Enhancer 
CCBs CACNA2D1 chr7:81833679-81834445 Enhancer 
CCBs CACNA2D1 chr7:81734523-81735564 Enhancer 
CCBs CACNA2D1 chr7:82034101-82034250 Enhancer 
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CCBs CACNA2D1 chr7:81920961-81922045 Enhancer 
CCBs CACNA2D1 chr7:81709702-81710455 Enhancer 
CCBs CACNA2D1 chr7:81914377-81914723 Enhancer 
CCBs CACNA2D1 chr7:81808741-81808930 Enhancer 
CCBs CACNA2D1 chr7:81739157-81739440 Enhancer 
CCBs CACNA2D1 chr7:81916621-81916770  Enhancer 
CCBs CACNA2D1 chr7:81787741-81787827 Enhancer 
CCBs CACNA2D1 chr7:81946361-81947530 Enhancer 
CCBs CACNA2D1 chr7:81941894-81943091 Enhancer 
CCBs CACNA2D1 chr7:81915266-81916265 Enhancer 
CCBs CACNA2D1 chr7:81914861-81914999 Enhancer 
CCBs CACNA2D1 chr7:81809481-81810272 Enhancer 
CCBs CACNA2D1 chr7:81739641-81739790 Enhancer 
CCBs CACNA2D1 chr7:81841421-81842618 Enhancer 
CCBs CACNA2D1 chr7:81813081-81813230 Enhancer 
CCBs CACNA2D1 chr7:81590210-81590492 Enhancer 
CCBs CACNA2D1 chr7:81678694-81681663 Enhancer 
CCBs CACNA2D1 chr7:81664197-81666962 Enhancer 
CCBs CACNA2D2 chr3:50400230-50541675 Encoding gene  
CCBs CACNA2D2 chr3:50540431-50541530  Promoter/Enhancer 
CCBs CACNA2D2 chr3:50535234-50535293 Promoter 
CCBs CACNA2D2 chr3:51420877-51430387 Promoter/Enhancer 
CCBs CACNA2D2 chr3:50510252-50511323 Enhancer 
CCBs CACNA2D2 chr3:50624952-50631056  Enhancer 
CCBs CACNA2D2 chr3:50486750-50489034 Enhancer 
CCBs CACNA2D2 chr3:50552257-50555213 Enhancer 
CCBs CACNA2D2 chr3:50557041-50557190 Enhancer 
CCBs CACNA2D2 chr3:50560739-50564041 Enhancer 
CCBs CACNA2D2 chr3:50483138-50484199 Enhancer 
CCBs CACNA2D2 chr3:50484337-50485546 Enhancer 
CCBs CACNA2D2 chr3:50473601-50473790 Enhancer 
CCBs CACNA2D2 chr3:50464650-50466328 Enhancer 
CCBs CACNA2D2 chr3:50401766-50403767 Promoter/Enhancer 
CCBs CACNA2D2 chr3:50479739-50481683 Enhancer 
CCBs CACNA2D2 chr3:50472754-50473413 Enhancer 
CCBs CACNA2D2 chr3:50467315-50469064 Enhancer 
CCBs CACNA2D2 chr3:50427643-50429192 Enhancer 
CCBs CACNA2D2 chr3:50410601-50411305 Enhancer 
CCBs CACNA2D2 chr3:50491422-50491591 Enhancer 
CCBs CACNA2D2 chr3:50425346-50425879 Enhancer 
CCBs CACNA2D2 chr3:50411624-50411893 Enhancer 
CCBs CACNB1 chr17:37329709-37353956 Encoding gene 
CCBs CACNB1 chr17:37347421-37359080 Promoter/Enhancer 
CCBs CACNB1 chr17:37330363-37331930 Enhancer 
CCBs CACNB1 chr17:37170207-37173852 Enhancer 
CCBs CACNB1 chr17:37392822-37395535 Enhancer 
CCBs CACNB1 chr17:37512839-37515343 Enhancer 
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CCBs CACNB1 chr17:37401081-37401270 Enhancer 
CCBs CACNB1 chr17:37401361-37401510 Enhancer 
CCBs CACNB1 chr17:37174255-37175468 Enhancer 
CCBs CACNB1 chr17:37332121-37332270 Enhancer 
CCBs CACNB1 chr17:37333681-37333850 Enhancer 
CCBs CACNB1 chr17:37395941-37396110 Enhancer 
CCBs CACNB1 chr17:37364621-37367146 Enhancer 
CCBs CACNB1 chr17:37427341-37427490 Enhancer 
CCBs CACNB1 chr17:37326315-37327866 Enhancer 
CCBs CACNB1 chr17:37325454-37325653 Enhancer 
CCBs CACNB1 chr17:37328301-37328450 Enhancer 
CCBs CACNB1 chr17:37329881-37330030  Enhancer 
CCBs CACNB1 chr17:37420122-37420730 Enhancer 
CCBs CACNB1 chr17:37566364-37566971  Enhancer 
CCBs CACNB1 chr17:37749329-37749495 Enhancer 
CCBs CACNB1 chr17:37334901-37335070 Enhancer 
CCBs CACNB1 chr17:37334100-37334787 Enhancer 
CCBs CACNB2 chr10:18429606-18830798 Encoding gene 
CCBs CACNB2 chr10:18428674-18431380 Promoter/Enhancer 
CCBs CACNB2 chr10:18688989-18690673 Promoter/Enhancer 
CCBs CACNB2 chr10:18629529-18630129 Promoter 
CCBs CACNB2 chr10:18549618-18549677 Promoter 
CCBs CACNB2 chr10:18452390-18454590 Enhancer 
CCBs CACNB2 chr10:18467498-18470172 Enhancer 
CCBs CACNB2 chr10:18451281-18451430 Enhancer 
CCBs CACNB2 chr10:18493061-18493210 Enhancer 
CCBs CACNB2 chr10:18592794-18593791 Enhancer 
CCBs CACNB2 chr10:18725955-18730327 Enhancer 
CCBs CACNB2 chr10:18473833-18475245  Enhancer 
CCBs CACNB2 chr10:18383961-18384110 Enhancer 
CCBs CACNB2 chr10:18475337-18476696 Enhancer 
CCBs CACNB2 chr10:18406301-18406450 Enhancer 
CCBs CACNB2 chr10:18759506-18760793 Enhancer 
CCBs CACNB2 chr10:18550812-18550951 Enhancer 
CCBs CACNB2 chr10:18775187-18776352 Enhancer 
CCBs CACNB2 chr10:18700589-18701887 Enhancer 
CCBs CACNB2 chr10:18578722-18579070 Enhancer 
CCBs CACNB2 chr10:18433444-18435058  Enhancer 
CCBs CACNB2 chr10:18447501-18448892  Enhancer 
CCBs CACNB2 chr10:18446528-18447484 Enhancer 
CCBs CACNB2 chr10:18534018-18534028  Enhancer 
CCBs CACNB2 chr10:18435549-18436688 Enhancer 
CCBs CACNB2 chr10:18504001-18504170 Enhancer 
CCBs CACNB2 chr10:18486006-18486731 Enhancer 
CCBs CACNB2 chr10:18707269-18708134 Enhancer 
CCBs CACNB2 chr10:18527921-18528030 Enhancer 
CCBs CACNB2 chr10:18522241-18522992 Enhancer 
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CCBs CACNB2 chr10:18505561-18505670 Enhancer 
CCBs CACNB2 chr10:18601402-18602376 Enhancer 
CCBs CACNB2 chr10:18436916-18441361 Enhancer 
CCBs CACNB2 chr10:18482789-18485238 Enhancer 
CCBs CACNB2 chr10:18333406-18335050  Enhancer 
CCBs CACNB2 chr10:18790055-18790529 Enhancer 
CCBs CACNB2 chr10:18691881-18692030 Enhancer 
CCBs CACNB2 chr10:18688181-18688330  Enhancer 
CCBs CACNB2 chr10:18567741-18568674 Enhancer 
CCBs CACNB2 chr10:18621941-18623677 Enhancer 
CCBs CACNB2 chr10:18762421-18762610 Enhancer 
CCBs CACNB2 chr10:18760801-18761292 Enhancer 
CCBs CACNB2 chr10:18712923-18713793 Enhancer 
CCBs CACNB2 chr10:18794315-18795372 Enhancer 
CCBs CACNB2 chr10:18745609-18746373 Enhancer 
CCBs CACNB2 chr10:18514101-18514250 Enhancer 
CCBs CACNB2 chr10:18348427-18349711 Enhancer 
CCBs CACNB2 chr10:18583664-18583897 Enhancer 
CCBs CACNB2 chr10:18738269-18739296 Enhancer 
CCBs CACNB2 chr10:18744481-18744630 Enhancer 
CCBs CACNB2 chr10:18744181-18744330 Enhancer 
CCBs CACNB2 chr10:18528875-18530208  Enhancer 
CCBs CACNB2 chr10:18718065-18718645 Enhancer 
CCBs CACNB2 chr10:18751830-18756160 Enhancer 
CCBs CACNB2 chr10:18749922-18751579 Enhancer 
CCBs CACNB2 chr10:18579741-18580614 Enhancer 
CCBs CACNB2 chr10:18567265-18567424 Enhancer 
CCBs CACNB2 chr10:18648500-18649316 Enhancer 
CCBs CACNB2 chr10:18702212-18703692  Enhancer 
CCBs CACNB2 chr10:18703721-18704168 Enhancer 
CCBs CACNB2 chr10:18778915-18780659 Enhancer 
CCBs CACNB2 chr10:18787912-18789147 Enhancer 
CCBs CACNB2 chr10:18792942-18793535 Enhancer 
CCBs CACNB2 chr10:18817341-18817490 Enhancer 
CCBs CACNB2 chr10:18816741-18816890 Enhancer 
CCBs CACNB2 chr10:18740308-18740990 Enhancer 
CCBs CACNB2 chr10:18741628-18742721 Enhancer 
CCBs CACNB2 chr10:18732026-18732639 Enhancer 
CCBs CACNB2 chr10:18723647-18724379 Enhancer 
CCBs CACNB3 chr12:49207577-49222726 Encoding gene 
CCBs CACNB3 chr12:49203763-49210435 Promoter/Enhancer 
CCBs CACNB3 chr12:49211575-49213450 Promoter/Enhancer 
CCBs CACNB3 chr12:49448916-49455655 Promoter/Enhancer 
CCBs CACNB3 chr12:49108721-49111783 Promoter/Enhancer 
CCBs CACNB3 chr12:49522862-49527437 Promoter/Enhancer 
CCBs CACNB3 chr12:49657029-49663594 Promoter/Enhancer 
CCBs CACNB3 chr12:49180347-49184467 Promoter/Enhancer 
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CCBs CACNB3 chr12:48225635-48230585 Enhancer 
CCBs CACNB3 chr12:49687781-49689222 Promoter/Enhancer 
CCBs CACNB3 chr12:49147321-49147490 Enhancer 
CCBs CACNB3 chr12:49173178-49175941 Enhancer 
CCBs CACNB3 chr12:49159161-49159930 Enhancer 
CCBs CACNB3 chr12:49580149-49584425 Promoter/Enhancer 
CCBs CACNB3 chr12:49162061-49162210 Enhancer 
CCBs CACNB3 chr12:49144534-49144559 Enhancer 
CCBs CACNB3 chr12:49160229-49161861 Enhancer 
CCBs CACNB3 chr12:49179679-49180345 Enhancer 
CCBs CACNB3 chr12:49217901-49218190 Enhancer 
CCBs CACNB3 chr12:49267159-49267283 Enhancer 
CCBs CACNB4 chr2:152689285-152955593 Encoding gene 
CCBs CACNB4 chr2:152954056-152956046 Promoter/Enhancer 
CCBs CACNB4 chr2:152830115-152830847 Promoter/Enhancer 
CCBs CACNB4 chr2:152918555-152920030  Enhancer 
CCBs CACNB4 chr2:152894160-152895545 Enhancer 
CCBs CACNB4 chr2:152851019-152853401 Enhancer 
CCBs CACNB4 chr2:152910872-152912587 Enhancer 
CCBs CACNB4 chr2:152855681-152855810 Enhancer 
CCBs CACNB4 chr2:152882049-152882769 Enhancer 
CCBs CACNB4 chr2:152779338-152780439 Enhancer 
CCBs CACNB4 chr2:152803715-152805070 Enhancer 
CCBs CACNB4 chr2:152906315-152907630 Enhancer 
CCBs CACNB4 chr2:153308651-153311667 Enhancer 
CCBs CACNB4 chr2:152564775-152568412 Enhancer 
CCBs CACNB4 chr2:152573345-152574228 Enhancer 
CCBs CACNB4 chr2:152700971-152701203 Enhancer 
CCBs CACNB4 chr2:153319291-153319615 Enhancer 
CCBs CACNB4 chr2:152757130-152757527 Enhancer 
CCBs CACNB4 chr2:152860915-152861914 Enhancer 
CCBs CACNB4 chr2:152945115-152946314  Enhancer 
CCBs CACNB4 chr2:152899381-152899610 Enhancer 
CCBs CACNB4 chr2:152036987-152037136 Enhancer 
CCBs CACNB4 chr2:152735004-152736098 Enhancer 
CCBs CACNB4 chr2:152742479-152743543 Enhancer 
CCBs CACNB4 chr2:152887915-152888514  Enhancer 
CCBs CACNB4 chr2:152971717-152971973 Enhancer 
CCBs CACNB4 chr2:152699171-152700353 Enhancer 
CCBs CACNB4 chr2:152714201-152714370 Enhancer 
CCBs CACNB4 chr2:152789657-152790028 Enhancer 
CCBs CACNB4 chr2:152748315-152748714 Enhancer 
CCBs CACNB4 chr2:152774315-152775314 Enhancer 
CCBs CACNB4 chr2:152800230-152802596 Enhancer 
CCBs CACNB4 chr2:152800061-152800210 Enhancer 
CCBs CACNG1 chr17:65040652-65052913 Encoding gene 
CCBs CACNG1 chr17:65038563-65044391 Promoter/Enhancer 
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CCBs CACNG1 chr17:65239492-65244198 Promoter/Enhancer 
CCBs CACNG1 chr17:65049530-65051511 Enhancer 
CCBs CACNG1 chr17:65106597-65109013  Enhancer 
CCBs CACNG1 chr17:65090722-65092662 Enhancer 
CCBs CACNG1 chr17:65253360-65257469 Enhancer 
CCBs CACNG1 chr17:65154098-65154970 Enhancer 
CCBs CACNG1 chr17:65276135-65278586 Enhancer 
CCBs CACNG1 chr17:65052236-65053547 Enhancer 
CCBs CACNG1 chr17:65234500-65237415 Enhancer 
CCBs CACNG1 chr17:65045559-65048695 Enhancer 
CCBs CACNG1 chr17:65103906-65106201 Enhancer 
CCBs CACNG1 chr17:65211601-65212541 Enhancer 
CCBs CACNG1 chr17:65072516-65072985 Enhancer 
CCBs CACNG1 chr17:65055208-65056211 Enhancer 
TDs SLC12A3 chr16:56899119-56949762 Encoding gene 
TDs SLC12A3 chr16:56899070-56899129 Promoter 
TDs SLC12A3 chr16:56964403-56974458  Promoter/Enhancer 
TDs SLC12A3 chr16:56839748-56841942 Enhancer 
TDs SLC12A3 chr16:56834256-56834865 Enhancer 
TDs SLC12A3 chr16:56893506-56897709 Enhancer 
TDs SLC12A3 chr16:56903512-56904197 Enhancer 
TDs SLC12A3 chr16:56901241-56901712 Enhancer 
TDs SLC12A3 chr16:56905112-56905513 Enhancer 
TDs SLC12A3 chr16:56948424-56953992 Enhancer 
TDs SLC12A3 chr16:56942554-56948010 Enhancer 
TDs SLC12A3 chr16:56908210-56909649 Enhancer 
TDs SLC12A3 chr16:56932921-56933070 Enhancer 
TDs SLC12A3 chr16:56922841-56922990 Enhancer 
CCBs CACNA1C chr12:2079952-2807115 Encoding gene 
CCBs CACNA1C chr12:2161566-2164566 Promoter/Enhancer 
CCBs CACNA1C chr12:2081194-2082566  Enhancer 
CCBs CACNA1C chr12:2079295-2081006  Enhancer 
CCBs CACNA1C chr12:2691972-2692849 Enhancer 
CCBs CACNA1C chr12:2143967-2144936 Enhancer 
CCBs CACNA1C chr12:2183654-2186279 Enhancer 
CCBs CACNA1C chr12:2372777-2379299 Enhancer 
CCBs CACNA1C chr12:2216896-2226195 Enhancer 
CCBs CACNA1C chr12:1767798-1773105 Enhancer 
CCBs CACNA1C chr12:2161154-2161552 Enhancer 
CCBs CACNA1C chr12:2419663-2421680 Enhancer 
CCBs CACNA1C chr12:2228156-2230922 Enhancer 
CCBs CACNA1C chr12:2206541-2209473 Enhancer 
CCBs CACNA1C chr12:2364427-2364812 Enhancer 
CCBs CACNA1C chr12:2444050-2449090 Enhancer 
CCBs CACNA1C chr12:2181896-2183390 Enhancer 
CCBs CACNA1C chr12:2210028-2211778 Enhancer 
CCBs CACNA1C chr12:2200243-2201838 Enhancer 
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CCBs CACNA1C chr12:2112379-2114467 Promoter/Enhancer 
CCBs CACNA1C chr12:2101946-2105129 Enhancer 
CCBs CACNA1C chr12:2044799-2047397 Enhancer 
CCBs CACNA1C chr12:2118861-2119010 Enhancer 
CCBs CACNA1C chr12:2121501-2121650 Enhancer 
CCBs CACNA1C chr12:2048444-2049910 Enhancer 
CCBs CACNA1C chr12:2122654-2123350 Enhancer 
CCBs CACNA1C chr12:2075648-2076741 Enhancer 
CCBs CACNA1C chr12:2058121-2060041 Enhancer 
CCBs CACNA1C chr12:2055375-2057136 Enhancer 
CCBs CACNA1C chr12:2120201-2121450 Enhancer 
CCBs CACNA1C chr12:2117981-2118130 Enhancer 
CCBs CACNA1C chr12:2173006-2173941 Enhancer 
CCBs CACNA1C chr12:2082932-2084071 Enhancer 
CCBs CACNA1C chr12:2069591-2073188 Enhancer 
CCBs CACNA1C chr12:2089853-2091243 Enhancer 
CCBs CACNA1C chr12:2125886-2127966 Enhancer 
CCBs CACNA1C chr12:2166481-2166670 Enhancer 
CCBs CACNA1C chr12:2466656-2469074 Enhancer 
CCBs CACNA1C chr12:2403410-2405816 Enhancer 
CCBs CACNA1C chr12:2356637-2359010 Enhancer 
CCBs CACNA1C chr12:2057237-2057501 Enhancer 
CCBs CACNA1C chr12:2431967-2434188 Enhancer 
CCBs CACNA1C chr12:2352323-2354776 Enhancer 
CCBs CACNA1C chr12:2365074-2366654 Enhancer 
CCBs CACNA1C chr12:2391640-2398088 Enhancer 
CCBs CACNA1C chr12:2450181-2451861 Enhancer 
CCBs CACNA1C chr12:2164767-2165166 Enhancer 
CCBs CACNA1C chr12:2277277-2279377 Enhancer 
CCBs CACNA1C chr12:2271349-2274081 Enhancer 
CCBs CACNA1C chr12:2322103-2323450 Enhancer 
CCBs CACNA1C chr12:2110661-2111403  Enhancer 
CCBs CACNA1C chr12:2288839-2290765 Enhancer 
CCBs CACNA1C chr12:2347936-2349143 Enhancer 
CCBs CACNA1C chr12:2415078-2416557 Enhancer 
CCBs CACNA1C chr12:2306940-2308560 Enhancer 
CCBs CACNA1C chr12:2292498-2294028 Enhancer 
CCBs CACNA1C chr12:2453367-2455170 Enhancer 
CCBs CACNA1C chr12:2084572-2086775 Enhancer 
CCBs CACNA1C chr12:2087127-2087591 Enhancer 
CCBs CACNA1C chr12:2095160-2096573  Enhancer 
CCBs CACNA1C chr12:2139487-2143377  Enhancer 
CCBs CACNA1C chr12:2175103-2177148 Enhancer 
CCBs CACNA1C chr12:2262602-2264090 Enhancer 
CCBs CACNA1C chr12:2193334-2194490 Enhancer 
CCBs CACNA1C chr12:2409918-2412424 Enhancer 
CCBs CACNA1C chr12:2158809-2159784  Enhancer 
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CCBs CACNA1C chr12:2359329-2360982 Enhancer 
CCBs CACNA1C chr12:2428657-2429566  Enhancer 
CCBs CACNA1C chr12:2400461-2400630  Enhancer 
CCBs CACNA1C chr12:2119384-2120057 Enhancer 
CCBs CACNA1C chr12:2203341-2204336 Enhancer 
CCBs CACNA1C chr12:2170143-2171251 Enhancer 
CCBs CACNA1C chr12:2281781-2281930 Enhancer 
CCBs CACNA1C chr12:2260436-2262389 Enhancer 
CCBs CACNA1C chr12:2302013-2306687 Enhancer 
CCBs CACNA1C chr12:2368400-2369290 Enhancer 
CCBs CACNA1C chr12:2442171-2442390 Enhancer 
CCBs CACNA1C chr12:2270781-2270930 Enhancer 
CCBs CACNA1C chr12:2339165-2339784 Enhancer 
CCBs CACNA1C chr12:2238381-2238550  Enhancer 
CCBs CACNA1C chr12:2268934-2269887 Enhancer 
CCBs CACNA1C chr12:2254615-2256378 Enhancer 
CCBs CACNA1C chr12:2342039-2342990 Enhancer 
CCBs CACNA1C chr12:2428367-2428566 Enhancer 
CCBs CACNA1C chr12:2427157-2427717 Enhancer 
CCBs CACNA1C chr12:2398761-2400405 Enhancer 
CCBs CACNA1C chr12:2335414-2336748 Enhancer 
CCBs CACNA1C chr12:2167767-2169880 Enhancer 
CCBs CACNA1C chr12:2148495-2149324 Enhancer 
CCBs CACNA1C chr12:2138706-2139344 Enhancer 
CCBs CACNA1C chr12:2171351-2172258 Enhancer 
CCBs CACNA1C chr12:2245167-2245366 Enhancer 
CCBs CACNA1C chr12:2246831-2248330 Enhancer 
CCBs CACNA1C chr12:2280498-2280632 Enhancer 
CCBs CACNA1C chr12:2281401-2281550 Enhancer 
CCBs CACNA1C chr12:2265561-2265750 Enhancer 
CCBs CACNA1C chr12:2407617-2408956 Enhancer 
CCBs CACNA1C chr12:2192366-2192566 Enhancer 
CCBs CACNA1C chr12:2274261-2274410  Enhancer 
CCBs CACNA1C chr12:2281201-2281350 Enhancer 
CCBs CACNA1C chr12:2177211-2178762 Enhancer 
CCBs CACNA1C chr12:2442567-2442967 Enhancer 
CCBs CACNA1C chr12:2441541-2441690 Enhancer 
CCBs CACNA1C chr12:2451967-2452766  Enhancer 
CCBs CACNA1C chr12:2416801-2416950 Enhancer 
CCBs CACNA1C chr12:2323730-2325500 Enhancer 
CCBs CACNA1C chr12:2349249-2351414 Enhancer 
CCBs CACNA1C chr12:2380803-2386142 Enhancer 
CCBs CACNA1C chr12:2336889-2337604 Enhancer 
CCBs CACNA1C chr12:2457223-2458492  Enhancer 
CCBs CACNA1C chr12:2249789-2251721 Enhancer 
CCBs CACNA1C chr12:2294781-2295709 Enhancer 
CCBs CACNA1C chr12:2186647-2187626 Enhancer 
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CCBs CACNA1C chr12:2438360-2439517 Enhancer 
CCBs CACNA1C chr12:2407095-2407603 Enhancer 
CCBs CACNA1C chr12:2386355-2387332 Enhancer 
CCBs CACNA1C chr12:2328750-2331231 Enhancer 
CCBs CACNA1C chr12:2400774-2402962 Enhancer 
CCBs CACNA1C chr12:2245404-2246734 Enhancer 
CCBs CACNA1C chr12:2274438-2275487 Enhancer 
CCBs CACNA1C chr12:2195393-2196970 Enhancer 
CCBs CACNA1C chr12:2233400-2237679 Enhancer 
CCBs CACNA1C chr12:2283997-2286741 Enhancer 
CCBs CACNA1C chr12:2287176-2288132 Enhancer 
CCBs CACNA1C chr12:2258324-2259667 Enhancer 
CCBs CACNA1C chr12:2343203-2345601 Enhancer 
CCBs CACNA1C chr12:2299019-2299959 Enhancer 
CCBs CACNA1C chr12:2412745-2414119 Enhancer 
CCBs CACNA1C chr12:2188468-2189111  Enhancer 
CCBs CACNA1C chr12:2434584-2435528 Enhancer 
CCBs CACNA1C chr12:2316947-2318292  Enhancer 
CCBs CACNA1C chr12:2333218-2334248  Enhancer 
CCBs CACNA1C chr12:2331290-2332420 Enhancer 
CCBs CACNA1C chr12:2440488-2441051 Enhancer 
CCBs CACNA1C chr12:2320137-2320914 Enhancer 
CCBs CACNA1C chr12:2326691-2328736 Enhancer 
CCBs CACNA1C chr12:2649836-2650311  Enhancer 
CCBs CACNA1C chr12:2506981-2507050 Enhancer 
CCBs CACNA1C chr12:2659879-2661404 Enhancer 
CCBs CACNA1C chr12:2515793-2516578 Enhancer 
CCBs CACNA1C chr12:2522460-2525715 Enhancer 
CCBs CACNA1C chr12:2526621-2527392 Enhancer 
CCBs CACNA1C chr12:2695181-2696063 Enhancer 
CCBs CACNA1C chr12:2543714-2545518 Enhancer 
CCBs CACNA1C chr12:2721754-2724057  Enhancer 
CCBs CACNA1C chr12:2547538-2548942  Enhancer 
CCBs CACNA1C chr12:2497459-2500942 Enhancer 
CCBs CACNA1C chr12:2733321-2734829 Enhancer 
CCBs CACNA1C chr12:2555271-2555641 Enhancer 
CCBs CACNA1C chr12:2558507-2559370 Enhancer 
CCBs CACNA1C chr12:2649619-2649812 Enhancer 
CCBs CACNA1C chr12:2736852-2737810 Enhancer 
CCBs CACNA1C chr12:2504526-2506285  Enhancer 
CCBs CACNA1C chr12:2740641-2741724 Enhancer 
CCBs CACNA1C chr12:2511126-2512729 Enhancer 
CCBs CACNA1C chr12:2512831-2514124 Enhancer 
CCBs CACNA1C chr12:2565222-2568247 Enhancer 
CCBs CACNA1C chr12:2749071-2750838 Enhancer 
CCBs CACNA1C chr12:2518209-2521853 Enhancer 
CCBs CACNA1C chr12:2463531-2463940 Enhancer 
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CCBs CACNA1C chr12:2792481-2792530 Enhancer 
CCBs CACNA1C chr12:2792101-2792350 Enhancer 
CCBs CACNA1C chr12:2791561-2791670  Enhancer 
CCBs CACNA1C chr12:2791761-2791970 Enhancer 
CCBs CACNA1C chr12:2473710-2474314 Enhancer 
CCBs CACNA1C chr12:2799725-2801764 Promoter/Enhancer 
CCBs CACNA1C chr12:2603721-2603850 Enhancer 
CCBs CACNA1C chr12:2724729-2726058 Enhancer 
CCBs CACNA1C chr12:2500386-2500884 Enhancer 
CCBs CACNA1C chr12:2552550-2553765  Enhancer 
CCBs CACNA1C chr12:2561981-2563825 Enhancer 
CCBs CACNA1C chr12:2559627-2561813 Enhancer 
CCBs CACNA1C chr12:2488061-2488210 Enhancer 
CCBs CACNA1C chr12:2531341-2532583 Enhancer 
CCBs CACNA1C chr12:2537218-2542473 Enhancer 
CCBs CACNA1C chr12:2489067-2491096 Enhancer 
CCBs CACNA1C chr12:2471978-2473410 Enhancer 
CCBs CACNA1C chr12:2608221-2608370 Enhancer 
CCBs CACNA1C chr12:2613061-2613207 Enhancer 
CCBs CACNA1C chr12:2610308-2611812 Enhancer 
CCBs CACNA1C chr12:2481105-2484809 Enhancer 
CCBs CACNA1C chr12:2486081-2486390 Enhancer 
CCBs CACNA1C chr12:2491894-2495082  Enhancer 
 
ACEI: angiotensin converting enzyme inhibitors; ARB: angiotensin II receptor blockers; BB: beta blockers; 
CCB: calcium channel blockers; TD: thiazide diuretics.  
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Table e-5. Sensitivity analyses for the Mendelian randomization associations between genetically determined 
systolic and diastolic blood pressure and risk of stroke and stroke subtypes. 
Outcome  
SBP (10 mm Hg increment) DBP (5 mm Hg increment) 
Any stroke OR 95%CI p OR 95%CI p 
IVW (primary analysis) 1.39 (1.33-1.44) 1.9E-60 1.27 (1.23-1.32) 1.2E-42 
MR Egger 1.54 (1.40-1.71) 6.0E-17 1.36 (1.25-1.48) 5.2E-13 
Egger Intercept 1.00 (0.99-1.00) 0.056 1.00 (1.00-1.00) 0.136 
Weighted median 1.42 (1.35-1.50) 2.0E-38 1.28 (1.22-1.34) 1.3E-27 
Weighted modal 1.44 (1.30-1.60) 1.2E-11 1.32 (1.21-1.44) 9.2E-10 
IVW after exclusion of MR-PRESSO outliers 1.38 (1.33-1.43) 1.2E-63 1.28 (1.24-1.32) 9.2E-54 
IVW restricted in Europeans 1.37 (1.32-1.43) 4.5E-47 1.26 (1.21-1.31) 1.8E-35 
IVW based on UKB summary statistics not adjusted 
for antihypertensive medication use or BMI 1.43 (1.36-1.50) 2.4E-51 1.32 (1.26-1.37) 8.5E-38 
       
Ischemic stroke OR 95%CI p OR 95%CI p 
IVW (primary analysis) 1.41 (1.35-1.47) 1.3E-53 1.28 (1.24-1.33) 2.6E-40 
MR Egger 1.56 (1.40-1.74) 5.9E-16 1.40 (1.28-1.53) 3.0E-13 
Egger Intercept 1.00 (0.99-1.00) 0.134 1.00 (1.00-1.00) 0.134 
Weighted median 1.45 (1.37-1.54) 4.7E-38 1.30 (1.25-1.36) 2.0E-33 
Weighted modal 1.51 (1.35-1.69) 5.6E-13 1.37 (1.22-1.53) 1.0E-07 
IVW after exclusion of MR-PRESSO outliers 1.40 (1.35-1.46) 5.9E-59 1.28 (1.24-1.32) 1.2E-47 
IVW restricted in Europeans 1.40 (1.34-1.47) 3.6E-49 1.27 (1.22-1.32) 3.6E-33 
IVW based on UKB summary statistics not adjusted 
for antihypertensive medication use or BMI 1.45 (1.38-1.52) 6.4E-50 1.32 (1.26-1.38) 6.5E-35 
       
Large artery stroke OR 95%CI p OR 95%CI p 
IVW (primary analysis) 1.68 (1.54-1.84) 5.2E-30 1.34 (1.25-1.44) 1.0E-14 
MR Egger 1.69 (1.35-2.12) 5.2E-06 1.41 (1.18-1.69) 1.7E-04 
Egger Intercept 1.00 (0.99-1.01) 0.999 1.00 (1.00-1.00) 0.505 
Weighted median 1.70 (1.48-1.95) 1.0E-13 1.37 (1.24-1.52) 1.3E-09 
Weighted modal 1.73 (1.30-2.29) 1.5E-04 1.28 (0.94-1.74) 1.2E-01 
IVW after exclusion of MR-PRESSO outliers 1.67 (1.53-1.82) 2.1E-31 1.36 (1.26-1.46) 2.4E-17 
IVW restricted in Europeans 1.81 (1.63-2.00) 7.1E-29 1.35 (1.24-1.47) 2.0E-11 
IVW based on UKB summary statistics not adjusted 
for antihypertensive medication use or BMI 1.81 (1.64-2.00) 4.5E-32 1.38 (1.27-1.51) 3.1E-13 
       
Cardioembolic stroke OR 95%CI p OR 95%CI p 
IVW (primary analysis) 1.24 (1.16-1.34) 9.9E-09 1.17 (1.10-1.24) 2.7E-06 
MR Egger 1.49 (1.24-1.80) 2.3E-05 1.33 (1.14-1.56) 3.2E-04 
Egger Intercept 0.99 (0.99-1.00) 0.066 1.00 (0.99-1.00) 0.096 
Weighted median 1.30 (1.17-1.45) 1.1E-06 1.24 (1.13-1.36) 2.3E-06 
Weighted modal 1.31 (0.99-1.75) 0.060 1.54 (1.26-1.89) 3.5E-05 
IVW after exclusion of MR-PRESSO outliers 1.25 (1.17-1.35) 1.0E-09 1.18 (1.11-1.25) 1.8E-07 
IVW restricted in Europeans 1.21 (1.12-1.31) 1.2E-06 1.15 (1.08-1.23) 4.4E-05 
IVW based on UKB summary statistics not adjusted 
for antihypertensive medication use or BMI 1.27 (1.17-1.38) 8.8E-09 1.19 (1.10-1.28) 8.0E-06 
       
Small vessel stroke OR 95%CI p OR 95%CI p 
IVW (primary analysis) 1.47 (1.36-1.58) 3.5E-22 1.36 (1.27-1.45) 7.8E-19 
MR Egger 1.44 (1.19-1.76) 2.7E-04 1.39 (1.17-1.64) 1.3E-04 
Egger Intercept 1.00 (1.00-1.01) 0.739 1.00 (1.00-1.00) 0.739 
Weighted median 1.54 (1.37-1.73) 9.5E-14 1.43 (1.31-1.56) 9.5E-16 
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Weighted modal 1.74 (1.38-2.18) 1.9E-06 1.54 (1.24-1.92) 9.8E-05 
IVW after exclusion of MR-PRESSO outliers 1.47 (1.36-1.58) 7.1E-23 1.38 (1.29-1.47) 4.5E-23 
IVW restricted in Europeans 1.57 (1.43-1.72) 1.3E-21 1.39 (1.28-1.50) 1.5E-15 
IVW based on UKB summary statistics not adjusted 
for antihypertensive medication use or BMI 1.52 (1.39-1.66) 4.8E-21 1.41 (1.30-1.53) 5.1E-17 
       
Intracerebral hemorrhage OR 95%CI p OR 95%CI p 
IVW (primary analysis) 1.41 (1.11-1.79) 8.3E-03 1.29 (1.05-1.57) 0.019 
MR Egger 1.49 (0.81-2.74) 0.201 1.22 (0.72-2.07) 0.457 
Egger Intercept 1.00 (0.98-1.02) 0.824 1.00 (0.99-1.01) 0.841 
Weighted median 1.49 (1.09-2.03) 0.012 1.31 (1.00-1.71) 0.047 
Weighted modal 1.56 (0.80-3.04) 0.192 1.81 (0.89-3.71) 0.103 
IVW after exclusion of MR-PRESSO outliers 1.41 (1.11-1.79) 0.005 1.29 (1.05-1.57) 0.014 
IVW based on UKB summary statistics not adjusted 
for antihypertensive medication use or BMI 1.43 (1.09-1.87) 0.009 1.36 (1.07-1.73) 0.013 
       
Lobar intracerebral hemorrhage OR 95%CI p OR 95%CI p 
IVW (primary analysis) 1.04 (0.77-1.40) 0.389 0.97 (0.76-1.25) 0.391 
MR Egger 1.03 (0.48-2.21) 0.936 1.02 (0.53-1.97) 0.960 
Egger Intercept 1.00 (0.98-1.02) 0.999 1.00 (0.99-1.01) 0.868 
Weighted median 1.26 (0.85-1.87) 0.259 1.12 (0.77-1.63) 0.563 
Weighted modal 1.19 (0.62-2.31) 0.596 1.14 (0.62-2.08) 0.671 
IVW after exclusion of MR-PRESSO outliers 1.04 (0.77-1.40) 0.819 0.97 (0.76-1.25) 0.837 
IVW based on UKB summary statistics not adjusted 
for antihypertensive medication use or BMI 1.06 (0.79-1.48) 0.738 0.98 (0.71-1.33) 0.889 
       
Deep intracerebral hemorrhage OR 95%CI p OR 95%CI p 
IVW (primary analysis) 1.73 (1.30-2.32) 8.3E-04 1.54 (1.21-1.97) 8.2E-04 
MR Egger 1.86 (0.89-3.87) 0.097 1.24 (0.66-2.34) 0.506 
Egger Intercept 1.00 (0.98-1.02) 0.856 1.00 (0.99-1.02) 0.505 
Weighted median 1.59 (1.01-2.48) 0.043 1.45 (0.99-2.12) 0.055 
Weighted modal 1.15 (0.38-3.52) 0.800 1.40 (0.49-3.96) 0.530 
IVW after exclusion of MR-PRESSO outliers 1.77 (1.33-2.35) 8.2E-05 1.54 (1.21-1.97) 4.3E-04 
IVW based on UKB summary statistics not adjusted 
for antihypertensive medication use or BMI 1.79 (1.30-2.47) 4.1E-04 1.66 (1.24-2.23) 6.6E-04 
       
WMH volume β 95%CI p β 95%CI p 
IVW (primary analysis) 0.101 (0.053, 0.149) 3.8E-05 0.107 (0.064, 0.150) 1.1E-06 
MR Egger 0.159 (0.034, 0.284) 0.013 0.113 (0.007, 0.218) 0.036 
Egger Intercept -0.002 (-0.006, 0.002) 0.323 0.000 (-0.004, 0.004) 0.909 
Weighted median 0.130 (0.057, 0.202) 1.5E-06 0.115 (0.051, 0.179) 4.9E-04 
Weighted modal 0.211 (-0.026, 0.447) 0.081 0.172 (-0.011, 0.355) 0.065 
IVW after exclusion of MR-PRESSO outliers 0.108 (0.059, 0.156) 1.6E-05 0.110 (0.068, 0.151) 3.7E-07 
IVW based on UKB summary statistics not adjusted 
for antihypertensive medication use or BMI 0.088 (0.042, 0.134) 1.9E-04 0.097 (0.053, 0.141) 1.6E-05 
BMI: body mass index, DBP: diastolic blood pressure; IVW: inverse variance weighted; MR-PRESSO: Mendelian randomization pleiotropy residual 
sum and outlier; OR: Odds ratio; SBP: systolic blood pressure; WMH: white matter hyperintensities. 
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Table e-6. Sensitivity analyses for the Mendelian randomization associations between geneic proxies for beta blockers 
and calcium channel blockers and risk of stroke, risk of stroke subtypes, and WMH volume. 
Outcome BB (10 mm Hg decrease in SBP) CCB (10 mm Hg decrease in SBP) 
Any stroke OR 95%CI p OR 95%CI p 
Primary MR analysis with SNPs clumped at r2<0.4 & 
adjusted for LD correlation 1.00 (0.84-1.18) 0.997 0.69 (0.64-0.74) 1.7E-26 
IVW (SNPs clumped at r2<0.1) 0.90 (0.71-1.15) 0.397 0.67 (0.59-0.76) 1.4E-08 
MR Egger 1.00 (0.23-4.27) 0.997 0.78 (0.56-1.11) 0.179 
Egger Intercept 1.00 (0.95-1.05) 0.885 0.99 (0.98-1.01) 0.318 
Weighted median 0.89 (0.65-1.23) 0.485 0.67 (0.55-0.81) 4.5E-05 
Weighted modal 0.90 (0.61-1.33) 0.600 0.66 (0.53-0.83) 2.6E-04 
IVW after exclusion of MR-PRESSO outliers 0.93* (0.70-1.23) 0.597 0.67 (0.59-0.76) 1.4E-08 
       
Ischemic stroke OR 95%CI p OR 95%CI p 
Primary MR analysis with SNPs clumped at r2<0.4 & 
adjusted for LD correlation 1.02 (0.86-1.23) 0.795 0.71 (0.66-0.76) 4.3E-20 
IVW (SNPs clumped at r2<0.1) 0.89 (0.72-1.15) 0.439 0.69 (0.60-0.79) 6.7E-07 
MR Egger 0.98 (0.17-5.62) 0.978 0.80 (0.56-1.14) 0.220 
Egger Intercept 1.00 (0.94-1.06) 0.909 1.00 (0.98-1.01) 0.404 
Weighted median 0.95 (0.68-1.32) 0.757 0.71 (0.58-0.86) 7.3E-04 
Weighted modal 0.94 (0.64-1.38) 0.752 0.71 (0.57-0.88) 1.5E-03 
IVW after exclusion of MR-PRESSO outliers* 0.94* (0.70-1.27) 0.690 0.69 (0.60-0.79) 2.1E-07 
       
Large artery stroke OR 95%CI p OR 95%CI p 
Primary MR analysis with SNPs clumped at r2<0.4 & 
adjusted for LD correlation 0.89 (0.57-1.37) 0.586 0.85 (0.73-0.99) 0.037 
IVW (SNPs clumped at r2<0.1) 0.91 (0.48-1.75) 0.783 0.83 (0.59-1.17) 0.277 
MR Egger 2.12 (0.25-18.1) 0.491 0.75 (0.29-1.94) 0.546 
Egger Intercept 0.97 (0.90-1.05) 0.422 1.00 (0.97-1.03) 0.789 
Weighted median 1.04 (0.49-2.21) 0.917 0.82 (0.50-1.33) 0.421 
Weighted modal 1.13 (0.45-2.85) 0.797 0.85 (0.54-1.33) 0.469 
IVW after exclusion of MR-PRESSO outliers* 0.91** (0.48-1.75) 0.783 0.83** (0.57-1.20) 0.312 
       
Cardioembolic stroke OR 95%CI p OR 95%CI p 
Primary MR analysis with SNPs clumped at r2<0.4 & 
adjusted for LD correlation 1.31 (0.90-1.91) 0.153 0.88 (0.82-0.95) 3.6E-04 
IVW (SNPs clumped at r2<0.1) 1.03 (0.60-1.77) 0.919 0.82 (0.61-1.10) 0.183 
MR Egger 0.72 (0.06-9.22) 0.801 0.84 (0.40-1.77) 0.645 
Egger Intercept 1.01 (0.92-1.11) 0.774 1.00 (0.98-1.02) 0.933 
Weighted median 1.07 (0.52-2.21) 0.858 0.82 (0.52-1.31) 0.408 
Weighted modal 1.57 (0.62-4.00) 0.345 0.77 (0.46-1.26) 0.296 
IVW after exclusion of MR-PRESSO outliers* 1.03** (0.60-1.77) 0.919 0.82** (0.61-1.10) 0.180 
       
Small vessel stroke OR 95%CI p OR 95%CI p 
Primary MR analysis with SNPs clumped at r2<0.4 & 
adjusted for LD correlation 1.09 (0.75-1.59) 0.646 0.60 (0.52-0.71) 4.4E-10 
IVW (SNPs clumped at r2<0.1) 0.77 (0.45-1.33) 0.344 0.63 (0.46-0.85) 2.9E-03 
MR Egger 0.87 (0.02-34.78) 0.942 0.69 (0.25-1.90) 0.474 
Egger Intercept 1.00 (0.87-1.13) 0.941 1.00 (0.97-1.03) 0.841 
Weighted median 0.79 (0.4-1.57) 0.497 0.55 (0.35-0.87) 0.010 
Weighted modal 0.83 (0.43-1.59) 0.567 0.50 (0.31-0.81) 4.9E-03 
IVW after exclusion of MR-PRESSO outliers* 0.89** (0.47-1.69) 0.726 0.63** (0.44-0.90) 0.010 
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Intracerebral hemorrhage OR 95%CI p OR 95%CI p 
Primary MR analysis with SNPs clumped at r2<0.4 & 
adjusted for LD correlation 1.25 (0.40-3.88) 0.704 1.09 (0.65-1.83) 0.746 
IVW (SNPs clumped at r2<0.1) 2.56 (0.29-22.4) 0.396 1.23 (0.49-3.08) 0.665 
MR Egger 34.8 (0.08-15930) 0.256 3.93 (0.40-38.5) 0.240 
Egger Intercept 0.91 (0.73-1.12) 0.372 0.96 (0.90-1.03) 0.274 
Weighted median 3.89 (0.27-55.5) 0.316 1.04 (0.27-4.06) 0.951 
Weighted modal 5.71 (0.35-86.7) 0.23 1.00 (0.21-5.08) 0.960 
IVW after exclusion of MR-PRESSO outliers* 2.56** (0.29-22.4) 0.396 1.23** (0.49-3.08) 0.665 
       
Lobar intracerebral hemorrhage OR 95%CI p OR 95%CI p 
Primary MR analysis with SNPs clumped at r2<0.4 & 
adjusted for LD correlation 1.66 (0.05-57.49) 0.779 1.70 (0.67-4.35) 0.379 
IVW (SNPs clumped at r2<0.1) 5.98 (0.33-108) 0.225 1.26 (0.38-4.18) 0.706 
MR Egger 4060 (1.22-13537849) 0.045 8.26 (0.42-161) 0.164 
Egger Intercept 0.78 (0.59-1.04) 0.092 0.94 (0.86-1.03) 0.175 
Weighted median 11.6 (0.36-369) 0.166 1.52 (0.26-8.87) 0.641 
Weighted modal 30.7 (0.12-9537) 0.228 1.50 (0.21-10.6) 0.676 
IVW after exclusion of MR-PRESSO outliers* 5.98** (0.33-108) 0.225 1.26** (0.38-4.18) 0.706 
       
Deep intracerebral hemorrhage OR 95%CI p OR 95%CI p 
Primary MR analysis with SNPs clumped at r2<0.4 & 
adjusted for LD correlation 1.74 (0.07-41.9) 0.733 0.66 (0.31-1.40) 0.167 
IVW (SNPs clumped at r2<0.1) 2.28 (0.18-29.6) 0.528 0.83 (0.28-2.44) 0.734 
MR Egger 1.41 (0.01-1905) 0.926 0.95 (0.07-13.5) 0.971 
Egger Intercept 1.02 (0.79-1.31) 0.888 1.01 (0.93-1.09) 0.848 
Weighted median 3.03 (0.14-67.0) 0.482 0.80 (0.18-3.59) 0.772 
Weighted modal 5.72 (0.08-395) 0.416 0.91 (0.15-5.72) 0.911 
IVW after exclusion of MR-PRESSO outliers* 2.28** (0.18-29.6) 0.528 0.83** (0.28-2.44) 0.734 
       
WMH volume β 95%CI p β 95%CI p 
Primary MR analysis with SNPs clumped at r2<0.4 
& adjusted for LD correlation -0.146 (-0.448, 0.157) 0.345 -0.491 (-0.591, -0.391) 3.5E-07 
IVW (SNPs clumped at r2<0.1) -0.345 (-1.279, 0.588) 0.469 -0.510 (-0.701, -0.319) 1.5E-07 
MR Egger -1.390 (-4.620, 1.840) 0.399 -0.831 (-1.284, -0.377) 3.2E-04 
Egger Intercept 0.040 (-0.078, 0.158) 0.505 0.012 (-0.003, 0.027) 0.128 
Weighted median -0.682 (-1.152, -0.213) 0.004 -0.553 (-0.841, -0.265) 1.7E-04 
Weighted modal -0.744 (-1.315, -0.173)  0.011 -0.537 (-0.858, -0.216) 9.1E-04 
IVW after exclusion of MR-PRESSO outliers* -0.515* (-1.142, 0.112) 0.249 
-
0.510** (-0.701, -0.319) 1.5E-07 
 
* rs4359161 and rs460718 were identified as outliers with the MR-PRESSO approach. 
** No outliers identified with the MR-PRESSO approach. 
IVW: inverse-variance weigted; LD: linkage disequilibrium; MR-PRESSO: Mendelian randomization pleiotropy residual sum and outlier; OR: odds ratio; 
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Supplementary Table 1. Descriptive characteristics of the genome-wide association studies 
(GWAS) that were included in our Mendelian randomization analysis.  
GWAS Phenotype Sample size Ancestry Adjustmentsa 
Instrument 
selection     
GLGC & MVP HDL-C, LDL-C, TG  
617,303 
individuals Multi-ancestry age, age2, sex 
GLGC 
HDL-C, LDL-C, TG (for 
lipid-modifying drug targets 
& sensitivity analyses) 
188,577 







age, sex, time 
from last meal 
Examined 
outcomes     
MEGASTROKE Small vessel stroke 
11,710 cases; 
287,067 controls Multi-ancestry age, sex 





British) age, sex 
ISGC ICH 
ICH and subtypes (lobar, 
deep ICH) 
1,537 cases/ 
1,490 controls European age, sex 
a All GWAS studies have further adjusted for principal components. 
Abbreviations. GLGC, global lipids genetics consortium; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol; MVP, Million Veteran Program; NMR, Nuclear Magnetic Resonance; TG, triglycerides. 
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Supplementary Table 2. Genetic instruments for blood lipid levels selected from the meta-
analyzed datasets of the Million Veterans Program (MVP) and the Global Lipids Genetics 
Consortium (GLGC). 
 
Phenotype SNP Chr Position (hg18) Eff_allele Effect SE P-value R2 F 
HDL-C rs1767141 1 23734350 a 
-
0.026 0.004 1.4E-10 0.0001 64.5 
HDL-C rs6668958 1 26902388 t 0.020 0.003 2.3E-12 0.0001 81.0 
HDL-C rs17162330 1 27236212 t 0.041 0.003 1.5E-35 0.0004 258.0 
HDL-C rs12144891 1 28344980 a 0.017 0.003 1.3E-10 0.0001 69.4 
HDL-C rs4660293 1 40028180 a 0.040 0.002 2.5E-62 0.0006 342.9 
HDL-C rs1168089 1 63113719 t 
-
0.015 0.002 1.8E-10 0.0001 63.6 
HDL-C rs4847399 1 93584606 a 
-
0.022 0.002 8.3E-25 0.0002 136.2 
HDL-C rs2878349 1 107549245 a 
-
0.015 0.003 2.1E-09 0.0001 61.3 
HDL-C rs12740374 1 109817590 t 0.045 0.002 9.6E-79 0.0007 430.3 
HDL-C rs7550711 1 110082886 t 
-
0.049 0.006 1.6E-16 0.0001 82.5 
HDL-C rs28362581 1 110163879 a 
-
0.028 0.004 4.0E-13 0.0001 67.1 
HDL-C rs333947 1 110470764 a 
-
0.027 0.003 4.3E-15 0.0002 113.6 
HDL-C rs267738 1 150940625 t 
-
0.024 0.003 9.9E-22 0.0002 109.5 
HDL-C rs12145743 1 156700651 t 
-
0.014 0.002 2.0E-10 0.0001 53.0 
HDL-C rs1011731 1 172346548 a 0.013 0.002 1.9E-11 0.0001 54.5 
HDL-C rs4650994 1 178515312 a 
-
0.019 0.002 4.7E-22 0.0002 115.1 
HDL-C rs2243976 1 182157235 a 0.029 0.002 2.0E-33 0.0004 234.2 
HDL-C rs16856110 1 205631767 a 0.020 0.003 5.0E-10 0.0001 84.0 
HDL-C rs6694509 1 219631981 t 
-
0.019 0.002 2.6E-17 0.0002 111.2 
HDL-C rs2807834 1 220970593 t 
-
0.024 0.003 1.8E-21 0.0002 145.1 
HDL-C rs4846914 1 230295691 a 0.047 0.002 9.2E-110 0.0011 663.0 
HDL-C rs1043900 1 230416744 a 0.023 0.003 8.3E-16 0.0002 109.6 
HDL-C rs558971 1 234853406 a 
-
0.014 0.002 8.1E-09 0.0001 59.1 
HDL-C rs11553746 2 272203 t 0.016 0.002 5.7E-14 0.0001 68.7 
HDL-C rs2867125 2 622827 t 0.017 0.003 3.2E-11 0.0001 52.4 
HDL-C rs4850047 2 3634753 t 0.020 0.003 1.0E-09 0.0001 63.3 
HDL-C rs676210 2 21231524 a 0.062 0.002 4.7E-143 0.0013 787.0 
HDL-C rs562338 2 21288321 a 0.018 0.003 1.8E-12 0.0001 60.7 
HDL-C rs36020289 2 53992622 c 0.046 0.008 2.0E-09 0.0001 43.0 
HDL-C rs12990465 2 65281401 t 0.026 0.003 1.9E-18 0.0003 164.3 
HDL-C rs13389219 2 165528876 t 0.033 0.002 1.2E-54 0.0005 314.9 
HDL-C rs6435161 2 203519783 t 0.018 0.002 1.6E-13 0.0001 82.2 
HDL-C rs2943641 2 227093745 t 0.039 0.002 2.5E-77 0.0007 427.1 
HDL-C rs11712666 3 11619958 a 
-
0.014 0.002 1.0E-09 0.0001 60.7 
HDL-C rs2067819 3 12359049 a 0.021 0.003 5.6E-14 0.0002 93.9 
HDL-C rs2292101 3 12434901 t 
-
0.044 0.007 1.8E-11 0.0002 95.1 
HDL-C rs6777217 3 36979042 a 
-
0.013 0.002 1.1E-10 0.0001 51.0 
HDL-C rs2305637 3 47045846 t 
-
0.026 0.003 1.1E-19 0.0002 119.1 
HDL-C rs6762477 3 50093209 a 0.023 0.002 2.1E-28 0.0003 162.8 
HDL-C rs13326165 3 52532118 a 0.021 0.003 1.3E-16 0.0001 89.4 
HDL-C rs11242 3 53125922 t 0.015 0.002 2.3E-10 0.0001 68.0 
HDL-C rs35000036 3 123190731 t 
-
0.013 0.002 3.3E-10 0.0001 50.5 
HDL-C rs1279840 3 136006576 t 0.028 0.003 3.4E-25 0.0003 177.9 
HDL-C rs3773910 3 152171870 c 
-
0.017 0.003 4.1E-10 0.0001 65.9 
HDL-C rs900399 3 156798732 a 
-
0.021 0.002 1.4E-26 0.0002 134.2 
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HDL-C rs7633675 3 185510613 t 0.013 0.002 2.2E-10 0.0001 49.0 
HDL-C rs4234589 3 185818882 a 0.022 0.003 6.2E-11 0.0001 72.3 
HDL-C rs11248051 4 858332 t 
-
0.019 0.003 8.5E-09 0.0001 40.8 
HDL-C rs10019888 4 26062990 a 0.024 0.003 4.6E-15 0.0002 102.8 
HDL-C rs293429 4 69591612 t 
-
0.013 0.002 1.5E-09 0.0001 45.5 
HDL-C rs10023050 4 88064431 a 
-
0.015 0.002 3.7E-11 0.0001 68.9 
HDL-C rs3822072 4 89741269 a 
-
0.021 0.002 1.4E-20 0.0002 141.0 
HDL-C rs2602836 4 100014805 a 0.013 0.002 2.0E-10 0.0001 48.7 
HDL-C rs112519623 4 103184239 a 
-
0.047 0.008 8.8E-09 0.0001 39.8 
HDL-C rs13107325 4 103188709 t 
-
0.078 0.004 6.3E-80 0.0009 540.0 
HDL-C rs6855363 4 157670537 t 
-
0.019 0.002 1.3E-14 0.0002 93.2 
HDL-C rs7735253 5 53297611 a 
-
0.021 0.003 6.5E-16 0.0002 105.7 
HDL-C rs459193 5 55806751 a 0.026 0.002 9.2E-33 0.0003 168.5 
HDL-C rs9686661 5 55861786 t 
-
0.034 0.003 3.5E-42 0.0004 229.0 
HDL-C rs4976033 5 67714246 a 0.013 0.002 1.8E-11 0.0001 55.1 
HDL-C rs10057967 5 74997756 t 
-
0.021 0.003 2.8E-14 0.0002 121.3 
HDL-C rs4705986 5 132349654 t 
-
0.035 0.006 2.0E-09 0.0001 87.9 
HDL-C rs390299 5 153363334 a 
-
0.015 0.002 4.6E-12 0.0001 60.4 
HDL-C rs2434612 5 158022041 a 0.023 0.003 8.1E-16 0.0002 104.0 
HDL-C rs7730898 5 170459675 a 
-
0.018 0.003 1.9E-12 0.0001 81.4 
HDL-C rs1265099 6 31105413 a 0.017 0.002 1.2E-16 0.0001 86.2 
HDL-C rs184070214 6 31526080 a 
-
0.045 0.007 1.5E-09 0.0001 46.8 
HDL-C rs9332739 6 31903804 c 
-
0.029 0.005 1.8E-09 0.0001 43.9 
HDL-C rs3135006 6 32667119 t 
-
0.019 0.003 3.0E-13 0.0001 84.9 
HDL-C rs2894342 6 33774394 a 0.015 0.002 1.3E-09 0.0001 46.4 
HDL-C rs1759645 6 34194866 t 0.024 0.003 3.3E-13 0.0002 97.4 
HDL-C rs16885998 6 34268107 t 0.051 0.006 3.0E-16 0.0002 138.8 
HDL-C rs11755393 6 34824636 a 0.030 0.002 5.9E-45 0.0004 262.9 
HDL-C rs41270076 6 35467891 t 0.039 0.006 6.2E-10 0.0001 48.2 
HDL-C rs4711698 6 41987451 t 0.018 0.003 2.8E-11 0.0001 76.4 
HDL-C rs2274517 6 42932715 t 0.016 0.002 1.4E-11 0.0001 74.5 
HDL-C rs6905288 6 43758873 a 
-
0.030 0.002 5.5E-49 0.0004 262.8 
HDL-C rs35349911 6 43785255 t 
-
0.014 0.002 1.0E-11 0.0001 57.9 
HDL-C rs881858 6 43806609 a 
-
0.014 0.002 9.5E-11 0.0001 49.3 
HDL-C rs2754820 6 109246891 a 0.020 0.003 3.1E-09 0.0001 76.6 
HDL-C rs884366 6 109574095 a 
-
0.014 0.002 8.1E-11 0.0001 54.0 
HDL-C rs3756772 6 116325142 t 0.013 0.002 1.6E-10 0.0001 49.4 
HDL-C rs2745353 6 127452935 t 
-
0.020 0.002 6.5E-24 0.0002 125.5 
HDL-C rs6925103 6 137076010 t 
-
0.012 0.002 1.3E-09 0.0001 45.5 
HDL-C rs643381 6 139839423 a 0.021 0.002 2.5E-25 0.0002 133.5 
HDL-C rs41272114 6 161006077 t 0.066 0.006 3.4E-27 0.0003 181.0 
HDL-C rs1652507 6 161082461 t 0.046 0.003 9.6E-51 0.0006 365.4 
HDL-C rs1997243 7 1083777 a 
-
0.022 0.003 2.2E-15 0.0001 80.2 
HDL-C rs2303361 7 6449496 t 
-
0.024 0.002 4.1E-23 0.0002 118.6 
HDL-C rs10282707 7 17911038 t 
-
0.026 0.002 7.6E-32 0.0003 200.3 
HDL-C rs1534696 7 26397239 a 0.019 0.003 1.3E-13 0.0002 104.1 
HDL-C rs2726070 7 36170883 a 
-
0.017 0.003 2.0E-10 0.0001 90.4 
HDL-C rs4917014 7 50305863 t 
-
0.014 0.002 5.0E-11 0.0001 50.2 
6 
 
HDL-C rs1178979 7 72856430 t 
-
0.034 0.003 6.2E-41 0.0003 206.0 
HDL-C rs11556924 7 129663496 t 0.013 0.002 2.0E-09 0.0001 44.8 
HDL-C rs972283 7 130466854 a 0.028 0.002 2.9E-43 0.0004 233.6 
HDL-C rs3735080 7 150217309 t 
-
0.014 0.002 2.7E-09 0.0001 41.1 
HDL-C rs7787577 7 150521026 a 0.031 0.005 8.3E-12 0.0002 102.0 
HDL-C rs11774381 8 9183339 t 
-
0.028 0.003 5.1E-24 0.0003 192.0 
HDL-C rs4841132 8 9183596 a 
-
0.108 0.003 1.9E-215 0.0020 1207.7 
HDL-C rs9657541 8 10643164 t 
-
0.025 0.003 3.6E-17 0.0002 124.0 
HDL-C rs1801177 8 19805708 a 
-
0.120 0.009 2.3E-44 0.0005 324.7 
HDL-C rs264 8 19813180 a 0.033 0.003 6.1E-23 0.0003 161.6 
HDL-C rs268 8 19813529 a 0.238 0.008 5.5E-213 0.0018 1108.5 
HDL-C rs13702 8 19824492 t 
-
0.059 0.005 4.4E-32 0.0014 890.5 
HDL-C rs17091872 8 19831977 a 
-
0.056 0.004 2.6E-36 0.0009 573.9 
HDL-C rs2410622 8 19854773 t 
-
0.026 0.004 1.4E-10 0.0002 113.1 
HDL-C rs6983170 8 19860161 t 0.093 0.010 5.6E-19 0.0005 281.3 
HDL-C rs6651485 8 19861854 a 0.054 0.004 1.9E-36 0.0011 650.1 
HDL-C rs2083637 8 19865175 a 
-
0.048 0.005 3.5E-22 0.0009 557.7 
HDL-C rs7837677 8 19889872 t 
-
0.034 0.004 3.8E-16 0.0005 317.9 
HDL-C rs10106652 8 19928160 a 0.031 0.005 4.6E-11 0.0004 230.1 
HDL-C rs34859606 8 19930682 c 
-
0.019 0.003 9.0E-09 0.0001 70.4 
HDL-C rs6586892 8 19941145 a 0.036 0.004 5.5E-22 0.0006 377.0 
HDL-C rs6983999 8 19955920 a 0.024 0.003 2.3E-15 0.0003 176.9 
HDL-C rs4512408 8 71099094 t 0.026 0.004 5.5E-12 0.0001 80.8 
HDL-C rs2957447 8 106357374 a 0.014 0.002 8.9E-09 0.0001 58.2 
HDL-C rs2293889 8 116599199 t 
-
0.030 0.002 2.7E-52 0.0004 275.0 
HDL-C rs4871137 8 121868551 t 
-
0.021 0.002 4.4E-22 0.0002 127.3 
HDL-C rs17405319 8 126449406 t 
-
0.025 0.003 9.0E-16 0.0002 110.9 
HDL-C rs2954026 8 126484526 t 
-
0.049 0.002 1.3E-108 0.0010 622.1 
HDL-C rs581080 9 15305378 c 0.037 0.003 1.5E-49 0.0004 266.9 
HDL-C rs13292026 9 107557315 a 
-
0.044 0.007 4.9E-09 0.0001 66.2 
HDL-C rs2230808 9 107562804 t 
-
0.024 0.002 3.8E-23 0.0002 129.8 
HDL-C rs76881554 9 107578620 a 
-
0.164 0.025 3.4E-11 0.0001 56.4 
HDL-C rs2066714 9 107586753 t 
-
0.051 0.003 3.5E-69 0.0006 398.0 
HDL-C rs3905000 9 107657070 a 
-
0.055 0.003 6.8E-56 0.0008 477.7 
HDL-C rs10120087 9 107661150 a 0.044 0.004 1.5E-26 0.0004 228.8 
HDL-C rs1800978 9 107665978 c 0.057 0.004 3.7E-52 0.0007 460.3 
HDL-C rs13284054 9 107669073 t 0.054 0.005 1.5E-27 0.0006 375.3 
HDL-C rs1800977 9 107690450 a 0.026 0.003 3.2E-24 0.0003 186.2 
HDL-C rs10733608 9 117148430 t 0.014 0.002 6.3E-09 0.0001 59.9 
HDL-C rs635634 9 136155000 t 0.015 0.003 6.6E-09 0.0001 40.9 
HDL-C rs11255744 10 8601074 t 
-
0.018 0.003 1.3E-09 0.0001 80.4 
HDL-C rs10904908 10 17260290 a 
-
0.012 0.002 4.1E-09 0.0001 42.0 
HDL-C rs970548 10 46013277 a 
-
0.025 0.002 1.7E-26 0.0002 137.0 
HDL-C rs2068888 10 94839642 a 0.021 0.002 1.1E-24 0.0002 128.9 
HDL-C rs2862954 10 101912064 t 
-
0.017 0.002 6.0E-18 0.0001 90.6 
HDL-C rs2792751 10 113940329 t 0.028 0.002 2.5E-36 0.0003 197.6 
HDL-C rs2148489 10 114048792 t 0.022 0.003 1.8E-15 0.0002 108.0 
HDL-C rs7076938 10 115789375 t 0.017 0.002 5.2E-15 0.0001 73.1 
HDL-C rs140201358 11 823586 c 0.052 0.009 2.8E-09 0.0001 43.3 
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HDL-C rs16928809 11 2936952 a 
-
0.025 0.004 7.7E-12 0.0001 62.1 
HDL-C rs6486121 11 13355770 t 
-
0.015 0.002 2.5E-10 0.0001 65.3 
HDL-C rs2303975 11 14276999 a 0.019 0.003 1.4E-10 0.0001 49.5 
HDL-C rs925946 11 27667202 t 
-
0.012 0.002 6.6E-09 0.0001 37.8 
HDL-C rs7927401 11 32481177 t 
-
0.021 0.003 1.2E-11 0.0002 98.1 
HDL-C rs3824866 11 47258853 t 0.033 0.004 4.4E-19 0.0003 178.2 
HDL-C rs326214 11 47298360 a 
-
0.025 0.003 1.0E-20 0.0003 162.9 
HDL-C rs10838738 11 47663049 a 0.019 0.002 1.6E-17 0.0002 103.0 
HDL-C rs61897793 11 61599347 a 0.024 0.004 3.7E-09 0.0002 98.3 
HDL-C rs174583 11 61609750 t 
-
0.042 0.002 1.1E-68 0.0008 498.3 
HDL-C rs35169799 11 64031241 t 
-
0.040 0.004 5.0E-22 0.0002 109.7 
HDL-C rs644740 11 65561468 t 0.016 0.002 3.9E-12 0.0001 78.0 
HDL-C rs622082 11 68703959 a 0.015 0.002 1.6E-13 0.0001 63.3 
HDL-C rs499974 11 75455021 a 
-
0.025 0.003 1.5E-22 0.0002 116.6 
HDL-C rs746463 11 109995944 t 
-
0.017 0.002 6.3E-14 0.0001 71.9 
HDL-C rs180349 11 116611827 a 0.017 0.003 1.8E-10 0.0001 75.4 
HDL-C rs10488698 11 116633947 a 0.045 0.004 1.2E-25 0.0002 131.4 
HDL-C rs964184 11 116648917 c 0.132 0.003 0.0E+00 0.0044 2730.3 
HDL-C rs138326449 11 116701354 a 0.716 0.026 2.1E-170 0.0031 1896.5 
HDL-C rs138407155 11 116707044 a 0.356 0.042 2.4E-17 0.0002 93.6 
HDL-C rs12281729 11 116838130 a 0.077 0.005 3.5E-49 0.0007 402.5 
HDL-C rs10892063 11 116896155 a 0.042 0.003 9.4E-45 0.0008 515.0 
HDL-C rs12269901 11 116973929 c 0.027 0.003 3.3E-23 0.0003 191.3 
HDL-C rs593245 11 117183650 t 0.015 0.002 2.0E-09 0.0001 64.9 
HDL-C rs7941030 11 122522375 t 
-
0.023 0.002 3.3E-30 0.0002 151.4 
HDL-C rs4937122 11 126228659 t 0.032 0.004 6.0E-13 0.0002 93.7 
HDL-C rs7134375 12 20473758 a 0.022 0.002 6.2E-27 0.0002 139.1 
HDL-C rs7134150 12 20591332 a 
-
0.031 0.005 6.3E-11 0.0001 76.1 
HDL-C rs4963975 12 26443030 a 
-
0.020 0.003 2.3E-13 0.0001 88.5 
HDL-C rs1126930 12 49399132 c 
-
0.037 0.006 2.9E-11 0.0001 52.5 
HDL-C rs784563 12 53866619 t 0.015 0.002 3.1E-11 0.0001 71.5 
HDL-C rs11613352 12 57792580 t 0.023 0.003 5.4E-17 0.0002 110.3 
HDL-C rs2373459 12 101873956 t 0.016 0.002 2.9E-11 0.0001 70.2 
HDL-C rs7298565 12 109937534 a 0.028 0.002 1.8E-44 0.0004 240.9 
HDL-C rs3184504 12 111884608 t 
-
0.024 0.002 5.0E-31 0.0003 182.5 
HDL-C rs72650673 12 111885310 a 
-
0.172 0.028 1.4E-09 0.0001 47.2 
HDL-C rs1183910 12 121420807 a 0.013 0.002 1.7E-09 0.0001 43.1 
HDL-C rs12369179 12 122963550 t 
-
0.031 0.005 3.8E-10 0.0001 92.3 
HDL-C rs1798192 12 123200768 t 
-
0.019 0.002 3.6E-21 0.0002 113.5 
HDL-C rs940904 12 123491572 a 
-
0.023 0.003 1.8E-16 0.0002 121.0 
HDL-C rs4759375 12 123796238 t 0.049 0.004 6.0E-35 0.0004 257.2 
HDL-C rs12317176 12 124404718 t 
-
0.022 0.002 5.2E-20 0.0002 141.9 
HDL-C rs863750 12 124505444 t 
-
0.017 0.002 3.1E-13 0.0001 88.0 
HDL-C rs12230272 12 125083696 a 0.022 0.003 5.7E-11 0.0002 102.9 
HDL-C rs838880 12 125261593 t 
-
0.025 0.002 6.3E-31 0.0003 173.3 
HDL-C rs10773105 12 125283766 t 
-
0.026 0.002 3.6E-27 0.0003 201.1 
HDL-C rs150728540 12 125292360 a 0.476 0.058 1.6E-16 0.0001 83.8 
HDL-C rs5891 12 125299542 t 0.078 0.009 2.2E-18 0.0001 91.1 
HDL-C rs7306660 12 125327384 a 
-
0.029 0.002 2.4E-32 0.0004 232.8 
8 
 
HDL-C rs7298751 12 125380232 a 
-
0.043 0.004 5.1E-32 0.0004 244.7 
HDL-C rs17532301 13 41609047 a 
-
0.027 0.005 3.4E-09 0.0001 59.4 
HDL-C rs10483776 14 65914867 a 0.015 0.003 3.9E-09 0.0001 40.4 
HDL-C rs8021180 14 70783943 a 0.014 0.002 3.3E-09 0.0001 61.9 
HDL-C rs13379043 14 74250126 t 
-
0.018 0.002 1.4E-15 0.0001 78.1 
HDL-C rs4983559 14 105277209 a 
-
0.025 0.002 2.2E-36 0.0003 190.0 
HDL-C rs9944249 15 41847176 t 
-
0.013 0.002 9.1E-09 0.0001 53.0 
HDL-C rs55707100 15 43820717 t 
-
0.093 0.006 3.1E-51 0.0004 277.0 
HDL-C rs4622454 15 58646332 t 0.021 0.003 1.0E-14 0.0002 119.4 
HDL-C rs4775041 15 58674695 c 0.039 0.004 9.1E-24 0.0006 381.0 
HDL-C rs16940147 15 58676119 a 0.050 0.008 1.1E-09 0.0002 146.8 
HDL-C rs117901517 15 58678869 t 0.038 0.006 3.2E-10 0.0002 111.4 
HDL-C rs34718390 15 58682690 a 0.053 0.006 1.1E-18 0.0003 204.5 
HDL-C rs1532085 15 58683366 a 0.062 0.004 2.9E-68 0.0018 1137.3 
HDL-C rs7165077 15 58686809 t 
-
0.027 0.004 8.5E-13 0.0002 104.1 
HDL-C rs6494003 15 58690048 a 0.093 0.011 5.0E-18 0.0004 247.8 
HDL-C rs16940233 15 58702941 t 
-
0.048 0.006 7.0E-18 0.0003 198.5 
HDL-C rs12912415 15 58721447 a 0.040 0.004 2.6E-25 0.0004 246.5 
HDL-C rs6494006 15 58730571 t 0.044 0.006 1.7E-11 0.0002 145.5 
HDL-C rs17301746 15 58731395 t 0.088 0.010 8.6E-20 0.0003 169.8 
HDL-C rs936960 15 58751877 t 0.052 0.004 7.9E-32 0.0005 286.4 
HDL-C rs1869138 15 58779039 t 
-
0.028 0.004 3.1E-11 0.0001 88.4 
HDL-C rs6083 15 58838010 a 
-
0.016 0.003 5.0E-09 0.0001 77.0 
HDL-C rs17269397 15 58857378 a 
-
0.026 0.003 6.4E-18 0.0003 208.7 
HDL-C rs424346 15 59010962 t 0.054 0.009 2.2E-09 0.0002 133.3 
HDL-C rs181181625 15 59377940 t 0.348 0.033 1.3E-26 0.0003 208.9 
HDL-C rs12148597 15 61955338 a 
-
0.016 0.003 5.3E-09 0.0001 54.7 
HDL-C rs34317102 15 63414083 a 
-
0.019 0.002 1.5E-16 0.0001 80.0 
HDL-C rs2228510 15 63970456 t 
-
0.012 0.002 4.6E-09 0.0001 42.4 
HDL-C rs139271800 15 90214777 a 
-
0.248 0.037 3.2E-11 0.0001 53.2 
HDL-C rs7202647 16 985891 t 0.017 0.003 4.6E-09 0.0001 70.1 
HDL-C rs12928822 16 11403893 t 0.018 0.003 1.6E-10 0.0001 53.3 
HDL-C rs1421085 16 53800954 t 0.028 0.002 3.4E-45 0.0004 236.0 
HDL-C rs12929759 16 54410447 a 0.018 0.003 3.0E-13 0.0001 89.4 
HDL-C rs4238772 16 55029160 a 0.029 0.005 1.2E-09 0.0001 84.2 
HDL-C rs8044753 16 56883438 a 0.025 0.003 3.9E-19 0.0003 189.0 
HDL-C rs36049418 16 56921840 a 0.066 0.009 1.4E-14 0.0002 101.5 
HDL-C rs11648751 16 56937262 t 
-
0.030 0.004 1.0E-11 0.0002 117.6 
HDL-C rs37029 16 56949168 a 
-
0.024 0.003 2.0E-21 0.0003 177.8 
HDL-C rs9989419 16 56985139 a 
-
0.034 0.002 1.4E-41 0.0005 334.5 
HDL-C rs72786786 16 56985514 a 0.058 0.004 3.0E-40 0.0014 869.0 
HDL-C rs76315536 16 56986976 t 0.161 0.016 1.1E-24 0.0005 290.3 
HDL-C rs4783961 16 56994894 a 0.026 0.004 2.1E-12 0.0003 208.7 
HDL-C rs1800775 16 56995236 a 0.032 0.005 3.7E-11 0.0005 310.2 
HDL-C rs34065661 16 56995935 c 
-
0.485 0.019 1.5E-138 0.0021 1273.2 
HDL-C rs7203984 16 56999258 a 0.074 0.005 2.2E-56 0.0018 1104.4 
HDL-C rs1532624 16 57005479 a 0.113 0.005 1.7E-121 0.0062 3859.4 
HDL-C rs12708974 16 57005550 t 
-
0.086 0.005 4.5E-73 0.0015 956.9 
HDL-C rs5883 16 57007353 t 0.167 0.006 4.7E-186 0.0030 1877.3 
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HDL-C rs289714 16 57007451 a 0.082 0.005 8.4E-70 0.0021 1312.3 
HDL-C rs5880 16 57015091 c 
-
0.138 0.005 1.5E-147 0.0018 1113.2 
HDL-C rs506829 16 57383759 t 0.019 0.003 2.2E-09 0.0001 78.3 
HDL-C rs16962034 16 60419220 t 
-
0.016 0.003 6.2E-09 0.0001 72.5 
HDL-C rs7202185 16 67714560 a 
-
0.037 0.005 3.4E-14 0.0002 115.6 
HDL-C rs16942887 16 67928042 a 0.074 0.003 3.1E-134 0.0012 765.1 
HDL-C rs1345868 16 71669624 a 0.014 0.003 7.8E-09 0.0001 55.0 
HDL-C rs12443634 16 81524274 a 
-
0.031 0.003 2.0E-25 0.0004 244.8 
HDL-C rs3803800 17 7462969 a 
-
0.013 0.002 5.7E-09 0.0001 40.4 
HDL-C rs2071379 17 26695832 a 0.014 0.002 5.1E-10 0.0001 61.3 
HDL-C rs11078915 17 37715426 t 
-
0.027 0.004 6.4E-13 0.0003 157.4 
HDL-C rs11869286 17 37813856 c 0.024 0.003 1.8E-18 0.0003 161.7 
HDL-C rs11556624 17 37815304 c 0.087 0.007 8.9E-37 0.0003 213.2 
HDL-C rs4794822 17 38156712 t 
-
0.018 0.002 1.9E-16 0.0001 91.1 
HDL-C rs72836561 17 41926126 t 
-
0.187 0.006 7.6E-228 0.0021 1293.7 
HDL-C rs231539 17 41942109 t 
-
0.036 0.004 4.2E-23 0.0004 221.1 
HDL-C rs17679445 17 46022065 a 0.030 0.004 6.1E-13 0.0001 66.0 
HDL-C rs11652146 17 47422363 a 
-
0.017 0.003 6.6E-12 0.0001 78.1 
HDL-C rs12602912 17 65870073 t 
-
0.018 0.002 2.2E-13 0.0001 59.4 
HDL-C rs10852765 17 66884879 a 0.016 0.002 1.1E-11 0.0001 73.8 
HDL-C rs2292642 17 76395430 t 0.032 0.002 1.6E-55 0.0005 297.9 
HDL-C rs2289750 17 76437343 a 
-
0.028 0.005 6.5E-09 0.0001 77.2 
HDL-C rs1788783 18 21161134 t 0.015 0.002 7.0E-11 0.0001 69.4 
HDL-C rs8093249 18 47097398 a 0.034 0.004 9.5E-22 0.0003 184.7 
HDL-C rs77960347 18 47109955 a 
-
0.250 0.009 7.7E-166 0.0017 1033.2 
HDL-C rs117623631 18 47113165 t 0.343 0.025 1.0E-41 0.0005 333.8 
HDL-C rs3786248 18 47118219 t 
-
0.059 0.006 2.8E-26 0.0004 221.8 
HDL-C rs7241918 18 47160953 t 0.074 0.003 4.3E-120 0.0015 902.9 
HDL-C rs4939886 18 47176793 a 0.020 0.003 8.8E-10 0.0002 110.5 
HDL-C rs11660468 18 47209143 t 0.025 0.002 1.2E-25 0.0003 190.2 
HDL-C rs9956279 18 57942799 t 
-
0.017 0.003 1.0E-10 0.0001 71.5 
HDL-C rs12975319 19 3414088 a 
-
0.015 0.003 3.7E-09 0.0001 62.1 
HDL-C rs10408844 19 7244884 t 0.018 0.003 5.2E-10 0.0001 63.6 
HDL-C rs4804833 19 7970635 a 
-
0.015 0.002 4.9E-10 0.0001 66.5 
HDL-C rs116843064 19 8429323 a 0.246 0.007 1.3E-252 0.0031 1913.2 
HDL-C rs2913968 19 8467235 t 0.017 0.003 2.0E-10 0.0001 68.3 
HDL-C rs6511720 19 11202306 t 0.020 0.003 1.1E-10 0.0001 49.4 
HDL-C rs17616661 19 11303554 a 0.026 0.004 1.2E-12 0.0001 62.1 
HDL-C rs737337 19 11347493 t 0.057 0.003 1.2E-62 0.0006 375.5 
HDL-C rs2111504 19 32917455 a 0.017 0.003 1.4E-10 0.0001 48.1 
HDL-C rs731839 19 33899065 a 0.018 0.002 2.4E-17 0.0001 89.5 
HDL-C rs2075650 19 45395619 a 0.038 0.003 7.7E-28 0.0003 209.7 
HDL-C rs77301115 19 45396973 a 
-
0.066 0.009 2.0E-13 0.0002 134.3 
HDL-C rs7412 19 45412079 t 0.086 0.004 3.0E-85 0.0011 650.4 
HDL-C rs439401 19 45414451 t 0.014 0.002 7.9E-11 0.0001 58.3 
HDL-C rs4420638 19 45422946 a 0.042 0.004 2.9E-29 0.0005 318.0 
HDL-C rs5167 19 45448465 t 
-
0.038 0.002 2.4E-78 0.0007 405.2 
HDL-C rs8111071 19 46307406 a 0.028 0.004 1.1E-14 0.0001 72.3 
HDL-C rs2303108 19 47589895 t 0.014 0.002 7.9E-11 0.0001 49.7 
10 
 
HDL-C rs3752125 19 52327784 t 
-
0.020 0.003 3.4E-16 0.0002 105.8 
HDL-C rs12975366 19 54759361 t 0.021 0.002 1.4E-19 0.0002 132.8 
HDL-C rs386000 19 54792761 c 0.044 0.003 5.7E-48 0.0006 395.1 
HDL-C rs12979085 19 54837165 a 0.020 0.003 1.1E-12 0.0002 105.2 
HDL-C rs1132274 20 17596155 a 
-
0.016 0.003 3.9E-09 0.0001 42.6 
HDL-C rs2268086 20 32648738 a 0.014 0.002 3.4E-09 0.0001 60.2 
HDL-C rs1415771 20 33734493 a 
-
0.013 0.002 1.9E-10 0.0001 51.3 
HDL-C rs1800961 20 43042364 t 
-
0.142 0.006 5.1E-137 0.0012 745.5 
HDL-C rs3827066 20 44586023 t 0.050 0.004 4.2E-37 0.0007 413.4 
HDL-C rs8123864 20 44598670 t 0.048 0.003 2.2E-55 0.0010 643.8 
HDL-C rs1211644 20 45592842 t 
-
0.018 0.003 3.2E-09 0.0001 73.7 
HDL-C rs11700063 20 46153148 a 0.021 0.003 3.3E-14 0.0002 101.2 
HDL-C rs4239651 20 46340596 t 
-
0.021 0.003 8.4E-10 0.0001 82.2 
HDL-C rs6025606 20 56098733 t 0.012 0.002 2.9E-09 0.0001 40.6 
HDL-C rs310631 20 62196253 a 0.013 0.002 7.4E-09 0.0001 52.9 
HDL-C rs6062343 20 62695931 a 0.014 0.002 7.6E-12 0.0001 57.7 
HDL-C rs235314 21 46271452 t 
-
0.015 0.002 7.2E-11 0.0001 69.0 
HDL-C rs12482088 21 46901973 a 0.019 0.003 5.0E-10 0.0001 77.3 
HDL-C rs181362 22 21932068 t 
-
0.030 0.002 1.3E-36 0.0003 202.2 
HDL-C rs4823006 22 29451671 a 
-
0.013 0.002 9.1E-11 0.0001 51.4 
HDL-C rs17738540 22 30888527 t 
-
0.018 0.002 1.6E-14 0.0001 71.1 
HDL-C rs738322 22 38569006 a 
-
0.020 0.002 4.2E-23 0.0002 121.0 
HDL-C rs738409 22 44324727 c 0.016 0.002 1.5E-11 0.0001 51.9 
LDL-C rs2992753 1 18808292 a 
-
0.012 0.002 3.9E-09 0.0001 44.0 
LDL-C rs35172831 1 25850206 t 0.019 0.003 8.1E-12 0.0002 111.8 
LDL-C rs12748152 1 27138393 t 0.026 0.004 7.6E-12 0.0001 57.3 
LDL-C rs17111483 1 55485098 t 0.040 0.005 1.9E-16 0.0003 190.5 
LDL-C rs11206510 1 55496039 t 0.068 0.003 2.7E-111 0.0013 832.9 
LDL-C rs2479409 1 55504650 a 
-
0.022 0.002 1.1E-22 0.0002 140.7 
LDL-C rs11583680 1 55505668 t 0.027 0.004 1.9E-12 0.0002 105.8 
LDL-C rs10888896 1 55509213 c 0.029 0.003 1.0E-20 0.0003 200.2 
LDL-C rs693668 1 55521109 a 0.029 0.004 4.5E-15 0.0004 232.2 
LDL-C rs562556 1 55524237 a 0.130 0.008 4.9E-61 0.0047 2926.2 
LDL-C rs61739739 1 55548991 t 0.080 0.011 1.7E-12 0.0001 81.2 
LDL-C rs1165222 1 55638075 a 
-
0.135 0.008 1.7E-63 0.0047 2908.7 
LDL-C rs1475701 1 55638546 t 
-
0.068 0.006 1.8E-26 0.0003 211.8 
LDL-C rs7551981 1 55719166 t 0.030 0.003 7.2E-27 0.0004 258.6 
LDL-C rs10489488 1 55792722 a 
-
0.093 0.011 5.3E-17 0.0002 152.8 
LDL-C rs12742537 1 63346976 a 0.015 0.002 2.5E-14 0.0001 70.2 
LDL-C rs10874746 1 93323971 t 
-
0.015 0.002 2.3E-13 0.0001 66.4 
LDL-C rs1730859 1 107617707 a 
-
0.019 0.003 2.6E-13 0.0002 98.5 
LDL-C rs12740374 1 109817590 t 
-
0.160 0.002 0.0E+00 0.0086 5379.2 
LDL-C rs4745 1 155106227 a 0.012 0.002 5.7E-10 0.0001 47.5 
LDL-C rs867772 1 220972343 a 
-
0.026 0.003 5.8E-19 0.0003 173.2 
LDL-C rs558971 1 234853406 a 
-
0.036 0.002 1.2E-51 0.0007 406.6 
LDL-C rs1473886 2 20368519 t 
-
0.015 0.002 2.1E-10 0.0001 65.9 
LDL-C rs12710745 2 21112689 a 0.020 0.003 1.0E-14 0.0002 119.0 
LDL-C rs6547409 2 21190209 t 
-
0.095 0.006 8.9E-62 0.0009 573.7 
LDL-C rs1801702 2 21225485 c 0.097 0.007 1.5E-47 0.0005 281.4 
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LDL-C rs1042023 2 21229446 c 0.086 0.011 5.5E-15 0.0001 85.9 
LDL-C rs12713843 2 21238367 t 
-
0.188 0.016 8.2E-33 0.0003 191.3 
LDL-C rs12713844 2 21238413 c 0.074 0.011 5.0E-12 0.0001 63.7 
LDL-C rs679899 2 21250914 a 
-
0.029 0.002 7.0E-37 0.0004 267.5 
LDL-C rs515135 2 21286057 t 
-
0.088 0.003 1.4E-202 0.0024 1489.3 
LDL-C rs62122515 2 21295227 a 0.026 0.003 8.2E-14 0.0003 183.0 
LDL-C rs4635554 2 21389659 t 
-
0.022 0.003 2.9E-18 0.0002 133.9 
LDL-C rs1260327 2 27711893 a 0.015 0.002 2.1E-11 0.0001 67.5 
LDL-C rs814295 2 27743215 a 0.031 0.003 1.2E-19 0.0002 153.4 
LDL-C rs11556157 2 44028013 a 
-
0.020 0.002 2.0E-18 0.0002 94.7 
LDL-C rs72796748 2 44080310 t 0.059 0.007 2.6E-19 0.0003 189.1 
LDL-C rs4077440 2 44081042 t 0.117 0.005 1.1E-122 0.0067 4167.0 
LDL-C rs6718187 2 44082362 a 
-
0.070 0.005 2.0E-43 0.0024 1501.7 
LDL-C rs4148218 2 44099582 a 
-
0.060 0.003 7.7E-70 0.0011 676.7 
LDL-C rs11125936 2 62871225 t 0.025 0.003 1.1E-13 0.0001 66.5 
LDL-C rs10185855 2 101642260 a 0.014 0.002 8.9E-09 0.0001 55.2 
LDL-C rs10490626 2 118835841 a 
-
0.045 0.004 2.4E-30 0.0003 168.7 
LDL-C rs1808458 2 118879253 t 0.031 0.005 2.6E-10 0.0001 74.7 
LDL-C rs6706968 2 121310269 a 
-
0.023 0.003 3.9E-16 0.0003 157.6 
LDL-C rs2198562 2 158465673 c 0.035 0.006 2.9E-10 0.0001 68.8 
LDL-C rs2287623 2 169830155 a 
-
0.018 0.002 1.4E-19 0.0002 97.5 
LDL-C rs6435161 2 203519783 t 0.024 0.003 4.3E-21 0.0002 146.1 
LDL-C rs1048013 2 204154552 t 0.012 0.002 8.8E-10 0.0001 46.2 
LDL-C rs887829 2 234668570 t 
-
0.021 0.002 1.7E-22 0.0002 115.3 
LDL-C rs7616006 3 12267648 a 0.022 0.002 2.3E-20 0.0002 149.7 
LDL-C rs7640978 3 32533010 t 
-
0.032 0.004 4.7E-20 0.0002 104.4 
LDL-C rs2251219 3 52584787 t 
-
0.014 0.002 7.6E-11 0.0001 54.9 
LDL-C rs13315871 3 58381287 a 
-
0.032 0.004 3.2E-19 0.0002 101.4 
LDL-C rs1979848 3 132165178 a 0.026 0.004 2.3E-09 0.0001 69.6 
LDL-C rs10513551 3 160086055 t 
-
0.015 0.002 1.4E-10 0.0001 73.0 
LDL-C rs3748034 4 3446091 t 0.018 0.003 2.4E-09 0.0001 49.1 
LDL-C rs3816873 4 100504664 t 0.014 0.002 4.1E-09 0.0001 43.3 
LDL-C rs13107325 4 103188709 t 
-
0.029 0.004 9.9E-13 0.0001 76.5 
LDL-C rs870992 5 52193237 a 
-
0.027 0.004 1.8E-10 0.0001 71.5 
LDL-C rs10062361 5 74565153 t 0.025 0.003 1.9E-13 0.0002 132.1 
LDL-C rs3846662 5 74651084 a 
-
0.057 0.002 2.1E-131 0.0016 980.6 
LDL-C rs11955819 5 74782412 a 
-
0.058 0.008 4.8E-13 0.0002 108.9 
LDL-C rs4530754 5 122855416 a 0.016 0.002 1.8E-14 0.0001 79.1 
LDL-C rs10065787 5 131436486 t 
-
0.019 0.003 2.2E-09 0.0002 109.2 
LDL-C rs2522056 5 131801726 a 
-
0.018 0.002 1.2E-13 0.0001 70.1 
LDL-C rs4704825 5 156382308 a 
-
0.028 0.003 5.1E-25 0.0004 221.9 
LDL-C rs2235215 6 16131156 t 0.025 0.003 1.8E-18 0.0003 163.8 
LDL-C rs1800562 6 26093141 a 
-
0.049 0.004 6.6E-29 0.0003 159.9 
LDL-C rs129128 6 26125342 t 0.021 0.004 3.4E-09 0.0001 62.5 
LDL-C rs2249741 6 31240712 a 
-
0.020 0.003 7.8E-14 0.0002 126.2 
LDL-C rs13192471 6 32671103 t 
-
0.034 0.003 5.8E-33 0.0003 179.2 
LDL-C rs3800406 6 35133074 a 0.028 0.004 1.1E-12 0.0002 95.6 
LDL-C rs1129187 6 42932200 t 
-
0.012 0.002 8.5E-10 0.0001 45.9 
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LDL-C rs2239619 6 52453220 a 0.016 0.002 4.0E-14 0.0001 73.3 
LDL-C rs17789218 6 100600097 t 0.022 0.003 4.0E-16 0.0002 109.7 
LDL-C rs9390698 6 101296389 a 0.013 0.002 1.3E-10 0.0001 50.0 
LDL-C rs3798236 6 116309649 t 0.018 0.003 1.8E-13 0.0002 93.5 
LDL-C rs9376090 6 135411228 t 0.028 0.002 5.6E-33 0.0003 172.8 
LDL-C rs1044418 6 139229872 t 0.018 0.003 1.2E-10 0.0001 52.6 
LDL-C rs12208357 6 160543148 t 0.062 0.004 2.7E-52 0.0005 319.8 
LDL-C rs34130495 6 160560824 a 0.048 0.007 2.5E-13 0.0001 66.9 
LDL-C rs62440901 6 160569068 t 0.036 0.004 1.1E-20 0.0003 199.5 
LDL-C rs3798220 6 160961137 t 
-
0.136 0.008 1.2E-64 0.0007 410.3 
LDL-C rs10455872 6 161010118 a 
-
0.088 0.006 4.6E-54 0.0010 610.7 
LDL-C rs12175867 6 161019138 t 0.025 0.003 1.8E-14 0.0002 145.5 
LDL-C rs1652507 6 161082461 t 0.027 0.003 1.2E-19 0.0002 125.7 
LDL-C rs10263252 7 1049949 a 
-
0.023 0.003 6.3E-12 0.0002 107.4 
LDL-C rs1997243 7 1083777 a 
-
0.016 0.003 6.7E-09 0.0001 43.9 
LDL-C rs144787122 7 2296552 a 
-
0.104 0.018 4.0E-09 0.0001 44.1 
LDL-C rs2282889 7 21476188 a 
-
0.016 0.003 5.0E-09 0.0001 80.4 
LDL-C rs12670798 7 21607352 t 
-
0.029 0.002 1.4E-34 0.0003 196.1 
LDL-C rs4722551 7 25991826 t 
-
0.039 0.003 3.2E-42 0.0004 256.4 
LDL-C rs2391211 7 26008233 t 0.023 0.004 7.7E-11 0.0002 106.7 
LDL-C rs4302748 7 36191699 a 0.015 0.003 1.2E-09 0.0001 44.7 
LDL-C rs35803101 7 44578500 a 
-
0.139 0.017 1.1E-15 0.0001 82.8 
LDL-C rs10260606 7 44584551 c 0.037 0.003 1.2E-32 0.0004 260.1 
LDL-C rs1014283 7 87076587 a 
-
0.019 0.003 2.0E-09 0.0001 63.9 
LDL-C rs330093 8 9175958 c 0.029 0.003 2.0E-20 0.0003 187.1 
LDL-C rs11774381 8 9183339 t 
-
0.029 0.003 1.9E-24 0.0003 203.9 
LDL-C rs11782386 8 9201787 t 
-
0.025 0.003 8.5E-13 0.0001 72.3 
LDL-C rs4921914 8 18272438 t 
-
0.018 0.002 4.9E-14 0.0001 73.3 
LDL-C rs9298506 8 55437524 a 
-
0.022 0.003 8.4E-16 0.0002 92.9 
LDL-C rs2081687 8 59388565 t 0.027 0.002 2.5E-37 0.0003 202.4 
LDL-C rs2737245 8 116658583 t 
-
0.018 0.003 2.7E-09 0.0001 76.6 
LDL-C rs2954029 8 126490972 a 0.024 0.003 4.1E-18 0.0003 178.7 
LDL-C rs4870941 8 126498828 c 0.044 0.004 3.3E-33 0.0007 422.8 
LDL-C rs2954038 8 126507389 a 
-
0.037 0.003 8.5E-32 0.0006 344.9 
LDL-C rs3780181 9 2640759 a 0.033 0.004 4.1E-17 0.0001 89.4 
LDL-C rs67710536 9 19376255 a 
-
0.027 0.003 3.7E-15 0.0001 80.5 
LDL-C rs10757272 9 22088260 t 
-
0.020 0.003 2.9E-10 0.0002 117.8 
LDL-C rs3905000 9 107657070 a 
-
0.018 0.003 6.7E-10 0.0001 51.0 
LDL-C rs635634 9 136155000 t 0.075 0.003 1.5E-182 0.0018 1094.2 
LDL-C rs3812594 9 139368953 a 
-
0.014 0.002 1.6E-09 0.0001 44.9 
LDL-C rs7080366 10 17254832 t 0.019 0.003 8.5E-15 0.0002 115.9 
LDL-C rs41274050 10 52573772 t 0.077 0.011 4.8E-12 0.0002 142.2 
LDL-C rs2068888 10 94839642 a 
-
0.017 0.002 1.1E-17 0.0001 89.7 
LDL-C rs2274224 10 96039597 c 
-
0.014 0.002 3.0E-09 0.0001 61.7 
LDL-C rs2792751 10 113940329 t 0.026 0.002 1.1E-32 0.0003 176.5 
LDL-C rs1891110 10 124610027 a 0.021 0.002 3.0E-26 0.0002 137.3 
LDL-C rs4752805 11 48018355 a 
-
0.015 0.002 7.0E-10 0.0001 50.7 
LDL-C rs174449 11 61640379 a 0.027 0.003 1.1E-26 0.0003 204.8 
LDL-C rs2521567 11 61699055 a 
-
0.015 0.002 5.9E-10 0.0001 66.6 
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LDL-C rs3816492 11 66297363 t 
-
0.017 0.002 3.4E-12 0.0001 61.4 
LDL-C rs11603023 11 118486067 t 0.013 0.002 3.0E-10 0.0001 47.9 
LDL-C rs7941030 11 122522375 t 
-
0.014 0.002 5.7E-12 0.0001 55.0 
LDL-C rs10893500 11 126250774 t 
-
0.043 0.003 4.0E-36 0.0004 271.7 
LDL-C rs1521516 12 51055708 t 
-
0.016 0.003 1.2E-10 0.0001 73.2 
LDL-C rs61754230 12 72179446 t 0.052 0.008 2.3E-11 0.0001 55.4 
LDL-C rs3184504 12 111884608 t 
-
0.026 0.002 1.4E-34 0.0003 204.5 
LDL-C rs1169288 12 121416650 a 
-
0.035 0.002 1.1E-55 0.0005 326.9 
LDL-C rs10773003 12 123775127 a 0.024 0.004 3.1E-09 0.0001 56.7 
LDL-C rs11571836 13 32973439 a 0.021 0.003 4.1E-10 0.0002 94.1 
LDL-C rs3742318 13 33017043 t 0.020 0.003 9.2E-16 0.0001 78.6 
LDL-C rs4773173 13 111025118 a 0.016 0.003 5.4E-11 0.0001 75.4 
LDL-C rs9646133 14 71096344 t 
-
0.019 0.002 2.0E-20 0.0002 101.4 
LDL-C rs13379043 14 74250126 t 0.014 0.002 5.5E-11 0.0001 52.7 
LDL-C rs28929474 14 94844947 t 0.071 0.008 5.0E-19 0.0002 102.5 
LDL-C rs3812945 15 75289722 t 
-
0.015 0.002 4.1E-10 0.0001 68.7 
LDL-C rs35259348 16 72003952 c 0.020 0.003 7.7E-13 0.0001 90.1 
LDL-C rs7197453 16 72079127 c 0.025 0.004 1.5E-12 0.0003 177.3 
LDL-C rs217181 16 72114002 t 
-
0.049 0.003 1.3E-48 0.0008 492.6 
LDL-C rs9302635 16 72144174 t 0.055 0.004 1.9E-41 0.0009 559.9 
LDL-C rs28555129 16 83984776 a 0.013 0.002 1.1E-09 0.0001 48.7 
LDL-C rs8069974 17 4670972 c 0.015 0.003 3.4E-09 0.0001 62.2 
LDL-C rs314253 17 7091650 t 0.020 0.002 4.6E-22 0.0002 115.1 
LDL-C rs871841 17 8216468 t 
-
0.015 0.002 2.5E-13 0.0001 66.1 
LDL-C rs6502640 17 18122485 a 0.019 0.003 3.6E-09 0.0001 75.4 
LDL-C rs704 17 26694861 a 0.020 0.002 2.2E-23 0.0002 124.4 
LDL-C rs12601110 17 27035335 a 0.027 0.005 4.9E-09 0.0001 71.0 
LDL-C rs1487971 17 28572753 t 
-
0.016 0.002 8.3E-11 0.0001 71.9 
LDL-C rs11080150 17 29629326 a 0.015 0.002 2.3E-11 0.0001 57.7 
LDL-C rs72836561 17 41926126 t 
-
0.037 0.006 2.5E-10 0.0001 51.2 
LDL-C rs4968318 17 45451894 a 0.022 0.002 1.7E-27 0.0002 142.7 
LDL-C rs118004742 17 45468858 t 0.029 0.005 2.2E-09 0.0001 52.4 
LDL-C rs12939848 17 65370808 t 
-
0.014 0.002 5.6E-09 0.0001 56.8 
LDL-C rs12602912 17 65870073 t 0.016 0.002 7.2E-11 0.0001 46.9 
LDL-C rs77542162 17 67081278 a 
-
0.177 0.009 1.9E-84 0.0011 667.1 
LDL-C rs4968839 17 67125840 t 0.039 0.003 5.8E-47 0.0006 395.5 
LDL-C rs72852601 17 67149972 t 0.048 0.008 2.5E-09 0.0001 48.2 
LDL-C rs2886232 17 67150176 t 0.041 0.005 6.6E-17 0.0003 202.3 
LDL-C rs4485425 17 73767437 a 
-
0.019 0.002 2.2E-16 0.0002 94.0 
LDL-C rs4129767 17 76403984 a 0.016 0.002 5.1E-15 0.0001 75.7 
LDL-C rs77960347 18 47109955 a 
-
0.080 0.009 1.1E-17 0.0002 104.4 
LDL-C rs7241918 18 47160953 t 0.019 0.003 9.0E-12 0.0001 60.0 
LDL-C rs941408 19 2814181 t 0.016 0.003 3.7E-10 0.0001 67.5 
LDL-C rs1982074 19 10668673 a 0.023 0.003 3.2E-18 0.0002 97.1 
LDL-C rs892010 19 11038843 c 0.040 0.005 2.3E-13 0.0002 120.0 
LDL-C rs10417443 19 11129429 c 0.032 0.003 1.5E-31 0.0005 322.9 
LDL-C rs1122608 19 11163601 t 
-
0.048 0.003 9.6E-63 0.0008 511.3 
LDL-C rs4300767 19 11163689 a 
-
0.095 0.006 3.8E-63 0.0017 1063.1 
LDL-C rs6511721 19 11206575 a 
-
0.037 0.003 1.1E-31 0.0007 425.7 
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LDL-C rs73015030 19 11207516 a 
-
0.079 0.009 4.8E-20 0.0004 223.7 
LDL-C rs3745677 19 11211077 a 0.077 0.008 4.0E-20 0.0007 432.9 
LDL-C rs11669576 19 11222300 a 0.064 0.007 3.6E-22 0.0004 238.5 
LDL-C rs45508991 19 11233886 t 0.106 0.015 3.5E-13 0.0001 82.0 
LDL-C rs5927 19 11233941 a 
-
0.030 0.004 7.9E-15 0.0003 208.9 
LDL-C rs2569538 19 11238548 a 
-
0.061 0.007 2.1E-20 0.0006 389.1 
LDL-C rs892115 19 11263650 t 
-
0.023 0.004 2.3E-10 0.0002 143.1 
LDL-C rs6511727 19 11315817 t 0.020 0.003 1.8E-15 0.0002 119.4 
LDL-C rs4804579 19 11358700 t 0.024 0.004 2.8E-10 0.0002 99.9 
LDL-C rs58542926 19 19379549 t 
-
0.098 0.004 7.5E-146 0.0013 816.7 
LDL-C rs150090162 19 44536189 a 0.161 0.019 1.0E-16 0.0002 115.4 
LDL-C rs8103315 19 45254168 a 0.028 0.004 2.0E-11 0.0002 102.2 
LDL-C rs35106910 19 45284266 a 0.032 0.005 1.3E-11 0.0001 58.6 
LDL-C rs1135062 19 45322744 a 
-
0.017 0.002 4.5E-13 0.0001 73.4 
LDL-C rs3852856 19 45361574 a 0.061 0.005 5.9E-38 0.0012 747.4 
LDL-C rs12610605 19 45370838 a 0.126 0.005 4.9E-164 0.0043 2678.6 
LDL-C rs8104483 19 45372354 t 
-
0.087 0.004 3.4E-116 0.0031 1927.4 
LDL-C rs6859 19 45382034 a 0.078 0.003 8.7E-132 0.0030 1842.4 
LDL-C rs11669338 19 45382984 t 0.050 0.006 8.0E-16 0.0004 255.7 
LDL-C rs3852861 19 45383061 t 
-
0.056 0.004 1.1E-45 0.0015 950.4 
LDL-C rs187706273 19 45385488 a 
-
0.108 0.016 4.4E-11 0.0001 76.1 
LDL-C rs157580 19 45395266 a 0.075 0.003 2.2E-113 0.0027 1659.5 
LDL-C rs157582 19 45396219 t 
-
0.032 0.005 7.3E-11 0.0004 226.2 
LDL-C rs115881343 19 45403216 t 0.195 0.009 6.8E-94 0.0018 1136.5 
LDL-C rs10119 19 45406673 a 0.067 0.004 1.9E-53 0.0018 1103.7 
LDL-C rs405509 19 45408836 t 0.173 0.004 0.0E+00 0.0149 9325.2 
LDL-C rs769450 19 45410444 a 0.060 0.005 2.9E-37 0.0018 1093.3 
LDL-C rs769452 19 45411110 t 
-
0.149 0.020 4.3E-14 0.0001 71.4 
LDL-C rs439401 19 45414451 t 0.029 0.003 4.6E-22 0.0004 249.3 
LDL-C rs59325138 19 45416291 t 0.098 0.004 1.0E-119 0.0046 2845.8 
LDL-C rs732841 19 46207810 a 0.041 0.006 6.0E-13 0.0002 103.2 
LDL-C rs17651629 19 46406463 t 
-
0.032 0.004 1.3E-17 0.0002 127.7 
LDL-C rs492602 19 49206417 a 
-
0.028 0.002 4.3E-40 0.0004 238.7 
LDL-C rs641738 19 54676763 t 0.014 0.002 1.0E-09 0.0001 59.7 
LDL-C rs35350976 19 59023174 a 
-
0.017 0.003 7.2E-09 0.0001 51.8 
LDL-C rs2143544 20 17789221 t 
-
0.016 0.003 5.5E-09 0.0001 80.9 
LDL-C rs2745865 20 17847735 t 0.039 0.004 2.1E-26 0.0004 239.8 
LDL-C rs6058302 20 34290037 t 
-
0.027 0.003 1.8E-15 0.0002 106.0 
LDL-C rs6016373 20 39154095 a 0.023 0.002 9.2E-30 0.0002 150.9 
LDL-C rs926663 20 39245775 a 0.014 0.003 8.3E-09 0.0001 62.1 
LDL-C rs6072328 20 39913996 t 
-
0.026 0.003 1.7E-22 0.0003 203.1 
LDL-C rs6062343 20 62695931 a 
-
0.015 0.002 2.9E-13 0.0001 65.6 
LDL-C rs2833487 21 33087863 a 
-
0.035 0.006 4.3E-10 0.0001 71.1 
LDL-C rs2183573 21 40574305 a 
-
0.014 0.002 4.0E-10 0.0001 61.7 
LDL-C rs138777 22 35711098 a 0.013 0.002 2.3E-09 0.0001 45.0 
LDL-C rs738409 22 44324727 c 0.015 0.002 6.8E-10 0.0001 47.2 
LDL-C rs13268 22 45996298 a 0.042 0.007 3.6E-10 0.0001 48.6 
TG rs1077514 1 23766233 t 0.021 0.003 2.4E-14 0.0001 71.0 
TG rs16826069 1 39797055 a 
-
0.024 0.002 5.4E-23 0.0002 116.7 
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TG rs2055491 1 50852769 t 
-
0.012 0.002 3.6E-09 0.0001 43.0 
TG rs10889353 1 63118196 a 0.075 0.002 2.0E-280 0.0025 1552.9 
TG rs2613503 1 72839774 a 0.020 0.003 1.5E-11 0.0001 74.0 
TG rs12740374 1 109817590 t 
-
0.015 0.002 1.8E-10 0.0001 48.9 
TG rs12043350 1 153854380 t 0.015 0.003 9.4E-10 0.0001 61.4 
TG rs1011731 1 172346548 a 
-
0.013 0.002 4.1E-11 0.0001 52.6 
TG rs78444298 1 184672098 a 
-
0.052 0.009 3.0E-09 0.0001 51.3 
TG rs2821231 1 203518382 t 0.016 0.003 3.9E-09 0.0001 77.8 
TG rs765751 1 219669226 t 
-
0.020 0.002 2.3E-17 0.0002 109.9 
TG rs10489615 1 230304988 a 0.039 0.002 3.2E-85 0.0007 461.5 
TG rs2273967 1 230415293 t 
-
0.018 0.003 8.8E-11 0.0001 69.0 
TG rs1473886 2 20368519 t 
-
0.017 0.002 1.2E-13 0.0001 89.8 
TG rs1801701 2 21228827 t 
-
0.030 0.004 2.2E-17 0.0001 89.0 
TG rs676210 2 21231524 a 
-
0.076 0.002 3.7E-211 0.0020 1208.9 
TG rs541041 2 21294975 a 0.023 0.003 1.2E-18 0.0002 102.0 
TG rs3208747 2 24431127 t 
-
0.150 0.022 6.3E-12 0.0001 66.5 
TG rs1049817 2 27550967 a 0.046 0.003 5.2E-49 0.0010 623.5 
TG rs11689803 2 27566520 a 
-
0.021 0.004 1.0E-09 0.0002 111.0 
TG rs11891554 2 27613617 a 
-
0.096 0.006 7.2E-63 0.0008 472.4 
TG rs79593977 2 27702663 a 0.269 0.029 2.0E-20 0.0013 806.8 
TG rs780090 2 27718474 t 0.048 0.005 1.9E-23 0.0004 237.5 
TG rs147073127 2 27726437 a 
-
0.213 0.019 2.7E-28 0.0003 162.7 
TG rs814295 2 27743215 a 0.077 0.004 9.3E-90 0.0016 982.0 
TG rs1919128 2 27801759 a 
-
0.046 0.003 1.4E-47 0.0008 499.0 
TG rs115289288 2 28006500 t 
-
0.222 0.019 1.4E-31 0.0022 1336.3 
TG rs4245791 2 44074431 t 
-
0.017 0.002 1.1E-14 0.0001 75.1 
TG rs1861410 2 58933591 t 
-
0.016 0.003 2.0E-09 0.0001 74.3 
TG rs2723062 2 65280220 a 
-
0.023 0.003 1.6E-17 0.0002 151.0 
TG rs2049019 2 66671858 a 
-
0.014 0.002 9.5E-09 0.0001 50.4 
TG rs13396091 2 146371961 a 0.014 0.002 2.0E-09 0.0001 57.8 
TG rs13389219 2 165528876 t 
-
0.035 0.002 2.1E-62 0.0006 364.9 
TG rs16849863 2 165728290 t 0.056 0.008 1.6E-12 0.0001 71.7 
TG rs3769823 2 202122995 a 
-
0.014 0.002 3.2E-10 0.0001 50.0 
TG rs6435161 2 203519783 t 0.015 0.002 1.4E-09 0.0001 55.5 
TG rs1344642 2 219555262 a 
-
0.013 0.002 5.1E-11 0.0001 52.5 
TG rs2943650 2 227105921 t 0.042 0.003 2.9E-48 0.0008 523.1 
TG rs1801282 3 12393125 c 0.034 0.003 3.7E-26 0.0002 149.4 
TG rs17819328 3 12489342 t 
-
0.025 0.002 3.3E-26 0.0003 191.2 
TG rs13326165 3 52532118 a 
-
0.017 0.003 1.4E-11 0.0001 56.1 
TG rs7621025 3 136272246 t 
-
0.021 0.003 4.1E-10 0.0002 96.8 
TG rs4683438 3 142652559 t 
-
0.017 0.002 8.1E-13 0.0001 82.8 
TG rs382534 3 155547274 t 0.015 0.003 4.5E-09 0.0001 54.4 
TG rs9822326 3 156803565 a 0.016 0.002 3.8E-11 0.0001 73.7 
TG rs10513687 3 170725730 t 0.022 0.003 6.7E-11 0.0001 67.4 
TG rs17600346 3 172223982 t 
-
0.046 0.007 3.3E-11 0.0002 101.7 
TG rs6599389 4 939113 a 0.022 0.004 6.9E-09 0.0001 45.5 
TG rs11248060 4 964359 t 0.022 0.003 6.1E-13 0.0001 64.6 
TG rs3748034 4 3446091 t 0.028 0.003 2.9E-19 0.0002 119.8 
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TG rs16844401 4 3449652 a 0.032 0.004 1.0E-14 0.0001 80.5 
TG rs6831256 4 3473139 a 
-
0.014 0.002 1.7E-11 0.0001 60.4 
TG rs9884830 4 26027797 t 0.019 0.003 2.4E-10 0.0001 62.0 
TG rs1037814 4 88049850 t 
-
0.024 0.002 2.8E-24 0.0003 177.9 
TG rs10029254 4 88160140 t 0.021 0.003 1.1E-13 0.0002 93.7 
TG rs13133548 4 89740128 a 0.012 0.002 3.3E-09 0.0001 43.2 
TG rs1126673 4 100045616 t 0.018 0.002 5.6E-16 0.0001 81.2 
TG rs13107325 4 103188709 t 0.033 0.004 1.7E-15 0.0002 95.3 
TG rs41278045 4 110638764 a 
-
0.199 0.029 4.0E-12 0.0001 58.7 
TG rs6054 4 155489608 t 0.123 0.018 7.2E-12 0.0001 67.4 
TG rs6855363 4 157670537 t 0.017 0.002 5.9E-12 0.0001 74.3 
TG rs4311394 5 53300662 a 
-
0.020 0.002 3.4E-20 0.0002 98.2 
TG rs459193 5 55806751 a 
-
0.035 0.002 3.7E-52 0.0005 300.7 
TG rs2448428 5 55844049 t 0.015 0.002 4.3E-10 0.0001 68.3 
TG rs9686661 5 55861786 t 0.044 0.003 2.3E-67 0.0006 374.1 
TG rs4976033 5 67714246 a 
-
0.016 0.002 1.2E-15 0.0001 78.1 
TG rs1045241 5 118729286 t 
-
0.017 0.003 3.7E-11 0.0001 71.3 
TG rs26008 5 131008194 t 0.024 0.004 2.3E-10 0.0001 49.1 
TG rs4705986 5 132349654 t 0.034 0.006 4.4E-09 0.0001 84.1 
TG rs4704820 5 156334681 t 0.022 0.003 1.0E-11 0.0001 88.6 
TG rs6882076 5 156390297 t 
-
0.042 0.002 6.7E-83 0.0008 501.2 
TG rs1650527 5 158022724 t 0.025 0.003 5.1E-16 0.0002 138.9 
TG rs2524060 6 31267422 a 
-
0.029 0.003 3.3E-20 0.0003 185.6 
TG rs2442719 6 31320538 t 
-
0.024 0.002 7.5E-32 0.0003 178.9 
TG rs17207867 6 31938412 t 0.027 0.004 5.0E-13 0.0001 70.2 
TG rs9271366 6 32586854 a 0.028 0.003 7.4E-19 0.0002 119.2 
TG rs9273368 6 32626475 a 
-
0.018 0.003 9.3E-09 0.0001 78.8 
TG rs11752643 6 32669373 t 0.066 0.006 3.7E-26 0.0003 155.8 
TG rs2395655 6 36645696 a 0.017 0.002 6.6E-13 0.0001 80.0 
TG rs6458349 6 43759789 a 0.038 0.003 4.1E-37 0.0006 353.7 
TG rs78807370 6 43761091 a 
-
0.043 0.004 3.9E-31 0.0005 293.1 
TG rs881858 6 43806609 a 0.020 0.002 1.8E-20 0.0002 107.2 
TG rs4715316 6 52628998 t 
-
0.016 0.003 8.5E-09 0.0001 68.8 
TG rs2745353 6 127452935 t 0.019 0.002 1.9E-20 0.0002 106.0 
TG rs9388768 6 130374102 a 0.013 0.002 1.2E-09 0.0001 45.4 
TG rs643381 6 139839423 a 
-
0.024 0.002 3.2E-32 0.0003 172.5 
TG rs12208357 6 160543148 t 0.030 0.004 1.1E-13 0.0001 75.1 
TG rs2665357 6 160848167 a 
-
0.018 0.002 1.9E-15 0.0002 104.3 
TG rs645718 6 161406239 a 
-
0.034 0.005 2.1E-10 0.0001 62.5 
TG rs12699758 7 15964238 a 0.016 0.003 3.6E-09 0.0001 58.1 
TG rs4410790 7 17284577 t 
-
0.012 0.002 1.4E-09 0.0001 43.2 
TG rs10235225 7 25905599 a 0.015 0.002 1.3E-09 0.0001 64.9 
TG rs4722551 7 25991826 t 0.019 0.003 1.1E-11 0.0001 63.7 
TG rs1534696 7 26397239 a 
-
0.019 0.002 2.9E-15 0.0002 110.6 
TG rs2070971 7 44197583 t 0.023 0.003 7.2E-12 0.0001 84.4 
TG rs3757838 7 44231310 a 0.030 0.005 3.8E-11 0.0001 71.5 
TG rs1178979 7 72856430 t 0.044 0.004 1.1E-30 0.0006 353.9 
TG rs799158 7 73019074 t 0.076 0.008 4.0E-21 0.0004 273.6 
TG rs3812316 7 73020337 c 0.087 0.005 4.3E-82 0.0016 987.5 
TG rs287621 7 130435181 t 0.022 0.003 4.7E-19 0.0002 123.0 
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TG rs3735080 7 150217309 t 0.016 0.002 2.6E-11 0.0001 56.2 
TG rs16884656 7 150512307 t 
-
0.024 0.004 8.3E-09 0.0001 75.6 
TG rs4240624 8 9184231 a 
-
0.034 0.004 1.2E-17 0.0002 108.7 
TG rs11776767 8 10683929 c 0.024 0.002 1.3E-27 0.0003 160.1 
TG rs2686187 8 11654796 a 
-
0.014 0.002 3.7E-09 0.0001 60.5 
TG rs3947 8 11702375 a 0.019 0.002 7.1E-15 0.0001 86.5 
TG rs1495741 8 18272881 a 
-
0.036 0.002 3.4E-56 0.0005 296.3 
TG rs1801177 8 19805708 a 0.095 0.009 1.1E-26 0.0003 202.0 
TG rs264 8 19813180 a 
-
0.028 0.003 7.9E-17 0.0002 120.1 
TG rs268 8 19813529 a 
-
0.232 0.008 5.5E-202 0.0017 1058.9 
TG rs301 8 19816934 t 0.062 0.005 2.8E-36 0.0015 904.3 
TG rs312 8 19817997 c 0.048 0.006 1.4E-13 0.0005 302.0 
TG rs326 8 19819439 a 0.078 0.005 6.7E-63 0.0026 1582.2 
TG rs12545984 8 19847259 t 0.044 0.006 2.1E-13 0.0005 316.6 
TG rs17091905 8 19849757 a 
-
0.042 0.006 1.5E-13 0.0004 237.7 
TG rs10105418 8 19875365 a 0.082 0.009 1.9E-21 0.0003 208.6 
TG rs4637851 8 19922610 a 
-
0.029 0.003 8.5E-22 0.0004 236.0 
TG rs13256965 8 19962962 a 0.017 0.002 7.5E-12 0.0001 84.7 
TG rs3736147 8 22471824 a 0.018 0.003 1.7E-10 0.0001 86.9 
TG rs1982768 8 25898565 a 
-
0.022 0.004 3.0E-09 0.0001 74.8 
TG rs2081687 8 59388565 t 0.019 0.002 9.5E-20 0.0002 102.6 
TG rs4738141 8 72469742 a 
-
0.017 0.003 1.6E-09 0.0001 67.1 
TG rs17730649 8 126465305 a 0.021 0.003 3.8E-16 0.0002 137.4 
TG rs6982502 8 126479362 t 
-
0.028 0.005 5.1E-09 0.0004 238.0 
TG rs2980876 8 126481694 t 
-
0.091 0.005 1.4E-73 0.0036 2230.5 
TG rs8180991 8 126500350 c 
-
0.034 0.003 2.6E-24 0.0004 260.5 
TG rs4871624 8 126629328 t 
-
0.020 0.003 1.0E-14 0.0002 100.1 
TG rs3927680 9 16887366 a 
-
0.016 0.002 1.2E-15 0.0001 78.1 
TG rs4120895 9 33787532 t 
-
0.018 0.003 4.3E-11 0.0001 92.3 
TG rs1800978 9 107665978 c 0.027 0.004 2.9E-13 0.0002 101.9 
TG rs17134592 10 5260682 c 0.021 0.003 4.3E-10 0.0001 64.6 
TG rs41274050 10 52573772 t 0.094 0.011 2.7E-17 0.0003 209.2 
TG rs7923609 10 65133822 a 0.030 0.003 1.2E-21 0.0004 270.8 
TG rs2298117 10 70346740 t 0.012 0.002 1.0E-09 0.0001 45.7 
TG rs7901016 10 74637326 t 
-
0.040 0.004 3.5E-20 0.0002 114.7 
TG rs10748579 10 94090498 a 
-
0.018 0.002 1.9E-18 0.0002 95.4 
TG rs7081888 10 94764660 t 
-
0.033 0.005 1.7E-11 0.0002 97.4 
TG rs2068888 10 94839642 a 
-
0.037 0.002 5.8E-71 0.0007 415.5 
TG rs2792751 10 113940329 t 
-
0.018 0.002 7.5E-16 0.0001 81.0 
TG rs11195943 10 114154815 t 
-
0.023 0.004 2.0E-10 0.0001 60.3 
TG rs10886863 10 122929493 t 
-
0.058 0.010 4.3E-09 0.0002 110.1 
TG rs7940646 11 10669228 t 
-
0.015 0.002 4.4E-12 0.0001 59.5 
TG rs10832027 11 13357183 a 0.016 0.002 1.8E-11 0.0001 68.7 
TG rs546383 11 18065663 t 
-
0.013 0.002 7.6E-09 0.0001 52.6 
TG rs925946 11 27667202 t 0.016 0.002 7.6E-14 0.0001 68.9 
TG rs326214 11 47298360 a 0.022 0.002 4.1E-26 0.0002 130.6 
TG rs2727271 11 61603358 a 
-
0.065 0.003 1.8E-78 0.0009 586.7 
TG rs174587 11 61612830 t 0.048 0.003 6.9E-50 0.0008 467.7 
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TG rs35169799 11 64031241 t 0.041 0.004 4.8E-24 0.0002 120.4 
TG rs4014195 11 65506822 c 
-
0.015 0.002 2.6E-12 0.0001 60.8 
TG rs2229738 11 68562328 t 0.024 0.004 1.6E-10 0.0001 50.8 
TG rs11237471 11 78082604 t 
-
0.022 0.003 1.7E-10 0.0001 83.7 
TG rs4938289 11 116458785 t 0.047 0.006 1.3E-14 0.0003 164.7 
TG rs12799766 11 116558427 a 0.042 0.005 3.7E-19 0.0006 377.5 
TG rs74360954 11 116582542 t 
-
0.113 0.008 1.5E-43 0.0013 804.6 
TG rs2000571 11 116585533 a 0.063 0.006 1.5E-26 0.0013 811.0 
TG rs180357 11 116599504 t 
-
0.049 0.005 4.2E-24 0.0010 626.6 
TG rs4938307 11 116604514 a 
-
0.073 0.007 4.7E-28 0.0011 683.7 
TG rs61730763 11 116631482 a 0.190 0.023 2.9E-16 0.0002 128.9 
TG rs17120029 11 116650118 t 0.142 0.009 1.2E-56 0.0025 1576.5 
TG rs11604424 11 116651115 t 
-
0.066 0.006 1.5E-27 0.0015 930.8 
TG rs619054 11 116660813 a 
-
0.057 0.004 1.1E-36 0.0012 716.3 
TG rs143292359 11 116661001 a 0.241 0.040 1.5E-09 0.0001 57.6 
TG rs662799 11 116663707 a 
-
0.106 0.008 1.2E-43 0.0015 914.6 
TG rs9804646 11 116665079 t 
-
0.060 0.006 2.8E-23 0.0006 355.6 
TG rs5104 11 116692334 t 
-
0.035 0.004 1.6E-17 0.0003 190.7 
TG rs11216157 11 116711180 a 0.055 0.007 1.2E-16 0.0007 434.1 
TG rs888246 11 116724232 t 0.071 0.006 9.5E-29 0.0009 550.3 
TG rs2075292 11 116732512 t 
-
0.063 0.005 8.4E-40 0.0009 545.8 
TG rs11216168 11 116741553 a 
-
0.069 0.006 5.3E-27 0.0012 726.5 
TG rs2000615 11 116915819 t 0.057 0.006 4.0E-21 0.0007 430.3 
TG rs490262 11 117222592 a 
-
0.019 0.003 2.2E-13 0.0001 67.1 
TG rs7134375 12 20473758 a 
-
0.014 0.002 7.4E-13 0.0001 61.9 
TG rs4149056 12 21331549 t 
-
0.032 0.003 3.3E-30 0.0003 159.4 
TG rs718314 12 26453283 a 
-
0.019 0.003 1.4E-14 0.0001 87.3 
TG rs7979398 12 46086708 t 0.015 0.002 9.3E-11 0.0001 68.1 
TG rs11613352 12 57792580 t 
-
0.025 0.003 5.8E-20 0.0002 131.4 
TG rs2075260 12 109696838 a 0.015 0.003 4.6E-09 0.0001 41.5 
TG rs3742004 12 111798553 a 0.016 0.003 9.8E-09 0.0001 53.4 
TG rs940904 12 123491572 a 0.015 0.003 4.2E-09 0.0001 55.3 
TG rs11057408 12 124464836 t 
-
0.022 0.002 2.7E-20 0.0002 138.5 
TG rs10846744 12 125312425 c 0.027 0.003 1.3E-15 0.0002 121.2 
TG rs2298058 13 95248566 t 0.024 0.003 5.4E-17 0.0003 157.7 
TG rs7400722 13 114527838 a 0.016 0.002 1.9E-12 0.0001 71.6 
TG rs7157785 14 64235556 t 0.020 0.003 7.1E-13 0.0001 71.3 
TG rs11634257 15 40388492 a 0.018 0.003 1.5E-09 0.0001 74.5 
TG rs17747633 15 40916237 a 
-
0.015 0.002 4.6E-12 0.0001 63.2 
TG rs16949992 15 44238869 c 
-
0.075 0.006 5.7E-34 0.0005 293.5 
TG rs11858955 15 44246293 a 
-
0.115 0.016 3.8E-13 0.0002 133.3 
TG rs493258 15 58687880 t 0.017 0.002 1.4E-17 0.0001 89.9 
TG rs12913346 15 63530965 a 0.024 0.004 4.1E-11 0.0001 83.5 
TG rs17184382 15 63792486 a 0.017 0.002 3.9E-13 0.0001 88.9 
TG rs2415168 15 73109629 a 0.015 0.003 3.2E-09 0.0001 55.8 
TG rs10152471 15 101890913 a 
-
0.016 0.003 4.9E-09 0.0001 74.6 
TG rs143076454 16 921179 a 0.048 0.008 6.8E-09 0.0001 48.6 
TG rs11075253 16 15148646 a 
-
0.027 0.003 2.6E-15 0.0003 185.3 
TG rs2032915 16 31117413 t 
-
0.017 0.002 5.4E-14 0.0001 87.0 
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TG rs9939609 16 53820527 a 0.019 0.002 2.0E-21 0.0002 106.8 
TG rs1800775 16 56995236 a 
-
0.023 0.002 3.4E-27 0.0003 162.2 
TG rs7203984 16 56999258 a 
-
0.022 0.003 5.2E-12 0.0002 97.0 
TG rs9940315 16 69876164 a 
-
0.019 0.003 4.7E-13 0.0002 107.5 
TG rs2000999 16 72108093 a 0.020 0.003 7.3E-15 0.0001 81.3 
TG rs12443634 16 81524274 a 0.018 0.003 9.3E-10 0.0001 84.4 
TG rs1053328 16 85711860 t 0.014 0.002 8.8E-09 0.0001 54.3 
TG rs3853818 17 7346302 t 0.016 0.002 6.5E-12 0.0001 75.9 
TG rs897453 17 17425631 t 
-
0.014 0.002 1.1E-12 0.0001 61.2 
TG rs1563631 17 18221134 t 
-
0.017 0.002 6.7E-15 0.0001 75.2 
TG rs3110454 17 28651363 t 
-
0.017 0.003 7.4E-10 0.0001 83.3 
TG rs2306590 17 34854280 a 
-
0.013 0.002 5.0E-10 0.0001 50.3 
TG rs2079005 17 41865627 t 
-
0.022 0.003 6.2E-15 0.0002 104.3 
TG rs1662750 17 42011823 a 
-
0.018 0.003 1.4E-11 0.0002 95.0 
TG rs2074108 17 42336149 t 
-
0.015 0.002 1.1E-09 0.0001 64.6 
TG rs11871606 17 45732774 a 0.016 0.002 3.4E-16 0.0001 82.2 
TG rs8075803 17 47346529 t 
-
0.019 0.002 1.3E-16 0.0002 111.7 
TG rs12602912 17 65870073 t 0.023 0.002 1.2E-21 0.0002 100.9 
TG rs2125345 17 73782191 t 0.013 0.002 1.8E-09 0.0001 46.5 
TG rs2292642 17 76395430 t 
-
0.021 0.002 4.3E-25 0.0002 125.4 
TG rs1652343 18 21131929 t 0.016 0.003 2.0E-09 0.0001 75.1 
TG rs17178414 19 4945250 t 0.019 0.003 1.0E-10 0.0002 97.1 
TG rs1799816 19 7125518 t 
-
0.068 0.011 6.4E-10 0.0001 47.6 
TG rs7248104 19 7224431 a 
-
0.019 0.002 1.5E-21 0.0002 108.6 
TG rs116843064 19 8429323 a 
-
0.265 0.007 3.8E-295 0.0036 2223.6 
TG rs140744493 19 8436373 t 
-
0.121 0.019 1.5E-10 0.0001 50.5 
TG rs1862644 19 18724315 a 
-
0.017 0.003 2.2E-09 0.0001 86.6 
TG rs117877390 19 19378416 t 
-
0.103 0.011 1.7E-21 0.0006 357.1 
TG rs10401969 19 19407718 t 0.095 0.004 5.2E-150 0.0013 824.6 
TG rs145702982 19 19579726 a 0.119 0.021 6.2E-09 0.0003 172.3 
TG rs8182584 19 33909710 t 0.017 0.002 2.7E-15 0.0001 81.6 
TG rs1688030 19 35556744 t 
-
0.033 0.005 5.5E-13 0.0001 78.8 
TG rs2018519 19 35559787 t 
-
0.021 0.003 8.9E-11 0.0001 74.7 
TG rs28399653 19 45315445 a 0.041 0.006 5.5E-12 0.0001 60.1 
TG rs4803760 19 45333834 t 0.021 0.003 1.3E-11 0.0001 83.5 
TG rs157582 19 45396219 t 0.042 0.004 7.5E-24 0.0006 383.4 
TG rs439401 19 45414451 t 
-
0.080 0.002 1.2E-229 0.0030 1869.3 
TG rs59325138 19 45416291 t 
-
0.040 0.003 1.2E-31 0.0008 469.6 
TG rs7259004 19 45432557 c 0.064 0.005 2.3E-45 0.0008 463.7 
TG rs2287922 19 49232226 a 0.018 0.002 4.0E-17 0.0002 96.4 
TG rs1132990 19 50028163 a 
-
0.018 0.003 4.2E-09 0.0001 63.0 
TG rs6029143 20 39118662 t 
-
0.035 0.005 8.6E-13 0.0001 92.4 
TG rs6016381 20 39180436 t 0.018 0.002 8.4E-15 0.0001 92.0 
TG rs1997833 20 39690342 t 
-
0.016 0.003 1.2E-09 0.0001 61.0 
TG rs3827066 20 44586023 t 
-
0.043 0.004 4.3E-28 0.0005 308.0 
TG rs8123864 20 44598670 t 
-
0.044 0.003 2.0E-46 0.0009 535.9 
TG rs1211644 20 45592842 t 0.024 0.003 2.8E-15 0.0002 131.0 
TG rs2426428 20 50886412 t 
-
0.031 0.005 2.3E-11 0.0001 92.2 
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TG rs6025606 20 56098733 t 
-
0.013 0.002 7.4E-10 0.0001 48.3 
TG rs41302559 20 56140439 a 
-
0.145 0.021 1.8E-12 0.0001 61.9 
TG rs114139997 21 46875775 a 
-
0.365 0.039 2.9E-21 0.0003 180.4 
TG rs200559406 21 46875817 a 0.282 0.036 6.6E-15 0.0001 78.5 
TG rs35665085 22 17625915 a 0.032 0.005 1.9E-12 0.0001 61.4 
TG rs738322 22 38569006 a 0.021 0.002 9.2E-26 0.0002 135.9 
TG rs5757161 22 38990662 a 0.016 0.003 1.6E-10 0.0001 72.5 





Supplementary Table 3. Trait-specific genetic instruments for blood lipid levels selected from 
the Global Lipids Genetics Consortium (GLGC) dataset. Variants were selected on the basis 
of their association with the respective trait at p<5E-8 and a p>0.01 regarding their 
association with the other two traits. 
   Associations with HDL-C Associations with LDL-C Associations with TG 
Phenotype SNP Eff_allele Effect SE P-value Effect SE P-value Effect SE P-value 
HDL-C rs103294 t 0.052 0.004 4.00E-30 0.007 0.005 0.123 -0.002 0.004 0.752 
HDL-C rs10773105 t 
-
0.036 0.004 3.20E-24 0.006 0.004 0.122 0.004 0.003 0.509 
HDL-C rs11246602 c 0.034 0.005 1.68E-10 0.002 0.006 0.526 -0.009 0.005 0.192 
HDL-C rs12226802 g 0.033 0.005 1.29E-09 0 0.005 0.619 -0.007 0.005 0.23 
HDL-C rs16942887 a 0.083 0.005 8.28E-54 0.001 0.005 0.798 -0.012 0.005 0.0296 
HDL-C rs17695224 g 0.029 0.004 2.42E-13 0.011 0.004 0.0125 -0.012 0.004 0.0113 
HDL-C rs181362 c 0.038 0.004 9.24E-18 0.007 0.005 0.0793 0.009 0.004 0.0281 
HDL-C rs205262 a 0.028 0.004 3.88E-13 0.009 0.004 0.0313 -0.003 0.004 0.803 
HDL-C rs2240327 g 0.024 0.003 1.11E-11 0.001 0.004 0.971 -0.002 0.003 0.867 
HDL-C rs2241210 g 0.033 0.004 2.49E-20 0.008 0.004 0.0855 0.003 0.003 0.247 
HDL-C rs2290547 a -0.03 0.005 3.69E-09 0.001 0.005 0.793 0.01 0.004 0.0221 
HDL-C rs2472509 g 0.023 0.004 1.21E-09 0 0.004 0.708 -0.002 0.004 0.722 
HDL-C rs2602836 g 
-
0.019 0.003 4.96E-08 0.001 0.004 0.831 0.009 0.003 0.0212 
HDL-C rs4650994 a 
-
0.021 0.003 6.70E-09 0.003 0.004 0.338 0.002 0.003 0.398 
HDL-C rs4917014 g 0.022 0.004 1.03E-08 0.005 0.004 0.246 -0.001 0.004 0.887 
HDL-C rs4983559 g 0.02 0.004 9.57E-09 0.003 0.004 0.583 0 0.004 0.971 
HDL-C rs499974 a 
-
0.026 0.004 1.12E-08 0.001 0.005 0.826 -0.009 0.004 0.0541 
HDL-C rs702485 g 0.024 0.003 6.45E-12 0.001 0.004 0.787 -0.002 0.003 0.475 
HDL-C rs838876 g 
-
0.049 0.004 7.33E-33 0.003 0.004 0.442 0.005 0.004 0.377 
LDL-C rs1010167 g 
-
0.004 0.004 0.396 0.025 0.004 6.22E-11 0.002 0.004 0.808 
LDL-C rs11563251 t 0.006 0.006 0.365 0.035 0.006 4.50E-08 0.008 0.006 0.0826 
LDL-C rs1250229 c 
-
0.003 0.004 0.404 0.024 0.004 3.13E-08 0.009 0.004 0.0139 
LDL-C rs12670798 c 
-
0.001 0.004 0.733 0.034 0.004 4.81E-14 0.01 0.004 0.0168 
LDL-C rs16831243 t 0.011 0.005 0.039 0.038 0.006 9.06E-12 -0.001 0.005 0.987 
LDL-C rs17508045 t 
-
0.009 0.006 0.0466 0.049 0.007 4.91E-12 -0.008 0.006 0.4 
LDL-C rs1800562 g 0.007 0.007 0.242 0.062 0.008 8.25E-14 -0.013 0.007 0.172 
LDL-C rs2030746 t 
-
0.003 0.004 0.306 0.021 0.004 8.61E-09 0.003 0.004 0.491 
LDL-C rs2294261 a 
-
0.009 0.004 0.0206 0.033 0.004 6.57E-17 0.002 0.003 0.587 
LDL-C rs2328223 c 0 0.005 0.859 0.03 0.005 5.63E-09 -0.007 0.005 0.115 
LDL-C rs314253 t 
-
0.003 0.004 0.353 0.024 0.004 3.44E-10 0.009 0.003 0.0298 
LDL-C rs364585 g 0.001 0.004 0.822 0.025 0.004 4.28E-10 -0.002 0.003 0.44 
LDL-C rs3780181 a 0.004 0.007 0.542 0.045 0.007 1.76E-09 -0.007 0.007 0.491 
LDL-C rs4148218 g 
-
0.003 0.004 0.456 0.044 0.005 6.76E-21 0.004 0.004 0.295 
LDL-C rs4530754 a 0.001 0.003 0.934 0.028 0.004 3.58E-12 0.002 0.003 0.742 
LDL-C rs6065311 c 0.002 0.003 0.437 0.042 0.004 1.66E-30 0.006 0.003 0.0227 
LDL-C rs6489818 a 0 0.005 0.928 0.028 0.005 4.57E-09 -0.004 0.004 0.54 
LDL-C rs6603981 t 0.004 0.004 0.381 0.034 0.004 3.10E-13 0.007 0.004 0.174 
LDL-C rs7225700 c 0.01 0.004 0.0235 0.03 0.004 3.56E-13 -0.005 0.004 0.236 
LDL-C rs7703051 a 0.002 0.004 0.421 0.073 0.004 1.40E-77 0.006 0.003 0.163 
LDL-C rs7832643 t 
-
0.001 0.004 0.595 0.034 0.004 2.67E-17 0.002 0.003 0.472 
LDL-C rs7832643 t 
-
0.001 0.004 0.595 0.034 0.004 2.67E-17 0.002 0.003 0.472 
LDL-C rs8017377 a 
-
0.004 0.004 0.434 0.03 0.004 2.52E-15 0.006 0.004 0.142 
LDL-C rs8176720 t 0.001 0.004 0.943 0.033 0.004 1.59E-17 -0.007 0.004 0.0609 
LDL-C rs903319 c 0.01 0.004 0.0122 0.027 0.004 5.22E-11 -0.005 0.004 0.138 
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TG rs10029254 t 
-
0.009 0.004 0.0487 0.006 0.004 0.205 0.027 0.004 7.55E-09 
TG rs1781930 g 0.002 0.005 0.625 0.01 0.005 0.057 0.031 0.004 2.51E-11 
TG rs603446 c 
-
0.002 0.004 0.873 0.009 0.004 0.0114 0.05 0.003 3.92E-43 
TG rs9693857 c 0.004 0.004 0.527 0.005 0.004 0.298 -0.02 0.003 1.69E-08 







Supplementary Table 4. Genetic instruments for the circulating cholesterol and triglyceride 
concentrations of the lipoprotein particles as selected and extracted from the dataset of the 
GWAS meta-analysis on Nuclear Magnetic Resonance (NMR)-measured circulating 
metabolites. 
Metabolite SNP Chr Position (hg18) Eff_allele Effect SE P-value R2 F 
L.HDL.C rs1077835 15 58723426 G 0.181 0.012 1.39E-53 0.0122 265.5 
L.HDL.C rs11076174 16 57003146 C 
-
0.134 0.016 1.17E-16 0.0035 76.7 
L.HDL.C rs11076176 16 57007446 G 
-
0.171 0.014 1.62E-34 0.0081 176.2 
L.HDL.C rs111543310 15 59531818 C 0.338 0.049 6.88E-12 0.0036 69.2 
L.HDL.C rs112835635 15 59351989 G 0.263 0.035 2.13E-13 0.0031 63.2 
L.HDL.C rs112884731 15 59504897 C 0.544 0.057 2.75E-21 0.0055 98.4 
L.HDL.C rs113298164 15 58855748 T 0.584 0.047 2.74E-34 0.0092 165.4 
L.HDL.C rs116142092 15 59751872 T 0.383 0.050 5.61E-14 0.0034 61.4 
L.HDL.C rs11633043 15 58837722 A 0.078 0.014 2.57E-08 0.0017 36.4 
L.HDL.C rs117901517 15 58678869 C 
-
0.142 0.023 5.22E-10 0.0030 58.2 
L.HDL.C rs1318175 15 58586129 T 
-
0.087 0.013 5.41E-11 0.0022 47.1 
L.HDL.C rs1367117 2 21263900 A 
-
0.063 0.011 1.50E-08 0.0016 35.1 
L.HDL.C rs1373657 15 58717762 T 0.165 0.030 4.42E-08 0.0021 38.2 
L.HDL.C rs138690293 15 59310760 C 0.722 0.107 2.61E-11 0.0039 62.4 
L.HDL.C rs142855631 15 59286876 T 0.737 0.108 1.33E-11 0.0039 63.1 
L.HDL.C rs146842281 15 59356659 T 0.154 0.022 3.53E-12 0.0027 52.8 
L.HDL.C rs148902553 15 59776836 C 0.388 0.051 3.48E-14 0.0036 62.1 
L.HDL.C rs16940472 15 58835317 A 0.130 0.020 2.49E-10 0.0026 56.9 
L.HDL.C rs16940810 15 59115159 T 0.252 0.030 5.86E-17 0.0038 77.2 
L.HDL.C rs17301746 15 58731395 T 0.265 0.038 5.18E-12 0.0029 63.1 
L.HDL.C rs174583 11 61609750 T 
-
0.078 0.010 2.92E-14 0.0029 62.4 
L.HDL.C rs17821274 15 58684478 C 
-
0.086 0.010 3.91E-16 0.0033 72.3 
L.HDL.C rs17821298 15 58690738 A 0.092 0.012 7.20E-15 0.0030 65.7 
L.HDL.C rs1800777 16 57017319 A 
-
0.234 0.035 4.04E-11 0.0027 51.6 
L.HDL.C rs181412360 15 59158953 C 0.378 0.038 6.01E-23 0.0059 106.4 
L.HDL.C rs182776276 15 59254589 G 0.573 0.060 2.84E-21 0.0056 96.2 
L.HDL.C rs183975744 15 59052479 T 0.747 0.120 7.21E-10 0.0028 43.1 
L.HDL.C rs185241689 15 59143155 G 0.810 0.114 1.96E-12 0.0039 64.0 
L.HDL.C rs185481 15 58666679 C 0.069 0.010 2.68E-11 0.0024 51.0 
L.HDL.C rs186924495 20 44686926 T 
-
0.207 0.037 3.38E-08 0.0018 32.6 
L.HDL.C rs1883025 9 107664301 T 
-
0.072 0.012 9.85E-09 0.0016 35.1 
L.HDL.C rs189375934 15 60196526 G 0.310 0.053 6.61E-09 0.0022 38.1 
L.HDL.C rs189418461 15 59725202 G 0.379 0.050 5.52E-14 0.0034 61.2 
L.HDL.C rs192630343 15 59286102 A 0.708 0.107 5.45E-11 0.0038 62.1 
L.HDL.C rs247617 16 56990716 A 0.210 0.011 1.93E-82 0.0184 403.3 
L.HDL.C rs261291 15 58680178 C 0.179 0.010 2.39E-68 0.0151 329.4 
L.HDL.C rs28370984 15 58629308 C 0.177 0.032 3.98E-08 0.0017 33.7 
L.HDL.C rs291 8 19815852 C 0.101 0.012 1.45E-17 0.0036 77.8 
L.HDL.C rs34718390 15 58682690 A 0.156 0.024 6.31E-11 0.0028 61.5 
L.HDL.C rs35547826 15 58720405 A 
-
0.084 0.014 7.63E-09 0.0017 37.6 
L.HDL.C rs429358 19 45411941 C 
-
0.092 0.013 1.46E-11 0.0024 51.1 
L.HDL.C rs435306 20 44538484 T 
-
0.073 0.011 2.88E-10 0.0020 42.2 
L.HDL.C rs517755 19 45009036 C 
-
0.229 0.041 3.58E-08 0.0019 36.8 
L.HDL.C rs55995508 16 56827946 A 0.159 0.025 4.93E-10 0.0023 44.6 
L.HDL.C rs6065904 20 44534651 A 
-
0.135 0.012 1.72E-30 0.0065 140.2 
24 
 
L.HDL.C rs6499857 16 56935090 C 
-
0.067 0.012 3.70E-08 0.0015 32.8 
L.HDL.C rs6507939 18 47176261 C 0.095 0.013 3.34E-12 0.0024 51.2 
L.HDL.C rs6544366 2 21204025 T 0.064 0.011 8.14E-09 0.0016 34.8 
L.HDL.C rs67053123 12 125353810 A 0.092 0.015 3.90E-10 0.0021 46.3 
L.HDL.C rs73959582 18 47148886 C 0.079 0.014 4.62E-08 0.0016 35.2 
L.HDL.C rs7412 19 45412079 T 0.158 0.025 8.48E-10 0.0026 48.2 
L.HDL.C rs75835816 8 19885513 C 
-
0.293 0.038 2.87E-14 0.0033 63.3 
L.HDL.C rs76083992 20 44544798 T 
-
0.229 0.032 2.01E-12 0.0026 51.8 
L.HDL.C rs76116860 15 59834938 C 0.277 0.041 2.66E-11 0.0027 52.2 
L.HDL.C rs79844529 15 58445279 T 0.190 0.032 3.43E-09 0.0024 45.8 
L.HDL.C rs8042174 15 58685970 C 
-
0.112 0.020 2.10E-08 0.0018 38.0 
L.HDL.C rs938507 15 58582034 A 0.101 0.014 2.89E-12 0.0024 51.2 
L.HDL.C rs964184 11 116648917 C 0.082 0.014 8.07E-09 0.0016 34.5 
M.LDL.C rs10424477 19 10636051 T 
-
0.071 0.011 1.53E-09 0.0021 46.4 
M.LDL.C rs111740198 19 44878217 A 
-
0.321 0.052 1.22E-09 0.0033 48.4 
M.LDL.C rs112635299 14 94838142 T 0.237 0.040 4.03E-09 0.0020 39.4 
M.LDL.C rs11587071 1 55522674 T 
-
0.092 0.014 1.95E-11 0.0023 49.1 
M.LDL.C rs116054287 1 56401689 C 
-
0.397 0.038 4.41E-25 0.0058 126.0 
M.LDL.C rs117261169 19 45491032 T 
-
0.361 0.055 1.44E-10 0.0025 48.6 
M.LDL.C rs117569256 19 45423330 G 
-
0.821 0.107 4.27E-14 0.0068 91.9 
M.LDL.C rs11878174 19 45723379 C 0.073 0.012 6.11E-10 0.0026 51.0 
M.LDL.C rs12043403 1 55431933 C 
-
0.138 0.018 3.27E-14 0.0038 73.8 
M.LDL.C rs12086676 1 55738663 T 
-
0.076 0.013 2.68E-09 0.0018 38.8 
M.LDL.C rs12916 5 74656539 C 0.084 0.010 1.86E-16 0.0034 73.7 
M.LDL.C rs137992968 19 11239696 T 
-
0.204 0.034 3.32E-09 0.0018 39.1 
M.LDL.C rs138270540 4 75353427 C 0.226 0.036 9.95E-10 0.0025 46.3 
M.LDL.C rs138287365 4 74781004 C 0.373 0.050 2.70E-13 0.0037 68.3 
M.LDL.C rs138525976 1 55960656 A 
-
0.103 0.018 2.24E-08 0.0017 35.7 
M.LDL.C rs140339333 4 75396456 A 0.288 0.045 2.32E-10 0.0030 55.3 
M.LDL.C rs140411770 19 45356517 A 
-
0.542 0.088 1.58E-09 0.0049 76.2 
M.LDL.C rs142130958 19 11190652 A 
-
0.221 0.016 2.19E-40 0.0092 200.6 
M.LDL.C rs143413051 4 75560225 T 0.381 0.055 1.05E-11 0.0034 57.9 
M.LDL.C rs143736900 4 72871285 C 0.594 0.083 2.35E-12 0.0045 71.5 
M.LDL.C rs144591518 19 10518992 T 
-
0.194 0.034 3.05E-08 0.0016 34.0 
M.LDL.C rs144721118 1 54196340 A 
-
0.270 0.040 1.94E-11 0.0034 65.0 
M.LDL.C rs146568567 1 54824117 A 
-
0.315 0.032 1.24E-22 0.0054 104.9 
M.LDL.C rs147319495 2 20912953 G 
-
0.064 0.011 8.09E-09 0.0017 36.9 
M.LDL.C rs147825223 19 45479553 C 0.173 0.028 1.92E-09 0.0022 39.8 
M.LDL.C rs148359521 2 21414212 T 
-
0.187 0.032 8.31E-09 0.0020 39.0 
M.LDL.C rs148382396 1 54639713 A 
-
0.390 0.051 5.53E-14 0.0044 70.1 
M.LDL.C rs149048538 19 45053024 A 
-
0.282 0.044 1.91E-10 0.0025 47.8 
M.LDL.C rs149844719 1 54519237 T 
-
0.183 0.028 1.18E-10 0.0023 50.7 
M.LDL.C rs149944945 1 56129361 G 
-
0.292 0.034 3.47E-17 0.0043 82.3 
M.LDL.C rs150785555 1 56005603 A 
-
0.451 0.036 1.28E-35 0.0090 175.6 
M.LDL.C rs150966173 19 45421204 T 0.225 0.039 1.01E-08 0.0020 39.4 
M.LDL.C rs150985779 19 45147992 T 
-
0.269 0.038 2.86E-12 0.0031 59.1 
M.LDL.C rs151193598 4 73303394 A 0.634 0.087 8.45E-13 0.0061 82.8 
M.LDL.C rs157594 19 45425175 G 0.133 0.012 4.31E-29 0.0086 167.0 
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M.LDL.C rs17111503 1 55503448 G 0.075 0.013 1.34E-08 0.0018 39.6 
M.LDL.C rs17395160 1 55085141 G 
-
0.086 0.012 2.42E-12 0.0025 53.1 
M.LDL.C rs180961170 1 57012269 G 
-
0.364 0.052 4.27E-12 0.0037 65.6 
M.LDL.C rs181066897 4 73499882 C 0.515 0.080 2.30E-10 0.0041 66.1 
M.LDL.C rs181169081 2 21312870 A 
-
0.185 0.032 1.07E-08 0.0020 38.2 
M.LDL.C rs181594442 1 57006537 A 
-
0.364 0.052 4.33E-12 0.0037 65.6 
M.LDL.C rs181847072 4 73134560 G 0.592 0.083 1.85E-12 0.0046 72.3 
M.LDL.C rs182300850 1 54389320 C 
-
0.371 0.060 1.06E-09 0.0032 48.4 
M.LDL.C rs182318839 19 45747128 T 0.300 0.054 3.77E-08 0.0027 47.3 
M.LDL.C rs184566992 19 44887996 T 
-
0.353 0.052 2.52E-11 0.0037 58.6 
M.LDL.C rs184650103 4 74850649 T 0.406 0.047 2.78E-17 0.0045 77.6 
M.LDL.C rs185049786 4 74644512 C 0.335 0.054 1.08E-09 0.0034 62.6 
M.LDL.C rs185415345 1 56625395 A 
-
0.168 0.027 1.48E-09 0.0025 48.2 
M.LDL.C rs185802315 19 10777054 G 
-
0.231 0.036 2.50E-10 0.0025 44.8 
M.LDL.C rs185886292 19 45565918 T 0.184 0.032 1.51E-08 0.0021 37.3 
M.LDL.C rs186538116 1 56840574 C 
-
0.421 0.045 1.49E-20 0.0059 105.9 
M.LDL.C rs188099946 19 45189605 T 
-
0.296 0.045 1.06E-10 0.0022 48.6 
M.LDL.C rs189409600 19 45341066 T 
-
0.749 0.103 8.32E-13 0.0060 83.6 
M.LDL.C rs189718275 19 45063850 A 
-
0.296 0.044 3.75E-11 0.0028 53.2 
M.LDL.C rs190217562 4 75180409 C 0.251 0.035 1.36E-12 0.0059 106.0 
M.LDL.C rs190934192 1 55334001 A 
-
0.385 0.040 2.23E-21 0.0069 134.8 
M.LDL.C rs191210370 1 54236244 G 
-
0.212 0.038 3.42E-08 0.0021 40.7 
M.LDL.C rs191404723 1 54636232 T 
-
0.390 0.051 4.44E-14 0.0041 71.1 
M.LDL.C rs191448950 1 55584844 A 
-
0.484 0.032 1.80E-51 0.0111 243.0 
M.LDL.C rs192012905 19 44463485 G 
-
0.340 0.053 1.93E-10 0.0029 52.4 
M.LDL.C rs192570155 1 55246601 C 
-
0.492 0.045 4.04E-27 0.0085 152.5 
M.LDL.C rs193084249 1 26987646 G 0.182 0.031 1.04E-08 0.0021 39.7 
M.LDL.C rs2007708 19 45410420 A 
-
0.831 0.104 3.41E-15 0.0054 99.4 
M.LDL.C rs207176 1 55791846 T 0.121 0.017 2.14E-12 0.0026 55.4 
M.LDL.C rs2207132 20 39142516 A 0.137 0.025 3.69E-08 0.0021 40.8 
M.LDL.C rs2927472 19 45349369 C 0.151 0.018 6.13E-17 0.0041 88.8 
M.LDL.C rs2965149 19 45190766 C 
-
0.069 0.011 1.57E-10 0.0022 47.7 
M.LDL.C rs2967668 19 45302951 G 
-
0.178 0.017 4.32E-25 0.0071 137.2 
M.LDL.C rs2980875 8 126481747 G 
-
0.058 0.010 5.86E-09 0.0017 36.1 
M.LDL.C rs312030 2 21462743 C 0.108 0.018 1.25E-09 0.0019 41.9 
M.LDL.C rs3185010 19 11275842 A 0.064 0.011 5.50E-09 0.0017 37.0 
M.LDL.C rs34722314 2 21271707 A 
-
0.124 0.014 6.82E-18 0.0037 80.2 
M.LDL.C rs3741298 11 116657561 T 
-
0.072 0.012 1.49E-09 0.0018 39.1 
M.LDL.C rs429358 19 45411941 C 0.220 0.013 2.46E-59 0.0136 298.2 
M.LDL.C rs4609471 1 55493584 A 
-
0.382 0.030 8.83E-37 0.0113 220.5 
M.LDL.C rs4803748 19 45247048 T 
-
0.080 0.011 1.32E-13 0.0030 65.5 
M.LDL.C rs55810502 5 74380959 G 0.070 0.012 8.93E-09 0.0017 36.5 
M.LDL.C rs58826447 19 45328379 A 0.070 0.011 1.05E-10 0.0022 48.3 
M.LDL.C rs62117161 19 45233385 G 
-
0.206 0.020 1.98E-24 0.0054 117.5 
M.LDL.C rs62120794 2 21100426 T 
-
0.177 0.024 4.41E-13 0.0028 56.8 
M.LDL.C rs629301 1 109818306 T 0.126 0.012 1.62E-25 0.0055 118.9 
M.LDL.C rs6511721 19 11206575 A 
-
0.092 0.011 6.23E-17 0.0042 91.7 
M.LDL.C rs6663252 1 55630151 C 
-
0.084 0.012 1.01E-11 0.0024 51.1 
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M.LDL.C rs6732011 2 21146521 T 
-
0.059 0.010 6.73E-09 0.0016 35.4 
M.LDL.C rs6859 19 45382034 G 
-
0.080 0.010 1.10E-15 0.0032 69.1 
M.LDL.C rs7255743 19 46018119 A 
-
0.178 0.032 4.50E-08 0.0016 35.0 
M.LDL.C rs73048351 19 45160086 A 
-
0.415 0.064 2.47E-10 0.0030 58.3 
M.LDL.C rs73066442 7 21592973 G 0.071 0.011 8.03E-10 0.0019 40.9 
M.LDL.C rs73556990 19 44888175 G 
-
0.326 0.052 8.98E-10 0.0036 50.7 
M.LDL.C rs73564218 19 45665952 C 0.173 0.030 1.27E-08 0.0020 35.4 
M.LDL.C rs74073060 1 55638930 A 
-
0.478 0.037 1.28E-36 0.0098 190.3 
M.LDL.C rs7412 19 45412079 T 
-
0.565 0.025 ####### 0.0338 638.4 
M.LDL.C rs75647206 1 56947591 T 
-
0.365 0.050 6.08E-13 0.0035 67.7 
M.LDL.C rs7604788 2 21190024 T 
-
0.176 0.022 3.01E-15 0.0033 72.3 
M.LDL.C rs76670936 19 45196581 A 
-
0.145 0.018 1.18E-14 0.0034 74.4 
M.LDL.C rs76866386 2 44075483 C 
-
0.142 0.018 1.42E-14 0.0029 63.2 
M.LDL.C rs77021821 4 75684215 T 0.251 0.041 1.71E-09 0.0023 42.2 
M.LDL.C rs78620068 2 21524000 A 
-
0.115 0.017 7.72E-11 0.0022 47.6 
M.LDL.C rs79668907 19 11257169 T 
-
0.091 0.012 7.58E-13 0.0031 66.3 
M.LDL.C rs79890446 19 45723446 T 
-
0.234 0.033 2.89E-12 0.0034 65.8 
M.LDL.C rs8106814 19 45441608 C 
-
0.101 0.014 4.47E-12 0.0035 68.2 
M.LDL.C rs8111962 19 10915324 T 
-
0.095 0.014 1.59E-11 0.0023 49.6 
M.LDL.C rs934197 2 21267461 A 0.113 0.011 3.50E-24 0.0052 113.4 
M.LDL.C rs984976 5 74910870 G 0.075 0.010 1.30E-13 0.0027 59.0 
IDL.TG rs10495713 2 21200519 G 
-
0.062 0.010 2.48E-09 0.0019 37.2 
IDL.TG rs113105798 15 59301460 A 0.198 0.036 4.06E-08 0.0018 35.2 
IDL.TG rs113298164 15 58855748 T 0.395 0.047 2.42E-16 0.0042 75.3 
IDL.TG rs113531395 17 4886829 T 
-
0.246 0.036 2.44E-11 0.0031 59.4 
IDL.TG rs114822153 4 73238544 A 0.244 0.043 1.68E-08 0.0025 48.0 
IDL.TG rs115849089 8 19912370 A 
-
0.098 0.017 2.05E-08 0.0017 33.7 
IDL.TG rs116054287 1 56401689 C 
-
0.282 0.038 5.00E-13 0.0031 60.0 
IDL.TG rs116302332 4 75370891 T 0.257 0.040 1.90E-10 0.0028 54.7 
IDL.TG rs11633043 15 58837722 A 0.079 0.014 4.38E-08 0.0018 34.4 
IDL.TG rs116802199 17 4801101 C 
-
0.235 0.032 3.08E-13 0.0031 58.1 
IDL.TG rs1168041 1 62960250 C 0.084 0.012 1.96E-12 0.0028 53.9 
IDL.TG rs117749052 15 58749309 C 0.216 0.037 9.78E-09 0.0027 51.9 
IDL.TG rs118095054 19 19621301 G 
-
0.137 0.024 1.34E-08 0.0022 42.5 
IDL.TG rs12043403 1 55431933 C 
-
0.101 0.018 3.23E-08 0.0020 39.2 
IDL.TG rs1268353 11 116639692 T 
-
0.064 0.011 1.66E-09 0.0020 37.9 
IDL.TG rs1318175 15 58586129 T 
-
0.088 0.014 2.89E-10 0.0022 42.6 
IDL.TG rs13329672 15 58699937 T 0.086 0.012 9.82E-13 0.0029 55.6 
IDL.TG rs138195472 15 58672107 T 0.223 0.035 3.10E-10 0.0025 44.3 
IDL.TG rs138287365 4 74781004 C 0.407 0.049 3.37E-16 0.0044 85.3 
IDL.TG rs140250995 4 73723860 C 0.636 0.100 3.37E-10 0.0035 64.6 
IDL.TG rs140339333 4 75396456 A 0.309 0.044 4.64E-12 0.0034 65.8 
IDL.TG rs143413051 4 75560225 T 0.404 0.055 3.05E-13 0.0037 66.9 
IDL.TG rs143736900 4 72871285 C 0.692 0.082 1.08E-16 0.0060 100.2 
IDL.TG rs145347194 15 58670135 C 0.135 0.023 3.51E-09 0.0024 46.2 
IDL.TG rs146568567 1 54824117 A 
-
0.208 0.032 1.02E-10 0.0024 45.7 
IDL.TG rs146842281 15 59356659 T 0.146 0.022 6.31E-11 0.0024 47.1 
IDL.TG rs149297353 19 20115517 G 
-
0.192 0.030 2.02E-10 0.0026 50.9 
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IDL.TG rs149944945 1 56129361 G 
-
0.248 0.034 9.23E-13 0.0031 59.1 
IDL.TG rs150392353 2 21320317 C 
-
0.228 0.032 1.93E-12 0.0030 58.2 
IDL.TG rs150536132 19 19679560 T 
-
0.183 0.030 1.13E-09 0.0028 50.4 
IDL.TG rs150785555 1 56005603 A 
-
0.328 0.036 1.74E-19 0.0048 92.2 
IDL.TG rs151193598 4 73303394 A 0.658 0.085 3.13E-14 0.0066 94.0 
IDL.TG rs1532085 15 58683366 G 
-
0.156 0.010 8.71E-49 0.0117 229.0 
IDL.TG rs157594 19 45425175 G 0.126 0.012 4.34E-26 0.0077 148.6 
IDL.TG rs1663255 15 58514242 T 
-
0.071 0.011 2.41E-10 0.0022 42.6 
IDL.TG rs16940213 15 58695337 T 0.126 0.013 1.70E-20 0.0046 89.8 
IDL.TG rs17001002 19 10948031 A 
-
0.094 0.016 8.44E-09 0.0022 35.2 
IDL.TG rs17216525 19 19662220 T 
-
0.132 0.021 4.39E-10 0.0021 40.7 
IDL.TG rs181066897 4 73499882 C 0.523 0.080 1.17E-10 0.0042 68.2 
IDL.TG rs181169081 2 21312870 A 
-
0.227 0.032 2.17E-12 0.0030 57.6 
IDL.TG rs181181625 15 59377940 T 0.388 0.058 3.00E-11 0.0027 48.4 
IDL.TG rs181275587 19 20486755 A 
-
0.167 0.029 2.02E-08 0.0022 39.0 
IDL.TG rs181412360 15 59158953 C 0.255 0.038 3.52E-11 0.0027 48.4 
IDL.TG rs1815786 11 116921390 C 
-
0.095 0.016 1.47E-09 0.0021 41.5 
IDL.TG rs181807530 17 4774814 G 
-
0.232 0.032 9.01E-13 0.0032 55.0 
IDL.TG rs181847072 4 73134560 G 0.692 0.082 5.83E-17 0.0062 102.2 
IDL.TG rs183162020 4 73690263 G 0.861 0.115 1.99E-13 0.0086 85.0 
IDL.TG rs183305631 19 19597444 A 
-
0.218 0.032 1.54E-11 0.0033 59.0 
IDL.TG rs1838504 15 58666410 T 0.099 0.010 1.20E-20 0.0049 94.4 
IDL.TG rs184650103 4 74850649 T 0.430 0.046 6.76E-20 0.0051 90.4 
IDL.TG rs1848922 2 21471603 C 0.113 0.013 7.08E-19 0.0044 84.5 
IDL.TG rs185049786 4 74644512 C 0.358 0.053 3.00E-11 0.0039 74.6 
IDL.TG rs1872741 15 59450895 T 0.073 0.013 3.91E-08 0.0017 32.2 
IDL.TG rs1883711 20 39179822 C 0.155 0.025 6.67E-10 0.0026 49.6 
IDL.TG rs189741280 19 19624481 G 
-
0.199 0.030 5.27E-11 0.0029 56.1 
IDL.TG rs190121281 19 19252779 A 
-
0.231 0.033 3.24E-12 0.0036 63.8 
IDL.TG rs190217562 4 75180409 C 0.327 0.040 1.00E-15 0.0040 72.1 
IDL.TG rs190934192 1 55334001 A 
-
0.246 0.040 1.37E-09 0.0028 55.0 
IDL.TG rs191448950 1 55584844 A 
-
0.319 0.032 4.51E-23 0.0053 103.5 
IDL.TG rs192570155 1 55246601 C 
-
0.335 0.045 2.46E-13 0.0039 70.4 
IDL.TG rs193092110 15 58730460 A 0.206 0.036 1.26E-08 0.0020 35.6 
IDL.TG rs247617 16 56990716 A 
-
0.084 0.011 4.51E-13 0.0029 56.3 
IDL.TG rs261334 15 58726744 C 
-
0.197 0.012 1.09E-56 0.0138 270.1 
IDL.TG rs2642636 15 58363242 G 
-
0.062 0.011 1.49E-08 0.0018 34.5 
IDL.TG rs28370984 15 58629308 C 0.215 0.032 3.09E-11 0.0026 49.7 
IDL.TG rs28395406 15 58629349 G 
-
0.108 0.016 2.50E-11 0.0026 49.6 
IDL.TG rs2954029 8 126490972 T 
-
0.083 0.010 1.36E-15 0.0035 67.2 
IDL.TG rs3005923 1 56801542 A 
-
0.250 0.036 1.13E-11 0.0033 64.7 
IDL.TG rs4075673 2 21150787 C 
-
0.102 0.010 5.92E-22 0.0050 97.5 
IDL.TG rs429358 19 45411941 C 0.122 0.014 3.02E-18 0.0042 81.1 
IDL.TG rs4609471 1 55493584 A 
-
0.254 0.030 3.64E-17 0.0050 97.2 
IDL.TG rs61999891 15 58299599 A 0.103 0.017 5.16E-09 0.0022 42.0 
IDL.TG rs6511720 19 11202306 T 
-
0.176 0.017 1.76E-23 0.0056 107.6 
IDL.TG rs6511721 19 11206575 A 
-
0.070 0.011 5.20E-10 0.0025 47.4 
IDL.TG rs660240 1 109817838 C 0.079 0.012 5.70E-10 0.0021 40.1 
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IDL.TG rs74073060 1 55638930 A 
-
0.323 0.037 1.80E-17 0.0044 86.1 
IDL.TG rs7412 19 45412079 T 
-
0.263 0.026 2.70E-23 0.0073 116.9 
IDL.TG rs7604788 2 21190024 T 
-
0.195 0.022 4.58E-18 0.0044 84.8 
IDL.TG rs77021821 4 75684215 T 0.266 0.040 7.83E-11 0.0025 49.2 
IDL.TG rs79192207 2 21417897 C 0.087 0.014 7.29E-10 0.0021 40.5 
IDL.TG rs79225634 5 74619639 T 0.062 0.011 1.60E-08 0.0018 34.0 
IDL.TG rs79660716 15 58521171 G 0.205 0.027 1.68E-13 0.0035 66.9 
IDL.TG rs8042174 15 58685970 C 
-
0.132 0.020 2.42E-10 0.0024 45.4 
IDL.TG rs8100204 19 19393714 A 
-
0.118 0.016 1.88E-12 0.0032 61.1 
IDL.TG rs9302635 16 72144174 C 
-
0.078 0.013 1.27E-08 0.0017 33.7 
IDL.TG rs964184 11 116648917 C 
-
0.149 0.015 7.59E-24 0.0054 104.8 
L.LDL.C rs10424477 19 10636051 T 
-
0.082 0.011 1.82E-12 0.0029 63.0 
L.LDL.C rs10449300 1 109381904 G 
-
0.060 0.011 3.73E-08 0.0016 34.3 
L.LDL.C rs111740198 19 44878217 A 
-
0.341 0.052 1.13E-10 0.0037 54.4 
L.LDL.C rs114664261 2 21410015 T 0.264 0.046 2.19E-08 0.0027 52.8 
L.LDL.C rs11587071 1 55522674 T 
-
0.099 0.014 7.48E-13 0.0026 56.0 
L.LDL.C rs116054287 1 56401689 C 
-
0.397 0.038 3.95E-25 0.0058 126.0 
L.LDL.C rs117261169 19 45491032 T 
-
0.396 0.055 1.99E-12 0.0030 58.4 
L.LDL.C rs117569256 19 45423330 G 
-
0.867 0.107 1.42E-15 0.0076 102.6 
L.LDL.C rs11878174 19 45723379 C 0.077 0.012 9.53E-11 0.0029 55.8 
L.LDL.C rs12043403 1 55431933 C 
-
0.141 0.018 1.20E-14 0.0039 76.2 
L.LDL.C rs12086676 1 55738663 T 
-
0.081 0.013 2.28E-10 0.0020 44.0 
L.LDL.C rs13014768 2 21514796 G 
-
0.117 0.017 2.48E-12 0.0025 54.8 
L.LDL.C rs137992968 19 11239696 T 
-
0.213 0.034 6.08E-10 0.0020 42.8 
L.LDL.C rs138270540 4 75353427 C 0.220 0.036 1.62E-09 0.0023 45.1 
L.LDL.C rs138287365 4 74781004 C 0.346 0.049 4.07E-12 0.0032 61.6 
L.LDL.C rs138525976 1 55960656 A 
-
0.107 0.018 7.47E-09 0.0018 38.1 
L.LDL.C rs140339333 4 75396456 A 0.266 0.044 2.49E-09 0.0025 48.8 
L.LDL.C rs140411770 19 45356517 A 
-
0.519 0.088 7.65E-09 0.0044 69.6 
L.LDL.C rs142130958 19 11190652 A 
-
0.233 0.016 1.07E-44 0.0102 222.7 
L.LDL.C rs143413051 4 75560225 T 0.363 0.055 6.07E-11 0.0030 53.8 
L.LDL.C rs143736900 4 72871285 C 0.540 0.082 1.08E-10 0.0037 60.7 
L.LDL.C rs144064722 4 73406173 G 0.232 0.034 1.82E-11 0.0027 51.3 
L.LDL.C rs144591518 19 10518992 T 
-
0.196 0.034 1.88E-08 0.0016 35.0 
L.LDL.C rs144721118 1 54196340 A 
-
0.292 0.040 3.96E-13 0.0039 75.9 
L.LDL.C rs144900553 19 10798974 T 
-
0.293 0.052 2.35E-08 0.0022 47.8 
L.LDL.C rs146568567 1 54824117 A 
-
0.332 0.032 4.40E-25 0.0060 116.9 
L.LDL.C rs147319495 2 20912953 G 
-
0.066 0.011 3.19E-09 0.0018 38.9 
L.LDL.C rs147825223 19 45479553 C 0.166 0.028 8.18E-09 0.0021 36.6 
L.LDL.C rs148359521 2 21414212 T 
-
0.194 0.032 2.43E-09 0.0022 41.8 
L.LDL.C rs148382396 1 54639713 A 
-
0.416 0.051 1.04E-15 0.0050 79.7 
L.LDL.C rs149048538 19 45053024 A 
-
0.310 0.044 2.45E-12 0.0030 57.7 
L.LDL.C rs149844719 1 54519237 T 
-
0.203 0.028 8.40E-13 0.0029 62.4 
L.LDL.C rs149944945 1 56129361 G 
-
0.298 0.034 8.05E-18 0.0044 85.5 
L.LDL.C rs150785555 1 56005603 A 
-
0.470 0.036 1.20E-38 0.0098 190.9 
L.LDL.C rs150966173 19 45421204 T 0.228 0.039 6.44E-09 0.0021 40.3 
L.LDL.C rs150985779 19 45147992 T 
-
0.284 0.038 1.53E-13 0.0034 66.0 
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L.LDL.C rs151330717 19 45196964 A 
-
0.329 0.058 2.07E-08 0.0025 48.4 
L.LDL.C rs157594 19 45425175 G 0.138 0.012 3.63E-31 0.0092 179.3 
L.LDL.C rs17111503 1 55503448 G 0.077 0.013 6.09E-09 0.0019 41.4 
L.LDL.C rs180961170 1 57012269 G 
-
0.380 0.052 4.36E-13 0.0040 71.6 
L.LDL.C rs181169081 2 21312870 A 
-
0.192 0.032 2.83E-09 0.0021 41.2 
L.LDL.C rs181594442 1 57006537 A 
-
0.380 0.052 4.36E-13 0.0040 71.6 
L.LDL.C rs181847072 4 73134560 G 0.537 0.082 9.04E-11 0.0037 61.4 
L.LDL.C rs182300850 1 54389320 C 
-
0.401 0.060 4.12E-11 0.0038 56.6 
L.LDL.C rs183162020 4 73690263 G 0.722 0.115 6.81E-10 0.0060 59.6 
L.LDL.C rs183383492 19 11232974 C 
-
0.352 0.063 3.52E-08 0.0019 33.5 
L.LDL.C rs184229638 19 45671925 A 
-
0.688 0.115 3.24E-09 0.0042 50.6 
L.LDL.C rs184566992 19 44887996 T 
-
0.371 0.052 2.06E-12 0.0041 64.9 
L.LDL.C rs184650103 4 74850649 T 0.381 0.046 5.88E-16 0.0040 71.0 
L.LDL.C rs185049786 4 74644512 C 0.323 0.053 2.07E-09 0.0031 60.6 
L.LDL.C rs185415345 1 56625395 A 
-
0.171 0.027 6.61E-10 0.0026 50.1 
L.LDL.C rs185802315 19 10777054 G 
-
0.235 0.036 1.30E-10 0.0026 46.1 
L.LDL.C rs186538116 1 56840574 C 
-
0.441 0.045 2.06E-22 0.0065 116.1 
L.LDL.C rs188099946 19 45189605 T 
-
0.276 0.045 1.65E-09 0.0020 42.3 
L.LDL.C rs189409600 19 45341066 T 
-
0.746 0.103 1.00E-12 0.0059 82.8 
L.LDL.C rs189718275 19 45063850 A 
-
0.323 0.044 4.55E-13 0.0033 63.6 
L.LDL.C rs190217562 4 75180409 C 0.293 0.040 6.82E-13 0.0032 57.7 
L.LDL.C rs190934192 1 55334001 A 
-
0.399 0.040 7.10E-23 0.0075 144.8 
L.LDL.C rs191210370 1 54236244 G 
-
0.236 0.038 7.05E-10 0.0026 50.7 
L.LDL.C rs191404723 1 54636232 T 
-
0.415 0.051 9.32E-16 0.0046 80.4 
L.LDL.C rs191448950 1 55584844 A 
-
0.498 0.032 1.03E-54 0.0119 258.4 
L.LDL.C rs192012905 19 44463485 G 
-
0.362 0.053 1.19E-11 0.0033 59.4 
L.LDL.C rs192570155 1 55246601 C 
-
0.511 0.045 3.38E-29 0.0092 164.7 
L.LDL.C rs193084249 1 26987646 G 0.180 0.031 1.48E-08 0.0020 38.8 
L.LDL.C rs2007708 19 45410420 A 
-
0.852 0.104 6.39E-16 0.0057 104.5 
L.LDL.C rs207176 1 55791846 T 0.125 0.017 4.57E-13 0.0027 58.7 
L.LDL.C rs2207132 20 39142516 A 0.142 0.025 1.13E-08 0.0023 43.8 
L.LDL.C rs261334 15 58726744 C 
-
0.070 0.012 6.63E-09 0.0017 37.2 
L.LDL.C rs2722641 19 44892775 A 
-
0.262 0.044 5.32E-09 0.0029 52.2 
L.LDL.C rs2954022 8 126482621 A 
-
0.058 0.010 6.03E-09 0.0017 36.1 
L.LDL.C rs2965149 19 45190766 C 
-
0.068 0.011 1.82E-10 0.0022 47.3 
L.LDL.C rs2967668 19 45302951 G 
-
0.187 0.017 1.28E-27 0.0078 151.7 
L.LDL.C rs312030 2 21462743 C 0.101 0.018 1.72E-08 0.0017 36.0 
L.LDL.C rs34042070 16 72101525 G 0.069 0.012 2.68E-08 0.0015 33.1 
L.LDL.C rs34722314 2 21271707 A 
-
0.138 0.014 1.22E-21 0.0046 98.5 
L.LDL.C rs3741298 11 116657561 T 
-
0.069 0.012 8.86E-09 0.0016 35.4 
L.LDL.C rs3935470 5 74352180 G 0.058 0.011 4.76E-08 0.0015 32.7 
L.LDL.C rs404935 19 45372794 A 
-
0.157 0.017 2.82E-19 0.0044 94.4 
L.LDL.C rs429358 19 45411941 C 0.208 0.013 2.54E-53 0.0122 266.6 
L.LDL.C rs4426495 2 21143982 T 
-
0.064 0.010 3.82E-10 0.0019 41.4 
L.LDL.C rs4609471 1 55493584 A 
-
0.401 0.030 1.78E-40 0.0125 243.3 
L.LDL.C rs4803748 19 45247048 T 
-
0.080 0.011 1.64E-13 0.0030 64.9 
L.LDL.C rs4804573 19 11277232 A 
-
0.057 0.010 2.60E-08 0.0016 35.3 
L.LDL.C rs495828 9 136154867 T 0.072 0.012 1.61E-09 0.0018 38.5 
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L.LDL.C rs58446550 19 45328380 A 0.070 0.011 9.41E-11 0.0022 48.4 
L.LDL.C rs58996925 1 56267033 G 
-
0.062 0.011 2.38E-08 0.0016 34.0 
L.LDL.C rs61770425 1 55085125 G 
-
0.083 0.012 1.26E-11 0.0023 50.1 
L.LDL.C rs62117161 19 45233385 G 
-
0.217 0.020 5.38E-27 0.0060 130.5 
L.LDL.C rs62120794 2 21100426 T 
-
0.185 0.024 3.51E-14 0.0031 62.1 
L.LDL.C rs629301 1 109818306 T 0.128 0.012 4.36E-26 0.0056 121.6 
L.LDL.C rs6511721 19 11206575 A 
-
0.091 0.011 1.76E-16 0.0041 88.9 
L.LDL.C rs6663252 1 55630151 C 
-
0.087 0.012 2.33E-12 0.0025 54.2 
L.LDL.C rs6756629 2 44065090 A 
-
0.141 0.018 2.03E-14 0.0029 62.2 
L.LDL.C rs6859 19 45382034 G 
-
0.079 0.010 2.22E-15 0.0031 67.6 
L.LDL.C rs7255743 19 46018119 A 
-
0.183 0.032 1.93E-08 0.0017 36.8 
L.LDL.C rs73048351 19 45160086 A 
-
0.419 0.064 1.57E-10 0.0031 59.4 
L.LDL.C rs73066442 7 21592973 G 0.073 0.011 2.90E-10 0.0020 43.0 
L.LDL.C rs73556990 19 44888175 G 
-
0.346 0.052 8.47E-11 0.0040 56.9 
L.LDL.C rs73564218 19 45665952 C 0.167 0.030 4.33E-08 0.0018 32.8 
L.LDL.C rs74073060 1 55638930 A 
-
0.496 0.037 2.63E-39 0.0105 204.6 
L.LDL.C rs7412 19 45412079 T 
-
0.573 0.025 ####### 0.0347 657.1 
L.LDL.C rs75647206 1 56947591 T 
-
0.382 0.050 4.90E-14 0.0038 74.1 
L.LDL.C rs7604788 2 21190024 T 
-
0.183 0.022 2.55E-16 0.0036 77.8 
L.LDL.C rs76488675 1 56885874 G 
-
0.134 0.024 2.5E-08 0.0020 38.9 
L.LDL.C rs76670936 19 45196581 A 
-
0.144 0.018 1.9E-14 0.0034 73.1 
L.LDL.C rs77021821 4 75684215 T 0.242 0.040 3.3E-09 0.0021 40.7 
L.LDL.C rs79225634 5 74619639 T 0.086 0.010 4.4E-16 0.0033 72.0 
L.LDL.C rs79668907 19 11257169 T 
-
0.092 0.012 4E-13 0.0031 67.8 
L.LDL.C rs79890446 19 45723446 T 
-
0.248 0.033 1.5E-13 0.0038 73.4 
L.LDL.C rs8106814 19 45441608 C 
-
0.103 0.014 1.6E-12 0.0037 70.9 
L.LDL.C rs8111962 19 10915324 T 
-
0.102 0.014 4E-13 0.0027 57.4 
L.LDL.C rs934197 2 21267461 A 0.114 0.011 1.7E-24 0.0053 114.8 
L.LDL.C rs9749236 19 45524553 C 
-
0.441 0.075 8.4E-09 0.0024 45.2 
L.LDL.C rs984976 5 74910870 G 0.071 0.010 1.5E-12 0.0025 53.8 
M.HDL.C rs117040820 16 57005762 T 0.320 0.052 1.1E-09 0.0027 52.4 
M.HDL.C rs1800777 16 57017319 A 
-
0.233 0.035 5.1E-11 0.0026 50.8 
M.HDL.C rs2126259 8 9185146 C 0.094 0.014 1.4E-10 0.0020 43.1 
M.HDL.C rs247617 16 56990716 A 0.165 0.011 7.6E-52 0.0114 249.2 
M.HDL.C rs286 8 19815256 T 0.124 0.021 4.2E-09 0.0018 39.2 
M.HDL.C rs28888131 16 56991624 A 
-
0.123 0.013 1.3E-19 0.0042 91.9 
M.HDL.C rs289743 16 57017796 A 
-
0.060 0.010 1.1E-08 0.0016 34.7 
M.HDL.C rs34932218 8 19855661 G 0.064 0.011 1.2E-08 0.0016 34.2 
M.HDL.C rs429358 19 45411941 C 
-
0.083 0.013 7.3E-10 0.0020 42.3 
M.HDL.C rs4939883 18 47167214 C 0.073 0.013 2.3E-08 0.0015 32.4 
M.HDL.C rs590820 1 230309619 G 
-
0.058 0.010 1.7E-08 0.0016 35.3 
M.HDL.C rs7499892 16 57006590 T 
-
0.171 0.013 1.5E-38 0.0085 184.0 
M.HDL.C rs75835816 8 19885513 C 
-
0.238 0.038 6.3E-10 0.0022 41.6 
IDL.C rs10424477 19 10636051 T 
-
0.083 0.012 5.1E-12 0.0029 56.7 
IDL.C rs10449300 1 109381904 G 
-
0.066 0.011 6E-09 0.0019 37.2 
IDL.C rs111740198 19 44878217 A 
-
0.327 0.052 6.2E-10 0.0034 50.1 
IDL.C rs114664261 2 21410015 T 0.259 0.047 4.1E-08 0.0026 50.8 
IDL.C rs11579068 1 55780213 C 
-
0.106 0.014 9.1E-14 0.0030 57.6 
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IDL.C rs116054287 1 56401689 C 
-
0.400 0.038 1.1E-24 0.0062 120.8 
IDL.C rs117261169 19 45491032 T 
-
0.367 0.055 6.9E-11 0.0026 50.3 
IDL.C rs11748027 5 74909972 T 0.072 0.010 6.2E-12 0.0026 49.6 
IDL.C rs117569256 19 45423330 G 
-
0.780 0.107 7.2E-13 0.0061 82.9 
IDL.C rs11878174 19 45723379 C 0.076 0.012 1.3E-10 0.0028 55.0 
IDL.C rs12043403 1 55431933 C 
-
0.132 0.018 4.5E-13 0.0035 67.1 
IDL.C rs12086676 1 55738663 T 
-
0.084 0.013 1.8E-10 0.0022 43.2 
IDL.C rs137992968 19 11239696 T 
-
0.228 0.035 1.3E-10 0.0023 44.4 
IDL.C rs138287365 4 74781004 C 0.305 0.049 1E-09 0.0025 47.8 
IDL.C rs138525976 1 55960656 A 
-
0.115 0.019 1.6E-09 0.0021 40.7 
IDL.C rs142130958 19 11190652 A 
-
0.238 0.017 4.2E-42 0.0103 201.3 
IDL.C rs143413051 4 75560225 T 0.313 0.055 1.7E-08 0.0022 40.0 
IDL.C rs144545816 2 21413077 A 0.093 0.012 1.7E-14 0.0033 63.1 
IDL.C rs144721118 1 54196340 A 
-
0.297 0.040 1.8E-13 0.0040 78.2 
IDL.C rs144900553 19 10798974 T 
-
0.346 0.053 1.6E-10 0.0030 58.5 
IDL.C rs146568567 1 54824117 A 
-
0.328 0.032 1.7E-24 0.0059 114.2 
IDL.C rs148359521 2 21414212 T 
-
0.203 0.032 4E-10 0.0024 46.0 
IDL.C rs148382396 1 54639713 A 
-
0.419 0.051 6.7E-16 0.0051 80.8 
IDL.C rs149048538 19 45053024 A 
-
0.311 0.044 2.2E-12 0.0030 58.0 
IDL.C rs149844719 1 54519237 T 
-
0.207 0.028 4.6E-13 0.0032 62.4 
IDL.C rs149944945 1 56129361 G 
-
0.289 0.034 7.9E-17 0.0042 80.5 
IDL.C rs150966173 19 45421204 T 0.221 0.039 1.9E-08 0.0020 37.9 
IDL.C rs150985779 19 45147992 T 
-
0.271 0.038 1.8E-12 0.0031 60.1 
IDL.C rs151193598 4 73303394 A 0.507 0.085 4.8E-09 0.0039 55.7 
IDL.C rs1532085 15 58683366 G 
-
0.091 0.011 2.1E-17 0.0040 76.5 
IDL.C rs157594 19 45425175 G 0.136 0.012 3.7E-30 0.0089 173.3 
IDL.C rs16940213 15 58695337 T 0.080 0.013 4.7E-09 0.0018 35.7 
IDL.C rs180961170 1 57012269 G 
-
0.375 0.052 9.5E-13 0.0039 69.6 
IDL.C rs181169081 2 21312870 A 
-
0.202 0.032 4E-10 0.0024 45.7 
IDL.C rs181594442 1 57006537 A 
-
0.375 0.052 9.4E-13 0.0039 69.6 
IDL.C rs182300850 1 54389320 C 
-
0.419 0.060 5.6E-12 0.0041 61.7 
IDL.C rs182896710 19 10962613 T 
-
0.182 0.032 2.5E-08 0.0021 40.7 
IDL.C rs183162020 4 73690263 G 0.651 0.115 2.8E-08 0.0049 48.4 
IDL.C rs183305631 19 19597444 A 
-
0.186 0.032 1E-08 0.0024 42.6 
IDL.C rs183383492 19 11232974 C 
-
0.362 0.063 1.5E-08 0.0020 35.5 
IDL.C rs184229638 19 45671925 A 
-
0.663 0.115 1.2E-08 0.0038 46.9 
IDL.C rs184566992 19 44887996 T 
-
0.353 0.052 2.4E-11 0.0037 58.7 
IDL.C rs184650103 4 74850649 T 0.327 0.046 3.8E-12 0.0029 52.4 
IDL.C rs185415345 1 56625395 A 
-
0.164 0.027 3.2E-09 0.0024 46.2 
IDL.C rs186538116 1 56840574 C 
-
0.439 0.045 3E-22 0.0064 115.3 
IDL.C rs188026950 1 55939497 A 
-
0.463 0.036 9.3E-38 0.0096 186.5 
IDL.C rs1883711 20 39179822 C 0.149 0.025 3E-09 0.0024 45.7 
IDL.C rs189409600 19 45341066 T 
-
0.650 0.103 5.3E-10 0.0045 62.8 
IDL.C rs189524519 19 11002852 G 
-
0.263 0.041 2.7E-10 0.0026 47.1 
IDL.C rs189718275 19 45063850 A 
-
0.322 0.044 5.5E-13 0.0033 63.2 
IDL.C rs190121281 19 19252779 A 
-
0.197 0.033 2.8E-09 0.0026 46.4 
IDL.C rs190217562 4 75180409 C 0.254 0.040 5.1E-10 0.0024 43.3 
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IDL.C rs190425759 19 10644246 A 
-
0.219 0.035 1.1E-09 0.0022 41.6 
IDL.C rs190934192 1 55334001 A 
-
0.388 0.040 1.2E-21 0.0070 136.7 
IDL.C rs191210370 1 54236244 G 
-
0.250 0.038 6.5E-11 0.0029 56.9 
IDL.C rs191404723 1 54636232 T 
-
0.416 0.051 8.9E-16 0.0046 80.5 
IDL.C rs191448950 1 55584844 A 
-
0.484 0.032 2.1E-51 0.0123 240.3 
IDL.C rs192012905 19 44463485 G 
-
0.347 0.053 8.1E-11 0.0031 54.6 
IDL.C rs192570155 1 55246601 C 
-
0.500 0.045 5.2E-28 0.0088 158.0 
IDL.C rs2007708 19 45410420 A 
-
0.751 0.104 1.1E-12 0.0044 80.9 
IDL.C rs2287029 19 10916684 T 
-
0.109 0.015 2.2E-13 0.0029 56.6 
IDL.C rs2479410 1 55505861 A 
-
0.081 0.012 8.1E-11 0.0026 50.3 
IDL.C rs261334 15 58726744 C 
-
0.119 0.012 2E-21 0.0050 97.0 
IDL.C rs2722641 19 44892775 A 
-
0.253 0.044 2E-08 0.0027 48.4 
IDL.C rs2965149 19 45190766 C 
-
0.070 0.011 4.6E-10 0.0023 44.3 
IDL.C rs2967668 19 45302951 G 
-
0.172 0.017 1.4E-23 0.0066 128.2 
IDL.C rs2980860 8 126485337 G 
-
0.065 0.010 5.2E-10 0.0021 40.6 
IDL.C rs312030 2 21462743 C 0.106 0.018 8.7E-09 0.0019 36.0 
IDL.C rs35913552 2 21272896 A 
-
0.143 0.015 3.9E-21 0.0049 94.6 
IDL.C rs395908 19 45373565 A 
-
0.161 0.018 2.6E-18 0.0044 85.7 
IDL.C rs429358 19 45411941 C 0.183 0.014 5.9E-39 0.0094 182.2 
IDL.C rs4609471 1 55493584 A 
-
0.394 0.030 4.5E-39 0.0120 234.6 
IDL.C rs4803748 19 45247048 T 
-
0.071 0.011 2.4E-10 0.0024 45.7 
IDL.C rs4804573 19 11277232 A 
-
0.059 0.011 4.5E-08 0.0017 33.2 
IDL.C rs565436 1 55524601 A 0.089 0.012 3.8E-13 0.0029 56.4 
IDL.C rs58446550 19 45328380 A 0.065 0.011 2.9E-09 0.0020 38.0 
IDL.C rs61770425 1 55085125 G 
-
0.086 0.013 1.3E-11 0.0026 49.3 
IDL.C rs62117161 19 45233385 G 
-
0.195 0.021 6.2E-21 0.0049 95.3 
IDL.C rs62120794 2 21100426 T 
-
0.182 0.024 1.9E-13 0.0032 56.9 
IDL.C rs62523994 8 145026582 A 0.060 0.011 2.3E-08 0.0017 33.2 
IDL.C rs629301 1 109818306 T 0.127 0.012 7.5E-24 0.0055 105.7 
IDL.C rs635634 9 136155000 T 0.083 0.013 2.1E-10 0.0022 42.4 
IDL.C rs6511721 19 11206575 A 
-
0.086 0.011 1.9E-14 0.0037 71.9 
IDL.C rs6663252 1 55630151 C 
-
0.091 0.012 5E-13 0.0029 55.1 
IDL.C rs6732011 2 21146521 T 
-
0.074 0.011 3.6E-12 0.0026 50.3 
IDL.C rs6756629 2 44065090 A 
-
0.129 0.019 1.7E-11 0.0025 47.8 
IDL.C rs6859 19 45382034 G 
-
0.071 0.010 1.1E-11 0.0025 49.1 
IDL.C rs7255743 19 46018119 A 
-
0.181 0.033 4.6E-08 0.0018 34.2 
IDL.C rs72740818 15 58654303 C 0.058 0.010 4.4E-08 0.0017 32.0 
IDL.C rs73048351 19 45160086 A 
-
0.377 0.064 8.5E-09 0.0025 48.1 
IDL.C rs73556990 19 44888175 G 
-
0.329 0.052 6.4E-10 0.0036 51.6 
IDL.C rs74073060 1 55638930 A 
-
0.487 0.037 6.7E-38 0.0101 197.0 
IDL.C rs7412 19 45412079 T 
-
0.533 0.026 5.1E-92 0.0298 490.8 
IDL.C rs75647206 1 56947591 T 
-
0.379 0.050 7.9E-14 0.0038 72.9 
IDL.C rs7604788 2 21190024 T 
-
0.189 0.022 3.8E-17 0.0041 80.1 
IDL.C rs76488675 1 56885874 G 
-
0.147 0.024 1.1E-09 0.0024 46.6 
IDL.C rs76670936 19 45196581 A 
-
0.142 0.019 2.1E-13 0.0033 63.0 
IDL.C rs7786322 7 21592766 T 0.070 0.012 9E-09 0.0018 35.1 
IDL.C rs78620068 2 21524000 A 
-
0.131 0.019 4.7E-12 0.0027 52.3 
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IDL.C rs79225634 5 74619639 T 0.090 0.011 2.5E-16 0.0037 71.5 
IDL.C rs79668907 19 11257169 T 
-
0.084 0.013 1.1E-10 0.0026 50.6 
IDL.C rs79890446 19 45723446 T 
-
0.238 0.033 1.3E-12 0.0035 67.8 
IDL.C rs8106814 19 45441608 C 
-
0.095 0.014 9.4E-11 0.0031 59.6 
IDL.C rs952275 2 21221399 G 0.109 0.010 3.6E-25 0.0058 112.4 
XS.VLDL.TG rs11076176 16 57007446 G 0.090 0.014 8.7E-10 0.0022 42.0 
XS.VLDL.TG rs11096689 2 21140540 T 
-
0.097 0.012 1.6E-16 0.0037 71.6 
XS.VLDL.TG rs113531395 17 4886829 T 
-
0.215 0.036 5.3E-09 0.0024 45.6 
XS.VLDL.TG rs115849089 8 19912370 A 
-
0.156 0.017 3.4E-19 0.0044 86.0 
XS.VLDL.TG rs116802199 17 4801101 C 
-
0.197 0.032 1.1E-09 0.0022 40.7 
XS.VLDL.TG rs1168041 1 62960250 C 0.094 0.012 4E-15 0.0035 67.2 
XS.VLDL.TG rs1260326 2 27730940 C 
-
0.081 0.011 6.6E-14 0.0030 58.8 
XS.VLDL.TG rs1268353 11 116639692 T 
-
0.081 0.011 2.5E-14 0.0031 60.7 
XS.VLDL.TG rs12747477 1 55448248 A 
-
0.219 0.033 9.9E-11 0.0027 52.5 
XS.VLDL.TG rs138287365 4 74781004 C 0.313 0.049 3.9E-10 0.0026 50.3 
XS.VLDL.TG rs143413051 4 75560225 T 0.308 0.055 2.9E-08 0.0022 38.8 
XS.VLDL.TG rs143736900 4 72871285 C 0.593 0.082 1.3E-12 0.0044 73.5 
XS.VLDL.TG rs146695330 19 20139610 A 
-
0.215 0.035 1.5E-09 0.0027 48.0 
XS.VLDL.TG rs150536132 19 19679560 T 
-
0.181 0.030 1.8E-09 0.0028 49.2 
XS.VLDL.TG rs150617279 19 20139234 A 
-
0.118 0.017 1.9E-11 0.0027 52.7 
XS.VLDL.TG rs150785555 1 56005603 A 
-
0.229 0.036 3.2E-10 0.0023 44.8 
XS.VLDL.TG rs151007118 11 116583864 T 0.221 0.033 8.6E-11 0.0025 48.6 
XS.VLDL.TG rs151193598 4 73303394 A 0.531 0.086 9.5E-10 0.0043 61.2 
XS.VLDL.TG rs157594 19 45425175 G 0.111 0.012 1.1E-20 0.0060 116.0 
XS.VLDL.TG rs17216525 19 19662220 T 
-
0.143 0.021 1.4E-11 0.0025 47.9 
XS.VLDL.TG rs174418 15 58687603 C 
-
0.088 0.010 1.5E-16 0.0038 73.1 
XS.VLDL.TG rs181169081 2 21312870 A 
-
0.213 0.032 5.1E-11 0.0026 50.5 
XS.VLDL.TG rs181847072 4 73134560 G 0.595 0.082 6.8E-13 0.0045 75.4 
XS.VLDL.TG rs183162020 4 73690263 G 0.711 0.116 1.5E-09 0.0059 57.8 
XS.VLDL.TG rs183305631 19 19597444 A 
-
0.212 0.032 6.1E-11 0.0031 55.7 
XS.VLDL.TG rs1838504 15 58666410 T 0.069 0.010 7E-11 0.0024 46.3 
XS.VLDL.TG rs184650103 4 74850649 T 0.340 0.046 5.7E-13 0.0032 56.5 
XS.VLDL.TG rs1848922 2 21471603 C 0.093 0.013 4E-13 0.0029 56.6 
XS.VLDL.TG rs1883711 20 39179822 C 0.149 0.025 3.3E-09 0.0024 45.6 
XS.VLDL.TG rs188651594 11 116673091 A 0.267 0.042 5.5E-10 0.0025 45.2 
XS.VLDL.TG rs189741280 19 19624481 G 
-
0.188 0.030 5.5E-10 0.0026 50.2 
XS.VLDL.TG rs190121281 19 19252779 A 
-
0.210 0.033 2.3E-10 0.0030 53.0 
XS.VLDL.TG rs190217562 4 75180409 C 0.251 0.040 7.5E-10 0.0024 42.5 
XS.VLDL.TG rs191164477 2 21267593 T 
-
0.212 0.032 3.8E-11 0.0026 51.0 
XS.VLDL.TG rs193260502 11 116611138 A 0.216 0.038 2.6E-08 0.0023 44.1 
XS.VLDL.TG rs247617 16 56990716 A 
-
0.116 0.011 2.2E-23 0.0055 106.9 
XS.VLDL.TG rs261334 15 58726744 C 
-
0.118 0.012 2.9E-21 0.0050 96.3 
XS.VLDL.TG rs2878419 5 74640490 T 0.061 0.010 9E-09 0.0018 35.0 
XS.VLDL.TG rs2954029 8 126490972 T 
-
0.086 0.010 2.8E-16 0.0037 70.6 
XS.VLDL.TG rs34041051 19 45442349 C 0.067 0.011 8.9E-09 0.0021 39.7 
XS.VLDL.TG rs34346326 7 73016181 C 
-
0.076 0.014 3.6E-08 0.0017 31.9 
XS.VLDL.TG rs429358 19 45411941 C 0.108 0.014 1.7E-14 0.0033 63.1 
XS.VLDL.TG rs4609471 1 55493584 A 
-
0.173 0.030 1E-08 0.0023 45.0 
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XS.VLDL.TG rs58542926 19 19379549 T 
-
0.153 0.021 7.9E-13 0.0028 53.6 
XS.VLDL.TG rs62123892 2 21084445 T 
-
0.090 0.016 2.2E-08 0.0018 33.9 
XS.VLDL.TG rs6511720 19 11202306 T 
-
0.145 0.017 1.9E-16 0.0038 73.1 
XS.VLDL.TG rs6511721 19 11206575 A 
-
0.064 0.011 1.4E-08 0.0020 39.5 
XS.VLDL.TG rs6544366 2 21204025 T 
-
0.121 0.011 2.9E-25 0.0058 112.3 
XS.VLDL.TG rs7115242 11 116908283 G 
-
0.125 0.016 5E-15 0.0034 66.7 
XS.VLDL.TG rs72660594 1 55636240 C 
-
0.201 0.029 7.2E-12 0.0027 52.9 
XS.VLDL.TG rs74073060 1 55638930 A 
-
0.229 0.037 1.8E-09 0.0022 43.2 
XS.VLDL.TG rs77182215 11 116942366 A 0.165 0.029 1.6E-08 0.0019 37.6 
XS.VLDL.TG rs79202680 17 4692640 T 
-
0.217 0.035 7.9E-10 0.0023 44.9 
XS.VLDL.TG rs964184 11 116648917 C 
-
0.216 0.015 9.4E-49 0.0114 222.7 
S.VLDL.TG rs10401845 19 11191536 C 
-
0.078 0.013 5.2E-09 0.0018 38.2 
S.VLDL.TG rs1042034 2 21225281 T 0.105 0.011 1.3E-20 0.0042 91.0 
S.VLDL.TG rs111648015 8 19724434 T 
-
0.168 0.030 3.3E-08 0.0018 38.3 
S.VLDL.TG rs112030397 19 8582383 G 
-
0.082 0.014 8.4E-09 0.0017 35.8 
S.VLDL.TG rs113560866 11 117015189 C 0.082 0.014 1.3E-08 0.0017 37.5 
S.VLDL.TG rs115849089 8 19912370 A 
-
0.176 0.017 1.6E-25 0.0059 129.0 
S.VLDL.TG rs1168041 1 62960250 C 0.086 0.011 3.8E-14 0.0030 64.1 
S.VLDL.TG rs116843064 19 8429323 A 
-
0.211 0.035 2.5E-09 0.0025 48.9 
S.VLDL.TG rs117001569 8 19574920 G 
-
0.232 0.041 2.6E-08 0.0017 33.7 
S.VLDL.TG rs1240659 11 116493950 G 0.071 0.013 4.5E-08 0.0016 34.2 
S.VLDL.TG rs1260326 2 27730940 C 
-
0.099 0.010 6.2E-22 0.0046 98.8 
S.VLDL.TG rs1268353 11 116639692 T 
-
0.085 0.010 5.1E-17 0.0034 74.0 
S.VLDL.TG rs12997242 2 21381177 A 0.062 0.010 2.7E-09 0.0017 37.7 
S.VLDL.TG rs145106713 8 19942183 T 
-
0.257 0.042 2.3E-09 0.0020 38.8 
S.VLDL.TG rs150617279 19 20139234 A 
-
0.106 0.017 1.3E-09 0.0022 42.8 
S.VLDL.TG rs151007118 11 116583864 T 0.268 0.033 2.5E-15 0.0037 71.6 
S.VLDL.TG rs17216525 19 19662220 T 
-
0.137 0.020 1E-11 0.0023 49.5 
S.VLDL.TG rs188651594 11 116673091 A 0.312 0.042 3.1E-13 0.0035 61.8 
S.VLDL.TG rs2980853 8 126478350 C 
-
0.072 0.010 4.1E-13 0.0026 56.3 
S.VLDL.TG rs34346326 7 73016181 C 
-
0.113 0.014 1.1E-14 0.0031 67.0 
S.VLDL.TG rs36229786 16 56993901 C 0.086 0.014 1.3E-09 0.0020 43.0 
S.VLDL.TG rs3826688 19 45418961 C 0.090 0.011 1.4E-15 0.0035 76.5 
S.VLDL.TG rs429358 19 45411941 C 0.106 0.013 5.8E-15 0.0032 68.6 
S.VLDL.TG rs4341893 2 21135577 G 
-
0.066 0.010 4.7E-10 0.0019 41.1 
S.VLDL.TG rs5167 19 45448465 G 0.058 0.010 3.8E-08 0.0016 31.8 
S.VLDL.TG rs579674 11 116528224 G 0.081 0.013 2.8E-10 0.0020 43.7 
S.VLDL.TG rs6065904 20 44534651 A 0.076 0.012 1.6E-10 0.0020 43.8 
S.VLDL.TG rs61905067 11 116578982 G 0.235 0.039 2E-09 0.0021 45.5 
S.VLDL.TG rs7115242 11 116908283 G 
-
0.127 0.016 8.8E-16 0.0033 71.9 
S.VLDL.TG rs72836561 17 41926126 T 0.215 0.036 3.1E-09 0.0023 43.5 
S.VLDL.TG rs72999033 19 19366632 T 
-
0.155 0.021 3.4E-13 0.0027 57.8 
S.VLDL.TG rs77182215 11 116942366 A 0.205 0.029 1.6E-12 0.0030 58.3 
S.VLDL.TG rs7826306 8 19900671 C 
-
0.064 0.010 1.4E-09 0.0018 39.1 
S.VLDL.TG rs821840 16 56993886 G 
-
0.109 0.012 3.1E-20 0.0046 99.1 
S.VLDL.TG rs9472125 6 43756169 T 
-
0.095 0.016 5.6E-09 0.0025 48.6 
S.VLDL.TG rs964184 11 116648917 C 
-
0.242 0.014 7.6E-66 0.0140 305.7 
S.VLDL.C rs1042034 2 21225281 T 0.107 0.011 2.1E-21 0.0044 94.6 
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S.VLDL.C rs115849089 8 19912370 A 
-
0.125 0.017 1.6E-13 0.0030 64.4 
S.VLDL.C rs11591147 1 55505647 T 
-
0.338 0.035 1E-21 0.0068 109.3 
S.VLDL.C rs116054287 1 56401689 C 
-
0.242 0.038 2.7E-10 0.0022 46.6 
S.VLDL.C rs1168041 1 62960250 C 0.076 0.011 1.9E-11 0.0023 50.4 
S.VLDL.C rs118146573 16 57000938 A 0.120 0.017 2.5E-12 0.0025 53.9 
S.VLDL.C rs11881315 19 10909953 T 
-
0.074 0.013 1.2E-08 0.0016 35.1 
S.VLDL.C rs1260326 2 27730940 C 
-
0.074 0.010 7.6E-13 0.0025 54.5 
S.VLDL.C rs1268353 11 116639692 T 
-
0.066 0.010 5.4E-11 0.0021 45.2 
S.VLDL.C rs1367117 2 21263900 A 0.098 0.011 1E-18 0.0040 85.5 
S.VLDL.C rs138287365 4 74781004 C 0.301 0.049 1.5E-09 0.0024 46.5 
S.VLDL.C rs140339333 4 75396456 A 0.259 0.044 5.8E-09 0.0024 46.3 
S.VLDL.C rs142130958 19 11190652 A 
-
0.173 0.016 2.4E-25 0.0056 122.0 
S.VLDL.C rs143413051 4 75560225 T 0.345 0.055 4.3E-10 0.0027 48.6 
S.VLDL.C rs143736900 4 72871285 C 0.520 0.082 4.3E-10 0.0034 56.4 
S.VLDL.C rs146568567 1 54824117 A 
-
0.221 0.032 5.8E-12 0.0027 51.5 
S.VLDL.C rs150103689 1 56105434 G 
-
0.327 0.044 1.5E-13 0.0036 63.7 
S.VLDL.C rs150617279 19 20139234 A 
-
0.107 0.017 8.5E-10 0.0023 43.6 
S.VLDL.C rs151007118 11 116583864 T 0.214 0.033 2.4E-10 0.0024 45.8 
S.VLDL.C rs151193598 4 73303394 A 0.528 0.085 9.5E-10 0.0043 60.4 
S.VLDL.C rs157594 19 45425175 G 0.102 0.012 1.1E-17 0.0050 96.9 
S.VLDL.C rs17216525 19 19662220 T 
-
0.131 0.020 7.3E-11 0.0021 45.3 
S.VLDL.C rs17414716 1 55759138 G 
-
0.281 0.033 1.4E-17 0.0038 82.6 
S.VLDL.C rs181847072 4 73134560 G 0.522 0.082 2.6E-10 0.0035 57.9 
S.VLDL.C rs183162020 4 73690263 G 0.682 0.115 5.2E-09 0.0054 53.1 
S.VLDL.C rs183305631 19 19597444 A 
-
0.184 0.032 1.3E-08 0.0023 41.7 
S.VLDL.C rs184650103 4 74850649 T 0.346 0.046 1.6E-13 0.0033 58.6 
S.VLDL.C rs188357577 4 75417188 G 0.335 0.051 9.4E-11 0.0026 50.8 
S.VLDL.C rs188651594 11 116673091 A 0.254 0.042 3.1E-09 0.0023 40.8 
S.VLDL.C rs190934192 1 55334001 A 
-
0.250 0.040 6.7E-10 0.0029 56.5 
S.VLDL.C rs192570155 1 55246601 C 
-
0.325 0.045 9.3E-13 0.0037 66.4 
S.VLDL.C rs2980875 8 126481747 G 
-
0.067 0.010 1.8E-11 0.0022 47.9 
S.VLDL.C rs3005923 1 56801542 A 
-
0.222 0.036 1.5E-09 0.0026 50.9 
S.VLDL.C rs312030 2 21462743 C 0.110 0.018 5.4E-10 0.0020 43.4 
S.VLDL.C rs3764261 16 56993324 A 
-
0.103 0.011 4E-21 0.0044 95.4 
S.VLDL.C rs429358 19 45411941 C 0.138 0.013 2.2E-24 0.0054 116.6 
S.VLDL.C rs4609471 1 55493584 A 
-
0.251 0.030 8.4E-17 0.0049 94.3 
S.VLDL.C rs562338 2 21288321 G 0.083 0.013 9.7E-11 0.0021 44.8 
S.VLDL.C rs61905067 11 116578982 G 0.222 0.039 1.5E-08 0.0019 40.6 
S.VLDL.C rs62123892 2 21084445 T 
-
0.092 0.015 4.6E-09 0.0018 37.9 
S.VLDL.C rs646776 1 109818530 T 0.070 0.012 5.6E-09 0.0017 36.8 
S.VLDL.C rs6511721 19 11206575 A 
-
0.068 0.011 5.3E-10 0.0023 50.2 
S.VLDL.C rs6720307 2 20921334 C 
-
0.061 0.010 2.9E-09 0.0018 38.1 
S.VLDL.C rs7115242 11 116908283 G 
-
0.103 0.016 6.2E-11 0.0022 47.5 
S.VLDL.C rs72999033 19 19366632 T 
-
0.147 0.021 4.8E-12 0.0024 52.1 
S.VLDL.C rs74073060 1 55638930 A 
-
0.308 0.037 4E-16 0.0040 78.3 
S.VLDL.C rs7412 19 45412079 T 
-
0.235 0.025 6.6E-20 0.0058 107.2 
S.VLDL.C rs77021821 4 75684215 T 0.231 0.040 1.5E-08 0.0019 37.0 
S.VLDL.C rs79225634 5 74619639 T 0.078 0.010 1.7E-13 0.0027 58.9 
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S.VLDL.C rs964184 11 116648917 C 
-
0.188 0.014 2.3E-40 0.0084 183.7 
S.VLDL.C rs984976 5 74910870 G 0.071 0.010 1.4E-12 0.0025 53.7 
M.VLDL.TG rs1168001 1 62933758 A 0.072 0.011 2.6E-11 0.0022 46.5 
M.VLDL.TG rs116843064 19 8429323 A 
-
0.210 0.035 3.4E-09 0.0025 47.5 
M.VLDL.TG rs1260326 2 27730940 C 
-
0.095 0.010 6.8E-20 0.0041 88.1 
M.VLDL.TG rs1268353 11 116639692 T 
-
0.079 0.010 1E-14 0.0029 62.4 
M.VLDL.TG rs149611002 8 19986935 T 
-
0.248 0.042 6.4E-09 0.0022 42.0 
M.VLDL.TG rs150617279 19 20139234 A 
-
0.096 0.017 4.1E-08 0.0018 34.6 
M.VLDL.TG rs151007118 11 116583864 T 0.246 0.034 4.7E-13 0.0031 59.2 
M.VLDL.TG rs17120347 11 116996539 A 0.091 0.015 7.4E-10 0.0019 40.5 
M.VLDL.TG rs17216525 19 19662220 T 
-
0.120 0.020 2.6E-09 0.0018 37.5 
M.VLDL.TG rs188632579 11 116611098 C 0.256 0.046 3.7E-08 0.0017 33.6 
M.VLDL.TG rs188651594 11 116673091 A 0.277 0.043 1.2E-10 0.0027 47.6 
M.VLDL.TG rs34121855 7 73040814 G 
-
0.117 0.013 2E-18 0.0039 83.4 
M.VLDL.TG rs42121 7 72842267 T 
-
0.107 0.018 7.7E-09 0.0024 45.3 
M.VLDL.TG rs439401 19 45414451 C 0.080 0.011 1.2E-12 0.0027 57.8 
M.VLDL.TG rs579674 11 116528224 G 0.081 0.013 3.6E-10 0.0020 42.7 
M.VLDL.TG rs59007384 19 45396665 T 0.069 0.012 1.2E-08 0.0017 36.2 
M.VLDL.TG rs6065904 20 44534651 A 0.077 0.012 9.1E-11 0.0021 44.5 
M.VLDL.TG rs61905067 11 116578982 G 0.222 0.039 1.7E-08 0.0019 40.0 
M.VLDL.TG rs6586886 8 19875408 A 
-
0.058 0.010 2.4E-08 0.0016 33.1 
M.VLDL.TG rs673548 2 21237544 A 
-
0.080 0.011 2.4E-12 0.0024 51.1 
M.VLDL.TG rs7115242 11 116908283 G 
-
0.114 0.016 4.1E-13 0.0027 57.8 
M.VLDL.TG rs72999033 19 19366632 T 
-
0.138 0.021 9E-11 0.0021 45.4 
M.VLDL.TG rs77182215 11 116942366 A 0.205 0.029 2.4E-12 0.0030 56.7 
M.VLDL.TG rs77697917 17 41840849 T 0.209 0.037 2.8E-08 0.0020 37.7 
M.VLDL.TG rs79236614 8 19860460 G 
-
0.166 0.017 1.6E-21 0.0045 96.2 
M.VLDL.TG rs821840 16 56993886 G 
-
0.070 0.012 3.3E-09 0.0019 40.4 
M.VLDL.TG rs9472125 6 43756169 T 
-
0.091 0.016 2.6E-08 0.0023 43.9 
M.VLDL.TG rs964184 11 116648917 C 
-
0.228 0.014 2.4E-58 0.0124 266.9 
S.LDL.C rs10180633 2 21144829 T 
-
0.065 0.010 1.6E-10 0.0020 42.8 
S.LDL.C rs10402524 19 45329344 C 0.065 0.010 1.1E-09 0.0019 41.6 
S.LDL.C rs10424477 19 10636051 T 
-
0.072 0.011 5E-10 0.0023 48.9 
S.LDL.C rs111740198 19 44878217 A 
-
0.293 0.052 2.8E-08 0.0028 40.1 
S.LDL.C rs112635299 14 94838142 T 0.249 0.040 6.6E-10 0.0021 43.1 
S.LDL.C rs116054287 1 56401689 C 
-
0.364 0.038 1.9E-21 0.0049 105.8 
S.LDL.C rs117261169 19 45491032 T 
-
0.320 0.055 1.2E-08 0.0020 38.2 
S.LDL.C rs117569256 19 45423330 G 
-
0.734 0.107 1.3E-11 0.0054 73.3 
S.LDL.C rs11878174 19 45723379 C 0.070 0.012 3.2E-09 0.0024 46.4 
S.LDL.C rs12043403 1 55431933 C 
-
0.131 0.018 5.5E-13 0.0034 66.3 
S.LDL.C rs12086676 1 55738663 T 
-
0.071 0.013 3E-08 0.0015 33.4 
S.LDL.C rs1260326 2 27730940 C 
-
0.061 0.010 4.3E-09 0.0017 36.7 
S.LDL.C rs137992968 19 11239696 T 
-
0.195 0.034 1.3E-08 0.0017 36.0 
S.LDL.C rs138270540 4 75353427 C 0.219 0.036 1.8E-09 0.0023 44.6 
S.LDL.C rs138287365 4 74781004 C 0.357 0.049 7.9E-13 0.0034 65.4 
S.LDL.C rs140339333 4 75396456 A 0.260 0.044 5.4E-09 0.0024 46.5 
S.LDL.C rs140411770 19 45356517 A 
-
0.527 0.088 4E-09 0.0046 72.0 
S.LDL.C rs142130958 19 11190652 A 
-
0.207 0.016 7.8E-36 0.0081 175.8 
37 
 
S.LDL.C rs143413051 4 75560225 T 0.364 0.055 4.7E-11 0.0030 54.1 
S.LDL.C rs143736900 4 72871285 C 0.584 0.082 2.5E-12 0.0043 71.1 
S.LDL.C rs144064722 4 73406173 G 0.252 0.034 2.5E-13 0.0031 60.6 
S.LDL.C rs144721118 1 54196340 A 
-
0.249 0.040 5.4E-10 0.0029 55.2 
S.LDL.C rs146568567 1 54824117 A 
-
0.288 0.032 2.6E-19 0.0045 87.8 
S.LDL.C rs146982841 19 10771544 T 
-
0.223 0.036 9.4E-10 0.0023 41.6 
S.LDL.C rs147825223 19 45479553 C 0.165 0.028 1E-08 0.0020 36.0 
S.LDL.C rs148359521 2 21414212 T 
-
0.180 0.032 2.9E-08 0.0019 36.0 
S.LDL.C rs148382396 1 54639713 A 
-
0.364 0.051 1.9E-12 0.0038 61.1 
S.LDL.C rs149048538 19 45053024 A 
-
0.242 0.044 4.5E-08 0.0018 35.0 
S.LDL.C rs149844719 1 54519237 T 
-
0.172 0.028 1.2E-09 0.0021 44.9 
S.LDL.C rs149944945 1 56129361 G 
-
0.286 0.034 1.3E-16 0.0041 78.7 
S.LDL.C rs150785555 1 56005603 A 
-
0.435 0.036 1.9E-33 0.0084 163.3 
S.LDL.C rs150966173 19 45421204 T 0.222 0.039 1.5E-08 0.0020 38.2 
S.LDL.C rs150985779 19 45147992 T 
-
0.245 0.038 1.9E-10 0.0025 48.8 
S.LDL.C rs157594 19 45425175 G 0.130 0.012 6.3E-28 0.0082 158.9 
S.LDL.C rs17111503 1 55503448 G 0.072 0.013 4.3E-08 0.0017 36.6 
S.LDL.C rs17395160 1 55085141 G 
-
0.081 0.012 3.5E-11 0.0022 47.3 
S.LDL.C rs180961170 1 57012269 G 
-
0.349 0.052 2.9E-11 0.0034 60.1 
S.LDL.C rs181169081 2 21312870 A 
-
0.178 0.032 3.5E-08 0.0018 35.3 
S.LDL.C rs181594442 1 57006537 A 
-
0.348 0.052 3E-11 0.0034 60.0 
S.LDL.C rs181847072 4 73134560 G 0.581 0.082 2.1E-12 0.0043 71.8 
S.LDL.C rs182300850 1 54389320 C 
-
0.350 0.060 7.7E-09 0.0029 43.1 
S.LDL.C rs182318839 19 45747128 T 0.298 0.054 4E-08 0.0027 46.8 
S.LDL.C rs183162020 4 73690263 G 0.760 0.115 7E-11 0.0067 66.2 
S.LDL.C rs184566992 19 44887996 T 
-
0.318 0.052 1.5E-09 0.0030 47.7 
S.LDL.C rs184650103 4 74850649 T 0.396 0.046 3.5E-17 0.0043 76.6 
S.LDL.C rs185049786 4 74644512 C 0.336 0.053 3.9E-10 0.0034 65.8 
S.LDL.C rs185415345 1 56625395 A 
-
0.159 0.027 8.5E-09 0.0022 43.4 
S.LDL.C rs186538116 1 56840574 C 
-
0.405 0.045 3.2E-19 0.0055 97.8 
S.LDL.C rs189409600 19 45341066 T 
-
0.713 0.103 8.8E-12 0.0054 75.6 
S.LDL.C rs189718275 19 45063850 A 
-
0.256 0.044 9.3E-09 0.0021 39.8 
S.LDL.C rs190217562 4 75180409 C 0.300 0.040 1.7E-13 0.0034 60.4 
S.LDL.C rs190934192 1 55334001 A 
-
0.359 0.040 6.8E-19 0.0060 117.1 
S.LDL.C rs191404723 1 54636232 T 
-
0.365 0.051 1.5E-12 0.0036 62.1 
S.LDL.C rs191448950 1 55584844 A 
-
0.469 0.032 1E-48 0.0105 228.0 
S.LDL.C rs192012905 19 44463485 G 
-
0.308 0.053 7.5E-09 0.0024 42.9 
S.LDL.C rs192570155 1 55246601 C 
-
0.458 0.045 7.8E-24 0.0074 132.0 
S.LDL.C rs193084249 1 26987646 G 0.177 0.031 2.3E-08 0.0019 37.6 
S.LDL.C rs2007708 19 45410420 A 
-
0.798 0.104 3.4E-14 0.0050 91.6 
S.LDL.C rs207176 1 55791846 T 0.114 0.017 3.8E-11 0.0023 48.8 
S.LDL.C rs2479408 1 55504188 G 
-
0.082 0.014 2E-08 0.0019 41.5 
S.LDL.C rs2927472 19 45349369 C 0.124 0.018 5.6E-12 0.0028 59.9 
S.LDL.C rs2954027 8 126485294 A 
-
0.069 0.010 5.2E-12 0.0023 50.7 
S.LDL.C rs2965149 19 45190766 C 
-
0.066 0.011 8.1E-10 0.0020 43.7 
S.LDL.C rs2967668 19 45302951 G 
-
0.163 0.017 1.8E-21 0.0060 115.3 
S.LDL.C rs34042070 16 72101525 G 0.076 0.012 8.6E-10 0.0019 40.0 
S.LDL.C rs35913552 2 21272896 A 
-
0.115 0.014 9.2E-16 0.0032 70.0 
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S.LDL.C rs429358 19 45411941 C 0.220 0.013 1.2E-59 0.0136 297.6 
S.LDL.C rs4609471 1 55493584 A 
-
0.355 0.030 3.2E-32 0.0098 190.5 
S.LDL.C rs4614977 2 44087024 G 
-
0.130 0.018 3.2E-12 0.0024 51.9 
S.LDL.C rs4703667 5 74613906 C 0.090 0.010 2.6E-18 0.0039 84.6 
S.LDL.C rs4803748 19 45247048 T 
-
0.083 0.011 2.1E-14 0.0032 69.4 
S.LDL.C rs533617 2 21233972 C 
-
0.172 0.022 4E-15 0.0032 68.5 
S.LDL.C rs562556 1 55524237 A 0.082 0.013 6.7E-10 0.0019 41.7 
S.LDL.C rs61457016 19 41085400 G 
-
0.317 0.056 3.1E-08 0.0019 39.2 
S.LDL.C rs62117161 19 45233385 G 
-
0.178 0.020 9.2E-19 0.0041 87.7 
S.LDL.C rs62120794 2 21100426 T 
-
0.165 0.024 1.5E-11 0.0024 49.1 
S.LDL.C rs629301 1 109818306 T 0.123 0.012 2E-24 0.0052 112.8 
S.LDL.C rs6511721 19 11206575 A 
-
0.084 0.011 2.1E-14 0.0035 76.1 
S.LDL.C rs6663252 1 55630151 C 
-
0.078 0.012 2.2E-10 0.0020 44.2 
S.LDL.C rs6859 19 45382034 G 
-
0.070 0.010 1.6E-12 0.0025 53.3 
S.LDL.C rs73048351 19 45160086 A 
-
0.390 0.064 2.4E-09 0.0027 51.5 
S.LDL.C rs73556990 19 44888175 G 
-
0.295 0.052 2.8E-08 0.0029 41.4 
S.LDL.C rs74073060 1 55638930 A 
-
0.455 0.037 2E-33 0.0088 171.7 
S.LDL.C rs7412 19 45412079 T 
-
0.492 0.025 5.5E-83 0.0256 480.1 
S.LDL.C rs75647206 1 56947591 T 
-
0.349 0.050 5.2E-12 0.0032 61.8 
S.LDL.C rs76670936 19 45196581 A 
-
0.129 0.018 5.7E-12 0.0027 58.9 
S.LDL.C rs77021821 4 75684215 T 0.243 0.040 2.7E-09 0.0021 40.9 
S.LDL.C rs78620068 2 21524000 A 
-
0.116 0.017 4.2E-11 0.0023 48.6 
S.LDL.C rs79668907 19 11257169 T 
-
0.076 0.012 1.9E-09 0.0021 46.3 
S.LDL.C rs79890446 19 45723446 T 
-
0.219 0.033 6.2E-11 0.0030 57.3 
S.LDL.C rs8106814 19 45441608 C 
-
0.097 0.014 2.6E-11 0.0032 62.8 
S.LDL.C rs8111962 19 10915324 T 
-
0.087 0.014 5.7E-10 0.0019 41.7 
S.LDL.C rs934197 2 21267461 A 0.103 0.011 2.2E-20 0.0043 93.6 
S.LDL.C rs964184 11 116648917 C 
-
0.106 0.014 6.7E-14 0.0027 58.4 
S.LDL.C rs984976 5 74910870 G 0.078 0.010 1E-14 0.0030 63.9 
S.HDL.TG rs11076174 16 57003146 C 0.096 0.016 2.7E-09 0.0018 39.8 
S.HDL.TG rs11076176 16 57007446 G 0.133 0.014 1.9E-21 0.0049 106.7 
S.HDL.TG rs117241420 8 19770344 A 
-
0.247 0.041 2.3E-09 0.0020 37.9 
S.HDL.TG rs1260326 2 27730940 C 
-
0.069 0.010 3.6E-11 0.0022 46.8 
S.HDL.TG rs1268353 11 116639692 T 
-
0.083 0.010 2.2E-16 0.0033 71.1 
S.HDL.TG rs138287365 4 74781004 C 0.288 0.049 7.2E-09 0.0022 42.7 
S.HDL.TG rs140339333 4 75396456 A 0.248 0.044 2.4E-08 0.0022 42.6 
S.HDL.TG rs151007118 11 116583864 T 0.202 0.034 2.7E-09 0.0021 40.5 
S.HDL.TG rs151193598 4 73303394 A 0.511 0.086 3.6E-09 0.0040 56.5 
S.HDL.TG rs157594 19 45425175 G 0.079 0.012 2.7E-11 0.0030 58.7 
S.HDL.TG rs1800777 16 57017319 A 0.202 0.035 1.4E-08 0.0020 38.2 
S.HDL.TG rs1815786 11 116921390 C 
-
0.118 0.015 3.6E-14 0.0031 67.4 
S.HDL.TG rs183365738 4 72954415 A 0.524 0.082 2.1E-10 0.0035 58.5 
S.HDL.TG rs184650103 4 74850649 T 0.313 0.046 2.8E-11 0.0027 47.9 
S.HDL.TG rs1848922 2 21471603 C 0.074 0.012 1.4E-09 0.0019 40.5 
S.HDL.TG rs188651594 11 116673091 A 0.236 0.042 3.7E-08 0.0020 35.3 
S.HDL.TG rs190217562 4 75180409 C 0.240 0.040 3.6E-09 0.0022 38.8 
S.HDL.TG rs2954029 8 126490972 T 
-
0.074 0.010 8.5E-14 0.0028 59.9 
S.HDL.TG rs34356624 8 19903935 C 0.222 0.039 2.3E-08 0.0018 35.1 
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S.HDL.TG rs3764261 16 56993324 A 
-
0.148 0.011 3.6E-42 0.0092 199.9 
S.HDL.TG rs429358 19 45411941 C 0.100 0.013 1.5E-13 0.0028 61.5 
S.HDL.TG rs4296389 2 21142994 T 
-
0.077 0.011 5.1E-13 0.0026 55.4 
S.HDL.TG rs6065904 20 44534651 A 0.090 0.012 2.8E-14 0.0029 62.0 
S.HDL.TG rs6511720 19 11202306 T 
-
0.098 0.017 7.3E-09 0.0018 37.9 
S.HDL.TG rs6586886 8 19875408 A 
-
0.057 0.010 3.7E-08 0.0015 32.7 
S.HDL.TG rs6957745 7 73056750 C 
-
0.090 0.013 2.4E-11 0.0023 50.6 
S.HDL.TG rs79236614 8 19860460 G 
-
0.165 0.017 4.4E-21 0.0044 95.3 
S.HDL.TG rs9472125 6 43756169 T 
-
0.092 0.016 1.9E-08 0.0023 45.2 
S.HDL.TG rs964184 11 116648917 C 
-
0.199 0.014 1.2E-44 0.0094 204.8 
XL.HDL.C rs11076174 16 57003146 C 
-
0.093 0.016 7.1E-09 0.0017 36.8 
XL.HDL.C rs111543310 15 59531818 C 0.322 0.049 4.2E-11 0.0033 63.1 
XL.HDL.C rs112835635 15 59351989 G 0.218 0.035 7.6E-10 0.0022 43.6 
XL.HDL.C rs112884731 15 59504897 C 0.527 0.057 2.3E-20 0.0052 92.3 
XL.HDL.C rs112925355 15 59125988 A 0.210 0.029 3.6E-13 0.0027 57.8 
XL.HDL.C rs113298164 15 58855748 T 0.554 0.047 2E-31 0.0083 148.4 
XL.HDL.C rs116142092 15 59751872 T 0.378 0.050 7.6E-14 0.0033 59.7 
XL.HDL.C rs12708967 16 56993211 C 
-
0.100 0.013 1.4E-13 0.0028 59.7 
XL.HDL.C rs138690293 15 59310760 C 0.638 0.107 2.9E-09 0.0030 48.8 
XL.HDL.C rs139066754 20 44224606 A 
-
0.106 0.018 6E-09 0.0018 39.9 
XL.HDL.C rs142855631 15 59286876 T 0.652 0.108 1.7E-09 0.0030 49.3 
XL.HDL.C rs142887188 15 60132580 G 0.246 0.042 3.9E-09 0.0023 39.0 
XL.HDL.C rs146842281 15 59356659 T 0.148 0.022 1.8E-11 0.0025 48.5 
XL.HDL.C rs148527372 3 159734448 A 
-
0.554 0.095 5.7E-09 0.0026 39.8 
XL.HDL.C rs148902553 15 59776836 C 0.382 0.051 5E-14 0.0035 60.2 
XL.HDL.C rs1532624 16 57005479 A 0.127 0.010 1.1E-37 0.0079 170.7 
XL.HDL.C rs174547 11 61570783 C 
-
0.085 0.010 3.9E-17 0.0034 74.5 
XL.HDL.C rs17821274 15 58684478 C 
-
0.075 0.010 8.3E-13 0.0025 54.9 
XL.HDL.C rs17821298 15 58690738 A 0.066 0.012 2E-08 0.0016 33.5 
XL.HDL.C rs181412360 15 59158953 C 0.344 0.038 1.5E-19 0.0049 88.0 
XL.HDL.C rs182776276 15 59254589 G 0.549 0.060 5.7E-20 0.0051 88.4 
XL.HDL.C rs183975744 15 59052479 T 0.671 0.120 2.4E-08 0.0022 34.9 
XL.HDL.C rs185241689 15 59143155 G 0.756 0.114 3.8E-11 0.0034 55.6 
XL.HDL.C rs185481 15 58666679 C 0.058 0.010 1.7E-08 0.0017 35.9 
XL.HDL.C rs189375934 15 60196526 G 0.318 0.053 1.9E-09 0.0023 40.2 
XL.HDL.C rs189418461 15 59725202 G 0.375 0.050 6E-14 0.0034 59.9 
XL.HDL.C rs192630343 15 59286102 A 0.619 0.107 7.6E-09 0.0029 47.4 
XL.HDL.C rs1943973 18 47179516 A 0.087 0.013 1.3E-10 0.0020 42.4 
XL.HDL.C rs2070895 15 58723939 A 0.168 0.012 5.8E-47 0.0104 226.0 
XL.HDL.C rs2575876 9 107665739 A 
-
0.100 0.013 2.7E-15 0.0030 65.2 
XL.HDL.C rs261291 15 58680178 C 0.154 0.010 3.3E-51 0.0110 240.3 
XL.HDL.C rs34718390 15 58682690 A 0.153 0.024 1.1E-10 0.0027 58.9 
XL.HDL.C rs4810479 20 44545048 T 0.117 0.011 1.2E-25 0.0053 115.5 
XL.HDL.C rs60439253 15 58874532 T 0.230 0.028 4E-16 0.0036 72.5 
XL.HDL.C rs61803025 1 161600591 C 
-
0.104 0.019 1.9E-08 0.0021 41.5 
XL.HDL.C rs67053123 12 125353810 A 0.081 0.015 2.7E-08 0.0017 35.9 
XL.HDL.C rs686030 9 15304782 A 0.083 0.015 1.5E-08 0.0015 33.1 
XL.HDL.C rs76116860 15 59834938 C 0.265 0.041 1.2E-10 0.0025 47.8 
XL.HDL.C rs7873387 9 107595602 C 0.093 0.016 9.2E-09 0.0016 34.4 
XL.HDL.C rs79844529 15 58445279 T 0.182 0.032 1.3E-08 0.0022 41.6 
40 
 
M.VLDL.C rs10401845 19 11191536 C 
-
0.088 0.013 2.4E-11 0.0023 49.7 
M.VLDL.C rs1042034 2 21225281 T 0.109 0.011 4.9E-22 0.0045 97.4 
M.VLDL.C rs113560866 11 117015189 C 0.083 0.014 5.9E-09 0.0018 39.1 
M.VLDL.C rs115849089 8 19912370 A 
-
0.164 0.017 2.7E-22 0.0051 111.0 
M.VLDL.C rs1168041 1 62960250 C 0.094 0.011 1.4E-16 0.0035 76.1 
M.VLDL.C rs117001569 8 19574920 G 
-
0.238 0.041 1.1E-08 0.0018 35.3 
M.VLDL.C rs1260326 2 27730940 C 
-
0.094 0.010 5E-20 0.0041 89.1 
M.VLDL.C rs1268353 11 116639692 T 
-
0.087 0.010 8.2E-18 0.0036 77.4 
M.VLDL.C rs145106713 8 19942183 T 
-
0.252 0.042 4.2E-09 0.0019 37.3 
M.VLDL.C rs146695330 19 20139610 A 
-
0.203 0.035 8.3E-09 0.0024 43.0 
M.VLDL.C rs150536132 19 19679560 T 
-
0.192 0.030 1.4E-10 0.0031 55.3 
M.VLDL.C rs150617279 19 20139234 A 
-
0.128 0.017 1.8E-13 0.0032 62.6 
M.VLDL.C rs151007118 11 116583864 T 0.263 0.033 7.1E-15 0.0036 68.9 
M.VLDL.C rs17145738 7 72982874 T 
-
0.110 0.015 4.3E-13 0.0027 57.3 
M.VLDL.C rs17216525 19 19662220 T 
-
0.153 0.020 2.6E-14 0.0029 61.8 
M.VLDL.C rs183130 16 56991363 T 
-
0.105 0.012 2.4E-18 0.0045 83.3 
M.VLDL.C rs183305631 19 19597444 A 
-
0.212 0.032 4.7E-11 0.0031 55.6 
M.VLDL.C rs188651594 11 116673091 A 0.317 0.042 1.1E-13 0.0036 63.8 
M.VLDL.C rs189741280 19 19624481 G 
-
0.180 0.030 2.6E-09 0.0024 45.7 
M.VLDL.C rs190121281 19 19252779 A 
-
0.196 0.033 2.6E-09 0.0026 46.0 
M.VLDL.C rs2954021 8 126482077 G 
-
0.069 0.010 2.8E-12 0.0024 51.4 
M.VLDL.C rs36229786 16 56993901 C 0.079 0.014 1.9E-08 0.0017 36.7 
M.VLDL.C rs3826688 19 45418961 C 0.092 0.011 2.2E-16 0.0037 80.4 
M.VLDL.C rs3846661 5 74639178 G 0.066 0.010 9E-11 0.0021 45.3 
M.VLDL.C rs429358 19 45411941 C 0.111 0.013 3.4E-16 0.0034 74.5 
M.VLDL.C rs579674 11 116528224 G 0.078 0.013 9.8E-10 0.0019 40.8 
M.VLDL.C rs61905067 11 116578982 G 0.239 0.039 1.1E-09 0.0022 46.9 
M.VLDL.C rs6586891 8 19914598 A 
-
0.065 0.010 8.1E-10 0.0018 39.9 
M.VLDL.C rs7115242 11 116908283 G 
-
0.117 0.016 8.9E-14 0.0028 61.5 
M.VLDL.C rs71480307 11 116516873 A 0.084 0.015 2.7E-08 0.0016 34.8 
M.VLDL.C rs72660594 1 55636240 C 
-
0.175 0.029 1.8E-09 0.0021 40.2 
M.VLDL.C rs72836561 17 41926126 T 0.208 0.036 9.9E-09 0.0021 40.4 
M.VLDL.C rs72999033 19 19366632 T 
-
0.176 0.021 1E-16 0.0035 74.8 
M.VLDL.C rs7533354 1 63217503 C 
-
0.082 0.015 3E-08 0.0016 33.5 
M.VLDL.C rs7575840 2 21273490 T 0.074 0.011 1.9E-11 0.0023 50.0 
M.VLDL.C rs77182215 11 116942366 A 0.206 0.029 1.2E-12 0.0030 58.6 
M.VLDL.C rs964184 11 116648917 C 
-
0.234 0.014 8.7E-62 0.0130 284.8 
M.VLDL.C rs984976 5 74910870 G 0.063 0.010 3.5E-10 0.0019 41.9 
L.VLDL.C rs10889331 1 62943007 T 0.086 0.012 3.8E-13 0.0032 55.9 
L.VLDL.C rs117241420 8 19770344 A 
-
0.232 0.041 2.2E-08 0.0017 32.9 
L.VLDL.C rs1260326 2 27730940 C 
-
0.089 0.010 8.5E-18 0.0037 78.1 
L.VLDL.C rs1268353 11 116639692 T 
-
0.073 0.010 8.6E-13 0.0025 53.3 
L.VLDL.C rs150617279 19 20139234 A 
-
0.109 0.017 4.7E-10 0.0023 44.6 
L.VLDL.C rs151007118 11 116583864 T 0.256 0.034 5E-14 0.0034 64.2 
L.VLDL.C rs17120347 11 116996539 A 0.091 0.015 6.2E-10 0.0019 40.9 
L.VLDL.C rs17216525 19 19662220 T 
-
0.134 0.020 3.1E-11 0.0022 46.8 
L.VLDL.C rs181583353 11 39151067 G 0.249 0.044 2.4E-08 0.0024 41.5 
L.VLDL.C rs188651594 11 116673091 A 0.289 0.043 2.1E-11 0.0029 51.5 
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L.VLDL.C rs191238346 11 39167052 A 0.247 0.044 2.9E-08 0.0023 40.6 
L.VLDL.C rs2001945 8 126477978 C 
-
0.058 0.010 7E-09 0.0017 35.2 
L.VLDL.C rs34482346 7 72915521 C 
-
0.128 0.015 1.4E-16 0.0035 74.5 
L.VLDL.C rs4296389 2 21142994 T 
-
0.074 0.011 4.1E-12 0.0024 50.4 
L.VLDL.C rs438811 19 45416741 T 0.094 0.012 1.8E-14 0.0032 67.5 
L.VLDL.C rs579674 11 116528224 G 0.088 0.013 1E-11 0.0024 50.4 
L.VLDL.C rs7115242 11 116908283 G 
-
0.092 0.016 5.1E-09 0.0018 37.5 
L.VLDL.C rs71480307 11 116516873 A 0.083 0.015 4E-08 0.0016 33.8 
L.VLDL.C rs72999033 19 19366632 T 
-
0.150 0.021 2.3E-12 0.0025 53.2 
L.VLDL.C rs76975037 8 19851508 A 
-
0.148 0.018 6.4E-17 0.0035 74.2 
L.VLDL.C rs77182215 11 116942366 A 0.200 0.029 7.1E-12 0.0029 54.2 
L.VLDL.C rs821840 16 56993886 G 
-
0.092 0.012 6.1E-15 0.0033 70.3 
L.VLDL.C rs9472125 6 43756169 T 
-
0.093 0.016 1.4E-08 0.0024 45.5 
L.VLDL.C rs964184 11 116648917 C 
-
0.214 0.014 2.7E-51 0.0109 233.8 
L.VLDL.TG rs10455872 6 161010118 G 
-
0.165 0.028 5.4E-09 0.0021 40.6 
L.VLDL.TG rs10889360 1 63173918 T 
-
0.064 0.011 3E-08 0.0016 33.7 
L.VLDL.TG rs1260326 2 27730940 C 
-
0.094 0.010 9.8E-20 0.0041 87.3 
L.VLDL.TG rs1268353 11 116639692 T 
-
0.068 0.010 3E-11 0.0022 46.0 
L.VLDL.TG rs13030345 2 28003174 T 0.070 0.013 4.2E-08 0.0015 32.6 
L.VLDL.TG rs145106713 8 19942183 T 
-
0.243 0.044 3.4E-08 0.0018 32.6 
L.VLDL.TG rs151007118 11 116583864 T 0.226 0.034 3.4E-11 0.0026 49.6 
L.VLDL.TG rs16996148 19 19658472 T 
-
0.123 0.020 6.9E-10 0.0019 40.4 
L.VLDL.TG rs17120347 11 116996539 A 0.086 0.015 4.8E-09 0.0017 36.6 
L.VLDL.TG rs17411024 8 19852134 A 
-
0.154 0.018 9.6E-18 0.0038 78.0 
L.VLDL.TG rs188651594 11 116673091 A 0.241 0.043 2.3E-08 0.0020 35.8 
L.VLDL.TG rs34346326 7 73016181 C 
-
0.110 0.013 9.4E-17 0.0035 74.1 
L.VLDL.TG rs4350231 1 62922660 A 
-
0.071 0.011 5.5E-11 0.0021 45.2 
L.VLDL.TG rs438811 19 45416741 T 0.090 0.012 2.9E-13 0.0029 61.2 
L.VLDL.TG rs579674 11 116528224 G 0.078 0.013 1.4E-09 0.0019 39.9 
L.VLDL.TG rs7115242 11 116908283 G 
-
0.099 0.016 3.9E-10 0.0020 43.0 
L.VLDL.TG rs72999033 19 19366632 T 
-
0.133 0.021 4.6E-10 0.0020 41.9 
L.VLDL.TG rs77182215 11 116942366 A 0.202 0.029 4.3E-12 0.0029 55.3 
L.VLDL.TG rs9472125 6 43756169 T 
-
0.091 0.016 3.1E-08 0.0023 43.4 
L.VLDL.TG rs964184 11 116648917 C 
-
0.206 0.014 7E-48 0.0101 217.5 
XL.VLDL.TG rs10455872 6 161010118 G 
-
0.181 0.028 1.2E-10 0.0026 49.3 
XL.VLDL.TG rs1168041 1 62960250 C 0.084 0.011 1E-13 0.0028 61.2 
XL.VLDL.TG rs1260326 2 27730940 C 
-
0.093 0.010 1.4E-19 0.0040 86.3 
XL.VLDL.TG rs1268353 11 116639692 T 
-
0.057 0.010 1.2E-08 0.0016 33.7 
XL.VLDL.TG rs13234157 7 72971728 A 
-
0.111 0.015 3.2E-13 0.0027 58.5 
XL.VLDL.TG rs151007118 11 116583864 T 0.209 0.033 5E-10 0.0023 43.7 
XL.VLDL.TG rs17120347 11 116996539 A 0.082 0.014 1.8E-08 0.0016 33.8 
XL.VLDL.TG rs17216525 19 19662220 T 
-
0.129 0.021 9.2E-10 0.0019 40.1 
XL.VLDL.TG rs17411024 8 19852134 A 
-
0.125 0.017 8.2E-13 0.0025 54.1 
XL.VLDL.TG rs181583353 11 39151067 G 0.242 0.044 4.6E-08 0.0022 39.8 
XL.VLDL.TG rs186696265 6 161111700 T 
-
0.326 0.057 1.9E-08 0.0020 35.1 
XL.VLDL.TG rs4296389 2 21142994 T 
-
0.059 0.011 2.4E-08 0.0015 32.5 
XL.VLDL.TG rs438811 19 45416741 T 0.081 0.013 5E-10 0.0023 44.6 
XL.VLDL.TG rs579674 11 116528224 G 0.081 0.013 2.6E-10 0.0020 43.4 
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XL.VLDL.TG rs72999033 19 19366632 T 
-
0.144 0.022 1.3E-10 0.0021 45.3 
XL.VLDL.TG rs77182215 11 116942366 A 0.182 0.029 3.1E-10 0.0024 45.7 
XL.VLDL.TG rs964184 11 116648917 C 
-
0.179 0.014 7E-37 0.0076 165.4 
XXL.VLDL.TG rs10455872 6 161010118 G 
-
0.194 0.028 4.8E-12 0.0029 56.6 
XXL.VLDL.TG rs1168041 1 62960250 C 0.077 0.011 7.7E-12 0.0024 51.6 
XXL.VLDL.TG rs1260326 2 27730940 C 
-
0.093 0.010 8E-20 0.0040 87.2 
XXL.VLDL.TG rs1268353 11 116639692 T 
-
0.056 0.010 3.1E-08 0.0015 31.7 
XXL.VLDL.TG rs13233571 7 72971231 T 
-
0.094 0.015 6.4E-10 0.0019 41.4 
XXL.VLDL.TG rs151007118 11 116583864 T 0.201 0.033 2.1E-09 0.0021 40.5 
XXL.VLDL.TG rs17217098 19 19702384 A 
-
0.117 0.021 1.9E-08 0.0015 33.3 
XXL.VLDL.TG rs483082 19 45416178 T 0.097 0.012 1.2E-15 0.0034 72.9 
XXL.VLDL.TG rs72999033 19 19366632 T 
-
0.126 0.021 2.3E-09 0.0018 38.3 
XXL.VLDL.TG rs77182215 11 116942366 A 0.167 0.029 6.8E-09 0.0020 38.6 
XXL.VLDL.TG rs77729186 8 19826318 G 
-
0.116 0.017 9.5E-12 0.0022 48.5 
XXL.VLDL.TG rs821840 16 56993886 G 
-
0.065 0.012 2.2E-08 0.0017 35.9 
XXL.VLDL.TG rs964184 11 116648917 C 
-
0.153 0.014 1.8E-27 0.0056 120.6 
XL.HDL.TG rs11096689 2 21140540 T 
-
0.073 0.011 9.9E-11 0.0021 44.4 
XL.HDL.TG rs111543310 15 59531818 C 0.492 0.049 1.5E-23 0.0076 147.3 
XL.HDL.TG rs112835635 15 59351989 G 0.331 0.035 2.3E-20 0.0050 100.3 
XL.HDL.TG rs112884731 15 59504897 C 0.712 0.057 1.8E-35 0.0094 169.1 
XL.HDL.TG rs112925355 15 59125988 A 0.290 0.029 1.9E-23 0.0051 110.7 
XL.HDL.TG rs113298164 15 58855748 T 0.750 0.047 1.1E-55 0.0152 273.8 
XL.HDL.TG rs113531395 17 4886829 T 
-
0.204 0.036 2.4E-08 0.0021 41.0 
XL.HDL.TG rs114716552 15 58600902 G 
-
0.152 0.021 9E-13 0.0031 60.6 
XL.HDL.TG rs116142092 15 59751872 T 0.473 0.050 1.5E-20 0.0052 93.6 
XL.HDL.TG rs11632970 15 58837515 C 0.078 0.012 5.5E-10 0.0022 48.3 
XL.HDL.TG rs11638718 15 58079462 G 
-
0.071 0.012 7.4E-09 0.0016 35.0 
XL.HDL.TG rs116802199 17 4801101 C 
-
0.217 0.032 1.1E-11 0.0027 49.8 
XL.HDL.TG rs116869421 15 58709436 C 
-
0.360 0.051 4.1E-12 0.0034 66.0 
XL.HDL.TG rs117386336 15 58568077 T 0.218 0.039 3.3E-08 0.0018 35.6 
XL.HDL.TG rs117459981 15 58619066 C 
-
0.279 0.047 4.3E-09 0.0020 43.1 
XL.HDL.TG rs117597286 15 58587369 C 
-
0.260 0.036 1.3E-12 0.0030 57.2 
XL.HDL.TG rs117749052 15 58749309 C 0.276 0.037 1.6E-13 0.0044 85.0 
XL.HDL.TG rs117806344 15 58693213 T 
-
0.377 0.051 2.6E-13 0.0037 70.8 
XL.HDL.TG rs118078695 15 58686409 A 0.295 0.051 1.3E-08 0.0025 48.2 
XL.HDL.TG rs12442723 15 59458663 C 0.102 0.013 1.2E-15 0.0032 69.7 
XL.HDL.TG rs1268353 11 116639692 T 
-
0.061 0.010 2.3E-09 0.0017 37.5 
XL.HDL.TG rs12899090 15 59901576 G 0.096 0.015 5.8E-10 0.0028 54.8 
XL.HDL.TG rs1318175 15 58586129 T 
-
0.157 0.013 1.3E-32 0.0072 155.1 
XL.HDL.TG rs13329672 15 58699937 T 0.156 0.011 3.3E-41 0.0095 206.9 
XL.HDL.TG rs138195472 15 58672107 T 0.357 0.035 2.6E-24 0.0064 114.3 
XL.HDL.TG rs138690293 15 59310760 C 0.719 0.107 3.1E-11 0.0038 62.0 
XL.HDL.TG rs142538594 15 58192308 G 0.383 0.055 7E-12 0.0057 91.8 
XL.HDL.TG rs142855631 15 59286876 T 0.728 0.108 2.5E-11 0.0038 61.4 
XL.HDL.TG rs142887188 15 60132580 G 0.257 0.042 1.1E-09 0.0025 42.5 
XL.HDL.TG rs144149061 15 58500098 T 0.838 0.131 2.3E-10 0.0049 66.7 
XL.HDL.TG rs145347194 15 58670135 C 0.221 0.022 4.4E-23 0.0063 135.9 
XL.HDL.TG rs146842281 15 59356659 T 0.256 0.022 4.4E-31 0.0075 146.3 
XL.HDL.TG rs148828254 15 58571224 A 0.209 0.031 5.1E-11 0.0023 50.7 
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XL.HDL.TG rs148902553 15 59776836 C 0.477 0.050 8.5E-21 0.0055 94.2 
XL.HDL.TG rs150536132 19 19679560 T 
-
0.166 0.030 3.2E-08 0.0023 41.1 
XL.HDL.TG rs1532085 15 58683366 G 
-
0.264 0.010 9E-155 0.0336 748.0 
XL.HDL.TG rs1540037 18 47182664 G 0.092 0.012 7.9E-14 0.0029 63.3 
XL.HDL.TG rs16939881 15 58471979 C 0.315 0.028 1E-29 0.0084 164.1 
XL.HDL.TG rs1711062 15 58508790 C 
-
0.105 0.011 4.9E-22 0.0052 112.0 
XL.HDL.TG rs17231506 16 56994528 T 0.069 0.011 3.1E-10 0.0020 43.2 
XL.HDL.TG rs181412360 15 59158953 C 0.483 0.038 1.1E-36 0.0097 174.4 
XL.HDL.TG rs181450801 15 59326120 A 0.463 0.076 1.9E-09 0.0031 58.6 
XL.HDL.TG rs181835401 1 63135955 A 
-
0.090 0.011 4.4E-15 0.0031 67.2 
XL.HDL.TG rs182776276 15 59254589 G 0.732 0.060 5.7E-34 0.0091 157.9 
XL.HDL.TG rs182785673 15 58073964 T 
-
0.466 0.076 1.3E-09 0.0028 50.4 
XL.HDL.TG rs183276229 15 58742906 C 0.310 0.035 6.3E-18 0.0046 81.3 
XL.HDL.TG rs183975744 15 59052479 T 0.803 0.120 3.4E-11 0.0032 50.0 
XL.HDL.TG rs185241689 15 59143155 G 0.836 0.114 3.8E-13 0.0042 68.1 
XL.HDL.TG rs185533289 15 58782289 C 
-
0.307 0.055 3.5E-08 0.0019 32.2 
XL.HDL.TG rs186603838 15 58865534 A 0.166 0.030 4E-08 0.0018 31.5 
XL.HDL.TG rs188131745 15 58553702 A 
-
0.464 0.079 6.2E-09 0.0027 51.3 
XL.HDL.TG rs189375934 15 60196526 G 0.429 0.053 8.4E-16 0.0042 73.1 
XL.HDL.TG rs189418461 15 59725202 G 0.470 0.050 9.9E-21 0.0053 94.0 
XL.HDL.TG rs190121281 19 19252779 A 
-
0.196 0.033 2.7E-09 0.0026 46.0 
XL.HDL.TG rs190548956 15 59985051 A 0.266 0.042 3.8E-10 0.0023 43.9 
XL.HDL.TG rs191448950 1 55584844 A 
-
0.217 0.032 1.3E-11 0.0022 48.4 
XL.HDL.TG rs192060595 15 58907990 C 0.329 0.057 9.8E-09 0.0025 43.1 
XL.HDL.TG rs192630343 15 59286102 A 0.709 0.107 5.1E-11 0.0038 62.3 
XL.HDL.TG rs192924868 15 59231939 C 0.115 0.021 3.1E-08 0.0020 37.9 
XL.HDL.TG rs193092110 15 58730460 A 0.303 0.035 2.8E-17 0.0044 77.7 
XL.HDL.TG rs1998013 1 55958030 T 
-
0.230 0.035 1.1E-10 0.0022 48.1 
XL.HDL.TG rs2044332 15 58646641 A 0.122 0.014 8.2E-17 0.0038 81.5 
XL.HDL.TG rs2070895 15 58723939 A 0.302 0.012 3E-148 0.0337 749.9 
XL.HDL.TG rs2217970 15 60090978 A 
-
0.130 0.019 3.8E-11 0.0025 49.2 
XL.HDL.TG rs2414585 15 58785756 G 
-
0.308 0.048 1.6E-10 0.0028 54.5 
XL.HDL.TG rs2642636 15 58363242 G 
-
0.072 0.010 3.7E-12 0.0024 52.5 
XL.HDL.TG rs28370984 15 58629308 C 0.344 0.032 9.9E-27 0.0066 127.5 
XL.HDL.TG rs28601761 8 126500031 G 
-
0.068 0.010 1.8E-11 0.0023 49.2 
XL.HDL.TG rs2881925 2 20390694 A 
-
0.056 0.010 1.4E-08 0.0016 34.0 
XL.HDL.TG rs2932196 15 57912338 T 0.056 0.010 2.5E-08 0.0015 32.4 
XL.HDL.TG rs34101191 15 58793567 A 0.075 0.010 1.4E-12 0.0028 59.8 
XL.HDL.TG rs35138338 15 58744481 T 
-
0.089 0.013 3E-11 0.0033 70.4 
XL.HDL.TG rs35684611 15 58721302 G 
-
0.138 0.014 2.4E-21 0.0047 100.8 
XL.HDL.TG rs426684 15 58662280 T 0.066 0.010 4.1E-11 0.0022 47.3 
XL.HDL.TG rs439401 19 45414451 C 0.086 0.011 1.3E-14 0.0032 68.3 
XL.HDL.TG rs4775039 15 58670897 G 0.160 0.011 1.4E-45 0.0129 280.9 
XL.HDL.TG rs479084 15 58666087 G 
-
0.120 0.010 1.1E-29 0.0067 145.7 
XL.HDL.TG rs490098 15 58691225 A 
-
0.179 0.013 1.9E-42 0.0093 202.4 
XL.HDL.TG rs4939873 18 47062054 T 0.133 0.023 1.4E-08 0.0017 36.4 
XL.HDL.TG rs55817218 15 58562006 A 
-
0.170 0.020 6.2E-17 0.0041 88.9 
XL.HDL.TG rs55861554 15 58761235 C 0.067 0.011 6.3E-10 0.0020 43.5 
XL.HDL.TG rs56296027 2 21134011 C 
-
0.062 0.011 3.2E-08 0.0015 32.7 
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XL.HDL.TG rs572107 15 59055810 C 
-
0.069 0.010 5.2E-11 0.0022 46.9 
XL.HDL.TG rs61999891 15 58299599 A 0.122 0.017 3.5E-12 0.0030 58.9 
XL.HDL.TG rs62001693 15 58614892 A 
-
0.221 0.034 1.3E-10 0.0028 59.5 
XL.HDL.TG rs6589592 11 116957907 G 
-
0.105 0.016 2E-11 0.0023 50.6 
XL.HDL.TG rs7178935 15 59368167 A 0.064 0.011 1E-08 0.0016 34.6 
XL.HDL.TG rs72739708 15 57733779 T 0.114 0.021 5E-08 0.0015 32.3 
XL.HDL.TG rs73424577 15 58869185 G 0.305 0.028 5.5E-27 0.0064 128.9 
XL.HDL.TG rs73959582 18 47148886 C 0.097 0.014 2.4E-11 0.0024 52.5 
XL.HDL.TG rs74073060 1 55638930 A 
-
0.218 0.037 8.1E-09 0.0020 39.1 
XL.HDL.TG rs74537322 15 58342102 G 
-
0.406 0.065 7.2E-10 0.0028 49.6 
XL.HDL.TG rs75870978 15 58177266 G 0.391 0.066 4.6E-09 0.0055 60.8 
XL.HDL.TG rs76116860 15 59834938 C 0.339 0.041 3.1E-16 0.0040 78.2 
XL.HDL.TG rs76212899 15 58263295 G 
-
0.157 0.027 5.2E-09 0.0022 42.6 
XL.HDL.TG rs76438892 15 58687932 G 
-
0.271 0.047 1.1E-08 0.0018 35.7 
XL.HDL.TG rs78321025 15 58108078 A 0.248 0.034 9.6E-13 0.0035 67.9 
XL.HDL.TG rs79202680 17 4692640 T 
-
0.242 0.035 5.2E-12 0.0029 55.8 
XL.HDL.TG rs8025975 15 59696602 G 0.097 0.015 4.2E-10 0.0021 44.8 
XL.HDL.TG rs8042174 15 58685970 C 
-
0.206 0.020 6.8E-25 0.0059 128.8 
XL.HDL.TG rs8043310 15 58731818 A 0.360 0.039 1.2E-19 0.0050 96.6 
XL.HDL.TG rs8100204 19 19393714 A 
-
0.096 0.016 4.3E-09 0.0021 44.9 
XL.HDL.TG rs935202 15 58457569 A 0.083 0.011 1.1E-14 0.0031 67.2 
XL.HDL.TG rs938507 15 58582034 A 0.139 0.014 6.8E-22 0.0045 97.2 
XL.HDL.TG rs964184 11 116648917 C 
-
0.155 0.014 1.1E-27 0.0057 123.4 





Supplementary Table 5. Genetic instruments for lipid drug targets, as selected and extracted 
from Global Lipids Genetics Consortium (GLGC) GWAS dataset. 
Phenotype  Target Proxy treatment SNP Chr 
Position 
(hg18) Eff_allele Effect SE 
P-
value R2 F 
HDL-C CETP CETP inhibitors rs12446867 16 57052901 G 0.034 0.004 1.8E-16 0.0005 84.0 
HDL-C CETP CETP inhibitors rs12448528 16 56985555 G 0.199 0.005 
2.1E-
344 0.0139 2577.3 
HDL-C CETP CETP inhibitors rs12597002 16 57002404 C 0.085 0.004 
1.1E-
102 0.0029 535.4 
HDL-C CETP CETP inhibitors rs12720917 16 57019392 C 0.098 0.006 5.9E-68 0.0023 407.0 
HDL-C CETP CETP inhibitors rs12928552 16 57048707 G 0.050 0.008 2.2E-09 0.0002 35.6 
HDL-C CETP CETP inhibitors rs13306673 16 56900931 C 0.098 0.006 2.8E-48 0.0016 288.0 
HDL-C CETP CETP inhibitors rs13306677 16 56926195 A 0.090 0.006 1.4E-50 0.0014 268.4 
HDL-C CETP CETP inhibitors rs1566439 16 57024662 C 0.027 0.004 3.5E-15 0.0004 67.9 
HDL-C CETP CETP inhibitors rs16963520 16 56936563 A 0.071 0.007 3.1E-25 0.0014 130.7 
HDL-C CETP CETP inhibitors rs17290922 16 57024317 G 0.055 0.008 3.4E-13 0.0006 58.9 
HDL-C CETP CETP inhibitors rs17370142 16 57050348 T 0.034 0.006 1.2E-11 0.0002 43.8 
HDL-C CETP CETP inhibitors rs1864163 16 56997233 G 0.225 0.004 
3.6E-
573 0.0198 3745.5 
HDL-C CETP CETP inhibitors rs1875236 16 57033696 A 0.059 0.007 1.4E-18 0.0006 113.9 
HDL-C CETP CETP inhibitors rs247615 16 56984763 A 0.076 0.004 2.9E-62 0.0020 371.2 
HDL-C CETP CETP inhibitors rs247616 16 56989590 T 0.243 0.004 
1.2E-
802 0.0245 4650.2 
HDL-C CETP CETP inhibitors rs289719 16 57009941 T 0.113 0.004 
5.4E-
173 0.0056 1048.7 
HDL-C CETP CETP inhibitors rs289726 16 57074451 T 0.036 0.004 1.3E-22 0.0006 112.2 
HDL-C CETP CETP inhibitors rs289745 16 57019532 A 0.028 0.004 2.3E-20 0.0004 66.6 
HDL-C CETP CETP inhibitors rs4329913 16 56905432 C 0.041 0.006 1.4E-11 0.0006 54.1 
HDL-C CETP CETP inhibitors rs5883 16 57007353 T 0.115 0.008 1.8E-31 0.0015 254.0 
HDL-C CETP CETP inhibitors rs7188963 16 56931565 C 0.059 0.004 3.2E-39 0.0012 220.1 
HDL-C CETP CETP inhibitors rs7204290 16 56968039 G 0.030 0.004 1.5E-14 0.0004 71.4 
HDL-C CETP CETP inhibitors rs7499911 16 57036440 G 0.060 0.011 1.3E-08 0.0004 40.4 
HDL-C CETP CETP inhibitors rs9938160 16 56984590 C 0.060 0.005 3.2E-25 0.0014 125.6 
LDL-C HMGCR Statins rs10066707 5 74560579 A 0.050 0.005 3.0E-19 0.0012 108.1 
LDL-C HMGCR Statins rs10515198 5 74641560 A 0.060 0.006 6.0E-22 0.0007 114.7 
LDL-C HMGCR Statins rs3857388 5 74620377 C 0.042 0.006 2.2E-11 0.0004 68.5 
LDL-C HMGCR Statins rs7703051 5 74625487 A 0.073 0.004 1.4E-77 0.0026 443.6 
LDL-C NPC1L1 Ezetimibe rs2073547 7 44582331 G 0.049 0.005 1.9E-21 0.0007 125.0 
LDL-C NPC1L1 Ezetimibe rs217386 7 44600695 G 0.036 0.004 1.2E-19 0.0006 110.2 
LDL-C NPC1L1 Ezetimibe rs7798185 7 44570717 A 0.041 0.007 1.9E-09 0.0004 37.3 
LDL-C PCSK9 PCSK9 inhibitors rs10493176 1 55538552 T 0.078 0.010 2.5E-14 0.0012 105.4 
LDL-C PCSK9 PCSK9 inhibitors rs11206510 1 55496039 T 0.083 0.005 2.4E-53 0.0018 312.2 
LDL-C PCSK9 PCSK9 inhibitors rs11583974 1 55551718 A 0.065 0.012 4.0E-09 0.0002 24.5 
LDL-C PCSK9 PCSK9 inhibitors rs12067569 1 55528629 A 0.089 0.010 2.0E-17 0.0005 85.3 
LDL-C PCSK9 PCSK9 inhibitors rs2479394 1 55486064 G 0.039 0.004 1.6E-19 0.0006 105.1 
LDL-C PCSK9 PCSK9 inhibitors rs2479409 1 55504650 G 0.064 0.004 2.5E-50 0.0018 317.0 
LDL-C PCSK9 PCSK9 inhibitors rs2483205 1 55518316 C 0.051 0.005 4.7E-20 0.0013 102.6 
LDL-C PCSK9 PCSK9 inhibitors rs4927193 1 55509872 T 0.035 0.006 4.3E-11 0.0003 48.7 
LDL-C PCSK9 PCSK9 inhibitors rs502576 1 55512882 G 0.065 0.007 2.9E-22 0.0015 122.3 
LDL-C PCSK9 PCSK9 inhibitors rs585131 1 55524116 T 0.064 0.005 2.7E-35 0.0012 205.3 
LDL-C PCSK9 PCSK9 inhibitors rs7552841 1 55518752 T 0.037 0.004 5.4E-15 0.0006 88.1 
LDL-C ABCG5G8 Bile acid resins rs10208987 2 44043135 T 0.049 0.007 2.4E-12 0.0004 66.8 
LDL-C ABCG5G8 Bile acid resins rs1025447 2 44022970 C 0.042 0.005 3.8E-16 0.0005 80.2 
LDL-C ABCG5G8 Bile acid resins rs4148214 2 44079004 T 0.039 0.004 3.8E-25 0.0007 129.8 
LDL-C ABCG5G8 Bile acid resins rs4953023 2 44074000 G 0.131 0.007 1.7E-66 0.0027 454.5 
LDL-C ABCG5G8 Bile acid resins rs6544713 2 44073881 T 0.081 0.004 4.8E-83 0.0027 467.8 
LDL-C ABCG5G8 Bile acid resins rs75279593 2 44085035 A 0.074 0.012 1.4E-08 0.0005 42.7 
46 
 
LDL-C LDLR LDL receptor rs1010679 19 11207102 T 0.102 0.006 3.5E-54 0.0030 253.7 
LDL-C LDLR LDL receptor rs3786721 19 11146499 T 0.047 0.004 2.9E-31 0.0011 178.3 
LDL-C LDLR LDL receptor rs3786722 19 11161537 C 0.075 0.004 5.5E-63 0.0021 358.8 
LDL-C LDLR LDL receptor rs379309 19 11284302 C 0.031 0.004 1.4E-13 0.0005 81.8 
LDL-C LDLR LDL receptor rs5742911 19 11243445 A 0.061 0.006 4.8E-24 0.0014 111.9 
LDL-C LDLR LDL receptor rs5927 19 11233941 G 0.035 0.005 2.8E-13 0.0005 75.9 
LDL-C LDLR LDL receptor rs6511720 19 11202306 G 0.221 0.006 
3.8E-
262 0.0086 1479.6 





Supplementary Table 6. Power calculations for the Mendelian randomization analyses 
performed in the current study. 





Small vessel stroke WMH volume 
Intracerebral 
hemorrhage 
Sample   298,777 10,597 3,026 
Number of cases  11,710  1,545 
Blood lipid levels OR  beta (max / min) OR (max / min) 
HDL-C 12.4% ≤0.93 & ≥1.08 ≤-0.06 / ≥0.06 ≤0.75 / ≥1.33 
LDL-C 11.6% ≤0.93 / ≥1.08 ≤-0.07/ ≥0.07 ≤0.74 / ≥1.35 
TG 9.31% ≤0.92 / ≥1.09 ≤-0.09 / ≥0.09 ≤0.71 / ≥1.40 
Lipid drug targets c  
  
CETP 9.43% ≤0.92 / ≥1.09 ≤-0.09 / ≥0.09 ≤0.72 / ≥1.39 
HMGCR 0.48% ≤0.72 / ≥1.39 ≤-0.39 / ≥0.39 ≤0.25 / ≥3.97 
NPC1L1 0.18% ≤0.58 / ≥1.68 ≤-0.64 / ≥0.64 ≤0.12 / ≥8.03 
PCSK9 1.11% ≤0.79 / ≥1.26 ≤-0.26 / ≥0.26 ≤0.39 / ≥2.57 
ABCG5/G8 0.74% ≤0.76 / ≥1.31 ≤-0.32 / ≥0.32 ≤0.32 / ≥3.13 
LDLR 1.87% ≤0.83 / ≥1.20 ≤-0.20 / ≥0.20 ≤0.48 / ≥2.08 
PPARA - - - - 
ANGPTL3 0.21% ≤0.63 / ≥1.59 ≤-0.60 / ≥0.60 ≤0.14 / ≥7.09 
ANGPTL4 - - - - 
APOC3 2.25% ≤0.85 / ≥1.18 ≤-0.19 / ≥0.19 ≤0.51 / ≥1.95 




   
S.HDL.TG 8.89% ≤0.92 / ≥1.09 ≤-0.09 / ≥0.09 ≤0.71 / ≥1.41 
M.HDL.C 4.37% ≤0.88 / ≥1.13 ≤-0.13 / ≥0.13 ≤0.62 / ≥1.62 
L.HDL.C 21.5% ≤0.94 / ≥1.06 ≤-0.05 / ≥0.05 ≤0.81 / ≥1.25 
XL.HDL.C 13.9% ≤0.93 / ≥1.07 ≤-0.06 / ≥0.06 ≤0.76 / ≥1.32 
XL.HDL.TG 47.8% ≤0.96 / ≥1.04 ≤-0.04 / ≥0.04 ≤0.86 / ≥1.16 
S.LDL.C 35.9% ≤0.95 / ≥1.05 ≤-0.05 / ≥0.05 ≤0.84 / ≥1.19 
M.LDL.C 42.2% ≤0.95 / ≥1.05 ≤-0.04 / ≥0.04 ≤0.85 / ≥1.17 
L.LDL.C 45.7% ≤0.96 / ≥1.04 ≤-0.04 / ≥0.04 ≤0.86 / ≥1.16 
IDL.C 42.1% ≤0.95 / ≥1.05 ≤-0.04 / ≥0.04 ≤0.85 / ≥1.17 
IDL.TG 30.8% ≤0.95 / ≥1.05 ≤-0.05 / ≥0.05 ≤0.83 / ≥1.21 
XS.VLDL.TG 17.4% ≤0.93 / ≥1.07 ≤-0.06 / ≥0.06 ≤0.78 / ≥1.28 
S.VLDL.C 16.3% ≤0.93 / ≥1.07 ≤-0.06 / ≥0.06 ≤0.78 / ≥1.29 
S.VLDL.TG 10.8% ≤0.93 / ≥1.08 ≤-0.08 / ≥0.08 ≤0.73 / ≥1.37 
M.VLDL.C 11.6% ≤0.93 / ≥1.08 ≤-0.07 / ≥0.07 ≤0.74 / ≥1.35 
M.VLDL.TG 7.86% ≤0.91 / ≥1.10 ≤-0.10 / ≥0.10 ≤0.69 / ≥1.44 
L.VLDL.C 7.04% ≤0.91 / ≥1.10 ≤-0.11 / ≥0.11 ≤0.68 / ≥1.47 
L.VLDL.TG 5.49% ≤0.89 / ≥1.12 ≤-0.12 / ≥0.12 ≤0.65 / ≥1.54 
XL.VLDL.TG 4.40% ≤0.88 / ≥1.13 ≤-0.13 / ≥0.13 ≤0.62 / ≥1.62 
XXL.VLDL.TG 3.30% ≤0.87 / ≥1.15 ≤-0.15 / ≥0.15 ≤0.57 / ≥1.74 
Shown are the rages of associations estimates that could be detected with a power of 1-β>0.8 and at a statistical 
significance threshold of α<0.05. 
a 𝑅2 = (𝑏𝑒𝑡𝑎 𝑥 √2 𝑥 𝑀𝐴𝐹(1 − 𝑀𝐴𝐹))2, where MAF is the minimum allele frequency and beta is the effect of the SNP on 
the respective cytokine levels (Park et al 2010, Nat. Genet. 42, 570–575).  
b Odds Ratios are presented for the binary outcomes (small vessel stroke, intracerebral hemorrhage) and beta 
coefficients for the continuous outcomes (white matter hyperintensities volume).  
c The R2 for CETP, HMGCR, NPC1L1, PCSK9, ABCG5/G8, LDLR, PPARA, ANGPTL3, ANGPTL4, APOC3, and LPL 





Supplementary Table 7. Mendelian randomization (MR) association estimates of cholesterol and 
triglyceride concentrations across lipoprotein particles with small vessel stroke and WMH volume. Shown 
are the results derived from IVW MR analyses. 
 Small vessel stroke  WMH volume 
Outcome SNPs (N) OR (95%CI) p-value p-het  SNPs (N) beta (95%CI) p-value p-het 
Cholesterol in HDL particles    
M.HDL.C 8 0.84 (0.73-0.96) 0.007 0.183  10 -0.09 (-0.16 to -0.02) 0.009 0.232 
L.HDL.C 42 0.99 (0.94-1.05) 0.781 0.509  54 0.00 (-0.03 to 0.03) 0.930 0.443 
XL.HDL.C 30 0.98 (0.91-1.06) 0.646 0.044  36 0.00 (-0.04 to 0.04) 0.884 0.915 
Cholesterol in LDL and larger particles       
S.LDL.C 36 1.08 (1.02-1.15) 0.010 0.539  46 0.06 (0.02 to 0.11) 0.002 0.012 
M.LDL.C 36 1.07 (1.01-1.14) 0.030 0.716  49 0.06 (0.02 to 0.10) 0.002 0.027 
L.LDL.C 40 1.07 (1.01-1.13) 0.022 0.614  57 0.06 (0.02 to 0.09) 0.002 0.095 
IDL.C 42 1.08 (1.02-1.14) 0.008 0.589  42 0.05 (0.01 to 0.09) 0.008 0.027 
S.VLDL.C 26 1.08 (1.00-1.18) 0.057 0.186  31 0.05 (-0.01 to 0.10) 0.091 0.367 
M.VLDL.C 24 1.09 (1.01-1.19) 0.033 0.137  24 -0.01 (-0.07 to 0.06) 0.866 0.472 
L.VLDL.C 17 1.05 (0.95-1.16) 0.354 0.116  17 -0.05 (-0.12 to 0.03) 0.215 0.791 
Triglycerides in lipoprotein particles       
S.HDL.TG 25 1.14 (1.04-1.23) 0.003 0.175  31 -0.04 (-0.09 to 0.02) 0.200 0.018 
XL.HDL.TG 76 1.03 (0.99-1.07) 0.165 0.437  88 0.00 (-0.02 to 0.03) 0.744 0.846 
IDL.TG 41 1.07 (1.01-1.14) 0.027 0.685  41 0.02 (-0.02 to 0.06) 0.355 0.013 
XS.VLDL.TG 27 1.07 (0.99-1.15) 0.095 0.325  28 -0.02 (-0.07 to 0.04) 0.568 0.039 
S.VLDL.TG 26 1.08 (0.99-1.17) 0.074 0.164  26 -0.03 (-0.09 to 0.03) 0.264 0.177 
M.VLDL.TG 18 1.03 (0.94-1.14) 0.509 0.162  21 -0.03 (-0.10 to 0.05) 0.486 0.857 
L.VLDL.TG 15 1.04 (0.94-1.17) 0.432 0.029  15 -0.06 (-0.14 to 0.02) 0.131 0.663 
XL.VLDL.TG 12 1.01 (0.89-1.15) 0.829 0.108  14 -0.04 (-0.13 to 0.04) 0.315 0.878 
XXL.VLDL.TG 8 1.03 (0.89-1.21) 0.673 0.213  10 -0.04 (-0.14 to 0.06) 0.432 0.751 
 
Bold indicates p-values <0.05 after adjustment for false discovery rate (FDR). 
Odds Ratios correspond to 1 SD increment in the corresponding variable. P-het values correspond to the p-value of the Cochran’s Q 






Supplementary Table 8. Multivariable Mendelian randomization (MR) association 
estimates of cholesterol and triglyceride concentrations across lipoprotein particles with 
small vessel stroke and WMH volume. 
 Small vessel stroke  WMH volume 
Outcome OR (95%CI) p-value  beta (95%CI) p-value 
Cholesterol in HDL particles [adjusted for LDL-C and TG] 
M.HDL.C 0.83 (0.76-0.91) 4.3x10-5  -0.08 (-0.13 to -0.02) 0.008 
L.HDL.C 0.95 (0.90-1.00) 0.063  -0.03 (-0.07 to 0.01) 0.145 
XL.HDL.C 0.95 (0.89-1.01) 0.090  -0.02 (-0.07 to 0.02) 0.314 
Cholesterol in LDL and larger particles [adjusted for HDL-C and TG] 
S.LDL.C 1.11 (1.03-1.19) 0.004  0.02 (-0.02 to 0.06) 0.366 
M.LDL.C 1.11 (1.04-1.18) 0.002  0.02 (-0.02 to 0.06) 0.325 
L.LDL.C 1.11 (1.04-1.19) 0.001  0.02 (-0.02 to 0.06) 0.338 
IDL.C 1.11 (1.04-1.18) 0.001  0.02 (-0.02 to 0.05) 0.413 
S.VLDL.C 1.15 (1.04-1.26) 0.005  -0.01 (-0.07 to 0.05) 0.821 
M.VLDL.C 1.17 (1.02-1.35) 0.024  -0.05 (-0.14 to 0.05) 0.326 
L.VLDL.C 1.08 (0.90-1.30) 0.420  -0.11 (-0.23 to 0.00) 0.058 
TG in any lipoprotein particles [adjusted for HDL-C and LDL-C] 
S.HDL.TG 1.11 (1.02-1.22) 0.016  -0.06 (-0.12 to 0.00) 0.047 
XL.HDL.TG 1.07 (1.02-1.14) 0.010  -0.03 (-0.07 to 0.01) 0.132 
IDL.TG 1.09 (1.01-1.17) 0.018  -0.05 (-0.09 to 0.00) 0.051 
XS.VLDL.TG 1.07 (1.00-1.15) 0.052  -0.04 (-0.08 to 0.01) 0.117 
S.VLDL.TG 1.05 (0.97-1.13) 0.242  -0.04 (-0.09 to 0.00) 0.072 
M.VLDL.TG 1.04 (0.96-1.13) 0.362  -0.06 (-0.10 to -0.01) 0.030 
L.VLDL.TG 1.03 (0.94-1.12) 0.524  -0.05 (-0.11 to 0.00) 0.063 
XL.VLDL.TG 1.00 (0.91-1.09) 0.937  -0.06 (-0.11 to 0.00) 0.038 
XXL.VLDL.TG 1.02 (0.93-1.13) 0.646  -0.05 (-0.11 to 0.01) 0.117 
 
Bold indicates p-values <0.05 after adjustment for false discovery rate (FDR). 
Odds Ratios correspond to 1 SD increment in the corresponding variable. 
For the multivariable MR analyses we used a genetic score for HDL-C, LDL-C and larger particle 
cholesterol, and for TGT, by combining all unique instruments significantly associated with HDL-C or 
cholesterol concentrations in HDL particles, LDL-C or cholesterol concentrations in LDL and larger ApoB 




Supplementary Table 9. Mendelian randomization (MR) association estimates of cholesterol 
and triglyceride concentrations across lipoprotein particles with small vessel stroke and WMH 
volume, as derived from alternative MR methods in case of heterogeneity (p<0.10 in Cochran’s 
Q) in the IVW analysis. Shown are the results derived from weighed median and MR-Egger analyses. 
Small vessel stroke MR method OR SE 95%CI p-value 
XL.HDL.C IVW 0.96 0.062 0.85 1.09 0.537 
 Weighted median 1.02 0.068 0.90 1.17 0.731 
 MR Egger 0.95 0.212 0.63 1.44 0.812 
 Egger Intercept 1.00 0.023 0.96 1.05 0.952 
L.VLDL.TG IVW 1.05 0.077 0.90 1.22 0.536 
 Weighted median 1.01 0.079 0.86 1.18 0.910 
 MR Egger 1.13 0.206 0.76 1.69 0.549 
 Egger Intercept 0.99 0.022 0.95 1.03 0.690 
WMH volume MR method beta SE 95%CI p-value 
S.LDL.C IVW 0.066 0.027 0.013 0.118 0.014 
 Weighted median 0.054 0.03 -0.005 0.114 0.072 
 MR Egger 0.098 0.05 0.000 0.197 0.050 
 Egger Intercept -0.005 0.006 -0.017 0.008 0.438 
M.LDL.C IVW 0.063 0.024 0.017 0.110 0.008 
 Weighted median 0.088 0.032 0.026 0.150 0.006 
 MR Egger 0.101 0.043 0.017 0.185 0.019 
 Egger Intercept -0.006 0.006 -0.017 0.005 0.292 
L.LDL.C IVW 0.058 0.021 0.017 0.099 0.005 
 Weighted median 0.065 0.03 0.005 0.124 0.033 
 MR Egger 0.099 0.037 0.027 0.171 0.007 
 Egger Intercept -0.007 0.005 -0.016 0.003 0.172 
IDL.C IVW 0.050 0.023 0.005 0.095 0.028 
 Weighted median 0.053 0.027 0.000 0.106 0.051 
 MR Egger 0.114 0.041 0.033 0.195 0.006 
 Egger Intercept -0.009 0.005 -0.018 0.001 0.067 
IDL.TG IVW 0.021 0.027 -0.031 0.073 0.428 
 Weighted median 0.013 0.036 -0.056 0.083 0.710 
 MR Egger 0.082 0.066 -0.047 0.211 0.214 
 Egger Intercept -0.008 0.008 -0.023 0.007 0.313 
XS.VLDL.TG IVW -0.016 0.037 -0.088 0.056 0.667 
 Weighted median 0.002 0.044 -0.084 0.088 0.964 
 MR Egger -0.036 0.119 -0.268 0.196 0.762 
 Egger Intercept 0.002 0.012 -0.022 0.026 0.858 
 





Supplementary Table 10. Mendelian randomization (MR) association estimates of HDL-C 
raising variants in/close to the CEPT locus, and risk of small vessel stroke, as derived from 
alternative MR methods. Shown are the results derived from weighed median and MR-Egger 
analyses, because the IVW MR analysis showed significant heterogeneity. 
Small vessel stroke MR method OR 95%CI p-value 
HDL-C raising 
variants in CETP 
IVW MR 0.82 (0.75-0.89) 0.001 
Weighted median 0.81 (0.68-0.96) 0.014 
 MR Egger 0.71 (0.57-0.89) 0.003 
 Egger Intercept 1.01 (0.99-1.03) 0.404 
 




Supplementary Table 11. Mendelian randomization (MR) association estimates of HDL-C 
raising variants in/close to the CEPT locus, and risk of small vessel stroke, WMH volume, 
and risk of intracerebral hemorrhage, as derived from IVW MR analyses and multivariable 
MR analyses adjusting for the effects of the variants on both HDL-C and LDL-C. Shown are 
the results derived from the IVW MR and multivariable MR analyses. 
 
 





 Effect estimate 
(95%CI) 
p-value 
Small vessel stroke OR   OR  
HDL-C (1 SD increment) 0.82 (0.75-0.89) 9.0x10-6  0.87 (0.74-1.02) 0.094 
LDL-C (1 SD decrement) 0.41 (0.23-0.73) 0.003  1.40 (0.64-3.06) 0.414 
WMH volume beta   beta  
HDL-C (1 SD increment) -0.08 (-0.13 to -0.02) 0.008  -0.27 (-0.64 to 0.11) 0.166 
LDL-C (1 SD decrement) -0.28 (0.00 to 0.56) 0.048  0.34 (-2.15 to 1.47) 0.714 
 
 




Supplementary Table 12. Mendelian randomization (MR) association estimates of cholesterol 
and triglyceride concentrations across lipoprotein particles with intracerebral hemorrhage. 
Shown are the results derived from IVW MR and multivariable MR analyses. 
 IVW MR  Multivariable MR 
Outcome SNPs (N) OR (95%CI) p-value p-het  OR (95%CI) p-value 
Cholesterol in HDL particles [adjusted for LDL-C and TG] 
   
M.HDL.C 8 1.33 (0.92-1.92) 0.124 0.183  1.51 (1.17-1.95) 0.001 
L.HDL.C 42 1.06 (0.89-1.26) 0.534 0.509  1.09 (0.93-1.29) 0.295 
XL.HDL.C 30 1.07 (0.85-1.34) 0.570 0.044  1.15 (0.94-1.40) 0.172 
Cholesterol in LDL and larger particles [adjusted for HDL-C and TG]  
S.LDL.C 36 0.76 (0.63-0.93) 0.007 0.702  0.84 (0.69-1.01) 0.066 
M.LDL.C 36 0.81 (0.67-0.97) 0.019 0.472  0.85 (0.71-1.02) 0.088 
L.LDL.C 40 0.79 (0.67-0.94) 0.008 0.283  0.83 (0.70-0.99) 0.036 
IDL.C 42 0.78 (0.65-0.92) 0.004 0.589  0.78 (0.66-0.93) 0.004 
S.VLDL.C 26 0.86 (0.66-1.12) 0.264 0.040  0.80 (0.61-1.05) 0.106 
M.VLDL.C 24 1.01 (0.78-1.32) 0.923 0.074  0.90 (0.60-1.34) 0.592 
L.VLDL.C 17 1.21 (0.86-1.69) 0.267 0.035  0.87 (0.51-1.49) 0.614 
Triglycerides in any lipoprotein particle [adjusted for HDL-C and LDL-C]  
S.HDL.TG 25 0.85 (0.66-1.10) 0.223 0.175  1.14 (0.87-1.50) 0.346 
XL.HDL.TG 76 0.93 (0.82-1.06) 0.291 0.437  0.94 (0.79-1.12) 0.477 
IDL.TG 41 0.84 (0.68-1.04) 0.117 0.171  0.88 (0.70-1.10) 0.265 
S.VLDL.TG 26 1.07 (0.82-1.39) 0.620 0.095  1.05 (0.84-1.31) 0.665 
XS.VLDL.TG 27 0.96 (0.74-1.24) 0.732 0.156  1.09 (0.87-1.37) 0.447 
M.VLDL.TG 18 1.13 (0.82-1.54) 0.458 0.050  1.23 (0.97-1.54) 0.085 
L.VLDL.TG 15 1.40 (0.98-2.00) 0.065 0.249  1.26 (0.99-1.60) 0.055 
XL.VLDL.TG 12 1.46 (0.99-2.14) 0.056 0.145  1.25 (0.97-1.60) 0.081 
XXL.VLDL.TG 8 1.19 (0.77-1.86) 0.434 0.124  1.22 (0.92-1.61) 0.165 
 
Bold indicates p-values <0.05 after adjustment for false discovery rate (FDR). 
Odds Ratios correspond to 1 SD increment in the corresponding variable. P-het values correspond to the p-value of the 
Cochran’s Q statistic exploring heterogeneity across the estimates. 
For the multivariable MR analyses we used a genetic score for HDL-C, LDL-C and larger particle cholesterol, and for 
triglycerides, by combining all unique instruments significantly associated with HDL-C or cholesterol concentrations in HDL 
particles, LDL-C or cholesterol concentrations in LDL and larger ApoB particles, and with TG or triglyceride concentrations 
in any TG particles. For the concentration of cholesterol in HDL particles, we have performed adjustments for LDL-C and 
TG, for concentration of cholesterol in LDL and larger ApoB particles, we have performed adjustments for HDL-C and TG, 





Supplementary Figure 1. Sensitivity Mendelian randomization (MR) analyses between 
genetic determinants of blood lipid levels (HDL-C, LDL-C, TG) with risk of small vessel 
stroke. Shown are the results derived from IVW MR, weighted median, MR-Egger, and the 
GSMR approach incorporated with the HEIDI-outlier detector. The genetic instruments are 
weighted either based on the estimates derived from the full GLGC+MVP sample, or form 
those derived from the restricted GLGC dataset, where patients under lipid-modifying 
treatment had been excluded.   
 
 
GLGC: global lipids genetics consortium; MVP: millions veteran program. 
* the HEIDI-outlier approach detected rs11875988, rs11065979, and rs12417015 as outliers and excluded 
them from the analyses 
p-het: derived from the Cochran Q statistic for the IVW analyses and from the global heterogeneity test for the 
GSMR analyses. 




Supplementary Figure 2. Sensitivity Mendelian randomization (MR) analyses between 
genetic determinants of blood lipid levels (HDL-C, LDL-C, TG) with WMH volume. 
Shown are the results derived from IVW MR, weighted median, MR-Egger, and the GSMR 
approach incorporated with the HEIDI-outlier detector. The genetic instruments are weighted 
either based on the estimates derived from the full GLGC+MVP sample, or form those 
derived from the restricted GLGC dataset, where patients under lipid-modifying treatment 
had been excluded.   
 
 
GLGC: global lipids genetics consortium; MVP: millions veteran program. 
* the HEIDI-outlier approach detected rs701106 and rs13116385 as outliers and excluded them from the 
analyses 
p-het: derived from the Cochran Q statistic for the IVW analyses and from the global heterogeneity test for the 
GSMR analyses. 




Supplementary Figure 3. Mendelian randomization (MR) associations between genetic 
determinants of blood lipid levels (HDL-C, LDL-C, TG) with (A) risk of small vessel 
stroke and (B) WMH volume when restricting instrument selection to those specific for 
the respective traits. Shown are the results derived from IVW MR. 
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Supplementary Figure 4. Mendelian randomization (MR) associations of all components of the HDL lipoprotein particles defined by size with (A) 
risk of small vessel stroke and (B) WMH volume. Shown are the results derived from IVW MR analyses. 
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The first part of the abbreviations for the particle components indicates the size of the particles (small, medium, large, extra-large); the second refers to the type of lipoprotein particles (here 
HDL); the third part indicates the measured component in the respective size-defined particle: c, total cholesterol; ce, cholesterol-esters; fc, free cholesterol; l, total lipids; p, concentration of 
this particle class; pl, phospholipids; tg, triglycerides. 
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Supplementary Figure 5. Mendelian randomization (MR) associations of cholesterol 
(C) and triglyceride (TG) concentrations in lipoprotein particles defined by size with 
intracerebral hemorrhage. Shown are the results derived from IVW MR analyses. 
 
Solid-centre circles indicate association estimates with a q-value <0.05 after adjusting for multiple testing 
comparisons with the false discovery rate (FDR). 
The black point estimates and confidence interval lines correspond to the results of the random-effects IVW MR 




Supplementary Figure 6. Mendelian randomization associations between HDL-C-raising and LDL-
C-lowering genetic variants in the loci of known lipid-modifying drug targets and risk of 
intracerebral hemorrhage. Shown are the results derived from IVW MR analyses.  
  
The results are scaled per 1 SD increment in circulating HDL-C levels for the HDL-C-raising drug targets and per 1 SD 
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Supplementary Figure 7. Mendelian randomization (MR) associations between HDL-C-raising 
genetic variants in the CETP locus and risk of (A) deep and (B) lobar intracerebral hemorrhage 
(ICH). Shown are the results from the IVW MR analyses. The results are scaled per 1 SD increment 
in circulating HDL-C levels. 
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